0001365916-21-000017.txt : 20210507 0001365916-21-000017.hdr.sgml : 20210507 20210507171930 ACCESSION NUMBER: 0001365916-21-000017 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210507 DATE AS OF CHANGE: 20210507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMYRIS, INC. CENTRAL INDEX KEY: 0001365916 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 550856151 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34885 FILM NUMBER: 21904033 BUSINESS ADDRESS: STREET 1: 5885 HOLLIS STREET, SUITE 100 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-0761 MAIL ADDRESS: STREET 1: 5885 HOLLIS STREET, SUITE 100 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: AMYRIS BIOTECHNOLOGIES INC DATE OF NAME CHANGE: 20060613 10-Q 1 amrs-20210331.htm 10-Q amrs-20210331
000136591612/312021Q1FALSEP5Y91100013659162021-01-012021-03-31xbrli:shares00013659162021-05-04iso4217:USD00013659162021-03-3100013659162020-12-31iso4217:USDxbrli:shares0001365916us-gaap:ProductMember2021-01-012021-03-310001365916us-gaap:ProductMember2020-01-012020-03-310001365916amrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916amrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916amrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:GrantsAndCollaborationsMember2020-01-012020-03-3100013659162020-01-012020-03-310001365916us-gaap:PreferredStockMember2020-12-310001365916us-gaap:CommonStockMember2020-12-310001365916us-gaap:AdditionalPaidInCapitalMember2020-12-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001365916us-gaap:RetainedEarningsMember2020-12-310001365916us-gaap:NoncontrollingInterestMember2020-12-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2020-12-310001365916amrs:MezzanineEquityCommonStockMember2020-12-310001365916us-gaap:CommonStockMember2021-01-012021-03-310001365916us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2021-01-012021-03-310001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-01-012021-03-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001365916us-gaap:RetainedEarningsMember2021-01-012021-03-310001365916us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001365916us-gaap:PreferredStockMember2021-03-310001365916us-gaap:CommonStockMember2021-03-310001365916us-gaap:AdditionalPaidInCapitalMember2021-03-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001365916us-gaap:RetainedEarningsMember2021-03-310001365916us-gaap:NoncontrollingInterestMember2021-03-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2021-03-310001365916amrs:MezzanineEquityCommonStockMember2021-03-310001365916us-gaap:PreferredStockMember2019-12-310001365916us-gaap:CommonStockMember2019-12-310001365916us-gaap:AdditionalPaidInCapitalMember2019-12-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001365916us-gaap:RetainedEarningsMember2019-12-310001365916us-gaap:NoncontrollingInterestMember2019-12-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2019-12-310001365916amrs:MezzanineEquityCommonStockMember2019-12-310001365916us-gaap:CommonStockMember2020-01-012020-03-310001365916us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2020-01-012020-03-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001365916us-gaap:RetainedEarningsMember2020-01-012020-03-310001365916us-gaap:PreferredStockMember2020-03-310001365916us-gaap:CommonStockMember2020-03-310001365916us-gaap:AdditionalPaidInCapitalMember2020-03-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001365916us-gaap:RetainedEarningsMember2020-03-310001365916us-gaap:NoncontrollingInterestMember2020-03-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2020-03-310001365916amrs:MezzanineEquityCommonStockMember2020-03-3100013659162019-12-3100013659162020-03-310001365916amrs:KoninklijkeDSMNVDSMMember2021-01-012021-03-310001365916amrs:KoninklijkeDSMNVDSMMember2020-01-012020-03-3100013659162010-09-272021-03-310001365916us-gaap:MachineryAndEquipmentMember2021-03-310001365916us-gaap:MachineryAndEquipmentMember2020-12-310001365916us-gaap:LeaseholdImprovementsMember2021-03-310001365916us-gaap:LeaseholdImprovementsMember2020-12-310001365916amrs:ComputerEquipmentAndSoftwareMember2021-03-310001365916amrs:ComputerEquipmentAndSoftwareMember2020-12-310001365916amrs:FurnitureAndOfficeEquipmentVehiclesAndLandMember2021-03-310001365916amrs:FurnitureAndOfficeEquipmentVehiclesAndLandMember2020-12-310001365916us-gaap:ConstructionInProgressMember2021-03-310001365916us-gaap:ConstructionInProgressMember2020-12-310001365916srt:MinimumMember2021-03-310001365916srt:MaximumMember2021-03-31xbrli:pure0001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916us-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916us-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:ForisConvertibleNoteMemberamrs:RelatedPartyConvertibleNotesMember2021-03-310001365916amrs:ForisConvertibleNoteMemberamrs:MeasurementInputStockPriceMemberus-gaap:ConvertibleDebtMember2020-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ConvertibleDebtMember2020-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:ConvertibleDebtMember2020-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:ConvertibleDebtMember2020-03-310001365916amrs:MeasurementInputProbabilityOfChangeInControlMemberamrs:ForisConvertibleNoteMemberus-gaap:ConvertibleDebtMember2020-03-310001365916amrs:ForisConvertibleNoteMember2021-01-012021-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:ConvertibleDebtMember2021-03-310001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916amrs:MeasurementInputStockPriceMemberus-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916us-gaap:MeasurementInputDiscountRateMemberus-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916amrs:MeasurementInputProbabilityOfChangeInControlMemberus-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916us-gaap:LongTermDebtMember2020-12-310001365916us-gaap:LongTermDebtMember2021-01-012021-03-310001365916us-gaap:LongTermDebtMember2021-03-310001365916us-gaap:FairValueInputsLevel3Memberamrs:DerivativeLiabilityDebtRelatedMember2020-12-310001365916us-gaap:FairValueInputsLevel3Memberamrs:DerivativeLiabilityDebtRelatedMember2021-01-012021-03-310001365916us-gaap:FairValueInputsLevel3Memberamrs:DerivativeLiabilityDebtRelatedMember2021-03-310001365916amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember2020-02-280001365916amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember2020-02-282020-02-280001365916amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember2021-03-310001365916amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember2021-01-012021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputSharePriceMember2021-03-310001365916srt:MaximumMemberus-gaap:MeasurementInputSharePriceMember2021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputSharePriceMember2020-12-310001365916srt:MaximumMemberus-gaap:MeasurementInputSharePriceMember2020-12-310001365916srt:MinimumMemberus-gaap:MeasurementInputExercisePriceMember2021-03-310001365916srt:MaximumMemberus-gaap:MeasurementInputExercisePriceMember2021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputExercisePriceMember2020-12-310001365916srt:MaximumMemberus-gaap:MeasurementInputExercisePriceMember2020-12-310001365916srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMember2021-03-310001365916srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMember2021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310001365916srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310001365916srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-03-310001365916srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-310001365916srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-310001365916srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2021-03-310001365916srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310001365916srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310001365916us-gaap:MeasurementInputExpectedDividendRateMember2021-03-310001365916us-gaap:MeasurementInputExpectedDividendRateMember2020-12-310001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2020-12-310001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2020-01-012020-12-310001365916us-gaap:ConvertibleDebtMember2021-03-310001365916us-gaap:ConvertibleDebtMember2021-01-012021-03-310001365916us-gaap:ConvertibleDebtMember2020-12-310001365916us-gaap:ConvertibleDebtMember2020-01-012020-12-310001365916amrs:ForisConvertibleNoteMemberamrs:RelatedPartyConvertibleNotesMember2021-01-012021-03-310001365916amrs:ForisConvertibleNoteMemberamrs:RelatedPartyConvertibleNotesMember2020-12-310001365916amrs:ForisConvertibleNoteMemberamrs:RelatedPartyConvertibleNotesMember2020-01-012020-12-310001365916amrs:RelatedPartyConvertibleNotesMember2021-03-310001365916amrs:RelatedPartyConvertibleNotesMember2021-01-012021-03-310001365916amrs:RelatedPartyConvertibleNotesMember2020-12-310001365916amrs:RelatedPartyConvertibleNotesMember2020-01-012020-12-310001365916us-gaap:LoansPayableMemberamrs:SchottenfeldNotesMember2021-03-310001365916us-gaap:LoansPayableMemberamrs:SchottenfeldNotesMember2021-01-012021-03-310001365916us-gaap:LoansPayableMemberamrs:SchottenfeldNotesMember2020-12-310001365916us-gaap:LoansPayableMemberamrs:SchottenfeldNotesMember2020-01-012020-12-310001365916us-gaap:LoansPayableMemberamrs:NikkoNotesMember2021-03-310001365916us-gaap:LoansPayableMemberamrs:NikkoNotesMember2021-01-012021-03-310001365916us-gaap:LoansPayableMemberamrs:NikkoNotesMember2020-12-310001365916us-gaap:LoansPayableMemberamrs:NikkoNotesMember2020-01-012020-12-310001365916us-gaap:LoansPayableMemberamrs:GinkgoCollaborationNoteMember2021-03-310001365916us-gaap:LoansPayableMemberamrs:GinkgoCollaborationNoteMember2021-01-012021-03-310001365916us-gaap:LoansPayableMemberamrs:GinkgoCollaborationNoteMember2020-12-310001365916us-gaap:LoansPayableMemberamrs:GinkgoCollaborationNoteMember2020-01-012020-12-310001365916us-gaap:LoansPayableMemberamrs:OtherLoansPayableMember2021-03-310001365916us-gaap:LoansPayableMemberamrs:OtherLoansPayableMember2021-01-012021-03-310001365916us-gaap:LoansPayableMemberamrs:OtherLoansPayableMember2020-12-310001365916us-gaap:LoansPayableMemberamrs:OtherLoansPayableMember2020-01-012020-12-310001365916us-gaap:LoansPayableMember2021-03-310001365916us-gaap:LoansPayableMember2021-01-012021-03-310001365916us-gaap:LoansPayableMember2020-12-310001365916us-gaap:LoansPayableMember2020-01-012020-12-310001365916amrs:ForisDebtMemberamrs:RelatedPartyLoanPayableMember2021-03-310001365916amrs:ForisDebtMemberamrs:RelatedPartyLoanPayableMember2021-01-012021-03-310001365916amrs:ForisDebtMemberamrs:RelatedPartyLoanPayableMember2020-12-310001365916amrs:ForisDebtMemberamrs:RelatedPartyLoanPayableMember2020-01-012020-12-310001365916amrs:DSMNoteMemberamrs:RelatedPartyLoanPayableMember2021-03-310001365916amrs:DSMNoteMemberamrs:RelatedPartyLoanPayableMember2021-01-012021-03-310001365916amrs:DSMNoteMemberamrs:RelatedPartyLoanPayableMember2020-12-310001365916amrs:DSMNoteMemberamrs:RelatedPartyLoanPayableMember2020-01-012020-12-310001365916amrs:TheNaxyrisLoanAgreementMemberamrs:RelatedPartyLoanPayableMember2021-03-310001365916amrs:TheNaxyrisLoanAgreementMemberamrs:RelatedPartyLoanPayableMember2021-01-012021-03-310001365916amrs:TheNaxyrisLoanAgreementMemberamrs:RelatedPartyLoanPayableMember2020-12-310001365916amrs:TheNaxyrisLoanAgreementMemberamrs:RelatedPartyLoanPayableMember2020-01-012020-12-310001365916amrs:RelatedPartyLoanPayableMember2021-03-310001365916amrs:RelatedPartyLoanPayableMember2021-01-012021-03-310001365916amrs:RelatedPartyLoanPayableMember2020-12-310001365916amrs:RelatedPartyLoanPayableMember2020-01-012020-12-3100013659162020-01-012020-12-310001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-02-040001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-02-042021-02-040001365916amrs:SchottenfeldSeptember2019CreditAgreementsMember2021-03-0100013659162021-03-012021-03-010001365916amrs:DSMCreditAgreementMember2017-12-280001365916amrs:DSMCreditAgreementMemberus-gaap:UnsecuredDebtMember2017-12-280001365916amrs:DSMCreditAgreementMember2017-12-282017-12-280001365916amrs:The2019DSMCreditAgreementMemberamrs:DSMInternationalBVMember2019-09-17amrs:installment00013659162019-09-170001365916amrs:DSMCreditAgreementMember2019-09-170001365916amrs:DSMCreditAgreementMemberus-gaap:UnsecuredDebtMember2019-09-170001365916us-gaap:UnsecuredDebtMemberamrs:DSMCreditAgreementMarch2021AmendmentRelatedTo25MillionDollarNoteMember2021-01-012021-03-310001365916us-gaap:UnsecuredDebtMemberamrs:DSMCreditAgreementMarch2021AmendmentMember2021-03-310001365916us-gaap:UnsecuredDebtMemberamrs:DSMCreditAgreementMarch2021AmendmentMember2021-01-012021-03-310001365916amrs:DSMCreditAgreementMemberus-gaap:UnsecuredDebtMember2021-01-012021-03-310001365916amrs:DSMCreditAgreementMemberus-gaap:UnsecuredDebtMember2021-03-310001365916amrs:LoansPayableAndCreditFacilitiesMember2021-03-310001365916amrs:RelatedPartyLoansPayableAndCreditFacilitiesMember2021-03-310001365916amrs:GatesFoundationPurchaseAgreementMember2021-03-310001365916amrs:GatesFoundationPurchaseAgreementMember2021-01-012021-03-310001365916amrs:HighTrailSilverbackWarrantsMember2021-03-310001365916amrs:January2020WarrantExerciseRightSharesMember2021-03-310001365916amrs:April2019PIPEWarrantsMember2021-03-310001365916srt:MinimumMemberamrs:April2019PIPEWarrantsMember2021-03-310001365916srt:MaximumMemberamrs:April2019PIPEWarrantsMember2021-03-310001365916amrs:NaxyrisLSAWarrantsMember2021-03-310001365916amrs:October2019NaxyrisWarrantMember2021-03-310001365916amrs:May20196.50NoteExchangeWarrantsMember2021-03-310001365916amrs:May2017CashWarrantsMember2021-03-310001365916amrs:May2017DilutionWarrantsMember2021-03-310001365916amrs:August2017DilutionWarrantsMember2021-03-310001365916amrs:July2015RelatedPartyDebtExchange3Member2021-03-310001365916amrs:OtherMember2021-03-310001365916amrs:PeriodEndCommonStockWarrantsMember2021-01-012021-03-310001365916amrs:PeriodEndCommonStockWarrantsMember2020-01-012020-03-310001365916amrs:ConvertiblePromissoryNotesMember2021-01-012021-03-310001365916amrs:ConvertiblePromissoryNotesMember2020-01-012020-03-310001365916amrs:StockOptionsToPurchaseCommonStockMember2021-01-012021-03-310001365916amrs:StockOptionsToPurchaseCommonStockMember2020-01-012020-03-310001365916us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001365916us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-310001365916amrs:PeriodEndPreferredSharesMember2021-01-012021-03-310001365916amrs:PeriodEndPreferredSharesMember2020-01-012020-03-310001365916amrs:AprinnovaJVMember2021-03-310001365916us-gaap:ProductMembercountry:US2021-01-012021-03-310001365916country:USamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916country:USamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916country:US2021-01-012021-03-310001365916us-gaap:ProductMembercountry:US2020-01-012020-03-310001365916country:USamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916country:USamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916country:US2020-01-012020-03-310001365916us-gaap:ProductMembersrt:EuropeMember2021-01-012021-03-310001365916srt:EuropeMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916srt:EuropeMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916srt:EuropeMember2021-01-012021-03-310001365916us-gaap:ProductMembersrt:EuropeMember2020-01-012020-03-310001365916srt:EuropeMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916srt:EuropeMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916srt:EuropeMember2020-01-012020-03-310001365916srt:AsiaMemberus-gaap:ProductMember2021-01-012021-03-310001365916srt:AsiaMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916srt:AsiaMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916srt:AsiaMember2021-01-012021-03-310001365916srt:AsiaMemberus-gaap:ProductMember2020-01-012020-03-310001365916srt:AsiaMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916srt:AsiaMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916srt:AsiaMember2020-01-012020-03-310001365916country:BRus-gaap:ProductMember2021-01-012021-03-310001365916country:BRamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916country:BRamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916country:BR2021-01-012021-03-310001365916country:BRus-gaap:ProductMember2020-01-012020-03-310001365916country:BRamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916country:BRamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916country:BR2020-01-012020-03-310001365916amrs:OtherAreaMemberus-gaap:ProductMember2021-01-012021-03-310001365916amrs:OtherAreaMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916amrs:OtherAreaMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:OtherAreaMember2021-01-012021-03-310001365916amrs:OtherAreaMemberus-gaap:ProductMember2020-01-012020-03-310001365916amrs:OtherAreaMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916amrs:OtherAreaMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916amrs:OtherAreaMember2020-01-012020-03-310001365916us-gaap:ProductMemberamrs:ConsumerMember2021-01-012021-03-310001365916amrs:ConsumerMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916amrs:ConsumerMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:ConsumerMember2021-01-012021-03-310001365916us-gaap:ProductMemberamrs:ConsumerMember2020-01-012020-03-310001365916amrs:ConsumerMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916amrs:ConsumerMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916amrs:ConsumerMember2020-01-012020-03-310001365916us-gaap:ProductMemberamrs:IngredientCustomerMember2021-01-012021-03-310001365916amrs:IngredientCustomerMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916amrs:IngredientCustomerMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:IngredientCustomerMember2021-01-012021-03-310001365916us-gaap:ProductMemberamrs:IngredientCustomerMember2020-01-012020-03-310001365916amrs:IngredientCustomerMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916amrs:IngredientCustomerMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916amrs:IngredientCustomerMember2020-01-012020-03-310001365916us-gaap:ProductMemberamrs:ResearchAndDevelopmentCustomerMember2021-01-012021-03-310001365916amrs:ResearchAndDevelopmentCustomerMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916amrs:ResearchAndDevelopmentCustomerMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:ResearchAndDevelopmentCustomerMember2021-01-012021-03-310001365916us-gaap:ProductMemberamrs:ResearchAndDevelopmentCustomerMember2020-01-012020-03-310001365916amrs:ResearchAndDevelopmentCustomerMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916amrs:ResearchAndDevelopmentCustomerMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916amrs:ResearchAndDevelopmentCustomerMember2020-01-012020-03-310001365916amrs:DSMInternationalBVMemberamrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:DSMInternationalBVMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:DSMInternationalBVMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:DSMInternationalBVMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMemberamrs:SephoraMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:SephoraMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:SephoraMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:SephoraMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:RenewableProductsMemberamrs:SephoraMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:SephoraMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:SephoraMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:SephoraMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:YifanMemberamrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:YifanMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:YifanMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:YifanMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:YifanMemberamrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:YifanMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:YifanMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:YifanMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMemberamrs:FirmenichMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:FirmenichMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:FirmenichMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:FirmenichMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:RenewableProductsMemberamrs:FirmenichMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:FirmenichMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:FirmenichMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:FirmenichMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMemberamrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:GivaudanInternationalSaMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:GrantsAndCollaborationsMemberamrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:RenewableProductsMemberamrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:GivaudanInternationalSaMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:GrantsAndCollaborationsMemberamrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMemberamrs:AllOtherCustomersMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:AllOtherCustomersMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:AllOtherCustomersMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:AllOtherCustomersMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:RenewableProductsMemberamrs:AllOtherCustomersMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:AllOtherCustomersMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:AllOtherCustomersMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:AllOtherCustomersMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMember2021-01-012021-03-310001365916amrs:RenewableProductsMember2020-01-012020-03-310001365916amrs:DSMInternationalBVMemberamrs:DSMLicenseAgreementMember2021-03-310001365916amrs:DSMInternationalBVMembersrt:MaximumMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:DSMLicenseAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:DSMLicenseAgreementMemberamrs:FinishedGoodsInventoryMember2021-03-310001365916amrs:DSMInternationalBVMemberamrs:ReceivablesMemberamrs:DSMLicenseAgreementMember2021-03-310001365916amrs:DSMInternationalBVMemberamrs:IntellectualPropertyLicenseMemberamrs:DSMLicenseAgreementMember2021-03-310001365916amrs:DSMInternationalBVMemberus-gaap:LicenseMemberamrs:DSMLicenseAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:ResearchAndDevelopmentCustomerMemberamrs:DSMPerformanceCollabrationMember2017-12-012017-12-310001365916amrs:DSMInternationalBVMemberamrs:ResearchAndDevelopmentCustomerMemberamrs:DSMPerformanceCollabrationMember2017-12-310001365916amrs:DSMInternationalBVMemberamrs:ResearchAndDevelopmentCustomerMemberamrs:DSMPerformanceCollabrationMember2021-01-012021-03-310001365916amrs:DSMIngredientsCollaborationMemberamrs:DSMInternationalBVMember2021-01-012021-03-310001365916amrs:DSMIngredientsCollaborationMemberamrs:DSMInternationalBVMemberamrs:ResearchAndDevelopmentCustomerMember2021-01-012021-03-310001365916amrs:DSMIngredientsCollaborationMemberamrs:DSMInternationalBVMemberamrs:ResearchAndDevelopmentCustomerMember2020-01-012020-03-310001365916amrs:YifanMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:YifanMemberamrs:GrantsAndCollaborationsMember2021-03-3100013659162021-04-012021-03-3100013659162022-01-012021-03-3100013659162023-01-012021-03-3100013659162024-01-012021-03-310001365916amrs:ForisNotesMemberamrs:RelatedPartyDebtMemberamrs:ForisVenturesLLCMember2021-03-310001365916amrs:ForisNotesMemberamrs:RelatedPartyDebtMemberamrs:ForisVenturesLLCMember2020-12-310001365916amrs:DSMNoteMemberamrs:RelatedPartyDebtMemberamrs:DSMInternationalBVMember2021-03-310001365916amrs:DSMNoteMemberamrs:RelatedPartyDebtMemberamrs:DSMInternationalBVMember2020-12-310001365916amrs:NaxyrisSAMemberamrs:RelatedPartyDebtMemberamrs:NaxyrisNoteMember2021-03-310001365916amrs:NaxyrisSAMemberamrs:RelatedPartyDebtMemberamrs:NaxyrisNoteMember2020-12-310001365916amrs:RelatedPartyDebtMember2021-03-310001365916amrs:RelatedPartyDebtMember2020-12-310001365916amrs:AccountsReceivableUnbilledRelatedPartyMemberamrs:DSMInternationalBVMember2021-03-310001365916amrs:AccountsReceivableUnbilledRelatedPartyMemberamrs:DSMInternationalBVMember2020-12-310001365916amrs:ContractAssetsRelatedPartyMemberamrs:DSMInternationalBVMember2021-03-310001365916amrs:ContractAssetsRelatedPartyMemberamrs:DSMInternationalBVMember2020-12-310001365916amrs:DSMInternationalBVMemberamrs:AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesMember2021-03-310001365916amrs:DSMInternationalBVMemberamrs:AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesMember2020-12-310001365916us-gaap:RestrictedStockUnitsRSUMember2020-12-310001365916us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001365916us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001365916us-gaap:RestrictedStockUnitsRSUMember2021-03-310001365916us-gaap:CostOfSalesMember2021-01-012021-03-310001365916us-gaap:CostOfSalesMember2020-01-012020-03-310001365916us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001365916us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-310001365916us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001365916us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-03-310001365916us-gaap:EmployeeStockOptionMember2021-03-310001365916us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001365916amrs:A2020EquityIncentivePlanMember2021-03-310001365916amrs:EquityIncentivePlan2010Member2021-03-310001365916amrs:PublicStockOfferingSharesFromSellingStockholdersMemberus-gaap:SubsequentEventMember2021-04-082021-04-080001365916amrs:PublicStockOfferingSharesFromSellingStockholdersMemberus-gaap:SubsequentEventMember2021-04-080001365916amrs:PublicStockOfferingSharesFromAmyrisMemberus-gaap:SubsequentEventMember2021-04-082021-04-080001365916us-gaap:SubsequentEventMember2021-04-080001365916us-gaap:SubsequentEventMember2021-04-082021-04-080001365916amrs:PublicStockOfferingSellingStockholdersUnderUnderwritingAgreementMemberus-gaap:SubsequentEventMember2021-04-082021-04-080001365916amrs:PublicStockOfferingAmyrisUnderUnderwritingAgreementMemberus-gaap:SubsequentEventMember2021-04-082021-04-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

-OR-
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-34885

AMYRIS, INC.
(Exact name of registrant as specified in its charter) 
Delaware
55-0856151
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
Amyris, Inc.
5885 Hollis Street, Suite 100
Emeryville, CA 94608
(510) 450-0761
(Address and telephone number of principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareAMRSThe Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No ☒

Shares outstanding of the Registrant's common stock:
Class
Outstanding as of May 4, 2021
Common Stock, $0.0001 par value per share
291,471,055




AMYRIS, INC.
TABLE OF CONTENTS

Page
PART I
Item 1.
Item 2.
Item 3.
Item 4.
PART II
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.



2



PART I
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
AMYRIS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except shares and per share amounts)March 31,
2021
December 31, 2020
Assets
Current assets:
Cash and cash equivalents$143,821 $30,152 
Restricted cash283 309 
Accounts receivable, net of allowance of $154 and $137, respectively
27,036 32,846 
Accounts receivable - related party, net of allowance of $0 and $0, respectively
391 12,110 
Contract assets6,589 4,178 
Contract assets - related party2,000 1,203 
Inventories47,639 42,862 
Deferred cost of products sold - related party5,220 9,801 
Prepaid expenses and other current assets19,246 13,103 
Total current assets252,225 146,564 
Property, plant and equipment, net31,933 32,875 
Deferred cost of products sold, noncurrent - related party9,391 9,939 
Restricted cash, noncurrent961 961 
Recoverable taxes from Brazilian government entities8,680 8,641 
Right-of-use assets under financing leases, net9,296 9,994 
Right-of-use assets under operating leases, net9,333 10,136 
Other assets4,770 3,704 
Total assets$326,589 $222,814 
Liabilities, Mezzanine Equity and Stockholders' Deficit
Current liabilities:
Accounts payable$44,154 $41,045 
Accrued and other current liabilities32,121 30,707 
Financing lease liabilities3,258 4,170 
Operating lease liabilities5,510 5,226 
Contract liabilities6,163 4,468 
Debt, current portion (includes instrument measured at fair value of $54,757 and $53,387, respectively)
55,904 54,748 
Related party debt, current portion 22,689 
Total current liabilities147,110 163,053 
Long-term debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively)
13,873 26,170 
Related party debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively)
413,687 159,452 
Operating lease liabilities, net of current portion8,209 9,732 
Derivative liabilities31,384 8,698 
Other noncurrent liabilities22,467 22,754 
Total liabilities636,730 389,859 
Commitments and contingencies
Mezzanine equity: Contingently redeemable common stock5,000 5,000 
Stockholders’ deficit:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 8,280 shares issued and outstanding as of March 31, 2021 and December 31, 2020
  
Common stock - $0.0001 par value, 350,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 273,266,917 and 244,951,446 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively
27 24 
Additional paid-in capital2,106,214 1,957,224 
Accumulated other comprehensive loss(49,413)(47,375)
Accumulated deficit(2,377,943)(2,086,692)
Total Amyris, Inc. stockholders’ deficit(321,115)(176,819)
Noncontrolling interest5,974 4,774 
Total stockholders' deficit(315,141)(172,045)
Total liabilities, mezzanine equity and stockholders' deficit$326,589 $222,814 

See the accompanying notes to the unaudited condensed consolidated financial statements.


3



AMYRIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

Three Months Ended March 31,
(In thousands, except shares and per share amounts)20212020
Revenue:
Renewable products (includes related party revenue of $1,662 and $49, respectively)
$28,179 $17,854 
Licenses and royalties (includes related party revenue of $143,612, and $3,750, respectively)
143,800 5,161 
Grants and collaborations (includes related party revenue of $2,000 and $3,018, respectively)
4,880 6,115 
Total revenue (includes related party revenue of $147,274 and $6,817, respectively)
176,859 29,130 
Cost and operating expenses:
Cost of products sold22,659 11,790 
Research and development23,332 17,126 
Sales, general and administrative37,922 32,014 
Total cost and operating expenses83,913 60,930 
Income (loss) from operations92,946 (31,800)
Other income (expense):
Interest expense(5,813)(15,002)
(Loss) gain from change in fair value of derivative instruments(22,745)3,282 
Loss from change in fair value of debt(326,785)(16,503)
Loss upon extinguishment of debt(27,313)(27,319)
Other (expense) income, net(678)4 
Total other expense, net(383,334)(55,538)
Loss before income taxes and loss from investment in affiliate(290,388)(87,338)
Provision for income taxes(55)(91)
Gain (loss) from investment in affiliate392 (415)
Net loss(290,051)(87,844)
Less: income attributable to noncontrolling interest in Aprinnova(1,200) 
Net loss attributable to Amyris, Inc.(291,251)(87,844)
Less: losses allocated to participating securities2,099 1,087 
Net loss attributable to Amyris, Inc. common stockholders, basic and diluted$(289,152)$(86,757)
Loss per share attributable to common stockholders, basic and diluted$(1.08)$(0.56)
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted267,733,555 155,065,635 

See the accompanying notes to the unaudited condensed consolidated financial statements.


4




AMYRIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)

Three Months Ended March 31,
(In thousands)20212020
Comprehensive loss:
Net loss$(290,051)$(87,844)
Foreign currency translation adjustment(2,038)(2,549)
Total comprehensive loss(292,089)(90,393)
Income attributable to noncontrolling interest(1,200) 
Comprehensive loss attributable to Amyris, Inc.$(293,289)$(90,393)

See the accompanying notes to the unaudited condensed consolidated financial statements.


5



AMYRIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT AND MEZZANINE EQUITY
(Unaudited)

Preferred StockCommon Stock
(In thousands, except number of shares)SharesAmountSharesAmountAdditional Paid-in CapitalAccumulated Other Comprehensive LossAccumulated DeficitNoncontrolling InterestTotal Stockholders' DeficitMezzanine Equity - Common Stock
Balances at December 31, 20208,280 $ 244,951,446 $24 1,957,224 $(47,375)$(2,086,692)$4,774 $(172,045)$5,000 
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock— — 496,341 — (2)— — — (2)— 
Issuance of common stock upon conversion of debt principal, net of 2,600,000 pre-delivery shares returned to Amyris
— — 5,827,164 1 110,574 — — — 110,575 — 
Issuance of common stock upon exercise of stock options— — 377,542 — 1,920 — — — 1,920 — 
Issuance of common stock upon exercise of warrants— — 15,557,480 2 32,217 — — — 32,219 — 
Issuance of common stock upon exercise of warrants - related party— — 6,056,944   — — —  — 
Stock-based compensation— — — — 4,281 — — — 4,281 — 
Foreign currency translation adjustment— — — — (2,038)— — (2,038)— 
Net loss attributable to Amyris, Inc.— — — — — $(291,251)$1,200 (290,051)— 
Balances at March 31, 20218,280 $ 273,266,917 $27 $2,106,214 $(49,413)$(2,377,943)$5,974 $(315,141)$5,000 
Balances at December 31, 20198,280 $ 117,742,677 $12 1,543,668 $(43,804)$(1,755,653)$609 $(255,168)$5,000 
Issuance of common stock and warrants upon conversion of debt principal and accrued interest— — 6,337,594 1 21,259 — — — 21,260 — 
Issuance of common stock in private placement — — 3,484,321 — 10,000 — — — 10,000 — 
Issuance of common stock in private placement - related party— — 10,505,652 1 27,188 — — — 27,189 — 
Issuance of common stock upon exercise of warrants— — 1,160,929 — 3,332 — — — 3,332 — 
Issuance of common stock upon exercise of warrants - related party— — 24,165,166 2 68,763 — — — 68,765 — 
Exercise of common stock rights warrant - related party— — — — 15,000 — — — 15,000 — 
Issuance of common stock right warrant - related party— — — — 8,904 — — — 8,904 — 
Modification of previously issued common stock warrants— — — — 1,286 — — — 1,286 — 
Derecognition of liability warrants to equity— — — — 5,200 — — — 5,200 — 
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock— — 495,581 — (8)— — — (8)— 
Stock-based compensation— — — — 3,504 — — — 3,504 — 
Foreign currency translation adjustment— — — — — (2,549)— — (2,549)— 
Net loss attributable to Amyris, Inc.— — — — — — (87,844)— (87,844)— 
Balances at March 31, 20208,280 $ 163,891,920 $16 $1,708,096 $(46,353)$(1,843,497)$609 $(181,129)$5,000 

See the accompanying notes to the unaudited condensed consolidated financial statements.


6



AMYRIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)


7



Three Months Ended March 31,
(In thousands)20212020
Operating activities
Net loss$(290,051)$(87,844)
Adjustments to reconcile net loss to net cash used in operating activities:
(Gain) loss from change in fair value of debt326,785 16,503 
Loss upon extinguishment of debt27,313 27,319 
(Gain) loss from change in fair value of derivative instruments22,745 (3,282)
Stock-based compensation4,281 3,504 
Depreciation and amortization2,114 1,719 
Amortization of right-of-use assets under operating leases750 668 
Accretion of debt discount713 1,292 
(Gain) loss on foreign currency exchange rates408 (109)
Other 42 
(Gain) loss from investment in affiliate(392)415 
Changes in assets and liabilities:
Accounts receivable17,275 (5,209)
Contract assets(3,208)(870)
Inventories(5,686)(4,392)
Deferred cost of products sold - related party5,129 142 
Prepaid expenses and other assets(8,207)(1,430)
Accounts payable4,154 318 
Accrued and other liabilities4,011 4,009 
Lease liabilities(1,185)(1,043)
Contract liabilities1,702 1,873 
Net cash provided by (used in) operating activities108,651 (46,375)
Investing activities
Purchases of property, plant and equipment(2,493)(1,040)
Net cash used in investing activities(2,493)(1,040)
Financing activities
Issuance costs incurred in connection with debt modification(2,500) 
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units(2)(8)
Principal payments on debt(23,196)(6,981)
Principal payments on financing leases(912)(866)
Proceeds from exercise of common stock rights warrant - related party 15,000 
Proceeds from exercises of common stock options1,920  
Proceeds from exercises of warrants32,219 3,332 
Proceeds from exercises of warrants - related party 13,998 
Proceeds from issuance of common and preferred stock in private placement, net of issuance costs 10,000 
Proceeds from issuance of common and preferred stock in private placement, net of issuance costs - related party 15,000 
Proceeds from issuance of debt, net of issuance costs 188 
Net cash provided by financing activities7,529 49,663 
Effect of exchange rate changes on cash, cash equivalents and restricted cash(44)19 
Net increase in cash, cash equivalents and restricted cash113,643 2,267 
Cash, cash equivalents and restricted cash at beginning of period31,422 1,699 
Cash, cash equivalents and restricted cash at end of the period$145,065 $3,966 
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents$143,821 $2,607 
Restricted cash, current283 399 
Restricted cash, noncurrent961 960 
Total cash, cash equivalents and restricted cash$145,065 $3,966 

See the accompanying notes to the unaudited condensed consolidated financial statements.


8



AMYRIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS, Continued
(Unaudited)

Three Months Ended March 31,
(In thousands)20212020
Supplemental disclosures of cash flow information:
Cash paid for interest$3,275 $3,152 
Supplemental disclosures of non-cash investing and financing activities:
Accrued interest added to debt principal$ $1,527 
Derecognition of derivative liabilities to equity upon extinguishment of debt$59 $ 
Derecognition of derivative liabilities upon exercise of warrants$ $5,200 
Exercise of common stock warrants in exchange for debt principal and accrued interest reduction$ $69,918 
Fair value of embedded features in connection with private placement$ $2,962 
Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances$ $188 
Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances - related party$ $747 
Issuance of common stock and warrants upon conversion of debt principal and accrued interest$110,575 $18,333 
Unpaid property, plant and equipment balances in accounts payable and accrued liabilities at end of period$1,121 $1,307 

See the accompanying notes to the unaudited condensed consolidated financial statements.


9



AMYRIS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)


1. Basis of Presentation and Summary of Significant Accounting Policies

As a leading synthetic biotechnology company active in the Clean Health and Beauty markets through our consumer brands and a top supplier of sustainable and natural ingredients, Amyris, Inc. and our subsidiaries (collectively, Amyris or the Company) apply the Company's proprietary Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products. The Company does so with the use of computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. The Company's biotechnology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that the Company manufactures at industrial scale. Through the combination of our biotechnology platform and our industrial fermentation process, the Company has successfully developed, produced and commercialized many distinct molecules.

The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 (the 2020 Form 10-K), from which the condensed consolidated balance sheet as of December 31, 2020 is derived. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

Significant Accounting Policies

Note 1, "Basis of Presentation and Summary of Significant Accounting Policies", to the audited consolidated financial statements in the 2020 Form 10-K includes a discussion of the significant accounting policies and estimates used in the preparation of the Company’s condensed consolidated financial statements. There have been no material changes to the Company's significant accounting policies and estimates during the three months ended March 31, 2021.

Use of Estimates and Judgements

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant


10



accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed.

Accounting Standards or Updates Recently Adopted

In the three months ended March 31, 2021, the Company adopted these accounting standards or updates:

Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

Accounting Standards or Updates Not Yet Adopted

Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. ASU 2016-13 will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

Convertible Debt, and Derivatives and Hedging In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures.

2. Balance Sheet Details

Allowance for Doubtful Accounts
(In thousands)Balance at Beginning of YearProvisionsWrite-offs, NetBalance at End of Period
Three months ended March 31, 2021$137 $17 $ $154 
Three months ended March 31, 2020$45 $ $ $45 

Inventories
(In thousands)March 31, 2021December 31, 2020
Raw materials$12,185 $11,800 
Work-in-process8,702 10,760 
Finished goods26,752 20,302 
Inventories$47,639 $42,862 

Deferred cost of products sold - related party


11



(In thousands)March 31, 2021December 31, 2020
Deferred cost of products sold - related party$5,220 $9,801 
Deferred cost of products sold, noncurrent - related party9,391 9,939 
Total $14,611 $19,740 

Amounts reported as "Deferred cost of products sold - related party" are in connection with an agreement with Koninklijke DSM N.V. (DSM) under which DSM will provide capacity for sweetener production at DSM's Brotas, Brazil manufacturing facility through December 2022. Deferred cost of products sold asset is being expensed to cost of products sold on a units of production basis as the Company's sweetener product is sold over the five-year term of the supply agreement. During the three months ended March 31, 2021 and 2020, the Company expensed $1.6 million and $0.1 million, respectively, of the deferred cost of products sold asset to cost of products sold. Inception-to-date amortization through March 31, 2021 totaled $4.9 million.

Prepaid expenses and other current assets
(In thousands)March 31, 2021December 31, 2020
Prepayments, advances and deposits$13,453 $6,637 
Non-inventory production supplies3,364 3,989 
Recoverable taxes from Brazilian government entities1,020 1,063 
Other1,409 1,414 
Total prepaid expenses and other current assets$19,246 $13,103 

Property, Plant and Equipment, Net
(In thousands)March 31, 2021December 31, 2020
Machinery and equipment$49,880 $50,415 
Leasehold improvements44,800 45,197 
Computers and software7,362 6,741 
Furniture and office equipment, vehicles and land3,450 3,507 
Construction in progress7,238 7,250 
112,730 113,110 
Less: accumulated depreciation and amortization(80,797)(80,235)
Property, plant and equipment, net$31,933 $32,875 

During the three months ended March 31, 2021 and 2020, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows:
Three Months Ended March 31,
(In thousands)20212020
Depreciation and amortization expense$2,114 $1,719 

Leases

Operating Leases

The Company has operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 to 5 years, and often include one or more options to renew. These renewal terms can extend the lease term from 1 to 5 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. The operating leases are classified as ROU assets under operating leases on the Company's condensed consolidated balance sheets and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make operating lease payments is included in "Lease liabilities" and "Lease liabilities, net of current portion" on the Company's condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company had $9.3 million and $10.1 million of right-of-use assets as of March 31, 2021 and December 31, 2020, respectively. Operating lease liabilities were $13.7 million and $15.0 million as of March 31, 2021 and December 31, 2020, respectively. During the three


12



ended March 31, 2021 and 2020, respectively, the Company recorded $1.8 million and $1.5 million of operating lease amortization that was charged to expense, of which $0.2 million and $0.3 million was recorded to cost of products sold.

Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company has certain contracts for real estate and marketing which may contain lease and non-lease components which it has elected to treat as a single lease component.

Information related to the Company's right-of-use assets and related lease liabilities were as follows:
Three Months Ended March 31,
20212020
Cash paid for operating lease liabilities, in thousands$1,185$1,893
Right-of-use assets obtained in exchange for new operating lease obligations, in thousands$$
Weighted-average remaining lease term2.73.2
Weighted-average discount rate18.0%18.0%

Financing Leases

The Company has financing leases primarily for laboratory and computer equipment. Assets purchased under financing leases are included in "Right-of-use assets under financing leases, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Accumulated amortization of assets under financing leases totaled $5.3 million and $4.6 million as of March 31, 2021 and December 31, 2020, respectively.

Maturities of Financing and Operating Leases

Maturities of lease liabilities as of March 31, 2021 were as follows:
Years ending December 31:
(In thousands)
Financing
Leases
Operating
Leases
Total Leases
2021 (Remaining Nine Months)$3,491 $5,644 $9,135 
2022 7,655 7,655 
2023 3,320 3,320 
2024 150 150 
2025   
Total lease payments3,491 16,769 20,260 
Less: amount representing interest(233)(3,050)(3,283)
Total lease liability$3,258 $13,719 $16,977 
Current lease liability$3,258 $5,510 $8,768 
Noncurrent lease liability 8,209 8,209 
Total lease liability$3,258 $13,719 $16,977 

Other Assets
(In thousands)March 31, 2021December 31, 2020
Equity-method investment$3,431 $2,380 
Deposits126 128 
Other1,213 1,196 
Total other assets$4,770 $3,704 



13



Accrued and Other Current Liabilities
(In thousands)March 31, 2021December 31, 2020
Payroll and related expenses$10,540 $8,230 
Accrued interest7,721 9,327 
Contract termination fees5,311 5,344 
Asset retirement obligation(1)
3,003 3,041 
Professional services1,604 994 
Ginkgo partnership payments obligation878 878 
Tax-related liabilities639 656 
Other2,425 2,237 
Total accrued and other current liabilities$32,121 $30,707 
______________
(1)    The asset retirement obligation represents liabilities incurred but not yet discharged in connection with our 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.


Other noncurrent liabilities
(In thousands)March 31, 2021December 31, 2020
Liability for unrecognized tax benefit$7,551 $7,496 
Ginkgo partnership payments obligation, net of current portion7,461 7,277 
Liability in connection with acquisition of equity-method investment7,216 6,771 
Contract liabilities, net of current portion111 111 
Other128 1,099 
Total other noncurrent liabilities$22,467 $22,754 




14



3. Fair Value Measurement

Liabilities Measured and Recorded at Fair Value on a Recurring Basis

The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy:

(In thousands)March 31, 2021December 31, 2020
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Liabilities
Foris Convertible Note (LSA Amendment)$ $ $379,439 $379,439 $ $ $123,164 $123,164 
Senior Convertible Notes  54,757 54,757   53,387 53,387 
Embedded derivatives bifurcated from debt instruments  188 188   247 247 
Freestanding derivative instruments issued in connection with other debt and equity instruments  31,196 31,196   8,451 8,451 
Total liabilities measured and recorded at fair value$ $ $465,580 $465,580 $ $ $185,249 $185,249 

The Company did not hold any financial assets to be measured and recorded at fair value on a recurring basis as of March 31, 2021 and December 31, 2020. Also, there were no transfers between the levels during the three months ended March 31, 2021 or the year ended December 31, 2020.

The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the asset or liability. The method of determining the fair value of embedded derivative liabilities is described subsequently in this note. Market risk associated with embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates.

Changes in fair value of derivative liabilities are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of derivative instruments".

Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of debt".

Fair Value of Debt — Foris Convertible Note

At March 31, 2021, the contractual outstanding principal of the Foris Convertible Note was $50.0 million, and fair value was $379.4 million. The Company remeasured the fair value of the Foris Convertible Note under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $19.10 stock price, (ii) 10% discount yield, (iii) 0.09% risk free interest rate (iv) 45% equity volatility and (v) 5% probability of change in control. The Company assumed that if a change of control event were to occur, it would occur at the end of the calendar year. The Company recorded a loss of $256.3 million related to change in fair value of the Foris Convertible Note for the three months ended March 31, 2021. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.00 conversion price.

Fair Value of Debt — Senior Convertible Notes

At March 31, 2021, the contractual outstanding principal of the Senior Convertible Notes was $10.0 million, and fair value was $54.8 million. The Company measured the fair value at March 31, 2021 under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $19.10 stock price, (ii) 210% discount yield, (iii) 0.02% risk free interest rate (iv) 45% equity volatility, and (v) 0% probability of change in control. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.50 conversion price.

For the three months ended March 31, 2021, the Company recorded a $70.5 million loss from change in fair value of debt in connection with fair value remeasurement of the Senior Convertible Notes, as follows:


15



In thousands
Fair value at December 31, 2020$53,387 
Loss from change in fair value70,510 
Less: principal converted into common stock(20,000)
Less: fair value adjustment extinguished upon conversion of debt principal(49,140)
Fair value at March 31, 2021$54,757 

Binomial Lattice Model

A binomial lattice model was used to determine whether the Foris Convertible Note and the Senior Convertible Notes (Debt Instruments) would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the convertible note will be converted early if the conversion value is greater than the holding value and (ii) the convertible note will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the convertible note is called, the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the convertible note. Using this lattice method, the Company valued the Debt Instruments using the "with-and-without method", where the fair value of the Debt Instruments including the embedded and freestanding features is defined as the "with," and the fair value of the Debt Instruments excluding the embedded and freestanding features is defined as the "without." This method estimates the fair value of the Debt Instruments by looking at the difference in the values of the Debt Instruments with the embedded and freestanding derivatives and the fair value of the Debt Instruments without the embedded and freestanding features. The lattice model uses the stock price, conversion price, maturity date, risk-free interest rate, estimated stock volatility, estimated credit spread and other instrument-specific assumptions. The Company remeasures the fair value of the Debt Instruments and records the change as a gain or loss from change in fair value of debt in the statement of operations for each reporting period.

Derivative Liabilities Recognized in Connection with the Issuance of Debt Instruments

The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3):
(In thousands)Derivative Liability
Balance at December 31, 2020$8,698 
Change in fair value of derivative instruments22,745 
Derecognition on settlement or extinguishment(59)
Balance at March 31, 2021$31,384 

Freestanding Derivative Instruments

On February 28, 2020, the Company entered into forbearance agreements with certain affiliates of the Schottenfeld Group LLC (the Lenders) related to certain defaults under the Schottenfeld Notes. In connection with entering into the forbearance agreements, the Company committed to issuing warrants (Warrants) to the Lenders under certain contingent events for 1.9 million shares of common stock at a $2.87 purchase price and a two-year term. The contingent obligation to issue the Warrants did not meet the derivative scope exception or equity classification criteria and was accounted for as a derivative liability and remeasured each reporting period until settled or extinguished with subsequent changes in fair value recorded through the statement of operations. The fair value of the Warrants derivative liability was determined using a Black-Scholes-Merton option pricing model based on the input assumptions for liability classified warrants table in the valuation methodology section below. At March 31, 2021, the fair value of the contingently issuable Warrants derivative liability was $31.2 million, and for the three months ended March 31, 2021, the Company recorded a $22.7 million loss on change in fair value of derivative instruments.

Valuation Methodology and Approach to Measuring the Derivative Liabilities

Substantially all the outstanding liabilities associated with the Company’s derivatives at March 31, 2021 and December 31, 2020 represent the fair value of freestanding equity instruments. See Note 4, "Debt", and Note 6, "Stockholders' Deficit" for further information regarding these host instruments. There is no current observable market for these types of


16



derivatives and, as such, the Company determined the fair value of the freestanding instruments using the Black-Scholes-Merton option pricing model, which is discussed in more detail below.

The Company used the Black-Scholes-Merton option pricing model to determine the fair value of its liability classified warrants as of March 31, 2021 and December 31, 2020. Input assumptions for these freestanding instruments are as follows:
Range for the Period
Input assumptions for liability classified warrants:March 31, 2021December 31, 2020
Fair value of common stock on issue date
$19.10 – $19.10
$2.56 – $6.18
Exercise price of warrants
$2.87 – $2.87
$2.87 – $3.25
Expected volatility
114% – 114%
94% – 117%
Risk-free interest rate
0.16% – 0.16%
0.13% – 1.58%
Expected term in years
22
12
Dividend yield0.0 %0.0 %

Changes in valuation assumptions can have a significant impact on the valuation of the freestanding derivative liabilities and debt that the Company elects to account for at fair value. For example, all other things being equal, generally, an increase in the Company’s stock price, change of control probability, risk-adjusted yields term to maturity/conversion or stock price volatility increases the value of the derivative liability.

Assets and Liabilities Recorded at Carrying Value

Financial Assets and Liabilities

The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and other current accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable and credit facilities are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of these instruments using observable market-based inputs (Level 2). The carrying amount (the total amount of net debt presented on the balance sheet) of the Company's debt at March 31, 2021 and at December 31, 2020, excluding the debt instruments recorded at fair value, was $49.3 million and $86.5 million, respectively. The fair value of such debt at March 31, 2021 and at December 31, 2020 was $51.1 million and $83.3 million, respectively, and was determined by (i) discounting expected cash flows using current market discount rates estimated for certain of the debt instruments and (ii) using third-party fair value estimates for the remaining debt instruments.


17




4. Debt

Net carrying amounts of debt are as follows:
March 31, 2021December 31, 2020
(In thousands)PrincipalUnaccreted Debt DiscountChange in Fair ValueNetPrincipalUnaccreted Debt DiscountChange in Fair ValueNet
Convertible notes payable
Senior convertible notes$10,020 $ $44,737 $54,757 $30,020 $ $23,367 $53,387 
Related party convertible notes payable
Foris convertible note50,041  329,398 379,439 50,041  73,123 123,164 
Loans payable and credit facilities
Schottenfeld notes    12,500 (240) 12,260 
Nikko notes2,737 (725) 2,012 2,802 (759) 2,043 
Ginkgo note12,000   12,000 12,000   12,000 
Other loans payable1,009   1,009 1,227   1,227 
15,746 (725) 15,021 28,529 (999) 27,530 
Related party loans payable
Foris note5,000   5,000 5,000   5,000 
DSM notes10,000 (4,254) 5,746 33,000 (2,443) 30,557 
Naxyris note23,914 (412) 23,502 23,914 (493) 23,421 
38,914 (4,666) 34,248 61,914 (2,936) 58,978 
Total debt$114,721 $(5,391)$374,135 483,465 $170,504 $(3,935)$96,490 263,059 
Less: current portion(55,904)(77,437)
Long-term debt, net of current portion$427,561 $185,622 

Senior Convertible Notes Conversion

On February 4, 2021, the Company received a notice of conversion from HT Investments MA, LLC (HT) with respect to $20.0 million of its outstanding Senior Convertible Notes, pursuant to which the Company was required to issue 5.7 million shares of common stock per the conversion price stated in the agreement and cancelled the outstanding Note. Also, under the terms of the Senior Convertible Note, HT was required to return 2.6 million shares of common stock outstanding under the Pre-Delivery Shares provision once the Company had fully repaid the principal balance. HT fulfilled its obligation to return these shares in accordance with the contractual requirement, and as a result the Company net settled the $20 million principal conversion by issuing 3.1 million of incremental shares to HT.

Upon conversion of the HT Senior Convertible Note, the Company recorded a $31.9 million loss upon extinguishment of debt, which was primarily comprised of a fair value adjustment upon repayment of the note's principal.

See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the Senior Convertible Notes.

Schottenfeld Note Exchange

On March 1, 2021, the Company entered into an Exchange and Settlement Agreement (Exchange Agreement) with Schottenfeld Opportunities Fund II, L.P. and certain other holders of notes under the Credit and Security Agreement dated November 14, 2019 (Schottenfeld Notes). Pursuant to the terms of the Exchange Agreement, the Company paid all accrued and unpaid interest on the $12.5 million principal balance outstanding under the Schottenfeld Notes, and issued 4.1 million net shares of common stock in a cashless exchange and cancellation of all amounts due and outstanding under the Notes and related loan documents and all warrants held by each of the holders of Schottenfeld Notes.

Upon conversion of the Schottenfeld note balance, the Company recorded a $28.9 million loss upon extinguishment of debt, which primarily represented the fair value of common shares issued in excess of debt principal extinguished.

See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the Schottenfeld Notes.


18




DSM Notes Amendments and Repayment

On December 28, 2017, the Company and DSM Finance, a wholly owned subsidiary of Koninklijke DSM N.V. (DSM), entered into a credit agreement (the DSM Credit Agreement) to make available to the Company an unsecured credit facility of $25.0 million. On December 28, 2017, the Company borrowed $25.0 million under the DSM Credit Agreement and issued a promissory note to DSM Finance. The $25 million Note matures on December 31, 2021 and accrues interest at 10% per annum, payable quarterly.

On September 17, 2019, the Company and DSM entered into a credit agreement (the 2019 DSM Credit Agreement) to make available to the Company a secured credit facility in an aggregate principal amount of $8.0 million. In September 2019, the Company borrowed the $8.0 million in three installments. The promissory notes issued under the 2019 DSM Credit Agreement (i) mature on August 7, 2022, (ii) accrue interest at a rate of 12.5% per annum, payable quarterly and (iii) are secured by a first-priority lien on certain Company intellectual property licensed to DSM.

In March 2021, the Company entered into amendments (the March 2021 Amendments) to the $25 million Note and the $8 million Note that provided for (i) the prepayment of the $8 million Note, (ii) a $15 million partial prepayment of the $25 million Note and (iii) extension of the maturity date from December 31, 2021 to April 15, 2022 for the remaining $10 million principal balance under the $25 million Note, in exchange for a $2.5 million prepayment fee The Company repaid $23 million on March 31, 2021 to extinguish the $8 million Note and to partially repay the $25 million Note.

The Company evaluated the March 2021 Amendments, and concluded the before and after cash flows resulting from the amendments were not significantly different and accounted for the amendments to the Notes as a debt modification. Consequently, the $2.5 million Prepayment Fee was recorded as an incremental debt discount to the remaining $10 million principal balance under the $25 million Note. The Company will accrete the adjusted discount over the Note’s amended remaining term using the effective interest method.

See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the DSM notes.

Future Minimum Payments

Future minimum payments under the Company's debt agreements as of March 31, 2021 are as follows:
(In thousands)Convertible NotesLoans
Payable and Credit Facilities
Related Party Convertible NotesRelated Party Loans Payable and Credit FacilitiesTotal
2021 (Remaining Nine Months)$11,189 $2,260 $ $2,782 $16,231 
2022 13,268 59,578 42,379 115,225 
2023 399   399 
2024 398   398 
2025 397   397 
Thereafter 1,473   1,473 
Total future minimum payments11,189 18,195 59,578 45,161 134,123 
Less: amount representing interest(1,169)(2,449)(9,537)(6,247)(19,402)
Present value of minimum debt payments10,020 15,746 50,041 38,914 114,721 
Less: current portion of debt principal(10,020)(1,280)  (11,300)
Noncurrent portion of debt principal$ $14,466 $50,041 $38,914 $103,421 

5. Mezzanine Equity

Mezzanine equity at March 31, 2021 and December 31, 2020 is comprised of proceeds from shares of common stock sold on May 10, 2016 to the Bill & Melinda Gates Foundation (the Gates Foundation). In connection with the stock sale, the Company and the Gates Foundation entered into an agreement under which the Company agreed to expend an aggregate amount not less than the proceeds from the stock sale to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. If the Company defaults in its obligation to use the proceeds from the stock sale as set forth above or defaults under certain other commitments in the agreement, the Gates Foundation will have the right to request that the Company redeem, or facilitate the purchase by a


19



third party, the shares then held by the Gates Foundation at a price per share equal to the greater of (i) the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable, or (ii) an amount equal to $17.10 plus a compounded annual return of 10%.

As of March 31, 2021, the Company's remaining research and development obligation under this arrangement was $0.3 million.

6. Stockholders' Deficit

Warrants and Rights Activity Summary

In connection with various debt and equity transactions (see Note 4, “Debt” above and Note 4, "Debt" and Note 6, “Stockholders’ Deficit” in Part II, Item 8 of the 2020 Form 10-K), the Company has issued warrants exercisable for shares of common stock. The following table summarizes warrants outstanding at March 31, 2021:
TransactionNumber Outstanding as of March 31, 2021Exercise Price per Share as of March 31, 2021
Blackwell and Silverback warrants1,000,000 $3.25 
January 2020 warrant exercise right shares4,209,608 $2.87 
April 2019 PIPE warrants1,381,940 
$4.76/$5.02
Naxyris LSA warrants2,000,000 $2.87 
October 2019 Naxyris warrant2,000,000 $3.87 
May 2019 6.50% Note Exchange warrants960,225 $2.87 
May 2017 cash warrants1,863,056 $2.87 
May 2017 dilution warrants3,085,893 $0.00 
August 2017 dilution warrants3,028,983 $0.00 
July 2015 related party debt exchange58,690 $0.15 
Other1,406 $160.05 
19,589,801 

Warrant Exercises

During the three months ended March 31, 2021, warrant-holders exercised warrants to purchase approximately 24.8 million shares of the Company’s common stock at a weighted-average exercise price of $3.06 per share, for net proceeds to the Company of $32.2 million. Some of the exercises were cashless or in connection with the Schottenfeld Note Exchange, which resulted in fewer shares being issued than the number of warrant-shares exercised. As a result, 21.6 million shares were issued.

7. Net Loss per Share Attributable to Common Stockholders

For the three months ended March 31, 2021 and 2020, basic loss per share was the same as diluted loss per share, because the inclusion of all potentially dilutive securities outstanding was antidilutive.

The Company follows the two-class method when computing net loss per common share when shares are issued that meet the definition of participating securities. The two-class method requires income available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The two-class method also requires losses for the period to be allocated between common stock and participating securities based on their respective rights if the participating security contractually participates in losses. The Company’s convertible preferred stock are participating securities as they contractually entitle the holders of such shares to participate in dividends and contractually require the holders of such shares to participate in the Company’s losses.


20




The following table presents the calculation of basic and diluted loss per share:
Three Months Ended March 31,
(In thousands, except shares and per share amounts)20212020
Numerator:
Net loss attributable to Amyris, Inc.$(291,251)$(87,844)
Less: losses allocated to participating securities2,099 1,087 
Net loss attributable to Amyris, Inc. common stockholders, basic and diluted$(289,152)$(86,757)
Denominator:
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted267,733,555 155,065,635 
Loss per share, basic and diluted$(1.08)$(0.56)

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive:
Three Months Ended March 31,
20212020
Period-end common stock warrants13,416,235 50,518,519 
Convertible promissory notes(1)
19,540,447 9,217,185 
Period-end stock options to purchase common stock6,205,576 5,578,264 
Period-end restricted stock units6,653,640 5,298,639 
Period-end preferred stock1,943,661 1,943,661 
Total potentially dilutive securities excluded from computation of diluted loss per share47,759,559 72,556,268 
______________
(1)    The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

8. Commitments and Contingencies

Guarantor Arrangements

The Company has agreements whereby it indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the executive officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of March 31, 2021 and December 31, 2020.

The Foris Convertible Note (see Note 4, "Debt") is collateralized by first-priority liens on substantially all of the Company's assets, including Company intellectual property, other than certain Company intellectual property licensed to DSM and the Company's shares of Aprinnova. Certain of the Company’s subsidiaries have guaranteed the Company’s obligations under the Foris Convertible Note.

The obligations of the Company under the Naxyris Note (see Note 4, "Debt") are (i) guaranteed by the Subsidiary Guarantors and (ii) secured by a perfected security interest in substantially all of the assets of the Company and the Subsidiary Guarantors (the Collateral), junior in payment priority to Foris subject to certain limitations and exceptions, as well as the terms of the Intercreditor Agreement.

The Nikko $3.9 million note is collateralized by a first-priority lien on 10.0% of the Aprinnova JV interests owned by the Company.


21




Other Matters

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but will only be recorded when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgement. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

On April 3, 2019, a securities class action complaint was filed against Amyris and our CEO, John G. Melo, and former CFO, Kathleen Valiasek, in the U.S. District Court for the Northern District of California. The complaint seeks unspecified damages on behalf of a purported class that would comprise all persons and entities that purchased or otherwise acquired our securities between March 15, 2018 and March 19, 2019. The complaint, which was amended by the lead plaintiff on September 13, 2019, alleges securities law violations based on statements and omissions made by the Company during such period. On October 25, 2019, the defendants filed a motion to dismiss the securities class action complaint, which was denied by the court on October 5, 2020. The Company filed its answer to the securities class action complaint on October 26, 2020. Subsequent to the filing of the securities class action complaint described above, on June 21, 2019 and October 1, 2019, respectively, two separate purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California (Bonner v. Doerr, et al., and Carlson v. Doerr, et al.) based on similar allegations to those made in the securities class action complaint and naming the Company, and certain of the Company’s current and former officers and directors, as defendants. The derivative lawsuits sought to recover, on the Company’s behalf, unspecified damages purportedly sustained by the Company in connection with allegedly misleading statements and omissions made in connection with the Company’s securities filings. The derivative lawsuits were dismissed on October 18, 2019 (Bonner) and December 10, 2019 (Carlson), without prejudice. On November 3, 2020, Bonner re-filed its derivative complaint against the Company in San Mateo County Superior Court. The Company filed its demurrer to the complaint on January 13, 2021 and attended a preliminary hearing on April 22, 2021. An additional shareholder derivative complaint (Kimbrough v. Melo, et al.), substantially identical to the Bonner complaint, was filed on December 18, 2020 in the United States District Court for the Northern District of California. On February 19, 2021, the Company filed its motion to dismiss the Kimbrough complaint. In response, the Kimbrough complaint was dismissed in federal court on March 4, 2021 and refiled in state court on March 12, 2021. By agreement, the Kimbrough and Bonner complaints were consolidated for all purposes on April 9, 2021. By May 10, 2021, the derivative shareholder plaintiffs will either file a new complaint or designate one of the existing complaints as operative. A briefing schedule on a demurrer to that complaint will be negotiated no later than May 24, 2021. The Company believes the securities class action and derivative complaints lack merit, and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result from these matters.

On September 10, 2020, LAVVAN, Inc. (Lavvan) filed a suit against the Company in the United States District Court for the Southern District of New York alleging breach of contract, patent infringement, and trade secret misappropriation in connection with that certain Research, Collaboration and License Agreement between Lavvan and Amyris, dated March 18, 2019, as amended (Cannabinoid Agreement). Amyris filed motions to compel arbitration or to dismiss on October 2, 2020. On October 30, Lavvan filed its opposition to the motions and the Company filed its reply to such opposition on November 13, 2020. The matter is fully briefed and the parties are awaiting an order from the Court. The Company believes the suit lacks merit and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result therefrom.

The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may arise in the ordinary course of business are subject to many uncertainties and outcomes, and are not predictable with reasonable assurance; therefore, an estimate of all the reasonably possible losses cannot be determined at this time. If one or more of these legal disputes or claims resulted in settlements or legal proceedings that were resolved against the Company for amounts in excess of management’s


22



expectations, the Company’s condensed consolidated financial statements for the relevant reporting period could be materially adversely affected.

9. Revenue Recognition and Contract Assets and Liabilities

Disaggregation of Revenue

The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer:
Three Months Ended March 31,
(In thousands)20212020
Renewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotalRenewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotal
United States$20,090 $ $250 $20,340 $11,944 $ $ $11,944 
Europe2,972 143,800 2,346 149,118 3,242 5,161 3,356 11,759 
Asia4,405 2,284 6,689 2,018  2,759 4,777 
Brazil313 313 577   577 
Other399 399 73   73 
$28,179 $143,800 $4,880 $176,859 $17,854 $5,161 $6,115 $29,130 

The following table presents revenue by major product and service, as well as by customer type:
Three Months Ended March 31,
(In thousands)20212020
Renewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotalRenewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotal
Consumer$15,653 $ $ $15,653 $9,065 $ $ $9,065 
Ingredients12,526 143,800  156,326 8,789 5,161  13,950 
Research and development  4,880 4,880   6,115 6,115 
$28,179 $143,800 $4,880 $176,859 $17,854 $5,161 $6,115 $29,130 

Revenue from Significant Revenue Agreements

In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2020 Form 10-K), the Company recognized the following revenue for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
(In thousands)20212020
Renewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotalRenewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotal
DSM - related party$1,662 $143,612 $2,000 $147,274 $49 $3,750 $3,018 $6,817 
Sephora4,441   4,441 4,446   4,446 
Yifan  2,284 2,284   2,709 2,709 
Firmenich379 188 205 772 1,229 1,411 161 2,801 
Givaudan210   210 2,109   2,109 
Subtotal revenue from significant revenue agreements6,692 143,800 4,489 154,981 7,833 5,161 5,888 18,882 
Revenue from all other customers21,487  391 21,878 10,021  227 10,248 
Total revenue from all customers$28,179 $143,800 $4,880 $176,859 $17,854 $5,161 $6,115 $29,130 

DSM License Agreement and Contract Assignment

On March 31, 2021, the Company and DSM entered into a license agreement and asset purchase agreement pursuant to which DSM acquired exclusive rights to the Company’s Flavor and Fragrance (F&F) product portfolio. The Company granted DSM exclusive licenses covering specific intellectual property (F&F Intellectual Property License) of the Company and assigned the Company’s rights and obligations under certain F&F ingredients supply agreements to DSM, in exchange for non-refundable upfront consideration totaling $150 million, and up to $235 million of contingent consideration if and when certain


23



commercial milestones are achieved in each of the calendar years 2022 through 2024. DSM also acquired the Company’s F&F finished goods inventory on-hand, unbilled accounts receivables and billed accounts receivable that were uncollected at closing. The Company and DSM also entered into a 15-year manufacturing agreement whereby the Company will manufacture certain F&F ingredients for DSM to supply to third parties.

The Company determined the licenses to be functional intellectual property licenses allowing DSM the immediate use of and benefit from the technology, and concluded the licenses and related assigned F&F ingredients supply agreements, the asset purchase agreement and the manufacturing agreement were revenue contracts within the scope of ASC 606. The Company identified three distinct performance obligations: (i) F&F license, (ii) finished goods inventory and (iii) receivables, that once delivered are satisfied at a point in time. The Company also concluded the additional contingent consideration and manufacturing supply agreement represent variable consideration that will be fully constrained until the commercial targets are probable of achievement and the products are manufactured and sold.

The Company allocated the $150 million transaction price to the three revenue performance obligations using the residual approach. The transaction price was first allocated to the transferred inventory and receivables at the stand-alone selling price for these performance obligations, and the residual consideration was allocated to the F&F intellectual property licenses:
Finished goods inventory - $1.5 million
Receivables - $4.9 million
F&F intellectual property licenses - $143.6 million

The Company also concluded the F&F intellectual property licenses and the assigned F&F supply agreements had been fully delivered with no further performance obligation upon closing the transaction, and recognized license revenue of $143.6 million in the period ended March 31, 2021.

Due to the related party nature of the transaction with DSM, who is a significant shareholder with two members on the Company’s board of directors, the Company performed a fair value assessment of the F&F intellectual property licenses under an income approach using a discounted cash flow model, in part with the assistance of a third-party valuation firm, and concluded the $143.6 million residual consideration received in exchange for the F&F intellectual property licenses approximated the fair value and stand-alone selling price of the F&F intellectual property licenses.

DSM Performance Agreement

In December 2017, the Company and DSM entered into a research and development services agreement (Performance Agreement), pursuant to which the Company would provide services to DSM relating to the further development of the technology underlying farnesene-related products in exchange for certain bonus payments in the event that specific performance metrics were achieved. If the Company did not meet the established metrics under the Performance Agreement, the Company would be required to pay $1.9 million to DSM. The Company accounted for the Performance Agreement under ASC 606 as a combined transaction with the Farnesene license granted to DSM in connection with the sale of the Brotas facility in December 2017. The Performance Agreement was allocated $1.2 million of the transaction price under a relative fair value allocation approach, and was recorded as a contract asset reflecting the Company’s right to receive additional consideration and deferred revenue reflecting the probability of returning to DSM a portion of the cash received under the combined transaction. In the first quarter of 2021, the Company and DSM determined the performance metrics would not be reasonably achieved without the Company providing further research and development services and concluded the Performance Agreement and related activities should be terminated. As a result, the Company paid DSM $1.9 million and reduced the deferred revenue liability, and expensed the contract asset balance and recorded $1.9 million of additional research and development expense during the three months ended March 31, 2021.

DSM Ingredients Collaboration

Pursuant to the September 2017 research and development collaboration agreement, as amended, the Company provides DSM with research and development services for specific field of use ingredients. The Company concluded the amended agreement contained a single performance obligation to provide research and development services delivered over time and that revenue recognition is based on an input measure of progress as labor hours are expended each quarter. DSM funds the development work with payments of $2.0 million quarterly from October 1, 2020 to September 30, 2021 for services singularly focused on achieving a certain fermentation yield and cost target over the twelve-month period. During the three months ended March 31, 2021 and 2020, the Company recognized $2.0 million and $3.0 million of collaboration revenue in connection with the amended agreement.



24



Yifan Collaborations

The Company has a collaboration agreement with Yifan Pharmaceutical Co., Ltd. (Yifan), a leading Chinese pharmaceutical company. During the three months ended March 31, 2021 and 2020, the Company recognized $2.3 million and $2.7 million of collaboration revenue, and $16.6 million of cumulative-to-date collaboration revenue in connection with the agreement. At March 31, 2021, the Company also recorded a $5.9 million contract asset in connection with the Collaboration Agreement.

For more information about the DSM ingredients collaboration and Yifan collaboration, see the Company's 2020 Form 10-K, Part II, Item 8, Note 10, "Revenue Recognition".

Contract Assets and Liabilities

When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional.

Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not passed to the customer.

Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade receivables are recorded for the sale of goods or the performance of services at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company.

Contract Balances

The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers:
(In thousands)March 31, 2021December 31, 2020
Accounts receivable, net$27,036 $32,846 
Accounts receivable - related party, net$391 $12,110 
Contract assets$6,589 $4,178 
Contract assets - related party$2,000 $1,203 
Contract liabilities$6,163 $4,468 
Contract liabilities, noncurrent(1)
$111 $111 

(1)As of March 31, 2021 and December 31, 2020, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets.

Remaining Performance Obligations

The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2021.
(In thousands)As of March 31, 2021
Remaining 2021$143 
20223,103 
20231,430 
2024 and thereafter429 
Total from all customers$5,105 

In accordance with the disclosure provisions of ASC 606, the table above excludes estimated future revenues for performance obligations that are part of a contract that has an original expected duration of one year or less or a performance obligation with variable consideration that is recognized using the sales-based royalty exception for licenses of intellectual


25



property. Additionally, approximately $297.8 million of estimated future revenue is excluded from the table above, as that amount represents constrained variable consideration.

10. Related Party Transactions

Related Party Debt

See Note 4, "Debt," for details of the DSM Notes Amendments and Repayments that occurred during the three months ended March 31, 2021.

Related party debt was as follows:
March 31, 2021December 31, 2020
In thousandsPrincipalUnaccreted Debt DiscountChange in Fair ValueNetPrincipalUnaccreted Debt DiscountChange in Fair ValueNet
Foris notes$55,041 $ $329,398 $384,439 $55,041 $ $73,123 $128,164 
DSM notes10,000 (4,254) 5,746 33,000 (2,443) 30,557 
Naxyris note23,914 (412) 23,502 23,914 (493) 23,421 
$88,955 $(4,666)$329,398 $413,687 $111,955 $(2,936)$73,123 $182,142 

Related Party Revenue

See Note 9, "Revenue Recognition", for information about the March 31, 2021 DSM License Agreement and Contract Assignment.

Related Party Accounts Receivable, Unbilled Receivables and Accounts Payable

Related party accounts receivable, contract assets and accounts payable were as follows:

(In thousands)March 31, 2021December 31, 2020
Accounts receivable - related party$391 $12,110 
Contract assets - related party$2,000 $1,203 
Accounts payable$10,302 $5,011 

11. Stock-based Compensation

The Company’s stock option activity and related information for the three months ended March 31, 2021 was as follows:
Quantity of Stock OptionsWeighted-
average
Exercise
Price
Weighted-average
Remaining
Contractual
Life, in Years
Aggregate
Intrinsic
Value, in Thousands
Outstanding - December 31, 20206,502,096 $7.64 7.6$8,875 
Granted131,408 $14.52 
Exercised(375,390)$5.12 
Forfeited or expired(52,538)$38.21 
Outstanding - March 31, 20216,205,576 $7.68 7.4$82,615 
Vested or expected to vest after March 31, 20215,697,447 $7.91 7.3$75,493 
Exercisable at March 31, 20211,259,029 $18.19 5.8$12,884 



26



The Company’s restricted stock units (RSUs) activity and related information for the three months ended March 31, 2021 was as follows:
Quantity of Restricted Stock UnitsWeighted-average Grant-date Fair ValueWeighted-average Remaining Contractual Life, in Years
Outstanding - December 31, 20207,043,909 $4.18 1.5
Awarded345,903 $13.53 
Released(496,492)$4.34 
Forfeited(239,680)$4.22 
Outstanding - March 31, 20216,653,640 $4.65 1.4
Vested or expected to vest after March 31, 20216,082,165 $4.65 1.3

Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three months ended March 31, 2021 and 2020 is reflected in the condensed consolidated statements of operations as follows:
Three Months Ended March 31,
(In thousands)20212020
Cost of products sold$63 $ 
Research and development1,062 1,065 
Sales, general and administrative3,156 2,439 
Total stock-based compensation expense$4,281 $3,504 

As of March 31, 2021, there was unrecognized compensation expense of $30.0 million related to stock options and RSUs. The Company expects to recognize this expense over a weighted-average period of 2.4 years.

Evergreen Shares for 2020 Equity Incentive Plan and 2010 Employee Stock Purchase Plan

In March 2021, the Board approved increases to the number of shares available for issuance under the Company's 2020 Equity Incentive Plan (the 2020 Equity Plan) and 2010 Employee Stock Purchase Plan (the 2010 ESPP).

The increase in shares in connection with the 2020 Equity Plan represented an automatic annual increase in the number of shares available for grant and issuance under the 2020 Equity Plan of 12,247,572 shares (Evergreen Shares). This increase is equal to approximately 5.0% of the 244,951,446 total outstanding shares of the Company’s common stock as of December 31, 2020. This automatic increase was effective as of January 1, 2021.

The increase in shares in connection with the 2010 ESPP represented an automatic annual increase in the number of shares reserved for issuance of 42,077 shares, which represents the remaining allowable under the existing 1,666,666 maximum limit for share issuance under the 2010 ESPP. This automatic increase was effective as of January 1, 2021.

12. Subsequent Events

Primary and Secondary Offering

On April 8, 2021, the Company entered into an underwriting agreement (the Underwriting Agreement) with J.P. Morgan Securities LLC and Cowen and Company, LLC (the Underwriters) and with certain stockholders of the Company (the Selling Stockholders), pursuant to which the Selling Stockholders agreed to sell 11,390,797 shares of common stock of the Company, par value $0.0001 per share and Amyris agreed to issue and sell 7,656,822, at a public offering price of $15.75 per share. DSM International B.V. and affiliates of Vivo Capital LLC were the Secondary Offering Selling Stockholders. Under the terms of the Underwriting Agreement, the Selling Stockholders and Amyris granted the Underwriters a 30-day option to purchase up to an additional 1,708,619 shares of Common Stock from the Selling Stockholders and 1,148,523 shares of Common Stock from Amyris. The Underwriters exercised this option in full.

Net proceeds to the Company from the 8,805,345 new shares issued by the Company were approximately $130.7 million (inclusive of the underwriters’ option to purchase additional shares), after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.


27




The Company did not receive any proceeds from the sale of common stock in the secondary offering by the Selling Stockholders.

Ingredion Agreement

On May 3, 2021, the Company and Ingredion Incorporated entered into a Membership Interest Purchase Agreement (MIPA) under which (i) the Company will assign and transfer certain contracts for the sale and distribution of RebM to Ingredion’s subsidiary, PureCircle, which will become the exclusive global business-to-business commercialization partner for the Company’s sugar reduction technology that includes fermented RebM; (ii) the Company and Ingredion will enter into certain intellectual property license agreements to make, have made, commercialize and advance the development of sustainably sourced, zero-calorie, nature-based sweeteners and potentially other types of fermentation-based ingredients; (iii) Ingredion will purchase 31% of all of the membership interests in Amyris RealSweet LLC, a wholly owned subsidiary of the Company incorporated on April 15, 2021 (RealSweet), which entity will own the new manufacturing facility under construction in Brazil, and; (iv) The parties will enter into an R&D collaboration agreement to create and advance the development of sustainably sourced, zero-calorie, nature-based sweeteners, and potentially other types of fermentation-based food ingredients. The Company will continue to own and market its Purecane™ consumer brand offering of tabletop and culinary sweetener products to consumers. Under the terms of the license agreement, the Company will receive an upfront $10 million license fee at closing and additional milestone payments in the aggregate of $35 million upon achievement of certain manufacturing cost targets and RebM sales revenue. The Company will also receive $30 million of cash and non-cash consideration from Ingredion in exchange for their 31% interest in RealSweet. Additionally, the Company will earn a profit share from future Reb M sales by PureCircle. The closing of the MIPA is subject to customary closing conditions.



28




ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the related notes that appear elsewhere in this Quarterly Report on Form 10-Q. These discussions contain forward-looking statements reflecting our current expectations that involve risks and uncertainties which are subject to safe harbors under the Securities Act of 1933, as amended (the Securities Act), and the Securities Exchange Act of 1934 (the Exchange Act). These forward-looking statements include, but are not limited to, statements concerning our strategy of achieving a significant reduction in net cash outflows in 2021 and 2022, aspects of our future operations, our future financial position, expectations for our future revenues, margins and projected costs, expectations regarding demand and acceptance for our technologies and products, introductions of new products, growth opportunities and trends in the market in which we operate, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q, in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the 2020 Form 10-K) and in our other filings with the Securities and Exchange Commission. We do not assume any obligation to update any forward-looking statements.

Overview

As a leading synthetic biotechnology company active in the Clean Health and Beauty markets through our consumer brands and a top supplier of sustainable and natural ingredients, we apply our proprietary Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products. We do so with the use of computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. Our biotechnology platform enables us to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that we manufacture at industrial scale. Through the combination of our biotechnology platform and our industrial fermentation process, we have successfully developed, produced and commercialized thirteen distinct molecules used in formulations by thousands of leading global brands.

We believe that synthetic biology represents a third industrial revolution, bringing together biology and engineering to generate new, more sustainable materials to meet the growing global demand for bio-based replacements of petroleum-based and traditional animal- or plant-derived ingredients. We continue to generate demand for our current portfolio of products through an extensive go-to-market network provided by our partners that are the leading companies in our target markets. Via our partnership model, our partners invest in the development of molecules to take it from the lab to commercial scale and use their extensive marketing and sales capabilities to sell our ingredients and formulations to their customers. We capture long-term revenue both through the production and sale of our molecules to our partners and through royalty revenues from our partners' product sales to their customers. We have also successfully formulated our unique, natural and sustainably-sourced ingredients into wholly-owned consumer brands, including Biossance® our clean beauty skincare brand, Pipette®, our baby and mother care brand, and PurecaneTM, our alternative sweetener brand. We are marketing our brands directly to consumers via our ecommerce platforms, in brick-and-mortar stores, and online via various retail partners.

We were founded in 2003 in the San Francisco Bay area by a group of scientists from the University of California, Berkeley. Through a grant in 2005 from the Bill & Melinda Gates Foundation, we developed technology capable of creating microbial strains that produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug.

We produced a renewable farnesene brand, Biofene®, a long-chain, branched hydrocarbon molecule that we manufacture through fermentation using engineered microbes. Our farnesene derivatives are sold in hundreds of products as nutraceuticals, skincare products, fragrances, solvents, polymers, and lubricant ingredients. In 2014, we began manufacturing additional molecules for the Flavor & Fragrance industry; in 2015, we began investing to expand our capabilities to other small molecule chemical classes via our collaboration with the Defense Advanced Research Projects Agency (DARPA); and in 2016, we expanded into proteins. We then made the strategic decision to transition our business model from low margin commodity markets to higher margin specialty ingredients markets. We began the transition by first commercializing and supplying farnesene-derived squalane as a cosmetic ingredient to formulators and distributors. We also entered into collaboration and supply agreements for the development and commercialization of molecules within the Flavor & Fragrance and Clean Beauty


29



markets. We partner with our customers to create sustainable, high performing, low-cost molecules that replace an ingredient in their supply chains. We commercially scale and manufacture those molecules. Our revenue is generated from research and development collaboration programs, grants, renewable product sales, and license and royalty revenues from our renewable product portfolios.

All of our non-government partnerships include commercial terms for the supply of molecules we produce at commercial scale. The first molecule to generate revenue for us outside of farnesene was a fragrance molecule launched in 2015. Since the launch, this and additional fragrance molecules have continued to generate sales year over year. Our partners for these molecules are indicating continued strong growth due to their cost advantaged position, high purity of our molecules and our sustainable production method. In 2019, we commercially produced and shipped our Reb M product that is an alternative sweetener and sugar replacement for food and beverages. In 2020, we added a total of six new ingredients to our portfolio. We have a pipeline that can deliver an estimated two to three new molecules each year over the coming years.

Our time to market for molecules has decreased from seven years to less than a year for our most recent molecule, mainly due to our ability to leverage our biotechnology platform with proprietary computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. Our state-of-the-art infrastructure includes industry-leading strain engineering and lab automation located in Emeryville, California, pilot-scale production facilities in Emeryville, California and Campinas, Brazil, and a commercial-scale production facility in Leland, North Carolina (owned and operated by our Aprinnova joint venture). We are able to use a wide variety of feedstocks for production but have focused on sourcing Brazilian sugarcane for our large-scale production because of its renewability, low cost and relative price stability. We are constructing a new purpose-built, large-scale specialty ingredients facility in Brazil, which we anticipate will allow for the manufacture of up to five products concurrently, including both our specialty ingredients portfolio and our alternative sweetener product. In September 2019, we obtained the necessary permits and broke ground for this facility and we expect construction to be completed by the end of 2021. During construction, we continue to manufacture our products at manufacturing sites in Brazil, the U.S. and Europe.

Sales and Revenue

We recognize revenue from consumer and ingredient product sales, license fees and royalties, and grants and collaborations.

We have research and development collaboration arrangements for which we receive payments from our collaboration partners, which include DARPA, Koninklijke DSM N.V. (DSM), Firmenich SA (Firmenich), Givaudan International SA (Givaudan), Yifan Pharmaceutical Co. Ltd. (Yifan) and others. Some of our collaboration arrangements provide for advance payments to us in consideration for grants of exclusivity or research efforts that we will perform. Our collaboration agreements, which may require us to achieve milestones prior to receiving payments, are expected to contribute revenues from product sales and royalties if and when they are commercialized. See Note 10, “Revenue Recognition” in Part II, Item 8 of the 2020 Form 10-K for additional information.

We have several other collaboration molecules in our development pipeline with partners including DSM, Givaudan, Firmenich and Yifan that we expect will contribute revenues from product sales and royalties if and when they are commercialized.

COVID-19 Business Update

We have been closely monitoring the impact of the global COVID-19 pandemic on all aspects of our business, including how it has and will impact our employees, partners, supply chain, and distribution network. Before the start of the pandemic in early 2020, we developed a comprehensive response strategy including establishing a cross-functional COVID-19 task force and implementing business continuity plans to manage the impact of the COVID-19 pandemic on our employees and our business. As the pandemic has progressed, we have applied recommended public health recommendations designed to prevent the spread of COVID-19 and have been focused on the health and welfare of our employees. These recommendations to mitigate the spread of COVID-19 infection across our businesses have included additional sanitation and cleaning procedures in our laboratories and other facilities, on-site COVID-19 testing, temperature and symptom confirmations, instituting remote working when possible, and implementing social distancing and staggered worktime requirements for our employees who must work on-site. Throughout this period, we have successfully managed to sustain ongoing critical production campaigns and infrastructure while keeping our employee population healthy with no evidence of disease transmission within our onsite operations. See “Risk Factors – Business and Operational Risks - The COVID-19 pandemic has impacted our business and


30



results of operations and could have a material adverse effect on our business, results of operations and financial condition in the future” in Part I, Item 1A of our 2020 Form 10-K.

Critical Accounting Policies and Estimates

Management's discussion and analysis of results of operations and financial condition are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP). We believe that the critical accounting policies described in this section are those that significantly impact our financial condition and results of operations and require the most difficult, subjective or complex judgements, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. Because of this uncertainty, actual results may vary from these estimates.

Our most critical accounting estimates include:
Recognition of revenue including arrangements with multiple performance obligations;
Valuation and allocation of fair value to various elements of complex related party transactions;
The valuation of freestanding and embedded derivatives, which impacts gains or losses on such derivatives, the carrying value of debt, interest expense and deemed dividends; and
The valuation of debt for which we have elected fair value accounting.

For a more detailed discussion of our critical accounting estimates and policies, see Note 1, "Basis of Presentation and Summary of Significant Accounting Policies" in Part II, Item 8 of our 2020 Form 10-K.

Results of Operations

Revenue
Three Months Ended March 31,
(In thousands)20212020
Revenue
Renewable products$28,179 $17,854 
Licenses and royalties143,800 5,161 
Grants and collaborations4,880 6,115 
Total revenue$176,859 $29,130 

Total revenue increased by 507% to $176.9 million for the three months ended March 31, 2021 compared to the same period in 2020. The increase was the primarily the result of $143.6 million of license revenue from the sale of flavor and fragrance (F&F) intellectual property licenses and the assignment of certain F&F supply agreements to DSM during the three months ended March 31, 2021 (see Note 9, "Revenue Recognition"), combined with a $10.3 million increase in renewable products revenue.

Renewable products revenue increased by 58% to $28.2 million for the three months ended March 31, 2021 compared to the same period in 2020, primarily driven by increased sales in our consumer product lines.

Licenses and royalties revenue increased by $138.6 million for the three months ended March 31, 2021 compared to the same period in 2020, due to the sale of flavor and fragrance (F&F) intellectual property licenses and the assignment of certain F&F supply agreements to DSM, as described in Note 9, "Revenue Recognition".

Grants and collaborations revenue decreased by 20% to $4.9 million for the three months ended March 31, 2021 compared to the same period in 2020, related to decreases from our customers DSM and Yifan.


31




Costs and Operating Expenses
Three Months Ended March 31,
(In thousands)20212020
Cost and operating expenses
Cost of products sold$22,659 $11,790 
Research and development23,332 17,126 
Sales, general and administrative37,922 32,014 
Total cost and operating expenses$83,913 $60,930 

Cost of Products Sold

Cost of products sold includes the costs of raw materials, labor and overhead, amounts paid to contract manufacturers, inventory write-downs resulting from applying lower of cost or net realizable value inventory adjustments, and costs related to production scale-up. Because of our product mix, our cost of products sold does not change proportionately with changes in renewable product revenue.

Cost of products sold increased by 92% to $22.7 million for the three months ended March 31, 2021 compared to the same period in 2020, primarily due to a 58% increase in total product revenue and $3.6 million of incremental costs related to raw materials price variances, inventory rework costs and manufacturing capacity fee adjustments related to our RebM ingredients product.

Research and Development Expenses

Research and development expenses increased by 36% to $23.3 million for the three months ended March 31, 2021 compared to the same period in 2020, primarily due to increases in outside services related to our new squalane adjuvant project, and employee compensation.

Sales, General and Administrative Expenses

Sales, general and administrative expenses increased by 18% to $37.9 million for the three months ended March 31, 2021 compared to the same period in 2020, primarily due to increases in selling, marketing and employee compensation costs related to our consumer product lines.

Other Expense, Net
Three Months Ended March 31,
(In thousands)20212020
Other income (expense):
Interest expense(5,813)(15,002)
(Loss) gain from change in fair value of derivative instruments(22,745)3,282 
Loss from change in fair value of debt(326,785)(16,503)
Loss upon extinguishment of debt(27,313)(27,319)
Other (expense) income, net(678)
Total other expense, net$(383,334)$(55,538)

Total other expense, net was $383.3 million in 2021, compared to total other expense of $55.5 million in 2020. The $327.8 million change was primarily comprised of a $310.3 million increase in loss from change in fair value of debt and a $26.0 million change from a gain to a loss in change in fair value of derivative instruments, partly offset by a $9.2 million decrease in interest expense.

The increase in loss from change in fair value of debt was primarily due to a significant increase (209%) in our stock price relative to a $3.00 and $3.50 conversion price of the two debt instruments measured under the fair value option during the three months ended March 31, 2021.



32



The change from a gain to a loss in change in fair value of derivative instruments was primarily due to a significant increase (209%) in our stock price relative to the $2.87 exercise price of the mark to market liability warrants during the three months ended March 31, 2021. See Note 3, "Fair Value Measurement" in Part II, Item 8 of this Quarterly Report on Form 10-Q for details regarding our outstanding derivative instruments.

The decrease in interest expense was primarily due to a 33% decrease in total debt principal owed at March 31, 2021 in comparison to March 31, 2020, and a significant decrease in debt discount accretion.

Provision for Income Taxes

For the three months ended March 31, 2021 and 2020, we recorded provisions of $0.1 million and $0.1 million for income taxes related to accrued interest on uncertain tax positions.

Liquidity and Capital Resources
(In thousands)March 31,
2021
December 31,
2020
Working capital (working capital deficit)$105,115 $(16,489)
Cash and cash equivalents$143,821 $30,152 
Debt and lease obligations$500,441 $282,187 
Accumulated deficit$(2,377,943)$(2,086,692)

Three Months Ended March 31,
(In thousands)20212020
Net cash (used in) provided by:
Operating activities$108,651 $(46,375)
Investing activities$(2,493)$(1,040)
Financing activities$7,529 $49,663 

Liquidity

Prior to the three months ended March 31, 2021, we have incurred operating losses since our inception, and we expect to incur losses and negative cash flows from operations through at least the next 12 months following the issuance of this Quarterly Report on Form 10-Q. As of March 31, 2021, we had working capital of $105.1 million, an accumulated deficit of $2.4 billion, and cash and cash equivalents of $143.8 million.

As of March 31, 2021, the principal amounts due under our debt instruments (including related party debt) totaled $114.7 million, of which $11.3 million is classified as current. Our debt agreements contain various covenants, including certain restrictions on our business — including restrictions on additional indebtedness, material adverse effect and cross default provisions — that could cause us to be at risk of default. A failure to comply with the covenants and other provisions of our debt instruments, including any failure to make payments when required, would generally result in events of default under such instruments, which could result in the acceleration of a substantial portion of such indebtedness. Acceleration would generally also constitute an event of default under our other outstanding debt instruments, which could result in the acceleration of a substantial portion of our debt repayment obligations.

Based on our cash and cash equivalents of $143.8 million as of March 31, 2021, plus $130.7 million of net proceeds from our April 2021 public stock offering, which together total $274.5 million, we believe that we have sufficient resources to fund our operations and capital expenditures for at least the next 12 months.

For details of our debt and equity, see the following Notes in Part I, Item 1 of this Quarterly Report on Form 10-Q:
Note 4, "Debt"
Note 5, "Mezzanine Equity"
Note 6, "Stockholders' Deficit"
Note 12. "Subsequent Events"



33



Cash Flows during the Three Months Ended March 31, 2021 and 2020

Cash Flows from Operating Activities

Our primary uses of cash from operating activities are costs related to the production and sale of our products and personnel-related expenditures, offset by cash received from renewable product sales, licenses and royalties, and grants and collaborations.

For the three months ended March 31, 2021, net cash provided by operating activities was $108.7 million, consisting primarily of a $290.1 million net loss, partially offset by $384.7 million of favorable non-cash adjustments that were primarily comprised of a $326.8 million loss from change in fair value of debt, a $27.3 million loss upon extinguishment of debt and a $22.7 million loss from change in fair value of derivative instruments. Additionally, there was a $14.0 million decrease in working capital.

For the three months ended March 31, 2020, net cash used in operating activities was $46.4 million, consisting primarily of an $87.8 million net loss, partially offset by $48.1 million of favorable non-cash adjustments that were primarily comprised of a $27.3 million loss upon extinguishment of debt, a $16.5 million loss from change in fair value of debt and $3.5 million of stock-based compensation. Additionally, there was a $6.6 million net increase in working capital balances.

Cash Flows from Investing Activities

For the three months ended March 31, 2021 and 2020, net cash used in investing activities was $2.5 million and $1.0 million, respectively, comprised of property, plant and equipment purchases.

Cash Flows from Financing Activities

For the three months ended March 31, 2021, net cash provided by financing activities was $7.5 million, primarily comprised of $32.2 million of proceeds from the exercise of warrants, partly offset by $23.2 million of debt principal payments and $2.5 million of issuance costs incurred in connection with a debt modification.
    
For the three months ended March 31, 2020, net cash provided by financing activities was $49.7 million, primarily comprised of $57.3 million of net proceeds from common stock issuances and deemed issuance, partly offset by $7.0 million of debt principal payments.

Off-Balance Sheet Arrangements

At March 31, 2021, we did not have any material off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K.

Contractual Obligations

The following is a summary of our contractual obligations as of March 31, 2021:

Payable by year ending December 31,
(In thousands)
Total20212022202320242025Thereafter
Principal payments on debt$114,720 $11,231 $101,235 $293 $307 $321 $1,333 
Interest payments on debt
19,403 5,001 13,989 106 91 76 140 
Construction costs in connection with new production facility23,107 23,107 — — — — — 
Marketing services commitments19,213 4,713 3,500 3,500 3,500 4,000 — 
Equity-method investment purchase obligation10,800 — 10,800 — — — — 
Contract termination fees5,311 5,311 — — — — — 
Financing leases3,491 3,491 — — — — — 
Operating leases16,769 5,644 7,655 3,320 150 — — 
Partnership payment obligation11,066 658 10,408 — — — — 
Total$223,880 $59,156 $147,587 $7,219 $4,048 $4,397 $1,473 



34



ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The market risk inherent in our market risk sensitive instruments and positions is the potential loss arising from adverse changes in the price of our common stock, foreign currency exchange rates, interest rates and commodity prices.

Amyris Common Stock Price Risk

We are exposed to potential losses related to the price of our common stock. At each balance sheet date, the fair value of our derivative liabilities and certain of our outstanding debt instruments for which we have elected fair value accounting, is remeasured using current fair value inputs, one of which is the price of our common stock.

During any particular period, if the price of our common stock increases, there will likely be increases in the fair value of our derivative liabilities and our debt instruments for which we have elected fair value accounting. Such increases in fair value will result in losses in our condensed consolidated statements of operations from change in fair value of derivative instruments and from change in fair value of debt. Conversely, a decrease in the price of our stock during any particular period will likely result in gains in relation to these derivative and debt instruments. Given the current and historical volatility of our common stock price, any changes period-over-period have and could in the future result in a significant change in the fair value of our derivative liabilities and convertible debt instruments and significantly impact our net income during the period of change.

Foreign Currency Exchange Risk

Most of our sales contracts are denominated in U.S. dollars, and therefore our revenues are not currently subject to significant foreign currency risk.
The functional currency of our consolidated Brazilian subsidiary is the local currency (Brazilian Real), in which recurring business transactions occur. We do not use currency exchange contracts as hedges against our investment in that subsidiary.
Our permanent investment in Brazil was $22.0 million as of March 31, 2021 and $18.5 million as of December 31, 2020, using the exchange rate at each date. A hypothetical 10% adverse change in Brazilian Real exchange rates would have had an adverse impact to Other Comprehensive Loss of $2.2 million as of March 31, 2021 and $1.9 million as of December 31, 2020.
We have also evaluated foreign currency exposure in relation to our other non-U.S. Dollar denominated assets and liabilities and determined that there would be an immaterial effect on our results of operations from 10% exchange rate fluctuations between those currencies and the U.S. Dollar.

Interest Rate Risk

Our exposure to market risk for changes in interest rates relates primarily to our outstanding debt obligations, including embedded derivatives therein. We generally invest our cash in investments with short maturities or with frequent interest reset terms. Accordingly, our interest income fluctuates with short-term market conditions. As of March 31, 2021, our investment portfolio consisted of money market funds and certificates of deposit, both of which are highly liquid. Due to the short-term nature of our investment portfolio, we do not believe that an immediate 10% increase in interest rates would have a material effect on the fair value of our portfolio. Since we believe we have the ability to liquidate our investment portfolio, we expect that our operating results or cash flows would not be materially affected by a sudden change in market interest rates on the portfolio.

In addition, while not likely in the current and significantly extended low interest rate environment, changes in interest rates could significantly change the fair value of our embedded derivative liabilities.
    
As of March 31, 2021, all of our outstanding debt is in fixed rate instruments. As a result, changes in interest rates would not affect interest expense and payments in relation to our debt.

Commodity Price Risk
Our primary exposure to market risk for changes in commodity prices relates to our procurement of products from contract manufacturers and other suppliers whose prices are affected by the price of sugar feedstocks. Our suppliers manage exposure to this risk primarily through the use of feedstock pricing agreements.



35




ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer (CEO) and chief financial officer (CFO), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that as of March 31, 2021, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (SEC), and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control

There were no changes in our internal control over financial reporting identified in management's evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.


36



PART II
ITEM 1. LEGAL PROCEEDINGS

For a description of our significant pending legal proceedings, please see Note 8, "Commitments and Contingencies" in the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.




37



ITEM 1A. RISK FACTORS

The risks described in Part I, Item 1A, "Risk Factors" in our 2020 Form 10-K could materially and adversely affect our business, financial condition and results of operations, and the trading price of our common stock could decline. These risk factors do not identify all risks that we face; our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. The “Risk Factors” section of the 2020 Form 10-K remains current in all material respects.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Item 8.01 Other Events

On May 7, 2021, the Company entered into a Securities Purchase Agreement (the Upland SPA) with Upland1, LLC (Upland) and the members of Upland (the Upland Selling Stockholders). Subject to the terms and conditions of the Upland SPA, the Company has agreed to acquire the outstanding membership units of Upland from the Upland Selling Stockholders and to settle and pay off certain convertible promissory notes of Upland held by certain holders (the Specified Upland Noteholders), for an aggregate consideration that consists of a payment of cash consideration and issuance by the Company of shares of the Company’s common stock representing, collectively, less than 1% of the Company’s outstanding shares (the Unregistered Securities) to certain Upland Selling Stockholders and Specified Upland Noteholders.

Furthermore, pursuant to the terms and conditions of the Upland SPA, the Company agreed to file a Prospectus Supplement, which supplements the Prospectus filed with the Securities and Exchange Commission on April 7, 2021 together with a Registration Statement on Form S-3, to register the resale of the Unregistered Securities (the Upland Offering). Each of the Upland Selling Stockholders and the Upland Noteholders will sell its respective Unregistered Securities. The Company will not receive any proceeds from the Upland Offering. A copy of the opinion of Fenwick & West LLP, relating to the validity of certain of the shares in connection with the Upland Offering, is filed as exhibit 5.1 to this Quarterly Report on Form 10-Q.


38



ITEM 6. EXHIBITS
Exhibit No.DescriptionIncorporation by Reference
FormFile No.ExhibitFiling DateFiled Herewith
4.01S-3ASR333-2551054.1804.07.2021
4.02x
4.03x
5.01x
10.01a
x
10.02x
23.01x
31.01x
31.02x
32.01b
x
32.02b
x
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

aPortions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated under the Exchange Act.
b
This certification shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.



39



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.

AMYRIS, INC.
By:
/s/ John G. Melo
John G. Melo
President and Chief Executive Officer
(Principal Executive Officer)
May 7, 2021
By:
/s/ Han Kieftenbeld
Han Kieftenbeld
Chief Financial Officer
(Principal Financial Officer)
May 7, 2021



40

EX-4.02 2 exhibit4022021q1.htm EX-4.02 Document
Exhibit 4.02
AMENDMENT TO NOTES
March 1, 2021
PARTIES:        Amyris, Inc., a Delaware corporation (“Borrower”)
DSM Finance B.V., a Netherlands private company with limited liability (“Lender”)
RECITALS
A.Borrower has issued to Lender a promissory note, dated as of December 28, 2017 (as amended, supplemented or modified from time to time, the “2017 Note”), in the aggregate principal amount of $25,000,000.00 pursuant to that certain Credit Agreement, dated as December 28, 2017 (as amended, supplemented or modified from time to time, the “2017 Credit Agreement”), by and between Borrower and Lender.
B.Borrower has issued to Lender (i) a secured promissory note, dated as of September 17, 2019 (as amended, supplemented or modified from time to time, the “First 2019 Note”), in the aggregate principal amount of $3,000,000.00, (ii) a secured promissory note, dated as of September 19, 2019 (as amended, supplemented or modified from time to time, the “Second 2019 Note”), in the aggregate principal amount of $3,000,000.00, and (iii) a secured promissory note, dated as of September 23, 2019 (as amended, supplemented or modified from time to time, the “Third 2019 Note” and, together with the First 2019 Note and the Second 2019 Note, the “2019 Notes”; the 2019 Notes, together with the 2017 Note, the “Notes”), in the aggregate principal amount of $2,000,000.00, in each case pursuant to that certain Credit Agreement, dated as September 17, 2019 (as amended, supplemented or modified from time to time, the “2019 Credit Agreement” and, together with the 2017 Credit Agreement, the “Credit Agreements”; the Credit Agreements, together with the Notes and the other Loan Documents (as defined in the 2019 Credit Agreement), the “Note Documents”), by and between Borrower and Lender.
C.Borrower has requested that an affiliate of Lender, and in connection with this amendment (this “Amendment”) such affiliate has agreed, to waive certain obligations arising under agreements between Borrower and such affiliate.
D.Borrower and Lender have agreed, subject to terms and conditions contained in this Amendment, to amend the Notes.
AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower and Lender agree as follows:
SECTION 1.Amendments to Notes. Subject to Section 3:
1.1    Amendments to 2017 Note.
1.1.1. The first paragraph of the 2017 Note is hereby amended by adding after the words “2.5% per quarter” the following words: “(or, from and after April 1, 2021 until December 31, 2021, solely to the extent that Company has not, prior to April 1, 2021, (i) repaid all Obligations under this Note, together with all accrued and unpaid interest and the Prepayment Fee in connection herewith, and (ii) repaid all Obligations (as defined in the 2019 Notes) outstanding under the 2019 Notes (including, without limitation, all accrued and unpaid interest and the Prepayment Fee in connection therewith) in full in cash, 5.85% per quarter (which such

|US-DOCS\121184127.7||


incremental interest of 3.35% (the “Incremental Interest”) represents the Prepayment Fee, to be paid over the nine-month period from April 1, 2021 to December 31, 2021)”.
1.1.2. Section 1 of the 2017 Note is hereby amended by adding the following proviso at the end thereof:
; provided that (i) if any redemption of this Note, in whole or in part, shall occur on or before March 31, 2021, the Prepayment Fee shall be due and payable in connection with, and on the same date as, the first such redemption and (ii) if the Prepayment Fee has not been paid pursuant to a redemption of this Note on or before March 31, 2021 and Borrower redeems this Note (or this Note is accelerated for any reason), in whole or in part, between April 1, 2021 and December 31, 2021, Borrower shall be required to pay to Lender a redemption fee equal to the Prepayment Fee (a) minus any Incremental Interest that Borrower has paid to Lender after April 1, 2021 through the date of such redemption (b) plus 4.00% per quarter on the Prepayment Fee, pro rata based on the number of days elapsed from April 1, 2021 through the date of such redemption (which such redemption shall occur no later than December 31, 2021).
1.1.3. Section 4 of the 2017 Note is hereby amended by adding the following defined terms in appropriate alphabetical order:
2019 Notes” has the meaning assigned to such term in the First Amendment.
First Amendment” means the Amendment to Notes, dated as of February 23, 2021, by and between Borrower and Lender.
Prepayment Fee” has the meaning assigned to such term in the First Amendment.
1.1.4. The 2017 Note is hereby amended by adding the following Section 6 immediately following Section 5 thereof:
6. Prepayment Fee.    Section 4 of the First Amendment is hereby incorporated herein by reference and made a part of this Note as if set forth herein in full.
1.1.5. The 2017 Note is hereby amended by adding the following Section 7 immediately following Section 6 thereof:
7. Interest Rate Limitation.     Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to this Note, together with all fees, charges and other amounts which are treated as interest on this Note under applicable law (collectively the “Charges”), shall exceed the maximum lawful rate (the “Maximum Rate”) which may be contracted for, charged, taken, received or reserved by the Lender in accordance with applicable law, the rate of interest payable in respect of this Note hereunder, together with all Charges payable in respect thereof, shall be limited to the Maximum Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of this Note but were not payable as a result of the operation of this Section 7 shall be cumulated and the interest and Charges payable to the Lender in respect of other Obligations or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with interest thereon to the date of repayment, shall have been received by the Lender.

2


1.2. Amendments to 2019 Notes.
1.2.1. Section 4 of each 2019 Note is hereby amended by adding the following defined term in appropriate alphabetical order:
First Amendment” means the Amendment to Notes, dated as of February 23, 2021, by and between Borrower and Lender.
Prepayment Fee” has the meaning assigned to such term in the First Amendment.
1.2.2. Each 2019 Note is hereby amended by adding the following Section 6 immediately following Section 5 thereof:
6. Prepayment Fee.    Section 4 of the First Amendment is hereby incorporated herein by reference and made a part of this Note as if set forth herein in full.
1.2.3. Each 2019 Note is hereby amended by adding the following Section 7 immediately following Section 6 thereof:
7. Interest Rate Limitation.     Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to this Note, together with all fees, charges and other amounts which are treated as interest on this Note under applicable law (collectively the “Charges”), shall exceed the maximum lawful rate (the “Maximum Rate”) which may be contracted for, charged, taken, received or reserved by the Lender in accordance with applicable law, the rate of interest payable in respect of this Note hereunder, together with all Charges payable in respect thereof, shall be limited to the Maximum Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of this Note but were not payable as a result of the operation of this Section 7 shall be cumulated and the interest and Charges payable to the Lender in respect of other Obligations or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with interest thereon to the date of repayment, shall have been received by the Lender.
1.2.4. Section 1(a) of the First 2019 Note is hereby amended by adding the following proviso at the end thereof:
; provided that, if any redemption of this Note, in whole or in part, shall occur on or before March 31, 2021, the Prepayment Fee shall be due and payable in connection with, and on the same date as, the first such redemption.
1.2.5. Section 1(a) of the Second 2019 Note is hereby amended by adding the following proviso at the end thereof:
; provided that, if any redemption of this Note, in whole or in part, shall occur on or before March 31, 2021, the Prepayment Fee shall be due and payable in connection with, and on the same date as, the first such redemption.
1.2.6    Section 1(a) of the Third 2019 Note is hereby amended by adding the following proviso at the end thereof:
3


; provided that, if any redemption of this Note, in whole or in part, shall occur on or before March 31, 2021, the Prepayment Fee shall be due and payable in connection with, and on the same date as, the first such redemption.
1.3.    The “Prepayment Fee” shall mean $2,500,000 in the aggregate for all redemptions, in whole or in part, during the period from the date of this Amendment through and including March 31, 2021 (or, solely with respect to clause (ii) of the proviso in Section 1 of the 2017 Note after giving effect to the Amendment, during the period from April 1, 2021 to December 31, 2021), of the 2017 Note and/or any 2019 Note.
SECTION 2.Representations and Warranties; Ratification.
2.1.    Borrower represents and warrants to Lender:
2.1.1.    The execution, delivery and performance by Borrower of this Amendment and the consummation by Borrower of the transactions contemplated hereby (i) are within the corporate power of Borrower and (ii) have been duly authorized by all necessary corporate actions on the part of Borrower.
2.1.2.    This Amendment has been duly executed and delivered by Borrower and constitutes a legal, valid and binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except in each case as may be limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.
2.1.3.    The execution and delivery by Borrower of this Amendment and the performance and consummation by Borrower of the transactions contemplated hereby do not and will not (i) violate the certificate of incorporation or bylaws of Borrower or any judgment, order, writ, decree, statute, rule or regulation applicable to Borrower; (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other Person to accelerate (whether after the giving of notice or lapse of time or both), any mortgage, indenture, agreement, instrument or contract to which Borrower is a party or by which it is bound except to the extent such violation, breach or acceleration could not reasonably be expected to result in a Material Adverse Effect (as defined in each Credit Agreement); or (iii) other than Liens (as defined in each Credit Agreement) securing the Obligations (as defined in each Credit Agreement), result in the creation or imposition of any Lien upon any property, asset or revenue of Borrower or the suspension, revocation, impairment, forfeiture, or nonrenewal of any permit, license, authorization or approval applicable to Borrower, its business or operations, or any of its assets or properties except to the extent such suspension, revocation, impairment, forfeiture or nonrenewal could not reasonably be expected to have a Material Adverse Effect.
2.1.4. As of the date hereof, no Event of Default (as defined in each applicable Note Document) shall have occurred and be continuing.
2.2. Borrower reaffirms the terms and conditions of each Note Document and acknowledges and agrees that each and every such Note Document remains in full force and effect and is hereby reaffirmed, ratified and confirmed.
SECTION 3.Conditions. The effectiveness of this Amendment is subject to the satisfaction of the following conditions precedent:
3.1. This Amendment shall have been executed by Borrower and Lender, and counterparts hereof as executed by Borrower (which may include electronic transmission of a signed signature page) shall have been delivered to Lender.
3.2. The representations and warranties made by Borrower in Section 2 of each Credit Agreement shall be true and correct as of the date hereof.
4



SECTION 4.
4.1. Notwithstanding anything to the contrary in this Amendment or any other Note Document, Borrower and Lender hereby acknowledge and agree that, if any of the Obligations (as defined in each Credit Agreement) are accelerated as a result of the occurrence and continuance of any Event of Default (as defined in each applicable Note Document) on or prior to December 31, 2021 (all such accelerated Obligations, the “Accelerated Obligations”) (including but not limited to (i) by operation of law or otherwise, (ii) acceleration in accordance with the terms of the Note Documents, (iii) the satisfaction, release, payment, restructuring, reorganization, replacement, reinstatement, defeasance or compromise of any of the Obligations (as defined in each Credit Agreement) in any voluntary or involuntary case or proceeding under any applicable federal or state bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent or other similar event in respect of Borrower described in Section 3(a)(v) of the 2017 Note or Section 3(a)(iv) of the 2019 Notes, (iv) the making of a distribution of any kind in any proceeding under the Title 11 of the United States Code, as amended (U.S. Bankruptcy Code) to Lender in full or partial satisfaction of the Obligations (as defined in each Credit Agreement) or (v) the termination of this Note Documents for any reason), the Prepayment Fee in respect of the Accelerated Obligations will also be due and payable on the date of such acceleration and will be treated and deemed as though the Notes were prepaid as of such date and shall constitute part of the Obligations (as defined in each Credit Agreement) for all purposes herein, in view of the impracticability and extreme difficulty of ascertaining actual damages and by mutual agreement of the parties as to a reasonable calculation of Lender’s lost profits as a result thereof. BORROWER EXPRESSLY WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE PROVISIONS OF ANY PRESENT OR FUTURE STATUTE OR LAW THAT PROHIBITS OR MAY PROHIBIT THE COLLECTION OF THE PREPAYMENT FEE IN CONNECTION WITH ANY SUCH ACCELERATION. Further, (i) Borrower and Lender expressly agree that the Prepayment Fee is reasonable and is the product of an arm’s length transaction between sophisticated business people, ably represented by counsel, and (ii) Borrower expressly agrees that (1) the Prepayment Fee shall be payable notwithstanding the then prevailing market rates at the time payment is made, (2) there has been a course of conduct between Lender and Borrower giving specific consideration in this transaction for such agreement to pay the Prepayment Fee, (3) Borrower shall be estopped hereafter from claiming differently than as agreed to in this Section 4.1 and (4) Borrower’s agreement to pay the Prepayment Fee is a material inducement to Lender to continue to hold the Notes.
SECTION 5.Miscellaneous.
5.1. This Amendment shall be a Note Document. All references to any Note Document shall be a reference to such Note Document as so amended by this Amendment.
5.2. This Amendment and the other Note Documents (as amended by this Amendment) constitute the full and entire understanding and agreement between the parties relating to the subject matter hereof and thereof and supersede any previous written or verbal agreements between the parties with regard to the subject matter hereof and thereof.
5.3. Notwithstanding any provision contained herein, nothing contained herein shall limit any rights or remedies under the Note Documents or applicable law based on any breaches, failures, defaults or Events of Default (as defined in each applicable Note Document) thereunder.
5.4. This Amendment and all actions arising out of or in connection with this Amendment shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law provisions of the State of New York.
5


5.5. The rights and obligations of Borrower and Lender hereunder shall be binding upon and inure to the benefit of the successors, assigns, heirs, administrators and transferees of the parties
5.6. This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall be deemed to constitute one instrument.
5.7. If any provision of this Amendment shall be judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
[Signature Pages Follow]

6


IN WITNESS WHEREOF, this Amendment is executed and delivered as of the day and year first above written.
Borrower:                    Amyris, Inc., a Delaware corporation

By: /s/ John Melo
Name: John Melo
Title: President and Chief Executive Officer

Lender:    DSM Finance B.V., a Netherlands private company with limited liability

By: /s/ B. Singh
Name: B. Singh
Title: Managing Director

By: /s/ L. Huang
Name: L. Huang
Title: Managing Director
[Signature Page – Amendment to Notes]
EX-4.03 3 exhibit4032021q1.htm EX-4.03 Document
Exhibit 4.03

EXECUTION VERSION
AMENDMENT TO NOTE
March 31, 2021
PARTIES:     Amyris, Inc., a Delaware corporation (“Borrower”)
DSM Finance B.V., a Netherlands private company with limited liability (“Lender”)
RECITALS
A. Borrower has issued to Lender a promissory note, dated as of December 28, 2017 (as amended, supplemented or modified from time to time, the “Note”), in the aggregate principal amount of $25,000,000.00 pursuant to that certain Credit Agreement, dated as December 28, 2017 (as amended, supplemented or modified from time to time, the “Credit Agreement” and, together with the Note, the “Note Documents”), by and between Borrower and Lender.
B. As of the date of this Amendment, Borrower has made (i) a partial prepayment of the Note of $15,000,000.00 of principal and (ii) a payment of the Prepayment Fee in the amount of $2,500,000.00 pursuant to the terms of the Note, which such payments have resulted in the remaining outstanding principal amount of $10,000,000.00 under the Note.
C. Borrower has requested that an affiliate of Lender, and in connection with this amendment (this “Amendment”) such affiliate has agreed, to waive certain obligations arising under agreements between Borrower and such affiliate.
D. Borrower and Lender have agreed, subject to terms and conditions contained in this Amendment, to amend the Note.

AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower and Lender agree as follows:
SECTION 1. Amendments to Note. Subject to Section 3:
1.1. The first paragraph of the Note is hereby amended by replacing the words “no later than December 31, 2021” therein with the words “no later than April 15, 2022”.
1.2. Notwithstanding anything to the contrary in the Note, the interest rate to be paid on the outstanding principal of the Note as of the date of this Amendment until final maturity shall be 2.5% per quarter.
SECTION 2. Representations and Warranties; Ratification.
2.1. Borrower represents and warrants to Lender:
2.1.1. The execution, delivery and performance by Borrower of this Amendment and the consummation by Borrower of the transactions contemplated hereby (i) are within the corporate power of Borrower and (ii) have been duly authorized by all necessary corporate actions on the part of Borrower.
2.1.2. This Amendment has been duly executed and delivered by Borrower and



constitutes a legal, valid and binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except in each case as may be limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.
2.1.3. The execution and delivery by Borrower of this Amendment and the performance and consummation by Borrower of the transactions contemplated hereby do not and will not (i) violate the certificate of incorporation or bylaws of Borrower or any judgment, order, writ, decree, statute, rule or regulation applicable to Borrower; (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other Person to accelerate (whether after the giving of notice or lapse of time or both), any mortgage, indenture, agreement, instrument or contract to which Borrower is a party or by which it is bound except to the extent such violation, breach or acceleration could not reasonably be expected to result in a Material Adverse Effect (as defined in the Credit Agreement); or (iii) other than Liens (as defined in the Credit Agreement) securing the Obligations (as defined in the Credit Agreement), result in the creation or imposition of any Lien upon any property, asset or revenue of Borrower or the suspension, revocation, impairment, forfeiture, or nonrenewal of any permit, license, authorization or approval applicable to Borrower, its business or operations, or any of its assets or properties except to the extent such suspension, revocation, impairment, forfeiture or nonrenewal could not reasonably be expected to have a Material Adverse Effect.
2.1.4. As of the date hereof, no Event of Default (as defined in each applicable Note Document) shall have occurred and be continuing.
2.2. Borrower reaffirms the terms and conditions of each Note Document and acknowledges and agrees that each and every such Note Document remains in full force and effect and is hereby reaffirmed, ratified and confirmed.
SECTION 3. Conditions. The effectiveness of this Amendment is subject to the satisfaction of the following conditions precedent:
3.1. This Amendment shall have been executed by Borrower and Lender, and counterparts hereof as executed by Borrower (which may include electronic transmission of a signed signature page) shall have been delivered to Lender.

3.2. The representations and warranties made by Borrower in Section 2 of the Credit Agreement shall be true and correct as of the date hereof.
SECTION 4. [Reserved].
SECTION 5. Miscellaneous.
5.1. This Amendment shall be a Note Document. All references to any Note Document shall be a reference to such Note Document as so amended by this Amendment.
5.2. This Amendment and the other Note Documents (as amended by this Amendment) constitute the full and entire understanding and agreement between the parties relating to the subject matter hereof and thereof and supersede any previous written or verbal agreements between the parties with regard to the subject matter hereof and thereof.
5.3. Notwithstanding any provision contained herein, nothing contained herein shall limit any rights or remedies under the Note Documents or applicable law based on any breaches, failures, defaults or
2




Events of Default (as defined in each applicable Note Document) thereunder.
5.4. This Amendment and all actions arising out of or in connection with this Amendment shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law provisions of the State of New York.
5.5. The rights and obligations of Borrower and Lender hereunder shall be binding upon and inure to the benefit of the successors, assigns, heirs, administrators and transferees of the parties
5.6. This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall be deemed to constitute one instrument.
5.7. If any provision of this Amendment shall be judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
[Signature Pages Follow]
3




IN WITNESS WHEREOF, this Amendment is executed and delivered as of the day and year first above written.
Borrower:                    Amyris, Inc., a Delaware corporation

By: /s/ Han Kieftenbeld
Name: Han Kieftenbeld
Title: Chief Financial Officer

Lender:    DSM Finance B.V., a Netherlands private company with limited liability

By: /s/ Vivian Huang
Name: Vivian Huang
Title: Corporate Finance Manager

By: /s/ Brune Singh
Name: Brune Singh
Title: Vice President Group Treasury


EX-5.01 4 exhibit5012021q1.htm EX-5.01 Document

Exhibit 5.01


image_03.jpg
May 7, 2021
Amyris, Inc.
5885 Hollis Street, Ste. 100
Emeryville, California 94608
Ladies and Gentlemen:
We deliver this opinion with respect to certain matters in connection with the offering by the Selling Stockholders (as defined below) of 98,352 shares of the common stock of Amyris, Inc., a Delaware corporation (the “Company”), par value $0.0001 per share (the “Shares”), issued to the Selling Stockholders (as defined below) pursuant to that certain Securities Purchase Agreement, dated as of May 7, 2021 (the “Purchase Agreement”), by and among the Company, Upland1, LLC (“Upland”), Francisco Costa, Michele Levy and other Upland’s securityholders listed on Schedule II thereto, and to certain noteholders of the Company (the “Selling Stockholders”). The Shares are registered and offered pursuant to an automatic shelf Registration Statement on Form S-3 (File No. 333-255105) filed by the Company with the Securities and Exchange Commission (the “Commission”) on April 7, 2021 (the “Registration Statement”), in connection with the registration under the Securities Act of 1933, as amended (the “Securities Act”) the prospectus filed therewith (the “Base Prospectus”) and the prospectus supplement dated May 7, 2021 (the “Prospectus Supplement”) filed with the Commission pursuant to Rule 424(b) under the Securities Act (The Base Prospectus and the Prospectus Supplement are collectively referred to as the “Prospectus”). The Shares may be sold from time to time by the Selling Stockholders, as set forth in the Registration Statement and the Prospectus. The offering of the Shares by the Selling Stockholders pursuant to the Registration Statement and the Prospectus is referred to herein as the “Offering.”
In connection with our opinion expressed below we have examined originals or copies of the Purchase Agreement, the Registration Statement, the Company’s Restated Certificate of Incorporation, as amended (the “Restated Certificate”) and the Company’s Restated Bylaws, as amended (the “Bylaws” and, together with the Restated Certificate, as each may be amended, modified or restated, the “Charter Documents”), certain minutes and consents of the Company’s board of directors (the “Board”) or a committee or committees thereof relating to the Registration Statement, the Charter Documents, the Purchase Agreement, the Offering, and such other agreements, documents, certificates and statements of the Company, its transfer agent and public or government officials, as we have deemed advisable, and have examined such questions of law as we have considered necessary. In giving our opinion, we have also relied upon a management certificate addressed to us and dated of even date herewith executed by the Company containing certain factual representations.
In our examination of documents we have assumed, and express no opinion as to, the genuineness of all signatures on documents submitted to us, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity of all persons or entities executing the same, the absence of any undisclosed termination, modification, waiver or amendment to any document reviewed by us, and the due authorization, execution and delivery of all such documents where due authorization, execution and delivery are prerequisites to the effectiveness thereof.




Amyris, Inc.
Page 2
May 7, 2021

We render this opinion only with respect to, and express no opinion herein concerning the application or effect of any laws other than the existing laws of the Delaware General Corporation Law.
In connection with our opinions expressed below, we have assumed that, (i) at or prior to the time of the issuance and delivery of any of the Shares by the Company to the Selling Stockholders and as of the date hereof, there will not have occurred any change in the law or the facts affecting the validity of the Shares, any change in actions of the Board or the Company’s stockholders, or any amendments to the Charter Documents, and (ii) at the time of the issuance and as of the date hereof, no stop order suspending the Registration Statement’s effectiveness will have been issued and remain in effect, and that the Registration Statement will not have been modified or rescinded. We also have assumed that the issuance and delivery of the Shares by the Company to the Selling Stockholders, immediately prior to the rendition of this opinion, is in compliance by the Company with the terms of the Shares and will not result in a violation of any provision of any of the Charter Documents or of any instrument or agreement then binding upon the Company or any restriction imposed by any court or governmental body then having jurisdiction over the Company.
Based upon the foregoing, we are of the following opinion: 98,352 Shares issued by the Company to the Selling Stockholders and to be sold from time to time by the Selling Stockholders, are validly issued, fully paid and nonassessable.
We consent to the use of this opinion as an exhibit to the Quarterly Report on Form 10-Q to be filed by the Company with the Commission, and further consent to all references to us, if any, in the Registration Statement, the Prospectus and any amendments or supplements thereto, as applicable. We do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.
[Concluding Paragraph Follows on Next Page]




Amyris, Inc.
Page 3
May 7, 2021

This opinion is intended solely for use in connection with the issuance and sale of the Shares by the Selling Stockholders subject to the Registration Statement and the Prospectus and is not to be relied upon for any other purpose. In providing this opinion, we are opining only as to the specific legal issues expressly set forth above and no opinion shall be inferred as to any other matter or matters. This opinion is rendered on, and speaks, only as of the date of this letter first written above and is based solely on our understanding of facts in existence as of such date after the aforementioned examination and does not address any potential change in facts or law that may occur after the date of this opinion letter. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention, whether or not such occurrence would affect or modify any of the opinions expressed herein.
Very truly yours,
/s/ Fenwick & West LLP
FENWICK & WEST LLP

EX-10.01 5 exhibit10012021q1.htm EX-10.01 Document
Exhibit 10.01

IN ACCORDANCE WITH ITEM 601(b)(10)(iv) OF REGULATION S-K, CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THIS DOCUMENT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. THE CONFIDENTIAL INFORMATION IS DENOTED HEREIN BY [*].


Execution Version

ASSET PURCHASE AGREEMENT
by and among
DSM Nutritional Products Ltd.,
as Buyer,
Amyris, Inc.,
as Seller,
dated as of March 31, 2021
image_01.jpg


Table of Contents
Definitions    1
Purchase and Sale of Assets    7
Assumed Liabilities    8
Excluded Assets    8
Excluded Liabilities    9
Withholding    10
Closing    11
Deliveries by Buyer    11
Deliveries by Seller    11
Further Assurances    12
Earn-Out Payments    12
Organization and Authority    16
No Conflicts; Consents    16
Consents and Approvals    17
Compliance with Law; Litigation and Claims    17
Assumed Contracts    18
Inventory    18
R&D Obligations    18
Brokers    18
No Implied Representations    19
Organization and Authority    19
No Conflicts; Consents    19
Consents and Approvals    19
Sufficient Funds    20
No Other Representations    20
image_21.jpgimage_01.jpg


Table of Contents
Expenses    20
Tax Matters    20
Cooperation in Litigation Matters    22
Escrow Agreement    22
Conduct of the Business    22
Survival    22
Buyer’s Off-Set Right    24
Public Statements    24
Notices    24
Assignment    25
Entire Agreement    26
Counterparts; Effectiveness; Third Party Beneficiaries    26
Representation by Legal Counsel    27
Section Headings; Construction    27
Validity    27
Specific Performance    27
image_21.jpgimage_01.jpg


Exhibits
Exhibit A — Form of Bill of Sale and Assignment and Assumption Agreement
Exhibit B — License and Drawing Rights Agreement
Exhibit C — Supply Agreement
Schedules
Schedule 1.1(a)
Schedule 2.1.2
Schedule 2.1.4
Schedule 2.1.5
Schedule 3.3
Schedule 3.5.1
Schedule 3.5.5
Assumed Contracts
Products and related Technical Transfer Packages
Accounts Receivable
Inventory
Conditions Precedent
Annual Launch Business EBITDA
Value Share Guarantee
image_21.jpgimage_01.jpg


ASSET PURCHASE AGREEMENT
This ASSET PURCHASE AGREEMENT is entered into as of March 31, 2021 by and among DSM Nutritional Products, Ltd. a Switzerland limited company (“Buyer”) and Amyris, Inc., a Delaware corporation (“Seller”).
RECITALS
WHEREAS, Seller desires to sell to Buyer, and Buyer desires to acquire from Seller, the Purchased Assets (as defined herein), and Buyer desires to assume, pay, perform and discharge the Assumed Liabilities (as defined herein), all on the terms and conditions set forth in this Agreement (as defined herein).
NOW, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements contained herein, Seller and Buyer, intending to be legally bound, hereby agree as set forth herein.
ARTICLE 1
DEFINITIONS
1.1.Definitions. For the purposes of this Agreement, capitalized terms used herein have the meaning set forth below (the singular shall be interpreted to include the plural and vice versa, unless the context clearly dictates otherwise):
2022 Value Share    Guarantee Amount”    has    the meaning    set    forth in Section 3.5.5.
2023 Value Share    Guarantee Amount”    has    the meaning    set    forth in Section 3.5.5.
2024 Value Share    Guarantee Amount”    has    the meaning    set    forth in Section 3.5.5.
Accounts Receivable” has the meaning set forth in Section 2.1.
Action” means any action, claim, demand, proceeding, citation, summons, subpoena, arbitration, audit, investigation, hearing, litigation or suit of any nature (whether civil, criminal, administrative or judicial, whether formal or informal, and whether public or private) commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Authority.
Affiliate” means, with respect to any Person, any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. For the avoidance of doubt, in no event shall Amyris or any of its Subsidiaries be deemed to be an Affiliate of Buyer or any of its direct or indirect equity holders or Subsidiaries for any purpose hereunder.
Aggregate Earn-Out Cap” has the meaning set forth in Section 3.5.1.



Agreement” means this Asset Purchase Agreement, and the Schedules and Exhibits hereto, as amended, modified or supplemented from time to time.
Annual Launch Business EBITDA” means, for each of the calendar years 2022, 2023 and 2024, the earnings before interest, taxes, depreciation and amortization for such calendar year, in each case, consisting of the accounts and items identified on Schedule 3.5.1, determined in accordance with GAAP, subject to the adjustments contemplated by Schedule 3.5.1, and in accordance with the sample calculation set forth on Schedule 3.5.1.
Arbitrating Accountant” has the meaning set forth in Section 3.5.2.
Assumed Contract” means each contract set forth on Schedule 1.1(a) hereto.
Assumed Liabilities” has the meaning set forth in Section 2.2.
Bill of Sale and Assignment and Assumption Agreement” means the Bill of Sale and Assignment and Assumption Agreement pursuant to which the Purchased Assets will be sold and transferred to, and the Assumed Liabilities will be assumed by, Buyer at the Closing, substantially in the form attached as Exhibit A hereto.
Bisabolol” means [*] and meeting the product specifications agreed by [*].
Business” means the business, operations and activities of Seller’s flavors and fragrances (F&F) business as conducted by the Seller and any of its Subsidiaries consisting of manufacturing, marketing, distribution and sale activities related to the Molecules, in each case, as conducted by Seller and its Subsidiaries prior to the Closing.
Business Books and Records” has the meaning set forth in Section 2.1.
Business Day” means a day, other than Saturday, Sunday or other day on which commercial banks in New York City, New York, Switzerland or the Netherlands are authorized or required by Law to close.
Business Tax Records” means all books and records relating to Taxes with respect to the Purchased Assets and the Assumed Liabilities.
Buyer” has the meaning set forth in the preamble to this Agreement.
Closing” has the meaning set forth in Section 3.1.
Closing Date” has the meaning set forth in Section 3.1.
Code” means the U.S. Internal Revenue Code of 1986, as amended.
Confidential Information” has the meaning set forth in Section 6.3.1.
Consent” means any consent, approval, authorization, consultation, waiver, permit, grant, agreement, certificate, exemption, order, registration, declaration, filing, license, notice of, with or to any Person or under any Law, in each case, required to permit the consummation of the Contemplated Transactions.



Contemplated Transactions” means the transactions contemplated by this Agreement and the other Transaction Documents.
Contract” means any loan or credit agreement, bond, debenture, note, mortgage, indenture, lease, supply agreement, license agreement, development agreement, purchase order or other contract, agreement, obligation, commitment or instrument that is legally binding, including all amendments, schedules and exhibits thereto.
Data Room” means the on-line “virtual data room” established by the Seller and/or its Representatives in connection with the Contemplated Transactions, hosted by Fenwick & West (available at: [*]).
Designated Court” has the meaning in Section 8.6.1.
Earn-Out Payment Statement of Objections” has the meaning set forth in Section 3.5.2.
Earn-Out Period” has the meaning set forth in Section 3.5.1.
Earn-Out Schedule” has the meaning set forth in Section 3.5.2.
Encumbrance” means any lien, mortgage, adverse ownership claim, attachment, levy, charge, easement, option or other right to acquire an interest, restriction, pledge, security interest, title defect, encroachment or other similar encumbrance, whether of record or not.
Enforceability Exceptions” has the meaning set forth in Section 4.1.
Escrow Agreement” means each of (i) the Strain Escrow Agreement by and between Amyris, Inc, Givaudan International, SA and SciSafe Inc. effective September 28, 2018 to be amended following Closing to include reference to Buyer (as may be amended or modified by the parties thereto), and (ii) the Escrow Agreement by and between Amyris, Inc., Firmenich SA and SciSafe Inc. effective August 22, 2013, as amended December 23, 2016 to be amended following closing to include reference to Buyer (as may be amended or modified by the parties thereto).
Excluded Assets” has the meaning set forth in Section 2.3.
Excluded Books and Records” has the meaning set forth in Section 2.3.3.
Excluded Liabilities” has the meaning set forth in Section 2.4.
Firmenich Collaboration Agreement” means the Collaboration Agreement dated as of March 13, 2013, by and between Seller and Firmenich SA as amended by Amendment 1 dated July 1, 2015, as further amended by Amendment 2 dated November 28, 2016, as further amended by Amendment 3 dated July 1, 2017, and as further amended by Amendment 5 dated December 18, 2019.
Firmenich Supply Agreement” means the Amended and Restated Supply Agreement by and between Amyris and Firmenich dated August 29, 2018.



Framework Supply Agreement” means the Framework Supply Agreement by and between Amyris and Givaudan dated January 1, 2019.
[*].
GAAP” means generally accepted accounting principles in the United States, as in effect from time to time and consistently applied.
Givaudan Collaboration Agreement” means the Collaboration Agreement dated as of September 14, 2018, by and between Seller and Givaudan International SA.
Governmental Authority” means any arbitrator, court, judicial, legislative, administrative or regulatory agency, commission, department, board, bureau or body or other government authority or instrumentality or any Person or entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, whether foreign or domestic, whether federal, national, supranational, state, provincial, municipal, local or other.
Guarantee Amount” has the meaning set forth in Section 3.5.6.
Indemnified Party” has the meaning set forth in Section 7.3.
Indemnifying Party” has the meaning set forth in Section 7.3.
Intellectual Propertyhas the meaning set forth in Section 1.21 of the License and Drawing Rights Agreement.
Knowledge of Seller” means the actual knowledge of the following officers of Seller: John Melo (Chief Executive Officer), Han Kieftenebld (Chief Financial Officer), Jim Iacoponi (SVP, Nutrition Ingredients) and Eduardo Alvarez (Chief Operating Officer) after reasonable inquiry of such Seller employees that such named individuals reasonably believe would have actual knowledge of the applicable matter.
Launch Business” means the sale of [*], Sclareol and Retinol pursuant to the applicable Assumed Contracts.
Launch Business Forecast Amount” means the forecasted sales for the Launch Business for a given year prepared by Buyer in good faith based on the budgets, forecasts or projected sales delivered to Buyer by the Launch Business customers.
Law” means, with respect to any Person, all international, national, federal, state, foreign or local statutes, laws, ordinances, regulations, rules, codes, judgments, orders or other requirements or rule of law of any Governmental Authority having jurisdiction over such Person.
Liability” or “Liabilities” means any and all debts, liabilities, commitments, guarantees and obligations, whether accrued or fixed, absolute or contingent, known or unknown, matured or unmatured, determined or determinable, and whether or not such item is required to be accrued as a liability in financial statements prepared in accordance with applicable accounting standards, including those arising under any Law or Action and those arising under any Contract.



License and Drawing Rights Agreementmeans the agreement pursuant to which (i) Seller grants Buyer an exclusive license in certain intellectual property relating to the Molecules and (ii) Buyer agrees to engage Seller to provide certain development and piloting services with respect to the Molecules, substantially in the form attached as Exhibit B hereto.
Loss” or “Losses” means losses, damages, adverse claims, Actions, obligations, demands, debts, fines, penalties, Liabilities, judgments, settlements, Taxes, costs or expenses, including costs of investigation, defense and settlement and documented attorneys’ and other professional fees and expenses.
Manool” means [*] and meeting the product specifications agreed by [*].
Molecules” means [*], Patchouli, Manool, Sandalwood, Bisabolol, [*], Sclareol and Retinol and Farnesene.
Non-Recourse Party” has the meaning set forth in Section 8.12.1.
Party” means each of Seller and Buyer, and “Parties” means Seller and Buyer.
Patchouli” means [*] and meeting the product specifications agreed by [*].
Permitted Encumbrance” means any Encumbrance for Taxes not yet due, assessed or payable.
Person” means an individual, a corporation, a limited liability company, a partnership, an association, a trust or other entity or organization, including a federal, state, local or foreign Governmental Authority or political subdivision or an agency or instrumentality thereof.
Pre-Closing Tax Period” means any taxable period ending on or before the Closing Date and the portion of any Straddle Period ending on and including the Closing Date.
Purchase Price” has the meaning set forth in Section 2.5.
Purchased Assets” has the meaning set forth in Section 2.1.
Representatives” means, with respect to any Person, the officers, directors, employees, accountants, counsel, consultants, advisors and agents and other authorized representatives of such Person, in each case acting in such capacity.
Retinol” means [*] and meeting the product specifications agreed by [*].
Review Period” has the meaning set forth in Section 3.5.2.
Sandalwood” means [*] and meeting the product specifications agreed by [*].
Sclareol” means [*] and meeting the product specifications agreed by [*].
Seller” has the meaning set forth in the preamble to this Agreement.
Shortfall Payment” has the meaning set forth in Section 3.5.4.



Specified IP Matters” means all Liabilities related to or arising out of any indemnification obligations set forth in the Firmenich Collaboration Agreement or the Givaudan Collaboration Agreement to the extent relating to any facts, circumstances, occurrences or developments that existed or occurred prior to the Closing Date.
Straddle Period” means a taxable period that includes but does not end on the Closing Date.
Subsidiary” means with respect to a Party, any corporation, or other business entity that, either directly or indirectly, is controlled by such Party by way of ownership of the voting stock of such entity.
Supply Agreement” means the supply agreement pursuant to which Seller will supply Buyer with its requirements for the Molecules, substantially in the form attached as Exhibit C hereto.
Takasago Agreement” means Farnesene Supply Agreement by and between Amyris and Takasago International Corporation dated December 18, 2015.
Tax” or “Taxes” means all U.S. and non-U.S., federal, state, provincial, municipal or other taxes, fees, levies, duties, tariffs, imposts and other assessments or charges of whatever kind (including taxes or other charges on, or measured by or with respect to, income or sales, use, excise, stamp, transfer, alternative minimum, estimated, property, windfall or other profits, value added, recording, registration, intangible, documentary, goods and services, escheat or unclaimed property, real estate, payroll, employment, social security, license, customs’ duties or similar fees, ad valorem, net worth, gains, gross receipts, withholding, environmental, and franchise taxes) and including repayments of any grants, subsidies, state aid or similar amounts from a Governmental Authority, together with any interest, penalties or additions payable in connection with such taxes, fees, levies, duties, tariffs, imposts and other assessments or charges imposed by any Governmental Authority or taxing authority, whether disputed or not and including any obligation to indemnify or otherwise assume or succeed to the Tax Liability of any other Person (other than any such obligation arising pursuant to a customary commercial contract entered into in the ordinary course of business with unrelated Persons the principal subject matter of which is not Taxes).
Tax Return” means, with respect to any jurisdiction (foreign or domestic), any return, declaration, statement, report, claim for refund, information return, declaration of estimated Tax or other documents filed or required to be filed with respect to Taxes, and any schedule or attachment thereto and any amendment thereof.
Third Party” means any Person other than the Parties and their respective Affiliates.
Transaction Documents” means, collectively, this Agreement, the Bill of Sale and Assignment and Assumption Agreement, the License and Drawing Rights Agreement and the Supply Agreement and any other documents, certificates, instruments, amendments, schedules and agreements executed in connection with, or required to be delivered by, any of the foregoing.



Transfer Documents” means, collectively, such deeds, bills of sale, assignments, assumptions (including Liability assumption agreements), affidavits and other instruments of sale, conveyance, transfer and assignment between Seller, on the one hand, and Buyer, on the other hand, in form and substance reasonably satisfactory to Seller and Buyer, as may be reasonably necessary or advisable under the Laws of the relevant jurisdictions to effect the Contemplated Transactions.
Transfer Taxes” means any and all transfer, documentary, sales, use, stamp, registration, value added, recording and other similar Taxes and fees, together with any interest, penalties or additions thereto, incurred in connection with the Contemplated Transactions; provided, however, that Transfer Taxes shall not include Taxes based upon or calculated by reference to income, profits or gains (including any such Taxes collected or assessed through withholding).
[*]
ARTICLE 2
PURCHASE AND SALE OF ASSETS
2.1 Purchase and Sale of Assets. Upon the terms and subject to the conditions of this Agreement, at the Closing, Seller shall sell, transfer, assign, convey and deliver to Buyer, and Buyer shall purchase and accept from Seller, all of Seller’s right, title and interest in, to and under all assets, properties, rights and interests of any kind and description (whether real, personal or mixed, tangible or intangible, or fixed, contingent or otherwise), as expressly set forth in this Section 2.1, wherever located and by whomever possessed (but excluding the Excluded Assets), as such assets exist on the Closing Date (collectively, the “Purchased Assets”), free and clear of all Encumbrances (other than Permitted Encumbrances). The Purchased Assets shall consist of the following:
2.1.1.the Assumed Contracts;
2.1.2.all books, records, manuals, reports, business plans, data, mailing lists, customer lists, supplier lists, price lists, sales records, vendor data, marketing information and procedures, sales and customer files, current product material, standard forms of documents and manuals of operations or business procedures (other than Intellectual Property), in each case to the extent relating solely to the Purchased Assets or the Assumed Liabilities, whether in hard copy or electronic format, including the Business Tax Records but excluding the Excluded Books and Records (collectively, the “Business Books and Records”), including the technical transfer packages set forth on Schedule 2.1.2; provided, that Seller may temporarily retain possession of and may utilize any Business Books and Records related to the manufacturing of the Molecules on behalf of Buyer to the extent required to comply with its obligations under the Supply Agreement until such time as Buyer has elected thereunder to manufacture one or more of the Molecules, at which time Seller shall deliver all such Business Books and Records (or portions thereof) solely applicable to said Molecules, which shall include such technical transfer packages, to Buyer; provided, further, that Seller shall not be required to deliver Business Tax Records to the extent separate books and records comprising the Business Tax Records are not readily available, but will provide reasonable access to the portions of such books and records comprising the Business Tax Records from time to time, as may be reasonably requested by Buyer.



2.1.3.all (a) rights under or pursuant to all express or implied warranties, representations and guarantees made by suppliers, vendors or other third parties in favor of Seller with respect to any of the other Purchased Assets, and (b) claims, causes of action, rights of recovery, rights of offset or set-off, defenses, warranties and indemnities in favor of Seller from or against any third parties, whether known or unknown, contingent or otherwise, including any encumbrances, security interests, pledges or other rights to payment or to enforce payment, to the extent arising out of the operation, lease or use of the Purchased Assets;
2.1.4.all trade accounts and notes receivable, any other receivables and other rights to receive payment to the extent arising out of the sale or other disposition of goods or performance of services by the Business pursuant to the Assumed Contracts, including the full benefit of all security for such receivables, and any claims, remedies or other rights related to any of the foregoing as listed on Schedule 2.1.4 (collectively, the “Accounts Receivable”);
2.1.5.certain finished goods inventory used, or held for use, in the Business listed on Schedule 2.1.5 (collectively, the “Inventory”); and
2.1.6.all goodwill and other intangible property (other than Intellectual Property) to the extent arising out of the operation, ownership, lease or use of the Purchased Assets, including the customer relationships of the Business to the extent related to the Business.
Nothing in this Section 2.1 shall obligate Buyer to assume any Liability related to Seller or any of its Affiliates, the Business, the Purchased Assets or otherwise, unless Buyer expressly assumes such Liability pursuant to Section 2.2.
2.2.Assumed Liabilities. At the Closing, on the terms and subject to the conditions of this Agreement, and as additional consideration for the Purchased Assets, Buyer shall assume and be liable for, effective as of the Closing, and thereafter shall pay, perform and discharge when due, all Liabilities of Seller to the extent first and solely arising out of or under the Purchased Assets after the Closing, but excluding any Excluded Liabilities (collectively, the “Assumed Liabilities”).
2.3.Excluded Assets. Notwithstanding anything to the contrary contained in Section 2.1, Seller and Buyer acknowledge and agree that the Purchased Assets shall not include, and Seller is not selling, assigning, transferring or conveying to Buyer any right, title or claim related to, or interest in, any of the following assets (collectively, the “Excluded Assets”):
2.1.all real property interests and equipment of Seller, raw materials inventory and other tangible personal property (provided, that, for the avoidance of doubt, the foregoing shall not be deemed to include any Business Books and Records);
2.2.all cash and cash equivalents of Seller;
2.3.(a) all corporate minute books (and other similar corporate records) of Seller, (b) any books and records to the extent relating to the other Excluded Assets, (c) all Tax Returns and other Tax records (including work papers) of Seller (but excluding all Business Tax Records) and (d) any books, records or other materials or permits that Seller (i) is required by Law to retain (copies of which, to the extent relating to the Purchased Assets or the Assumed Liabilities and to



the extent not prohibited by Law, will be made available to Buyer upon Buyer’s reasonable request) or (ii) is prohibited by Law from delivering to Buyer (collectively, the “Excluded Books and Records”); and
2.4.all Contracts (and all rights thereunder) other than the Assumed Contracts.
2.2.Excluded Liabilities. Buyer shall not assume, nor become responsible for, any Liabilities of Seller other than the Assumed Liabilities (collectively, the “Excluded Liabilities”), each of which shall remain the Liability of Seller. For the avoidance of doubt, Excluded Liabilities includes all Liabilities arising out of, in respect of or relating to:
2.1.the ownership of the Purchased Assets or the operation or conduct of the Business prior to the Closing;
2.2.all trade accounts payable, regardless of when incurred, billed or imposed, of Seller;
2.3.the Excluded Assets;
2.4.(a) the portion of the Transfer Taxes that are the responsibility of Seller pursuant to Section 6.2.1, (b) all Taxes of or imposed on Seller for any Tax period, and (c) any Taxes of or with respect to the Business or the Purchased Assets for any Pre-Closing Tax Period, (which in the case of a Straddle Period, shall be allocated to the Pre-Closing Tax Period in accordance with the methodology set forth in Section 6.2.3) including any such Taxes that Buyer is liable for as withholding agent or transferee;
2.5.any indebtedness of Seller;
2.6.all Liabilities related to the employment or service (or the termination of employment or service) of any Person at any time by Seller, including all Liabilities arising under, pursuant to or in connection with, any Seller employee plan or any other compensation or benefit plan, program, policy, Contract or other arrangement that is or was at any time established, sponsored, maintained or contributed to (or required to be contributed to) by Seller or with respect to which Seller has or could have any Liability or obligation (whether current or contingent);
2.7.this Agreement and the other Transaction Documents (other than Liabilities or obligations attributable to any failure by Buyer to comply with the terms hereof or thereof); and
2.8.the Specified IP Matters; and
2.9.all Liabilities of Seller outstanding at Closing with respect to the supply of any remaining quantity of the Initial Order or Expedited Initial Order pursuant to Section 3.4 of the Takasago Agreement to Takasago International Corporation for which payment, as the Extension Credit, has been made pursuant to Section 4.1(e) of the Takasago Agreement.
2.2.Initial Purchase Price.
2.5.1.In consideration of the sale and transfer of the Purchased Assets, Buyer agrees to assume the Assumed Liabilities and pay to Seller, a non-refundable Purchase Price of One Hundred Fifty Million ($150,000,000) US Dollars (the “Initial Purchase Price”), settlement of



which shall be made in accordance with the Funds Flow Instruction Letter mutually agreed and delivered by the Parties on the date hereof. The portion of the Initial Purchase Price payable to Seller shall be paid by wire transfer of immediately available funds in accordance with Funds Flow Instruction Letter.
2.5.2.The Parties acknowledge and agree that the Initial Purchase Price has been calculated in part based on the estimated Inventory and Accounts Receivable to be delivered hereunder. To the extent that the aggregate value of the Inventory and the Accounts Receivable delivered at the Closing is less than or more than $[*], the Earn-Out Payment for calendar year 2022, or in later years to the extent the 2022 Earn-Out Payment is insufficient, will be reduced or increased by such difference.
2.6.    Withholding. Notwithstanding anything in this Agreement to the contrary, Buyer shall be entitled to deduct and withhold from any amounts otherwise payable pursuant to the Agreement or otherwise pursuant to the Contemplated Transactions any amounts that it is required to deduct and withhold with respect to the making of such payments under any provision of applicable Law; provided, that Buyer shall (a) provide Seller with a written notice of its intention to withhold, along with reasonable details regarding the provisions of applicable Law that require such deduction or withholding, at least five (5) days prior to any such withholding, (b) use commercially reasonable efforts to cooperate with Seller in order to minimize any such withholdings or deductions (including by accepting any properly completed and duly executed documentation that is provided by Seller), (c) timely pay any withheld Taxes to the appropriate Governmental Authority and (d) provide proof of payment the withheld Taxes to Seller within fifteen (15) days following the date of such payment. Any such withheld amounts shall be treated for all purposes of this Agreement as having been paid to Seller. In the event that (a) Buyer assigns any or all rights under this Agreement to an Affiliate pursuant to Section 8.4 and (b) Buyer (or its Affiliate) is obligated to deduct and withhold from any amounts otherwise payable pursuant to the Agreement by Buyer arises under applicable Law, Buyer shall pay to Seller an additional amount so that the net amount received by Seller will equal the full amount which would have been received Seller had no such deductions or withholdings been made; provided, however, that no additional amounts shall be required to be paid to Seller under this Section 2.6 to the extent that withholding would have otherwise been required had Buyer acquired the Purchased Assets directly and not assigned all or a portion of its rights to the applicable Affiliate.
ARTICLE 3
CLOSING; CLOSING DELIVERIES
3.1.Closing. The closing of the Contemplated Transactions (the “Closing”) shall take place through the electronic exchange of deliveries and executed documents as the Parties agree (including remotely by exchange of signature pages by facsimile or in electronic format, including in PDF or similar format) on the date hereof (the “Closing Date”). The Closing will be deemed to occur at 12:01 a.m., Central European Time, on the Closing Date.
3.2.Deliveries by Buyer. At Closing, Buyer shall deliver, or cause to be delivered, to Seller, the following:
3.1the Bill of Sale and Assignment and Assumption Agreement, duly executed by Buyer;



3.2the License and Drawing Rights Agreement, duly executed by Buyer;
3.3the Supply Agreement, duly executed by Buyer;
3.4an annex to the written Consents of each of Givaudan and Firmenich to the assignment of the Assumed Contracts to which it is a party containing additional terms agreed to by Buyer, Seller and, as applicable, Givaudan and Firmenich, and duly executed by Buyer;
3.5the Initial Purchase Price, paid in accordance with Section 2.5.
3.3Deliveries by Seller. At Closing, Seller shall deliver, or cause to be delivered, to Buyer:
3.3.1.the Bill of Sale and Assignment and Assumption Agreement, duly executed by Seller;
3.3.2.the License and Drawing Rights Agreement, duly executed by Seller;
3.3.3.the Supply Agreement, duly executed by Seller;
3.3.4.a written Consent by each of Givaudan, Firmenich and Takasago with respect to the assignment of the Assumed Contracts to which it is a party to Buyer, and, in the case of Givaudan and Firmenich an Annex containing additional terms agreed to by Buyer, Seller and, as applicable, Givaudan and Firmenich, and duly executed by Seller;
3.3.5.a valid and duly executed IRS Form W-9 of Seller;
3.3.6.each of the items set forth on Schedule 3.3;
3.3.7.a complete and accurate electronic copy of the contents of the Data Room as at 9:00 a.m. New York time on the Business Day prior to the date of this Agreement, which for the avoidance of doubt will be delivered in Switzerland; and
subject to Section 3.4, physical possession of all tangible Purchased Assets, together with all such other Transfer Documents to vest in Buyer good and marketable title to all of the Purchased Assets, free and clear of all Encumbrances (other than Permitted Encumbrances).
3.4.Further Assurances. Seller shall use its reasonable best efforts to identify and locate the documents and records included in the Purchased Assets and at Closing will deliver the documents and records so located. From time to time, at Buyer’s or Seller’s request, whether on or after the Closing Date, Buyer or Seller, as the case may be, shall, for no further consideration, execute and deliver such further instruments of conveyance, transfer and assignment and take such other commercially reasonable actions as Buyer or Seller, as the case may be, may reasonably require of the other Party to more effectively assign, convey and transfer to Buyer the Purchased Assets and effect the assumption by Buyer of the Assumed Liabilities, in each case on the terms and conditions set forth in this Agreement.
3.5.Earn-Out Payments. Upon the terms and subject to the conditions of this Agreement, as additional consideration for the transfer of the Purchased Assets to Buyer pursuant to Section 2.1, Buyer shall pay to or for the account of the Seller an amount in cash calculated with respect to the Earn-Out Period as follows:



3.5.1.Subject to Section 3.5.4 and, Section 3.5.5 and Section 3.5.7 for the calendar year 2024, for each calendar year beginning on January 1, 2022 through December 31, 2024 (the “Earn-Out Period”), Buyer shall make the payments described in this Section 3.5.1 (each such annual amount, an “Earn-Out Payment”) in the manner set forth in Section 3.5.3; provided that the aggregate Earn-Out Payments to be paid pursuant to this Section 3.5 shall under no circumstances exceed $235,000,000 (the “Aggregate Earn-Out Cap”) (excluding any adjustment under Section 2.5.2):
(a)The Earn-Out Payment for calendar year 2022 shall be equal to (i) 9.0 multiplied by (ii) Annual Launch Business EBITDA for calendar year 2022;
(b)The Earn-Out Payment for calendar year 2023 shall be paid only if Annual Launch Business EBITDA for calendar year 2023 exceeds Annual Launch Business EBITDA for calendar year 2022. In such event, the Earn-Out Payment for calendar year 2023 shall be equal to (i) 9.0 multiplied by (ii) the difference of (A) Annual Launch Business EBITDA for calendar year 2023, minus (B) Annual Launch Business EBITDA for calendar year 2022; provided, that if Annual Launch Business EBITDA for calendar year 2023 is higher than the Launch Business Forecast Amount for calendar year 2024, such Earn-Out Payment shall be reduced by the amount of such difference;
(c)The Earn-Out Payment for calendar year 2024 shall be paid only if Annual Launch Business EBITDA for calendar year 2024 exceeds the greater of (x) Annual Launch Business EBITDA for calendar year 2022 and (y) Annual Launch Business EBITDA for calendar year 2023. In such event, the Earn-Out Payment for calendar year 2024 shall be equal to (i) 9.0 multiplied by (ii) the difference of (A) Annual Launch Business EBITDA for calendar year 2024, minus (B) the greater of (x) Annual Launch Business EBITDA for calendar year 2022 and (y) Annual Launch Business EBITDA for calendar year 2023.
3.5.2.As soon as reasonably practicable following each of the calendar years 2022, 2023 and 2024, Buyer will within sixty (60) days after the end of such calendar year, prepare and deliver to the Buyer a written schedule (the “Earn-Out Schedule”) setting forth its good faith calculations of Annual Launch Business EBITDA and the Earn-Out Payment for such calendar year, including the basis for such computations set forth in reasonable detail. Upon receipt of the Earn-Out Schedule, the Seller shall have thirty (30) days (the “Review Period”) to review the Earn-Out Schedule and related computations of Annual Launch Business EBITDA and the Earn-Out Payment. In connection with such review of the Earn-Out Schedule, Buyer shall, and shall cause the Launch Business to make available, to the Seller and its Representatives such documents, books, records, work papers, facilities, personnel and other information of Buyer and the Launch Business, in each case as the Seller may reasonably request in order to permit the timely review of the Earn-Out Schedule in accordance with this Section 3.5.2. If the Seller has accepted such EarnOut Schedule in writing or has not given written notice to Buyer setting forth in reasonable detail any objection of the Seller to the Earn-Out Schedule (an “Earn-Out Payment Statement of Objections”) prior to the expiration of the Review Period, then such Earn-Out Schedule shall be final and binding upon the parties, and the Earn-Out Payment set forth on such Earn-Out Schedule shall be deemed to be the final Earn-Out Payment for the Earn-Out Period. If the Seller delivers an Earn-Out Payment Statement of Objections during the Review Period, Buyer and the Seller shall use their reasonable efforts to agree on the amount of the Earn-



Out Payment for the Earn-Out Period within fifteen (15) days following the receipt by Buyer of the Earn-Out Payment Statement of Objections. If the parties are unable to reach an agreement as to such amounts within such 15 day period, then the matter shall be submitted to a mutually agreed internationally recognized certified public accounting firm that has not performed accounting, tax or auditing services for Buyer or Seller or any of their respective Affiliates during the past three years (the “Arbitrating Accountant”). The Arbitrating Accountant’s function will be to resolve each element of the EarnOut Payment Statement of Objections that has not been resolved by Buyer and Seller, to revise the Earn-Out Schedule to reflect such resolutions and to calculate the Earn-Out Payment, if any, based on the elements and amounts reflected on the revised Earn-Out Schedule. The Arbitrating Accountant shall make such determination within fifteen (15) days following the submission of the matter to the Arbitrating Accountant for resolution, and such determination shall be final and binding upon Buyer and the Seller. In making such determination, the Arbitrating Accountant will be bound by the provisions of this Agreement and may not revise any element of the Earn-Out Payment Statement of Objections that is not contested in the Earn-Out Payment Statement of Objections or assign a value to any disputed element of the Earn-Out Payment Statement of Objections greater than the greatest value for such item claimed by either party or less than the smallest value for such item claimed by either party. Each of the Arbitrating Accountant’s decision, the revised Earn-Out Payment Statement of Objections and the revised calculation of the Earn-Out Payment, if any, will be final and binding upon the parties, and judgment may be entered on the award. Buyer and Seller shall share the fees and expenses of the Arbitrating Accountant in inverse proportion to the relative amounts subject to the Earn-Out Payment Statement of Objections determined in favor of such party, in accordance with the following formulas: (i) Seller shall pay a portion of such fees and expenses equal to the total fees and expenses multiplied by a fraction, the numerator of which is the dollar amount subject to the Earn-Out Payment Statement of Objections resolved in favor of Buyer and the denominator of which is the total dollar amount subject to the Earn-Out Payment Statement of Objections and (ii) Buyer shall pay a portion of such fees and expenses equal to the total fees and expenses multiplied by a fraction, the numerator of which is the dollar amount subject to the Earn-Out Payment Statement of Objections resolved in favor of Seller and the denominator of which is the total dollar amount subject to the Earn-Out Payment Statement of Objections.
3.5.3.If Seller is entitled to an Earn-Out Payment for any of the calendar years 2022, 2023 or 2024, Buyer shall pay such Earn-Out Payment by wire transfer of immediately available funds, to the Seller or to such accounts as designated by the Seller in writing to Buyer, no later than March 31 of the immediately following calendar year (i.e., the Earn-Out Payment for calendar year 2022 shall be paid no later than March 31, 2023); provided, that if the amount of such Earn-Out Payment has not been finally determined in accordance with Section 3.5.2 prior to March 31, such EarnOut Payment shall be paid within 10 days following the date on which such Earn-Out Payment has been finally determined.
3.5.4.In the event that Annual Launch Business EBITDA for the calendar year 2024 is less than Annual Launch Business EBITDA for the calendar year 2022 or the calendar year 2023, then Seller shall pay to Buyer an amount equal to (a) 9.0 multiplied by (b) the amount by which Annual Launch Business EBITDA for the calendar year 2024 is less than the greater of (i) the Annual Launch Business EBITDA for the calendar year 2022 or (ii) the Annual Launch Business



EBITDA for the calendar year 2023 (such resulting product of clauses (a) and (b), the “Shortfall Payment”). If the Shortfall Payment is greater than $0, Seller shall pay the Shortfall Payment to Buyer by wire transfer of immediately available funds, to Buyer or to such accounts as designated by Buyer in writing to Seller, no later than March 31, 2025; provided, that if Annual Launch Business EBITDA for the calendar year 2024 has not been finally determined in accordance with Section 3.5.2 prior to March 31, 2025, such Shortfall Payment shall be paid within 10 days following the date on which Annual Launch Business EBITDA for the calendar year 2024. Notwithstanding the foregoing, Buyer may elect, in its sole discretion, to reduce the Earn-Out Payment for calendar year 2024 by the amount of the Shortfall Payment, and in such event, no further Shortfall Payment shall be required hereunder.
3.5.5.The Earn-Out Payment for the calendar year 2022 shall be reduced on a dollar-for- dollar basis by the amount by which the share profits actually paid by Firmenich to Buyer pursuant to Section 21.2 of the Firmenich Collaboration Agreement (excluding [*]) during the calendar years 2021 and 2022 are less than the target amounts for such periods set forth on Schedule 3.5.5 (the “2022 Value Share Guarantee Amount”); provided that if such actual payments are equal to 90% or more of such target amounts, the 2022 Value Share Guarantee Amount shall be zero ($0) dollars. The Earn-Out Payment for the calendar year 2023 shall be reduced on a dollar-for- dollar basis by the amount by which the share profits actually paid by Firmenich to Buyer pursuant to Section 21.2 of the Firmenich Collaboration Agreement during the calendar year 2023 is less than the target amounts for such period set forth on Schedule 3.5.5 (the “2023 Value Share Guarantee Amount”); provided that if such actual payments are equal to 90% or more of such target amounts, the 2023 Value Share Guarantee Amount shall be zero ($0) dollars. The Earn-Out Payment for the calendar year 2024 shall be reduced on a dollar-for-dollar basis by the amount by which the share profits actually paid by Firmenich to Buyer pursuant to Section 21.2 of the Firmenich Collaboration Agreement during the calendar year 2024 is less than the target amounts for such period set forth on Schedule 3.5.5 (the “2024 Value Share Guarantee Amount”); provided that if such actual payments are equal to 90% or more of such target amounts, the 2024 Value Share Guarantee Amount shall be zero ($0) dollars.
3.5.6.In the event that the Earn-Out Payment for any of the calendar years 2022, 2023 or 2024 is less than any of the 2022 Value Share Guarantee Amount, 2023 Value Share Guarantee Amount or 2024 Value Share Guarantee Amount (each, a “Guarantee Amount”), then Seller shall pay the difference of such Earn-Out Payment and Guarantee Amount to Buyer by wire transfer of immediately available funds or to such account as designated by Buyer in writing to Seller.
3.5.7.Notwithstanding the foregoing, subj ect to the Aggregate Earn-Out Cap, in the event that the aggregate volume of [*]sold by Buyer during the years 2022 through 2024 is equal to or less than [*], which reflects [*]% of the current forecast:
(a)the aggregate amount of Earn-Out Payments to which Seller shall be entitled to receive hereunder shall be no greater than an amount equal to the sum of: (i) (A) 8.0 multiplied by (B) the lesser of (x) $20,000,000 and (y) Annual Launch Business EBITDA for calendar year 2024, plus (ii) (I) 9.0 multiplied by (II) the extent to which Annual Launch Business EBITDA for calendar year 2024 exceeds $20,000,000 (the “[*] Adjustment Cap”), and the Earn-



Out Payment for the calendar year 2024 shall be reduced as may be necessary to give effect to the [*] Adjustment Cap; and
(b)if the aggregate amount of Earn-Out Payments previously paid to Seller under this Section 3.5 is greater than the [*] Adjustment Cap, Seller shall refund any such excess amounts by wire transfer of immediately available funds, to Buyer or to such accounts as designated by Buyer in writing to Seller, no later than March 31, 2025.
3.5.8.During the Earn-Out Period Buyer shall, and shall cause the Launch Business to maintain such books and records related to the Launch Business (including with respect to the inputs for the Launch Business Forecast Amount) sufficient to allow independent verification of the results of the operations of the Launch Business, including for purposes of calculating the Earn-Out Payment and the Launch Business Forecast Amount for each year. Buyer shall not, directly or indirectly, take any actions, or omit to take any actions, in bad faith for the purpose of avoiding or reducing an Earn-Out Payment.
3.5.9.It is the intention of Buyer and Seller that the sale and purchase of the Purchased Assets pursuant to this Agreement in exchange for Seller’s right to receive the Earn-Out Payments shall qualify as an “installment sale” within the meaning of Section 453 of the Code.
3.6.Wrong Pockets.
3.6.1.If at any time after the Closing, Seller (a) receives any payment, remittance or other amount in respect of any Purchased Asset or Assumed Liability or (b) is in possession of any Purchased Assets, then, in each case, Seller shall transfer such funds or assets to Buyer (or Buyer’s designee) as soon as reasonably practicable upon identification of such funds or assets, for no additional consideration; it being acknowledged and agreed that Buyer shall have already paid full consideration for all such funds and assets by payment of the Purchase Price. Prior to any such transfer, Seller shall preserve the value of and hold in trust for the use and benefit of Buyer of such funds or assets and provide to Buyer all of the benefits arising from such funds or assets and otherwise cause such funds or assets to be used as reasonably instructed by Buyer.
3.6.2.If at any time after the Closing, Buyer (a) receives any payment, remittance or other amount in respect of any Excluded Asset or Excluded Liability or (b) is in possession of any Excluded Assets that were transferred to Buyer in error, then, in each case, Buyer shall promptly transfer such funds or assets to Seller (or Seller’s designee) as soon as reasonably practicable upon identification of such funds or assets, for no consideration (net of any reasonable fees and expenses incurred by as a result of such error). Prior to any such transfer, Buyer shall preserve the value of and hold in trust for the use and benefit of Seller of such funds or assets and provide to Seller all of the benefits arising from such funds or assets and otherwise cause such funds or assets to be used as reasonably instructed by Seller.
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF SELLER
Seller hereby represents and warrants to Buyer, as of the date of this Agreement, that:



4.1.Organization and Authority. Seller is a corporation validly existing and in good standing under the laws of the State of Delaware. Seller has all necessary corporate power and authority to enter into, execute and deliver this Agreement and each other Transaction Document to which it is a party, to carry out its obligations hereunder and thereunder, and to consummate the Contemplated Transactions. The execution and delivery by Seller of this Agreement and of each other Transaction Document to which it is a party, the performance by Seller of its obligations hereunder and thereunder and the consummation by Seller of the Contemplated Transactions have been authorized by all requisite corporate action. This Agreement and each other Transaction Document to which Seller is a party has been duly and validly executed by Seller, and, assuming the due authorization, execution and delivery by Buyer, this Agreement and each such other Transaction Document is a legal, valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws now or hereafter in effect relating to or affecting creditors’ rights generally and rules of law and general equitable principles, including those governing specific performance, injunctive relief and other equitable remedies (the “Enforceability Exceptions”).
4.2.No Conflicts; Consents. The execution, delivery and performance of this Agreement and each other Transaction Document to which Seller is a party by Seller do not and will not, and the consummation of the Contemplated Transactions and compliance with the terms and conditions hereof and thereof by Seller do not and will not: (a) violate, conflict with or result in the breach of the organizational documents of Seller; (b) result in a material breach, material violation of, or material default under, or create in any Person the right to terminate, cancel, accelerate or modify, require any Consent under, or result in the loss of any material benefit to which Seller is entitled under (in each case whether after the giving of notice or the lapse of time of both), any Assumed Contracts or any other Contract to which any of the Purchased Assets is subject or Seller is bound;
(c)conflict with or violate, in any material respect, any Law applicable to Seller or the Purchased Assets; or (d) result in the creation of an Encumbrance upon any of the Purchased Assets except, in the case of clauses (b), (c) and (d), as would not, individually or in the aggregate, reasonably be expected to (i) prevent, materially delay or materially and adversely affect the ability of Seller to carry out its obligations under this Agreement or the other Transaction Documents or to consummate the Contemplated Transactions, (ii) result in material Liability to Buyer or (iii) materially impair the operation of the Business as currently conducted.
4.3.Consents and Approvals. The execution, delivery and performance of this Agreement and the other Transaction Documents by Seller, and the consummation of the Contemplated Transactions by Seller, do not require any Consent of any Governmental Authority or other Person, except to the extent failure to obtain such Consent would not (i) prevent, materially delay or materially and adversely affect the ability of Seller to carry out its obligations under this Agreement or the other Transaction Documents or to consummate the Contemplated Transactions, (ii) result in material Liability to Buyer or (iii) materially impair the operation of the Business as currently conducted. The Business does not (i) produce, design, test, manufacture, fabricate, or develop “critical technologies” as that term is defined in 31 C.F.R. § 800.215; (ii) perform the functions as set forth in column 2 of Appendix A to 31 C.F.R. part 800 with respect to covered investment “critical infrastructure”; or (iii) maintain or collect, directly or indirectly, “sensitive personal data” as that term is defined in 31 C.F.R. § 800.241; and, therefore, in turn, none of the



Persons conducting the Business is a “TID U.S. business” within the meaning of 31 C.F.R. § 800.248.
4.4.Compliance with Law; Litigation and Claims. Seller and each of its Affiliates is not in default or violation of any Law in any material respect applicable to the Purchased Assets or the Assumed Liabilities or by which any of the Purchased Assets or Assumed Liabilities is bound. There is no Action pending or, to the Knowledge of Seller, threatened, against Seller, related to the Purchased Assets or the Assumed Liabilities. There are no outstanding writs, injunctions, decrees, arbitration unsatisfied decisions, unsatisfied judgments or orders issued by any Governmental Authority outstanding against Seller or to which any of the Purchased Assets or Assumed Liabilities is subject or bound.
4.5.Purchased Assets.
4.5.1.Title to Purchased Assets. Seller has good and valid title to and the right to transfer (or cause to be transferred) all Purchased Assets, in accordance with the terms of this Agreement, free and clear of all Encumbrances (other than Permitted Encumbrances).
4.5.2.Completeness of Purchased Assets. The Purchased Assets, together with the Intellectual Property rights licensed to Buyer under the License and Drawing Rights Agreement, constitute all of the assets, rights, privileges and properties necessary for Buyer to conduct the Business in substantially the same manner immediately following the Closing as currently conducted by Seller, except that Buyer acknowledges that it is not purchasing any real property, manufacturing equipment or manufacturing Contracts or any other Excluded Assets that are necessary for Buyer to conduct the Business.
4.6.Tax Matters. All material Tax Returns required to have been filed by Seller or otherwise with respect to the Purchased Assets have been duly filed, and all Taxes required to have been paid by Seller or otherwise with respect to or that could become an Encumbrance on the Purchased Assets have been paid. There are no rulings, settlement or closing agreements or other transactions or agreements entered into prior to the Closing with respect to Taxes pertaining to the Purchased Assets that would bind Buyer or give rise to any Tax liability for Buyer or its Affiliates after the Closing. There are no Encumbrances for Taxes on any of the Purchased Assets, other than Permitted Encumbrances. There are no audits, examinations, investigations or other proceedings with respect to Taxes pending or threatened relating to or that could result in an Encumbrance on the Purchased Assets, and no claim has been made by a Governmental Authority that Tax Returns with respect to the Purchased Assets should be filed which have not been filed. None of the Purchased Assets are “tax-exempt use property” within the meaning of Section 168(h) of the Code, are “tax-exempt bond financed property” within the meaning of Section 168(g) of the Code, secure any debt the interest of which is tax-exempt under Section 103(a) of the Code or are subject to a “section 467 rental agreement” within the meaning of Section 467 of the Code (or in each case, similar or corresponding provisions of applicable state Tax Law). Notwithstanding anything in this Agreement to the contrary, the representations and warranties contained in this Section 4.6 (i) shall not apply to the extent that a breach of such representations or warranties would not result in any Taxes or other liabilities or obligations for Buyer and Buyer’s Affiliates and also would not result in any Encumbrances on the Purchased Assets and (ii) constitute the sole representations and warranties being made by Seller with respect to Taxes.



4.7.Assumed Contracts. Seller has made available to Buyer true and complete copies of all Assumed Contracts. Each Assumed Contract is a valid and binding obligation of Seller and, to the Knowledge of Seller, the other party thereto, and is in full force and effect, in each case subject to the Enforceability Exceptions. Neither Seller nor, to the Knowledge of Seller, any other party thereto is in material breach of, or material default under, any Assumed Contract, and no event has occurred that, with the giving of notice or lapse of time or both, would constitute a material breach or material default thereunder. Seller has not received written notice of termination, cancellation or non-renewal with respect to any Assumed Contract. No Assumed Contract has been amended or otherwise modified. Other than the Assumed Contracts, there are no Contracts between Seller, on the one hand, and any of Givaudan, Firmenich or Takasago, on the other hand, with respect to the Business.
4.8.Inventory. As of the Closing Date, the Inventory (a) is good, saleable and merchantable in the ordinary course of business with a shelf life of no less than [*], and [*] for volumes of Manool delivered at Closing exceeding [*], (b) was produced or manufactured in accordance with the specifications for the Molecule as set forth in material compliance with applicable Law and the Assumed Contracts and (c) is not adulterated and is of suitable quality. The Inventory has a fair market value of no less than $1,909,500, calculated in a manner consistent with GAAP as applied in Seller’s historical practice.
4.9.R&D Obligations. Seller has completed, and is in compliance with all of the obligations under the Assumed Contracts with respect to, all research and development actions and obligations in connection with all of the applicable products that have been commercialized by Givaudan and Firmenich.
4.10.Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of any of Seller for which Buyer would have any Liability.
4.11 No Implied Representations. Notwithstanding anything to the contrary contained in this Agreement, Seller has not made any representation or warranty whatsoever, express or implied, other than those representations and warranties of Seller expressly set forth in this Article 4. Neither Seller nor any of its Affiliates nor any of their respective Representatives make any representation or warranty to Buyer or any of its Affiliates or any of their respective Representatives with respect to any forward-looking projections, estimates or budgets heretofore made available to Buyer or any of its Affiliates or any of their respective Representatives of future revenues, expenses or expenditures or future results of operations of the Business or the Purchased Assets any other information or documents made available to Buyer or any of its Affiliates or any of their respective Representatives.
ARTICLE 5
REPRESENTATIONS AND WARRANTIES OF BUYER
Buyer represents and warrants to Seller as of the date of this Agreement:
5.1.Organization and Authority. Buyer is a corporation duly organized and in good standing under the laws of Switzerland. Buyer has all necessary corporate power and authority to enter into, execute and deliver this Agreement and each other Transaction Document to which it is a



party, to carry out its obligations hereunder and to consummate the Contemplated Transactions. The execution and delivery by Buyer of this Agreement and each other Transaction Document to which it is a party, the performance by Buyer of its obligations hereunder and thereunder and the consummation by Buyer of the Contemplated Transactions have been authorized by all requisite corporate action on the part of Buyer. This Agreement and each other Transaction Document to which Buyer is a party has been duly and validly executed and delivered by Buyer, and, assuming the due authorization, execution and delivery by Seller, this Agreement and each such other Transaction Document is a legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, subject to the Enforceability Exceptions.
5.2.No Conflicts; Consents. The execution, delivery and performance of this Agreement and of each other Transaction Document to which Buyer is a party by Buyer do not and will not, and the consummation of the Contemplated Transactions and compliance with the terms and condition hereof and thereof by Buyer do not and will not: (a) violate, conflict with or result in the breach of the organizational documents of Buyer; (b) result in a breach, violation of or default under (whether after the giving of notice or the lapse of time or both), or create in any Person the right to terminate, cancel, accelerate or modify, or require any Consent under, any Contract to which Buyer is a party or to which its properties or assets are subject; (c) conflict with or violate any Law applicable to Buyer, except, in the case of clauses (b) and (c), as would not, individually or in the aggregate, reasonably be expected to prevent, materially delay or materially and adversely affect the ability of Buyer to carry out its obligations under this Agreement or the other Transaction Documents or to consummate the Contemplated Transactions.
5.3.Consents and Approvals. The execution, delivery and performance of this Agreement and the other Transaction Documents by Buyer, and the consummation of the Contemplated Transactions by Buyer, do not require any Consent of any Governmental Authority or other Person, except to the extent failure to obtain such Consent would not prevent, materially delay or materially and adversely affect the ability of Buyer to carry out its obligations under this Agreement or the other Transaction Documents or to consummate the Contemplated Transactions.
5.4.Sufficient Funds. Buyer has full financial capacity to comply with the payment obligations provided in this Agreement.
5.5.No Other Representations. Except for the representations and warranties expressly set forth in Article 4, Buyer acknowledges that none of the Seller nor any of its Affiliates nor any of their respective Representatives nor any other Person makes, and Buyer acknowledges that it has not relied upon or otherwise been induced by, any express or implied representation or warranty with respect to Seller, the Business or the Purchased Assets or with respect to any other information provided or made available to Buyer or its Affiliates or their respective Representatives in connection with the Contemplated Transactions, including any information, documents, projections, forecasts or other material made available to Buyer or its Affiliates or their respective Representatives in certain “data rooms” or management presentations in expectation of the Contemplated Transactions or the accuracy or completeness of any of the foregoing, except, in each case for the representations and warranties expressly set forth in Article 4 hereof.



ARTICLE 6
COVENANTS
6.1.Expenses. All expenses, including the fees of any attorneys, accountants, investment bankers or others engaged by a Party, incurred in connection with this Agreement and the Contemplated Transactions, shall be paid by the Party incurring such fees and expenses, whether or not the Contemplated Transactions are consummated.
6.2.Tax Matters.
6.2.1.Any Transfer Taxes shall be borne and paid fifty percent (50%) by Buyer and fifty percent (50%) by Seller provided, that any Transfer Taxes that are fully refundable or creditable to a particular Person shall be borne exclusively by such Person. The Person required by applicable Law to file a Tax Return relating to Transfer Taxes and pay any Transfer Taxes shall do so within the time period prescribed by applicable Law. If Seller remits to the appropriate Governmental Authority a payment for any Transfer Taxes (including as a result of an audit or examination of Seller), Buyer shall promptly reimburse Seller for the full amount of Transfer Taxes paid by Seller to the Governmental Authority. Buyer and Seller shall, and shall cause their respective affiliates to, cooperate in connection with the filing of any Tax Return for Transfer Taxes including joining in the execution of such Tax Return for Transfer Taxes and in obtaining all available reductions in or exemptions from such Transfer Taxes.
6.2.2.After the Closing, upon reasonable request and without limiting the other provisions of the this Agreement, Buyer, on the one hand, and Seller, on the other hand, agree to furnish or cause to be furnished to each other and their Representatives reasonable cooperation with respect to Tax matters pertaining to the Purchased Assets and the Assumed Liabilities including the furnishing or making available of records, personnel, or other materials reasonably necessary for the preparation or filing of Tax Returns or the defense of an audit, examination, judicial or administrative proceeding; provided, however, that this Section 6.2.2 shall not require any Party to share its or its Affiliates’ Tax Returns with the other Party.
6.2.3.In the case of any Straddle Period, the amount of any property, ad valorem or similar Tax in respect of the Purchased Assets or the Assumed Liabilities shall be apportioned between the portion of such Straddle Period included and the Pre-Closing Tax Period and the remainder of such Straddle Period by allocating such Taxes on a daily basis for each day in the entire Straddle Period.
6.2.4.Unless the relevant action is expressly required by applicable Law, following the Closing, except as consented to by Seller (such consent not to be unreasonably withheld, conditioned or denied), Buyer shall not, and shall not permit its Affiliates to, (i) file any Tax Returns or amended Tax Returns which relate exclusively to the Purchased Assets or the Assumed Liabilities for a Pre-Closing Tax Period, (ii) take any action with respect to the Purchased Assets or the Assumed Liabilities on the Closing Date, but after the Closing, outside the ordinary course of business or (iii) initiate or enter into any voluntary disclosure agreement or similar program for Taxes with any Governmental Authority that relates to t the Purchased Assets or the Assumed Liabilities for a Pre-Closing Tax Period, in each case, if the applicable action would be reasonably expected to (A) increase the Taxes of Seller or (B) increase the amount of the indemnification obligations of Seller under Section 7.2.1 with respect to Taxes.



6.2.5.Except as otherwise required by applicable Law, Buyer and Seller shall, and shall cause their respective Affiliates to, treat any Earn-Out Payments under Section 3.5 and any indemnification payments made pursuant to Article 7 as adjustments to the aggregate consideration paid by Buyer for the Purchased Assets for applicable Tax purposes.
6.3    Confidentiality.
6.3.1.Seller agrees that, from and after the Closing, all non-public information included in the Purchased Assets and any other non-public information related to the Purchased Assets or the Assumed Liabilities other than information belonging to a Third Party is deemed to be confidential information of Buyer (“Confidential Information”) and Seller shall keep confidential and not disclose to any Third Party or use any such information; provided that Seller may use or disclose the Confidential Information (a) for the purpose of complying with or enforcing Seller’s rights, covenants and obligations under this Agreement or any other Transaction Document and (b) in connection with Seller’s defense against, or prosecution of, any Action relating to the Business or the Purchased Assets, including the defense against or prosecution of any Action relating to (i) the ownership of the Purchased Assets prior to the Closing, (ii) the Assumed Contracts with respect to any period prior to the Closing or (iii) the operation or conduct of the Business prior to the Closing.
6.3.2.Seller agrees, from and after the Closing, to enforce all rights of Seller in connection with any obligation of any current or former employees, independent contractors or consultants of the Business owed to Seller to refrain from competing with all or any portion of the Business or disclosing any Confidential Information or other non-public or proprietary information of the Business.
6.4.Cooperation in Litigation Matters. Each Party agrees to, after the Closing, reasonably cooperate with the other Party and any of the other Party’s Affiliates in connection with the defense by such requesting Party or any of its Affiliates against, or the prosecution of, any Action commenced by a Third Party relating to the Purchased Assets or the Assumed Liabilities, including by permitting the Representatives of such requesting Party (including legal counsel and accountants) to (a) have reasonable access at reasonable times, and in a manner so as not to interfere with the normal business operations of the other Party, to the other Party and its Representatives and to the books, records, contracts and documents included in the Purchased Assets or the Assumed Liabilities or otherwise to the extent relating to the Purchased Assets or the Assumed Liabilities and (b) make copies of any of the items described in clause (a).
6.5.Escrow Agreement. Following the Closing, and within the time frame(s) agreed by each of Givaudan and Firmenich, each of Buyer and Seller shall deliver the Escrow Agreement, duly executed by such party.
6.6.Conduct of the Business. Following the Closing, Seller will not enter into any Contracts related to the Business, the Molecules or the Future Molecules (as defined in the License Agreement) with any of Givaudan, Firmenich or Takasago or any of their respective Affiliates without the prior written consent of Buyer, which shall not be unreasonably withheld, except as it may relate to existing Firmenich research and development of the Molecules, and to the extent related to Firmenich, the Future Molecules (as defined in the License Agreement) or intellectual



property matters and in each case, subject to the confidentiality obligations imposed on Seller by Givaudan and Firmenich.
ARTICLE 7
INDEMNIFICATION
7.1.Survival. All of the representations, warranties and covenants contained in this Agreement (other than the representations and warranties set forth in Section 4.1, Section 4.9 and Section 5.1) shall survive the Closing until the twelve-month anniversary of the Closing Date. The representations and warranties set forth in Section 4.1, Section 4.9 and Section 5.1 shall survive until the six-year anniversary of the Closing Date. Notwithstanding the foregoing (a) any obligation to indemnify, defend and hold harmless pursuant to this Article 7 shall not terminate with respect to any item as to which the Indemnified Party shall have, before the expiration of the applicable survival period, previously made a claim by delivering a written notice of such claim to the Indemnifying Party in accordance with Section 7.4 and (b) nothing in this Section 7.1 shall be deemed to limit the survival of, or the ability of any Party to make a claim arising out of, any covenant or agreement of any Party that by its terms contemplates or requires performance after the Closing or that is set forth in this Article 7 (including Section 7.2.1(b) and Section 7.2.2) or Article 8.
7.2.Indemnification.
7.2.1.From and after the Closing, Seller shall indemnify and hold harmless Buyer, its Affiliates and its and their respective Representatives and controlling persons with respect to:
(a)any and Losses resulting from, arising out of or related to any breach or inaccuracy in any of the representations or warranties made by Seller in Article 4 of this Agreement;
(b)any and all Losses resulting from, arising out of or related to any Excluded Liability; and
(c)any compensation that may become payable to [*] in connection with Amendment 2, [*] of the Firmenich Collaboration Agreement and [*] of the Firmenich Supply Agreement.
7.2.2.From and after the Closing, Buyer shall indemnify and hold harmless Seller and its Representatives and controlling persons with respect to any and all Losses resulting from, arising out of or related to any Assumed Liability or the portion of the Transfer Taxes that are the responsibility of Buyer under Section 6.2.1 (excluding any Losses to the extent resulting from, arising out of or related to (a) a breach or inaccuracy in any of the representations or warranties made by Seller in Article 4 of this Agreement (assuming solely for this purpose that such representations and warranties survive the Closing indefinitely) or (b) Seller’s breach of any of its covenants set forth in this Agreement).
7.3 Claims Procedure.
7.3.1.In the event that Seller or Buyer should have a claim against the other Party under this Article 7, the Party seeking indemnification (the “Indemnified Party”) shall, as promptly as



reasonably practicable after discovery of such claim, deliver written notice of such claim to the other Party (the “Indemnifying Party”). The failure by the Indemnified Party so to notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability that it may have to such Indemnified Party under this Article 7, except to the extent that the Indemnifying Party demonstrates that it has been actually prejudiced by such failure.
7.3.2.If an Indemnified Party receives notice or otherwise learns of the assertion by any Third Party of any claim or demand or of the commencement by any Third Party of any Action as to which an Indemnifying Party may be obligated to provide indemnification pursuant to this Agreement (a “Third Party Claim”), the Indemnified Party shall notify the Indemnifying Party of the Third Party Claim in writing and in reasonable detail describing the basis for any claim for indemnification hereunder and including copies of all notices and documents received by the Indemnified Party from Third Parties relating to the Third Party Claim (subject to any bona fide claims of attorney-client privilege) promptly (and in any event within thirty (30) days after receipt by such Indemnified Party of written notice of the Third Party Claim); provided, however, that the failure to provide notice of any such Third Party Claim pursuant to this sentence shall not relieve the Indemnifying Party from any liability that it may have to such Indemnified Party under this Article 7, except to the extent that the Indemnifying Party demonstrates that it has been actually prejudiced by such failure. Thereafter, the Indemnified Party shall deliver to the Indemnifying Party, promptly (and in any event within five (5) business days) after the receipt thereof by the Indemnified Party, copies of any and all additional written notices and documents (including court papers) received by the Indemnified Party from Third Parties relating to the Third Party Claim, subject to any bona fide claims of attorney-client privilege.
7.3.3.The Indemnifying Party has the right, exercisable by written notice to the Indemnified Party within thirty (30) days after receipt of notice from the Indemnified Party, to assume and conduct the defense (including settlement) of such Third Party Claim in accordance with the limits set forth in this Agreement with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. If the Indemnifying Party does not assume the defense of a Third Party Claim in accordance with this Section 7.3.3, the Indemnified Party may continue to defend the Third Party Claim. If the Indemnifying Party has assumed the defense of a Third Party Claim as provided in this Section 7.3.3, the Indemnifying Party shall not be liable for any legal expenses subsequently incurred by the Indemnified Party in connection with the defense of the Third Party Claim. The Indemnifying Party, if it has assumed the defense of any Third Party Claim as provided in this Agreement, may not, without the prior written consent of the Indemnified Party, consent to a settlement or compromise of, or the entry of any judgment arising from, any such Third Party Claim that (a) does not include as an unconditional and irrevocable release of the Indemnified Party from all Liability in connection with the Third Party Claim, (b) provides for injunctive or other nonmonetary relief affecting the Indemnified Party or any of its Affiliates, (c) involves any finding or determination of wrongdoing or violation of Law by the Indemnified Party or any of its Affiliates, or (d) in the reasonable opinion of the Indemnified Party, would otherwise materially used adversely affect the Indemnified Party or any of its Affiliates. The Indemnified Party may consent to a settlement or compromise of, or the entry of any judgment arising from, any Third Party Claim, the defense of which has not been assumed by the Indemnifying Party, only with the prior written consent of the Indemnifying Party, not to be unreasonably withheld, conditioned or delayed.



7.4.Buyer’s Off-Set Right. Buyer shall have the right to deduct from and off-set against any Earn-Out Payment the amount of any Losses payable by Seller or any of its Affiliates pursuant to Section 3.5.4, Section 3.5.5, Section 3.5.6 or this Article 7 that have not been paid prior to the date of such Earn-Out Payment.
ARTICLE 8
GENERAL
8.1.Public Statements. Neither of the Parties shall issue or cause the publication of any press release or other public announcement with respect to this Agreement or the Contemplated Transactions without consulting with and obtaining the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed; provided, however, that such consent shall not be required where such release or announcement is required by Law (including disclosure requirements as may be applicable with respect to securities exchanges on which securities of a Party or its Affiliate are traded; provided, that the Parties shall use commercially reasonable efforts to consult with the other Party prior to any such release or announcement).
8.2.Notices. All communications, notices and consents provided for herein shall be in writing and given in person, by electronic mail, by nationally recognized overnight courier service or by registered or certified mail (postage prepaid, return receipt requested), and shall become effective: (a) on delivery if given in person; (b) on the date of transmission if sent by electronic mail and the sender does not receive a delivery failure message; (c) one (1) Business Day after sending by a nationally recognized overnight courier delivery service; or (d) four (4) Business Days after being mailed, with proper postage and documentation, for first-class registered or certified mail, prepaid.
Notices shall be addressed as follows (provided that if a Party shall have designated a different address by notice to the other Party delivered pursuant to this Section 8.2, then notices shall be addressed to the last address so designated):
8.2.1.if to Seller:
Amyris, Inc.
5885 Hollis Street, Suite 100
Emeryville, CA 94608
Attention: Nicole Kelsey, General Counsel
E-mail:
8.2.2.if to Buyer:
DSM Nutritional Products Ltd.

Attention:
E-mail:
with a copy to (which copy shall not constitute notice):
Latham & Watkins LLP
330 North Wabash Avenue



Suite 2800
Chicago, IL 60611
Attention: Shaun D. Hartley; Jason Morelli
E-mail:
8.3.Amendment; Waiver; Cumulative Rights.
8.3.1.Amendment. This Agreement may not be amended or modified except by an instrument in writing signed by or on behalf of each of Buyer and Seller.
8.3.2.Waiver. Failure or delay by either Party in exercising or enforcing any provision, right, or remedy under this Agreement, or waiver of any remedy hereunder, in whole or in part, shall not be deemed a waiver thereof, or prevent the subsequent exercise of that or any other rights or remedy. Any of the terms, covenants, representations, warranties or conditions in this Agreement may be waived only by an instrument in writing signed by or on behalf of the Party waiving such compliance.
8.3.3.Cumulative Rights. Except where otherwise expressly provided herein, the rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.
8.4.Assignment. The provisions of this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns; provided that this Agreement may not be assigned by either Party without the prior written consent of the other Party, except that Buyer may freely assign any or all rights under this Agreement, without the prior written consent of Seller, (a) to one of its Affiliates, (b) as collateral to any person providing debt financing to Buyer or its Affiliates or (c) if such assignment occurs in connection with a sale of all or substantially all of its assets to which this Agreement relates, regardless of whether such sale is structured as an asset sale, merger, reorganization or similar transaction; provided, further, that no assignment shall relieve the assigning Party of any of its obligations under this Agreement. Any attempted assignment, transfer or delegation in violation of the foregoing shall be null and void.
8.5.Entire Agreement. This Agreement, together with the other Transaction Documents, constitute the entire agreement between the Parties with respect to the subject matter hereof and thereof, and cancels and supersedes all other prior agreements, arrangements, understandings and undertakings, both written and oral, between the Parties with respect to the subject matter of this Agreement and the other Transaction Documents.
8.6.Governing Law; Jurisdiction; Waiver of Jury Trial.
8.6.1.This Agreement and the other Transaction Documents shall be governed in all respects, including validity, interpretation, construction, performance and effect, by the internal laws of the State of New York, without reference to choice of law principles that would result in the application of the law of any other state or jurisdiction. The Parties agree that the federal or state courts located in the State of Delaware or any appellate court therefrom (the “Designated Courts”) shall have exclusive jurisdiction over any dispute or controversy arising out of or relating to this Agreement, the other Transaction Documents or any of the Contemplated



Transactions. Each of the Parties waives any defense of inconvenient forum to the maintenance of any Action or proceeding so brought.
8.6.2.EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY CONTEMPLATED TRANSACTION. EACH PARTY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD SEEK TO AVOID THE FOREGOING WAIVER IN THE EVENT OF LITIGATION AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.6.2.
8.7.Counterparts; Effectiveness; Third Party Beneficiaries. This Agreement may be executed in two or more counterparts which together shall constitute a single agreement. Any counterpart may be signed and transmitted by facsimile or electronic mail (including in PDF or similar format) with the same force and effect as if such counterpart was an ink-signed original. This Agreement shall become effective when each Party shall have received a counterpart hereof signed by the other Party. No provision of this Agreement, except Sections 8.6 and 8.12 with respect to Non-Recourse Parties, is intended to confer any rights, benefits, remedies, obligations or Liabilities hereunder upon any Person other than the Parties and their respective successors and permitted assigns.
8.8.Representation by Legal Counsel. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption shall exist or be implied against the Party which drafted such terms and provisions.
8.9.Section Headings; Construction. The headings of Sections in this Agreement are provided for convenience only and will not affect its construction or interpretation. All references to “Section” or “Sections,” “Article” or “Articles” refer to the corresponding Section or Sections, or Article or Articles, of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Unless otherwise expressly provided, the words “including” or “includes” do not limit the preceding words or terms and shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” The word “or” when used in this Agreement is not exclusive. The word “extent” in the phrase “to the extent” shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply “if.” All Exhibits and Schedules annexed hereto or referred to herein are incorporated in and made a part of this Agreement as if set forth in full herein. References to any Person include the successors and permitted assigns of that Person. References from or through any date mean, unless otherwise specified, from and including or through and including, respectively.



8.10.Validity. If any provisions of this Agreement shall be held to be illegal, invalid or unenforceable under any Law, then such contravention or invalidity shall not invalidate the entire Agreement. Such provision shall be deemed to be modified to the extent necessary to render it legal, valid and enforceable, and if no such modification shall render it legal, valid and enforceable, then this Agreement shall be construed as if not containing the provision held to be invalid, and the rights and obligations of the Parties shall be construed and enforced accordingly.
8.11.Specific Performance. The Parties agree that irreparable damage would occur and that the Parties would not have any adequate remedy at law in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that each Party shall be entitled to an injunction or injunctions to prevent breaches of, and to enforce specifically, this Agreement and the terms and provisions hereof, in the applicable Designated Court, this being in addition to any other remedy to which such Party is entitled at law or in equity.
8.12.Non-Recourse.
8.12.1.This Agreement may only be enforced against, and any claim or cause of action based upon, arising out of, or related to this Agreement may only be brought against, the entities that are expressly named as Parties hereto and then only with respect to the specific obligations set forth herein with respect to such Party. Except to the extent a named Party to this Agreement (and then only to the extent of the specific obligations undertaken by such named Party in this Agreement), no past, present or future director, officer, employee, incorporator, member, partner, stockholder, Affiliate, lender, agent, attorney or other Representative of any Party hereto or any Affiliate, successor, heir or assignee of any of the foregoing (each, a “Non-Recourse Party”) shall have any Liability (whether in contract or in tort, in law or in equity, or based upon any theory that seeks to impose liability of an entity party against its owners or Affiliates) for any obligations or Liabilities of any Party under this Agreement or for any claim based on, in respect of, or by reason of, the Contemplated Transactions or in respect of any oral representations made or alleged to have been made in connection herewith.
8.12.2.The provisions of this Section 8.12 are intended to be for the benefit of, and enforceable by, the Non-Recourse Parties, and each such Non-Recourse Party shall be a third party beneficiary of this Section 8.12.
[Remainder of page intentionally left blank; signatures appear on following page.]



IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.
BUYER:
DSM NUTRITIONAL PRODUCTS LTD.

By: /s/ Michael Wahl
Name: Michael Wahl
Title: VP
By: /s/ Bruno Muller
Name: Bruno Muller
Title: VP
SELLER:
AMYRIS, INC.
By: /s/ John Melo    
Name: John Melo
Title: President and CEO
image_01.jpg
EX-10.02 6 exhibit10022021q1.htm EX-10.02 Document

Execution Version
Exhibit 10.02
AMENDMENT NO. 5 TO
SUPPLY AGREEMENT
This Amendment No. 5 to the Supply Agreement (this “Amendment”) is entered into as of March 31, 2021, between DSM Nutritional Products AG, Wurmisweg 576, 4303 Kaiseraugst, Switzerland, (hereinafter “DSM”) and Amyris, Inc., 5885 Hollis Street, Emeryville, CA 94608, USA (hereinafter “Amyris”) (each of DSM and Amyris hereinafter referred to as a “Party”, together referred to as the “Parties”).
WHEREAS, Amyris entered into a Supply Agreement, dated as of December 28, 2017, with DSM Produtos Nutricionais Brasil S.A. (the “Agreement”);
WHEREAS, On January 12, 2018, DSM’s affiliate DSM Produtos Nutricionais Brasil S.A. assigned all of its rights, title and interest in the Agreement to DSM;
WHEREAS, On November 19, 2018 the Parties entered into Amendment No. 1, on April 16, 2019 the Parties entered into Amendment No. 2, on September 30, 2019 the Parties entered into Amendment No. 3 to the Agreement and on December 20, 2020 the Parties entered into Amendment No. 5;
WHEREAS, the Parties desire to further amend the Agreement; and
NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
1.Amendments.
a.Section 1.1 of the Agreement is hereby amended to include the following definition: “Takasago Contract” shall mean the Farnesene Supply Agreement between Amyris and Takasago International Corporation, dated December 18, 2015.
b.Section 2.3 of the Agreement is hereby amended and restated (solely to include a reference therein to the “Takasago Contract”) and shall read in its entirety as follows:
Upon the Effective Date, Amyris will provide to DSM a product forecast for the calendar year 2018 (each, a “Product Forecast”). Thereafter, by the fifteenth (15th) business day of the first month of each new quarter, Amyris will provide to DSM a rolling quarterly forecast that consists of four (4) calendar quarters for any Product, which notice shall indicate the Product and the desired volume and completion date, together with any other information reasonably necessary for DSM to carry out such production. DSM shall carry out the Services in accordance with each such notice by Amyris so long as the forecast (i) does not exceed the capacity of the Facility; (ii) change is provided more than ninety (90) days in advance and; (iii) subject to DSM’s obligations to honor the terms of the Takasago



Contract, Vitamin E Contract and the Givaudan Contract. Furthermore, DSM will use reasonable efforts to deliver on any changes to the production forecast that are provided by Amyris less than ninety (90) days in advance. It is agreed by the Parties, however, that (i) where DSM is not reasonably able to decrease production with less than ninety (90) days’ prior notice, Amyris will be bound to purchase the original amount it projected for such period, and (ii) where DSM is not reasonably able to increase production with less than ninety (90) days’ prior notice, it shall not be required to provide to Amyris more than the original amount of Product(s) Amyris projected for such period. It is further agreed that Amyris shall be required to purchase all quantities of Non-Farnesene Products that DSM may produce for Amyris in response to a Product Forecast from Amyris. Amyris shall provide DSM with Product Strain(s) in amounts reasonably required to carry out such Services, as well as the then-current version of applicable Amyris Protocols.
2.Effective Date. This Amendment shall become effective as of March 31, 2021.
3.No Other Amendments. Except as expressly amended hereby, the terms and conditions of the Agreement shall remain unchanged and in full force and effect, and the execution of this Amendment is not a waiver by either Party of any of the terms or provisions of the Agreement. In the event of any conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall govern. Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are given in the Agreement. For clarity, any cross-references to Agreement Sections refer to those Agreement Sections as amended by this Amendment.
4.Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed and original, but all of which together shall constitute one and the same document.
image_02.jpg


IN WITNESS WHEREOF, DSM and Amyris have caused this Amendment to be executed as of the date first written above by their respective officers thereunto duly authorized.
DSM NUTRITIONAL PRODUCTS AG
By: /s/ Michael Wahl    
Name: Michael Wahl
Title: VP
DSM NUTRITIONAL PRODUCTS AG
By: /s/ Bruno Muller    
Name: Bruno Muller
Title: VP
AMYRIS, INC.

By: /s/ John Melo    
Name: John Melo
Title: President and CEO


EX-31.01 7 exhibit31012021q1.htm EX-31.01 Document

Exhibit 31.01

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(c) and 15d-(14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, John G. Melo, certify that:

    1.    I have reviewed this Quarterly Report on Form 10-Q of Amyris, Inc.;

    2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

    4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

    a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

    b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

    c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

    d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

    5.    The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

    a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

    b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2021
/s/ John G. Melo
John G. Melo
President and Chief Executive Officer

1

EX-31.02 8 exhibit31022021q1.htm EX-31.02 Document

Exhibit 31.02

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(c) and 15d-(14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Han Kieftenbeld, certify that:

    1.    I have reviewed this Quarterly Report on Form 10-Q of Amyris, Inc.;

    2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

    4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

    a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

    b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

    c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

    d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

    5.    The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

    a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

    b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2021
/s/ Han Kieftenbeld
Han Kieftenbeld
Chief Financial Officer

1

EX-32.01 9 exhibit32012021q1.htm EX-32.01 Document

Exhibit 32.01

Certification of CEO Furnished Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant To
Section 906 of The Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Amyris, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof, I, John G. Melo, Chief Executive Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge,

(i) the Quarterly Report of the Company on Form 10-Q for the quarterly period ended March 31, 2021 (the “Report”), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 7, 2021
/s/ John G. Melo
John G. Melo
President and Chief Executive Officer
(Principal Executive Officer)

1

EX-32.02 10 exhibit32022021q1.htm EX-32.02 Document

Exhibit 32.02

Certification of CFO Furnished Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant To
Section 906 of The Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Amyris, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof, I, Han Kieftenbeld, Chief Financial Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge,

(i) the Quarterly Report of the Company on Form 10-Q for the quarterly period ended March 31, 2021 (the “Report”), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 7, 2021
/s/ Han Kieftenbeld
Han Kieftenbeld
Chief Financial Officer
(Principal Financial Officer)



1

EX-101.SCH 11 amrs-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Operations (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity link:presentationLink link:calculationLink link:definitionLink 1407401 - Statement - Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1008008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Balance Sheet Details - Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Balance Sheet Details - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Balance Sheet Details - Deferred Cost of Products Sold - Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Balance Sheet Details - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2410407 - Disclosure - Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2411408 - Disclosure - Balance Sheet Details - Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2412409 - Disclosure - Balance Sheet Details - Depreciation and Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2413410 - Disclosure - Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2414411 - Disclosure - Balance Sheet Details - Maturities of Financing and Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2414411 - Disclosure - Balance Sheet Details - Maturities of Financing and Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2415412 - Disclosure - Balance Sheet Details - Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2416413 - Disclosure - Balance Sheet Details - Accrued and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2417414 - Disclosure - Balance Sheet Details - Other Noncurrent Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2118103 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 2319302 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2420415 - Disclosure - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2421416 - Disclosure - Fair Value Measurement - Fair Value of Debt — Foris Convertible Note (LSA Amendment) (Details) link:presentationLink link:calculationLink link:definitionLink 2422417 - Disclosure - Fair Value Measurement - Fair Value of Debt — Senior Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2423418 - Disclosure - Fair Value Measurement - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2424419 - Disclosure - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2425420 - Disclosure - Fair Value Measurement - Freestanding Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2426421 - Disclosure - Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) link:presentationLink link:calculationLink link:definitionLink 2427422 - Disclosure - Fair Value Measurement - Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2128104 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2329303 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2430423 - Disclosure - Debt - Debt Components (Details) link:presentationLink link:calculationLink link:definitionLink 2431424 - Disclosure - Debt - Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2432425 - Disclosure - Debt - Senior Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2433426 - Disclosure - Debt - Schottfield Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2434427 - Disclosure - Debt - DSM Amendments and Repayment (Details) link:presentationLink link:calculationLink link:definitionLink 2135105 - Disclosure - Mezzanine Equity link:presentationLink link:calculationLink link:definitionLink 2436428 - Disclosure - Mezzanine Equity (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2137106 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 2338304 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 2439429 - Disclosure - Stockholders' Deficit - Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2140107 - Disclosure - Net Loss Per Share Attributable to Common Shareholders link:presentationLink link:calculationLink link:definitionLink 2341305 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2442430 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2443431 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2144108 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2445432 - Disclosure - Commitments and Contingencies - Guarantor Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2146109 - Disclosure - Revenue Recognition and Contract Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 2347306 - Disclosure - Revenue Recognition and Contract Assets and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2448433 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2449434 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2450435 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2451436 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2451436 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2452437 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - DSM License Agreement and Contract Asset (Details) link:presentationLink link:calculationLink link:definitionLink 2453438 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - DSM Performance Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2454439 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - DSM Ingredients Collaboration (Details) link:presentationLink link:calculationLink link:definitionLink 2455440 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Yifan Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2156110 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2357307 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 2458441 - Disclosure - Related Party Transactions - Related Party Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2459442 - Disclosure - Related Party Transactions - Related Party Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2160111 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 2361308 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2462443 - Disclosure - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2463444 - Disclosure - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2464445 - Disclosure - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2465446 - Disclosure - Stock-based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2166112 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2467447 - Disclosure - Subsequent Events - Primary and Secondary Offering (Details) link:presentationLink link:calculationLink link:definitionLink 2468448 - Disclosure - Subsequent Events - Ingredion Agreement (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 amrs-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 amrs-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 amrs-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Awarded (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Non-inventory production supplies Non-inventory Production Supplies Non-inventory Production Supplies Document Type Document Type Outstanding (years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Other (expense) income, net Other Nonoperating Income (Expense) Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Less: fair value adjustment extinguished upon conversion of debt principal Derecognition on settlement or extinguishment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Related Party [Axis] Related Party [Axis] Accretion of debt discount Amortization of Debt Discount (Premium) Derecognition of derivative liabilities to equity upon extinguishment of debt Derecognition of Derivative Liabilities to Equity upon Extinguishment of Debt Derecognition of Derivative Liabilities to Equity upon Extinguishment of Debt Related party loans payable Related Party Loan Payable [Member] Represents information pertaining to related party loan payable. Released (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Automatic annual increase available for grant and issuance (in shares) Automatic Annual Increase in the Number of Shares Available for Grant and Issuance Automatic Annual Increase in the Number of Shares Available for Grant and Issuance Level 3 Fair Value, Inputs, Level 3 [Member] Loss upon extinguishment of debt Loss upon conversion or extinguishment of debt Represents the amount of loss recorded during the period upon the extinguishment of debt. 2022 Lease, Liability, Payments, Year one Lease, Liability, Payments, Year one Schedule of Stockholders' Equity Note, Warrants or Rights Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Deferred cost of products sold, amortization Deferred Cost of Products Sold, Amortization Deferred Cost of Products Sold, Amortization Proceeds from exercises of warrants Proceeds from Warrant Exercises Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities, Mezzanine Equity and Stockholders' Deficit Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Related party convertible notes payable Related Party Convertible Notes [Member] Represents information about related party convertible notes. Liability for unrecognized tax benefit Deferred Income Tax Liabilities, Net Proceeds from issuance of debt, net of issuance costs Proceeds from Issuance of Debt Preferred Stock Preferred Stock [Member] Security Exchange Name Security Exchange Name Exercise of common stock warrants in exchange for debt principal and accrued interest reduction Noncash Or Part Noncash, Exercise Of Common Stock Warrants For Debt Principal And Accrued Interest Reduction Noncash Or Part Noncash, Exercise Of Common Stock Warrants For Debt Principal And Accrued Interest Reduction Recoverable taxes from Brazilian government entities Recoverable taxes from Brazilian government entities The element that represents recoverable taxes on the purchase of fixed assets. Amyris RealSweet LLC Amyris RealSweet LLC [Member] Amyris RealSweet LLC Ingredion Ingredion [Member] Ingredion Income (loss) from operations Operating Income (Loss) Issuance costs incurred in connection with debt modification Payments of Debt Issuance Costs Schottenfeld notes Schottenfeld Notes [Member] Schottenfeld Notes Total current liabilities Liabilities, Current Contract with Customer, Asset and Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Professional services Accrued Professional Fees, Current DSM - related party DSM notes DSM International B.V. [Member] Represents information pertaining to DSM International B.V. Commitments and contingencies Commitments and Contingencies Total lease payments Finance Lease, Liability, Payment, Due Investment, Name [Axis] Investment, Name [Axis] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Residual Approach Performance Obligation [Axis] Residual Approach Performance Obligation [Axis] Residual Approach Performance Obligation Ginkgo note Ginkgo Collaboration Note [Member] Represents the secured promissory note to Ginkgo. Tax-related liabilities Taxes Payable, Current Entity Address, State or Province Entity Address, State or Province Released (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Related party debt, current portion Accounts payable Due to Related Parties, Current Cash paid for operating lease liabilities, in thousands Operating Lease, Payments Accounts payable Accounts Payable, Current Equity Incentive Plan, 2010 Equity Incentive Plan, 2010 [Member] Represents the equity incentive plan from 2010. Accumulated deficit Retained Earnings (Accumulated Deficit) Right-of-use assets under operating leases, net Operating Lease, Right-of-Use Asset Debt instrument, unamortized discount Debt Instrument, Unamortized Discount Loss upon extinguishment of debt Gain (loss) on extinguishment of debt Gain (Loss) on Extinguishment of Debt Yifan Yifan [Member] Yifan [Member] 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2022 Finance Lease, Liability, to be Paid, Year One Stockholders’ deficit: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Compensation expense related to stock options and RSUs Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Less: losses allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Contingent consideration received Contract With Customer, Contingent Consideration Paid Contract With Customer, Contingent Consideration Paid Customer [Axis] Customer [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Balance (in shares) Balance (in shares) Outstanding balance (in shares) Shares, Outstanding Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 8,280 shares issued and outstanding as of March 31, 2021 and December 31, 2020 Preferred Stock, Value, Issued Contingent considerations, maximum Revenue from Contract with Customer, Agreement Contingent Considerations Revenue from Contract with Customer, Agreement Contingent Considerations Lease, cost Lease, Cost Consideration transferred Payments to Acquire Equity Method Investments Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Mezzanine Equity - Common Stock Mezzanine Equity Common Stock [Member] Mezzanine Equity Common Stock [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Other noncurrent liabilities Total other noncurrent liabilities Other Liabilities, Noncurrent Total Deferred Cost of Products Sold - Related Party Deferred Cost of Products Sold - Related Party Principal payments on financing leases Finance Lease, Principal Payments Public Stock Offering - Amyris Underwriting Agreement Public Stock Offering - Amyris Under Underwriting Agreement [Member] Public Stock Offering - Amyris Under Underwriting Agreement Brazil BRAZIL Liability Class [Axis] Liability Class [Axis] Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Inventories Inventories Inventory, Net DSM Performance Collabration DSM Performance Collabration [Member] DSM Performance Collabration Measurement Frequency [Domain] Measurement Frequency [Domain] Stock price (in dollars per share) Share Price Lender Name [Axis] Lender Name [Axis] Aggregate Intrinsic Value, in Thousands Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Ingredients Ingredient Customer [Member] Ingredient Customer Geographical [Domain] Geographical [Domain] Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Statement [Line Items] Statement [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Forecast Forecast [Member] Numerator: Earnings Per Share, Basic and Diluted [Abstract] Proceeds from long-term lines of credit Proceeds from Long-term Lines of Credit Accrued interest Interest Payable, Current Thereafter Long-term Debt, Future Minimum Payments, Due after Four Years Represents the portion of the future minimum payments on debt that is due after four years. Measurement Input Type [Domain] Measurement Input Type [Domain] Statement [Table] Statement [Table] Write-offs, Net Accounts Receivable, Allowance for Credit Loss, Writeoff Statistical Measurement [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Debt instrument fair value disclosure Debt Instrument, Fair Value Disclosure Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Blackwell and Silverback warrants High Trail/Silverback Warrants [Member] High Trail/Silverback Warrants Accrued and Other Current Liabilities Schedule of Accrued and Other Current Liabilities [Table Text Block] Tabular disclosure of accrued and other current liabilities. Shares to be returned per agreement (in shares) Common Stock, Shares to be Returned Upon Conversion of Convertible Debt Common Stock, Shares to be Returned Upon Conversion of Convertible Debt Derivative liabilities Derivative Liability, Noncurrent Exercise price per share (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise of common stock rights warrant - related party Adjustment To Additional Paid In Capital, Exercise Of Common Stock Rights Warrant, Related Party Adjustment To Additional Paid In Capital, Exercise Of Common Stock Rights Warrant, Related Party Supply agreement term (years) Supply Agreement, Term Supply Agreement, Term Entity Small Business Entity Small Business Deferred cost of products sold - related party Deferred Cost of Products Sold, Related Party, Current Deferred Cost of Products Sold, Related Party, Current Operating Leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Revenue in Connection with Significant Revenue Agreement Revenue in Connection with Significant Revenue Agreement [Table Text Block] Tabular disclosure of revenue in connection with significant revenue agreement. Number of shares issued in sale of stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Exercisable (years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Prepayments, advances and deposits Prepaid Expense, Current DSM Credit Agreement - March 2021 Amendment Related To 25 Million Dollar Note DSM Credit Agreement - March 2021 Amendment Related To 25 Million Dollar Note [Member] DSM Credit Agreement - March 2021 Amendment Related To 25 Million Dollar Note Asset retirement obligation Asset Retirement Obligation, Current Sales, general and administrative Selling, General and Administrative Expenses [Member] Amendment Flag Amendment Flag Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair value, beginning balance Fair value, ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Remaining number of shares reserved for issuance, maximum limit Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Modification of previously issued common stock warrants Adjustments To Additional Paid In Capital, Modification Of Warrants Adjustments To Additional Paid In Capital, Modification Of Warrants Issuance of common stock right warrant - related party Adjustment To Additional Paid In Capital, Issuance Of Common Stock Rights Warrant, Related Party Adjustment To Additional Paid In Capital, Issuance Of Common Stock Rights Warrant, Related Party Repayments of debt Repayments of Debt Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Quarterly payments Revenue from Contract with Customer, Quarterly Payments Revenue from Contract with Customer, Quarterly Payments 2023 Long-term Debt, Future Minimum Payments, Due Year Two Represents the portion of the future minimum payments on debt that is due in two years. Proceeds from issuance of common and preferred stock in private placement, net of issuance costs Proceeds from Issuance of Private Placement Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Exercise price per share of warrant exercised (in dollars per share) Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights, Exercised Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights, Exercised Related Party [Domain] Related Party [Domain] Contract assets - related party Contract with Customer, Asset, Related Party, After Allowance for Credit Loss, Current Contract with Customer, Asset, Related Party, After Allowance for Credit Loss, Current Measurement Frequency [Axis] Measurement Frequency [Axis] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Financial Instruments [Domain] Financial Instruments [Domain] Geographical [Axis] Geographical [Axis] Subsequent Events Subsequent Events [Text Block] Computers and software Computer Equipment and Software [Member] Represents computer equipment and software. Fair value adjustment of warrants Fair Value Adjustment of Warrants Operating lease renewal term (years) Lessee, Operating Lease, Renewal Term Revenue from all other customers All Other Customers [Member] Represents all other customers that are not in connection with the significant revenue agreements. Noncurrent portion of debt principal Noncurrent portion of debt principal Represents the noncurrent portion of the present value of the net minimum payments on debt. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Derecognition of liability warrants to equity Adjustment To Additional Paid In Capital, Extinguishment Of Liability Warrants to Equity Adjustment To Additional Paid In Capital, Extinguishment Of Liability Warrants to Equity Accounts receivable, allowance Balance at Beginning of Year Balance at End of Period Accounts Receivable, Allowance for Credit Loss, Current Expected Diviend Yield Measurement Input, Expected Dividend Rate [Member] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Receivables Receivables [Member] Receivables Income Statement Location [Domain] Income Statement Location [Domain] (Gain) loss from investment in affiliate Gain (Loss) From Investment In Affiliate Gain (Loss) From Investment In Affiliate Measurement Input, Stock Price Measurement Input, Stock Price [Member] Measurement Input, Stock Price 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Sales, general and administrative Selling, General and Administrative Expense Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Lease, Cost Lease, Cost [Table Text Block] Senior Convertible Notes Senior Convertible Notes [Member] Senior Convertible Notes 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Other assets Total other assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] July 2015 related party debt exchange July 2015 Related Party Debt Exchange3 [Member] July 2015 Related Party Debt Exchange3 Issuance of common stock in private placement Stock Issued During Period, Value, New Issues May 2019 6.50% Note Exchange warrants May 2019 6.50% Note Exchange Warrants [Member] May 2019 6.50% Note Exchange Warrants Total assets Assets Related Party Transactions Related Party Transactions Disclosure [Text Block] Measurement input Long-term Debt, Measurement Input Scenario [Axis] Scenario [Axis] Deferred cost of products sold, noncurrent - related party Due from Related Parties, Noncurrent Outstanding , beginning balance (in shares) Outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Title of 12(b) Security Title of 12(b) Security Significant Revenue Agreement Significant Revenue Agreement [Member] Represent the information pertaining to the significant revenue agreement. Financing Leases Finance Lease, Liability, Payment, Due [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Conversion of stock, shares issued Conversion of Stock, Shares Issued Antidilutive Securities [Axis] Antidilutive Securities [Axis] Cost of products sold Cost of Sales [Member] Share Price Measurement Input, Share Price [Member] Other loans payable Other Loans Payable [Member] Represents other loans payable. Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Right-of-use assets obtained in exchange for new operating lease obligations, in thousands Right-of-use Asset Obtained in Exchange for Operating Lease Liability and Adoption of New Accounting Principle Right-of-use Asset Obtained in Exchange for Operating Lease Liability and Adoption of New Accounting Principle Interest expense Interest Expense Other Assets Schedule of Other Assets, Noncurrent [Table Text Block] Purchase price of sale of stock Sale of Stock, Consideration Received on Transaction Depreciation and amortization Depreciation, Depletion and Amortization 2021 (Remaining Nine Months) Long-term Debt, Future Minimum Payments, Remainder of the Year Represents the future minimum payments on debt that are due in the next fiscal year following the latest fiscal year. Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Vested or expected to vest (in dollars per share) Vested or expected to vest, weighted average grant-date fair value (in dollars per share) Represents the weighted average grant date fair value of equity options, other than options, expected to vest. Long-term debt, net of current portion amrs_LongtermDebtExcludingCurrentMaturitiesIncludingDueToRelatedParties Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent, including due to related parties and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations. Weighted-average period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Less: amount representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Vested or expected to vest (years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Constrained variable consideration amount Revenue, Remaining Performance Obligation Constrained Variable Consideration Amount Amount of transaction price allocated to performance obligation that has not been recognized as revenue and represents a constrained variable consideration. Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Net loss attributable to Amyris, Inc. common stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic, Total Net Income (Loss) Available to Common Stockholders, Basic Level 1 Fair Value, Inputs, Level 1 [Member] Operating lease expense Operating Lease, Expense Measurement Input, Exercise Price Measurement Input, Exercise Price [Member] Inventories Increase (Decrease) in Inventories Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Restricted cash, noncurrent Restricted Cash and Cash Equivalents, Noncurrent Accounts payable Increase (Decrease) in Accounts Payable Quantity of Restricted Stock Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Raw materials Inventory, Raw Materials, Net of Reserves (Gain) loss from change in fair value of derivative instruments Unrealized Gain (Loss) on Derivatives Fair value of embedded features in connection with private placement Fair Value Of Embedded Features In Connection With Private Placement Fair Value Of Embedded Features In Connection With Private Placement Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances Fair Value of Embedded Features in Connection with Debt Issuances and Modifications Fair Value of Embedded Features in Connection with Debt Issuances and Modifications Derecognition of derivative liabilities upon exercise of warrants Derecognition of derivative liabilities upon exercise of warrants Represents the amount of the settlement of derivative liability into equity during the period. Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Input, Expected Term Measurement Input, Expected Term [Member] Ginkgo partnership payments obligation Noncontrolling Interest in Operating Partnerships Other Other Operating Activities, Cash Flow Statement DSM License Agreement DSM License Agreement [Member] DSM License Agreement Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Mezzanine Equity Mezzanine Equity Disclosure [Text Block] The entire disclosure of mezzanine equity. Public Stock Offering - Shares from Amyris Public Stock Offering - Shares from Amyris [Member] Public Stock Offering - Shares from Amyris Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Other Other Assets, Miscellaneous, Noncurrent Public Stock Offering - Shares from Selling Stockholders Public Stock Offering - Shares from Selling Stockholders [Member] Public Stock Offering - Shares from Selling Stockholders Issuance of common stock and warrants upon conversion of debt principal Issuance of Common Stock and Warrants upon Conversion of Debt, Amount Issuance of Common Stock and Warrants upon Conversion of Debt, Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Less: current portion amrs_LongtermDebtCurrentMaturitiesIncludingDueToRelatedParties Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current including due to related parties. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations. Machinery and equipment Machinery and Equipment [Member] Equity-method investment Equity Method Investments Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Fair value of long-term debt Long-term Debt, Net, Fair Value Long-term Debt, Net, Fair Value Naxyris note Naxyris S.A. [Member] Represents Naxyris S.A. Freestanding derivative instruments issued in connection with other debt and equity instruments Freestanding derivative instruments in connection with the issuance of equity instruments Fair value of equity conversion feature freestanding derivative liability. August 2017 dilution warrants August 2017 Dilution Warrants [Member] August 2017 Dilution Warrants Recoverable taxes from Brazilian government entities Recoverable Taxes, From Brazilian Government Entities Recoverable Taxes, From Brazilian Government Entities Koninklijke DSM N.V (DSM) Koninklijke DSM N.V. (DSM) [Member] Koninklijke DSM N.V. (DSM) Research and development Research and Development Expense Issuance of common stock upon exercise of warrants - related party Stock Issued During Period Shares Warrants Exercised, Related Party Stock Issued During Period Shares Warrants Exercised, Related Party Subsequent Event Subsequent Event [Member] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Loss from change in fair value of debt Debt Changes in Fair Value, Gain (Loss) Debt Changes in Fair Value, Gain (Loss) Common stock, shares authorized (in shares) Common Stock, Shares Authorized Combined debt amount Debt, Long-term and Short-term, Combined Amount Property, plant and equipment, gross Property, Plant and Equipment, Gross Proceeds from exercises of common stock options Proceeds from Stock Options Exercised Embedded derivative liability, measurement input Embedded Derivative Liability, Measurement Input Allotment option agreement, term Allotment Option Agreement, Term Allotment Option Agreement, Term October 2019 Naxyris warrant October 2019 Naxyris Warrant [Member] October 2019 Naxyris Warrant Income Statement [Abstract] Income Statement [Abstract] January 2020 warrant exercise right shares January 2020 Warrant Exercise Right Shares [Member] January 2020 Warrant Exercise Right Shares Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Proceeds from exercise of common stock rights warrant - related party Proceeds from Common Stock Rights Warrant Exercises, Related Party Proceeds from Common Stock Rights Warrant Exercises, Related Party Aprinnova JV [Member] Aprinnova JV [Member] Aprinnova JV Operating lease liabilities, net of current portion Noncurrent lease liability Operating Lease, Liability, Noncurrent Revenue from contract with customer, cumulative to date Revenue From Contract With Customer, Cumulative To Date Revenue From Contract With Customer, Cumulative To Date Unaccreted debt discount Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Use of Estimates and Judgements Use of Estimates, Policy [Policy Text Block] Current assets: Assets, Current [Abstract] The 2019 DSM Credit Agreement The 2019 DSM Credit Agreement [Member] Represents information pertaining to the "2019 DSM Credit Agreement" entered into on September 17, 2019. Foris notes Foris Ventures LLC [Member] Foris Ventures LLC [Member] Grants and Collaborations Grants and Collaborations [Member] Represents the information pertaining to grants and collaborations. Related party debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively) Due to Related Parties, Noncurrent 2025 Lease Liability Payments Due Year Four Lease Liability Payments Due Year Four Comprehensive loss attributable to Amyris, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2024 Finance Lease, Liability, to be Paid, Year Three Consumer Consumer [Member] Consumer Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share License License [Member] Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block] Other Other Area [Member] Represents the other geographic area. Scenario [Domain] Scenario [Domain] Legal Entity [Axis] Legal Entity [Axis] Counterparty Name [Domain] Counterparty Name [Domain] City Area Code City Area Code Convertible promissory notes Convertible Promissory Notes [Member] Information related to convertible promissory notes. Document Period End Date Document Period End Date Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] DSM Credit Agreement - March 2021 Amendment DSM Credit Agreement - March 2021 Amendment [Member] DSM Credit Agreement - March 2021 Amendment Consideration transferred for license to sell and market Payments to Acquire Equity Method Investment, Consideration Transferred For License To Sell And Market Payments to Acquire Equity Method Investment, Consideration Transferred For License To Sell And Market (Loss) gain from change in fair value of derivative instruments Gain (Loss) on Derivative Instruments, Net, Pretax Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Accounts receivable - related party, net of allowance of $0 and $0, respectively Accounts receivable - related party, net Accounts Receivable, Related Parties, Current Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Loss before income taxes and loss from investment in affiliate Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Deferred Cost of Products Sold Deferred Cost of Products Sold [Table Text Block] Deferred Cost of Products Sold [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] April 2019 PIPE warrants April 2019 PIPE Warrants [Member] April 2019 PIPE Warrants Inventories Schedule of Inventory, Current [Table Text Block] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Entity [Domain] Entity [Domain] 2023 Lease Liability Payments Due Year Two Lease Liability Payments Due Year Two Payment of minimum employee taxes withheld upon net share settlement of restricted stock units Payment, Tax Withholding, Share-based Payment Arrangement Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Research and development obligation, remaining amount Research and Development Obligation, Remaining Amount Research and Development Obligation, Remaining Amount Cover [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Naxyris note Naxyris Note [Member] Naxyris Note 2022 Long-term Debt, Future Minimum Payments, Year One Represents the portion of the future minimum payments on debt that is due in two years. Loans payable and credit facilities Loans Payable [Member] Long term debt, fair value Net Net Long-term Debt Warrants and rights outstanding, derivative liability Warrants And Rights Outstanding, Derivative Liability Warrants And Rights Outstanding, Derivative Liability Contract liabilities Increase (Decrease) in Contract with Customer, Liability Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Research and development Research and Development Customer [Member] Research and Development Customer (Gain) loss from change in fair value of debt Debt Instrument, Gain (Loss) On Change In Fair Value Debt Instrument, Gain (Loss) On Change In Fair Value Related Party Loans Payable and Credit Facilities Related Party Loans Payable and Credit Facilities [Member] Related to related party loans payable and credit facilities. Cost of products sold Cost of Goods and Services Sold Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Issuance of common stock and warrants upon conversion of debt principal (in shares) Issuance of Common Stock and Warrants upon Conversion of Debt Issuance of Common Stock and Warrants upon Conversion of Debt Total cost and operating expenses Costs and Expenses Equity Components [Axis] Equity Components [Axis] Deferred cost of products sold - related party amrs_IncreaseDecreaseInDeferredCostsOfRevenue The amount of increase (decrease) in deferred costs of revenue. Finished goods Inventory, Finished Goods, Net of Reserves Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Nikko notes Nikko Notes [Member] Nikko Notes [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2024 Lease Liability Payments Due Year Three Lease Liability Payments Due Year Three Minimum Minimum [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Allowance for Doubtful Accounts Accounts Receivable, Allowance for Credit Loss [Table Text Block] Finished Goods Inventory Finished Goods Inventory [Member] Finished Goods Inventory Operating lease liabilities Current lease liability Operating Lease, Liability, Current Period-end preferred stock Period-end Preferred Shares [Member] Represents information pertaining to period-end preferred shares. Naxyris LSA warrants Naxyris LSA Warrants [Member] Naxyris LSA Warrants 2021 (Remaining Nine Months) Lease Liability Payments Remainder of Fiscal Year Lease Liability Payments Remainder of Fiscal Year Issuance of common stock in private placement - related party (in shares) Stock Issued During Period, Shares New Issues, Related Party Stock Issued During Period, Shares New Issues, Related Party Europe Europe [Member] Number of installments Debt, Number Of Installments Debt, Number Of Installments 2024 Long-term Debt, Future Minimum Payments, Due Year Three Represents the portion of the future minimum payments on debt that is due in three years. Less: income attributable to noncontrolling interest in Aprinnova Net Income (Loss) Attributable to Noncontrolling Interest Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Entity Interactive Data Current Entity Interactive Data Current United States UNITED STATES Compound annual return (percentage) Compound Annual Return The rate of annual return added on the redemption base price when the Company redeems its stock. Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Revenue: Revenues [Abstract] Deposits Deposits Assets, Noncurrent Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Stockholders' Deficit Stockholders' Equity Note Disclosure [Text Block] Noncurrent lease liability Operating and Finance Lease Liabilities, Noncurrent Operating and Finance Lease Liabilities, Noncurrent Customer [Domain] Customer [Domain] Weighted-average Remaining Contractual Life, in Years Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] DSM Credit Agreement DSM Credit Agreement [Member] Represents the information pertaining to DSM Credit Agreement. Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Issuance of common stock upon exercise of warrants Adjustments to Additional Paid-in Capital Warrant Exercised Adjustments to Additional Paid-in Capital Warrant Exercised Weighted- average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Schedule of Related Party Debt Schedule of Related Party Debt [Table Text Block] Tabular disclosure of information pertaining to related party debt. Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Less: amount representing interest Finance Lease, Liability, Undiscounted Excess Amount Estimated total unconstrained transaction price Estimated Total Unconstrained Transaction Price Estimated Total Unconstrained Transaction Price Less: amount representing interest Debt, Future Minimum Payments, Interest Included in Payments Represents the interest that is included in future payments on debt, which amount is subtracted from total future minimum payments in order to calculate the present value of minimum debt payments. Research and development Research and Development Expense [Member] Conversion of convertible securities Stock Issued During Period, Value, Conversion of Convertible Securities Other Liabilities Other Liabilities [Table Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Total lease payments Lessee, Operating Lease, Liability, to be Paid Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Shares issued (in dollars per share) Shares Issued, Price Per Share Less: amount representing interest Lease Liability Undiscounted Excess Amount Lease Liability Undiscounted Excess Amount Restricted cash, noncurrent Restricted Cash, Noncurrent Prepaid expenses and other assets amrs_IncreaseDecreaseOfRecoverableTaxesOnPurchaseOfFixedAssets Represents the amount of increase (decrease) of recoverable taxes on the purchase of fixed assets. Shares issued for conversion settlement (in shares) Common Stock, Shares Issued For Conversion Settlement Common Stock, Shares Issued For Conversion Settlement Current lease liability Operating and Finance Lease Liabilities, Current Operating and Finance Lease Liabilities, Current Operating lease remaining lease term (years) Lessee, Operating Lease, Remaining Lease Term Sale of Stock [Axis] Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Sephora Sephora [Member] Sephora DSM Ingredients Collaboration DSM Ingredients Collaboration [Member] DSM Ingredients Collaboration Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Schedule Of Depreciation and Amortization Schedule Of Depreciation And Amortization [Table Text Block] Schedule Of Depreciation And Amortization [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Document Transition Report Document Transition Report Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Firmenich Firmenich [Member] Represents information pertaining to Firmenich S.A., a global flavors and fragrances company. Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Class of warrant or right, outstanding (in shares) Class of Warrant or Right, Outstanding Work-in-process Work-in-process Amount, including adjustments, of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. Class of Warrant or Right [Table] Class of Warrant or Right [Table] Restricted cash, current Restricted Cash and Cash Equivalents, Current Debt instrument, face amount Debt Instrument, Face Amount Level 2 Fair Value, Inputs, Level 2 [Member] Automatic annual increase in shares available for grant and issuance, percentage of outstanding stock Automatic Annual Increase in Shares Available for Grant and Issuance, Percentage of Outstanding Stock Automatic Annual Increase in Shares Available for Grant and Issuance, Percentage of Outstanding Stock Accounts receivable, unbilled, related party Accounts Receivable, Unbilled, Related Party Accounts Receivable, Unbilled, Related Party Other Other Assets, Current Document Quarterly Report Document Quarterly Report Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Total Stockholders' Deficit Total Equity Excluding Mezzanine Equity [Member] Total Equity Excluding Mezzanine Equity Equity [Abstract] Equity [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Amortization of right-of-use assets under operating leases Operating Lease Right of use Asset Amortization Operating Lease Right of use Asset Amortization Supplemental disclosures of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Contract liabilities Contract liabilities Contract with Customer, Liability, Current Subsequent Event [Line Items] Subsequent Event [Line Items] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Vested or expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Credit Facility [Domain] Credit Facility [Domain] Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Debt instrument, convertible, conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Unaccreted Debt Discount Debt Instrument, Unamortized Discount (Premium), Net Loss per share attributable to common stockholders, basic (in dollars per share) Earnings Per Share, Basic Commitments and Contingencies Contingencies Disclosure [Text Block] 2025 Long-term Debt, Future Minimum Payments, Due Year Four Represents the portion of the future minimum payments on debt that is due in four years. Other income (expense): Other Income and Expenses [Abstract] Entity File Number Entity File Number Vested or expected to vest (years) Vested or expected to vest, weighted average remaining contractual life (Year) Weighted average remaining contractual term for fully vested and expected to vest equity instruments other than options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Senior convertible notes New Senior convertible notes due 2022 [Member] New Senior convertible notes due 2022 Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Furniture and office equipment, vehicles and land Furniture and Office Equipment, Vehicles and Land [Member] Equipment commonly used in offices, vehicles used for road transportation, and real estate held. Class of warrant or right, term amrs_Class Of Warrant Or Right, Term Represents term of warrants. Unsecured Debt Unsecured Debt [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Principal payments on debt Repayments of Long-term Debt Renewable Products Renewable Products [Member] Represents the information pertaining to Renewable Products. Revenue, remaining performance obligation, Amount Revenue, Remaining Performance Obligation, Amount Total stock-based compensation expense Share-based Payment Arrangement, Expense Balance Sheet Location [Axis] Balance Sheet Location [Axis] Revenue Revenue from Contract with Customer, Including Assessed Tax Revenue from Contract with Customer, Including Assessed Tax Counterparty Name [Axis] Counterparty Name [Axis] Denominator: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Common stock - $0.0001 par value, 350,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 273,266,917 and 244,951,446 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Givaudan Givaudan International, SA [Member] Represents Givaudan International, SA. Long-term Debt Long-term Debt [Member] Document Fiscal Year Focus Document Fiscal Year Focus Restricted cash Restricted Cash, Current Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Debt, current portion (includes instrument measured at fair value of $54,757 and $53,387, respectively) Long-term Debt, Current Maturities Contract assets - related party Contract Assets - Related Party [Member] Contract Assets - Related Party Entity Current Reporting Status Entity Current Reporting Status Loss from change in fair value Change in fair value of derivative instruments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 2025 Finance Lease, Liability, to be Paid, Year Four Accounts payable Accounts Payable, Accrued Liabilities, And Other Current Liabilities [Member] Accounts Payable, Accrued Liabilities, And Other Current Liabilities Other Other [Member] Other [Member] Debt change in fair value gain loss Debt Change in Fair Value Gain Loss Debt Changes in Fair Value Gain Loss Stock Price Volatility Measurement Input, Price Volatility [Member] Subsequent Event [Table] Subsequent Event [Table] Less: current portion of debt principal Debt Future Minimum Payments, Present Value of Net Minimum PaymentsCurrentMaturities Represents the current portion of the present value of the net minimum payments on debt. Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Contract assets Increase (Decrease) in Contract with Customer, Asset Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Awarded (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Schedule of Related Party Accounts Receivables Schedule of Related Party Accounts Receivables [Table Text Block] Tabular disclosure of related party accounts receivables. Revenue Recognition and Contract Assets and Liabilities Collaborative Arrangement Disclosure [Text Block] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Licenses and Royalties Licenses and Royalties [Member] Represents the information pertaining to licenses and royalties. Warrants Issued In Connection with September 2019 and November 2019 Shottenfeld Notes Warrants Issued In Connection with September 2019 and November 2019 Shottenfeld Notes [Member] Warrants Issued In Connection with September 2019 and November 2019 Shottenfeld Notes Risk-free Interest Rate Measurement Input, Risk Free Interest Rate [Member] Related party debt, net, fair value Related Party Debt, Net, Fair Value Related Party Debt, Net, Fair Value Operating lease liability Total lease liability Operating Lease, Liability Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Extinguishment of debt, amount Extinguishment of Debt, Amount Long-term debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively) Long-term Debt, Excluding Current Maturities Asia Asia [Member] Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Mezzanine equity: Contingently redeemable common stock Temporary Equity, Carrying Amount, Attributable to Parent Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Total Amyris, Inc. stockholders’ deficit Stockholders' Equity Attributable to Parent Total liabilities, mezzanine equity and stockholders' deficit Liabilities and Equity Loss Contingencies [Line Items] Loss Contingencies [Line Items] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Unpaid property, plant and equipment balances in accounts payable and accrued liabilities at end of period Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable Entity Address, City or Town Entity Address, City or Town Additional warrants issued (in shares) Additional Warrants Issued (in shares) The number of warrants or rights issued during the reporting period. Payroll and related expenses Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Period-end restricted stock units Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Issuance of common stock upon exercise of warrants (in shares) Exercises (in shares) Stock Issued During Period, Shares, Warrants Exercised Number of shares issued during the period as a result of exercise of warrants. Ingredion Agreement Ingredion Agreement [Member] Ingredion Agreement Financial Instrument [Axis] Financial Instrument [Axis] Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Product Renewable Products Product [Member] Equity Component [Domain] Equity Component [Domain] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Issuance of common stock in private placement - related party Stock Issued During Period, Value New Issues, Related Parties Stock Issued During Period, Value New Issues, Related Parties Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Construction in progress Construction in Progress [Member] Entity Tax Identification Number Entity Tax Identification Number Stock-based Compensation Share-based Payment Arrangement [Text Block] Net loss attributable to Amyris, Inc. Net loss attributable to Amyris, Inc. Net Income (Loss) Attributable to Parent Noncurrent lease liability Finance Lease, Liability, Noncurrent Intellectual Property License Intellectual Property License [Member] Intellectual Property License Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other Other Liabilities, Current 2021 (Remaining Nine Months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Investment, Name [Domain] Investment, Name [Domain] Foris note Foris Debt [Member] Foris Debt Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Liability in connection with acquisition of equity-method investment Liabilities Related to Equity Method Investments, Noncurrent Liabilities Related to Equity Method Investments, Noncurrent Earnings Per Share [Abstract] Earnings Per Share [Abstract] Foris note Foris Notes [Member] Foris Notes [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total lease liability Finance Lease, Liability Finance lease, right-of-use asset amortization Finance Lease, Right-of-Use Asset, Accumulated Amortization Class of warrant or right, number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Quantity of Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Gross Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Public Stock Offering - Selling Stockholders Underwriting Agreement Public Stock Offering - Selling Stockholders Under Underwriting Agreement [Member] Public Stock Offering - Selling Stockholders Under Underwriting Agreement Lessee, Lease Liability, Maturity Lessee Lease Liability Maturity [Table Text Block] Lessee Lease Liability Maturity [Table Text Block] May 2017 dilution warrants May 2017 Dilution Warrants [Member] Related to the may 2017 dilution warrants. Contract liabilities, net of current portion Contract liabilities, noncurrent Contract with Customer, Liability, Noncurrent Net loss attributable to Amyris, Inc. common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Residual Approach Performance Obligation [Domain] Residual Approach Performance Obligation [Domain] Residual Approach Performance Obligation [Domain] Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Embedded derivatives bifurcated from debt instruments Embedded derivatives in connection with the issuance of debt and equity instruments Fair value of equity conversion feature embedded derivative liability. Proceeds from issuance of common and preferred stock in private placement, net of issuance costs - related party Proceeds From Issuance of Private Placement, Related Party Proceeds From Issuance of Private Placement, Related Party Other Other Sundry Liabilities, Noncurrent Entity Filer Category Entity Filer Category Share-based Payment Arrangement, Expensed and Capitalized, Amount Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Contract termination fees Contract termination Carrying value as of the balance sheet date of contract termination liabilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Common Stock Common Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product and Service [Domain] Product and Service [Domain] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Foris Convertible Note (LSA Amendment) Foris Convertible Note [Member] Foris Convertible Note Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances - related party Fair Value of Embedded Features in Connection with Debt Issuances and Modifications of Related Party Fair Value of Embedded Features in Connection with Debt Issuances and Modifications of Related Party Convertible notes payable Convertible Debt [Member] Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Vested or expected to vest (in shares) Vested or expected to vest (in shares) Represents the number of equity instruments, other than options, that are expected to vest after the balance sheet date. 2020 Equity Incentive Plan 2020 Equity Incentive Plan [Member] 2020 Equity Incentive Plan Issuance of common stock in private placement (in shares) Issuance of common stock in public offering (in shares) Stock Issued During Period, Shares, New Issues Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Additional paid-in capital Additional paid-in capital Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions and amount of additional paid-in capital (APIC) classified as other. Period-end stock options to purchase common stock Stock Options to Purchase Common Stock [Member] Information related to stock options to purchase common stock. Loans Payable and Credit Facilities Loans Payable and Credit Facilities [Member] Related to both loans payable and credit facilities. Leasehold improvements Leasehold Improvements [Member] Temporary Equity Disclosure [Abstract] Temporary Equity Disclosure [Abstract] Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Provisions Accounts Receivable, Credit Loss Expense (Reversal) Naxyris note The Naxyris Loan Agreement [Member] The Naxyris Loan Agreement [Member] Related Party Debt Related Party Debt [Member] Represents the information pertaining to related party debt. Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Contract assets Contract with Customer, Asset, after Allowance for Credit Loss, Current Vested or expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Issuance of common stock upon exercise of warrants - related party (in shares) Stock Issued During Period Shares Warrants Exercised, Related Party, Shares Stock Issued During Period Shares Warrants Exercised, Related Party, Shares Issuance of common stock upon exercise of stock options (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Total future minimum payments Long-term Debt, Future Minimum Payments, Due Represents the total future minimum payments that will be due on debt. Related Party Transactions [Abstract] Related Party Transactions [Abstract] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total other expense, net Nonoperating Income (Expense) Right-of-use assets under financing leases, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Employee Stock Option Share-based Payment Arrangement, Option [Member] Basis of accounting Basis of Accounting, Policy [Policy Text Block] Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Schottenfeld Exchange Agreement Schottenfeld September 2019 Credit Agreements [Member] Schottenfeld September 2019 Credit Agreements Cost and operating expenses: Costs and Expenses [Abstract] Period-end common stock warrants Period-end Common Stock Warrants [Member] Represents information pertaining to period-end common stock warrants. Subsequent Events [Abstract] Subsequent Events [Abstract] Forfeited or expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Accrued and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accounts receivable, net of allowance of $154 and $137, respectively Accounts receivable, net Accounts Receivable Net Current Excluding Related Parties Accounts Receivable Net Current Excluding Related Parties Sale of Stock [Domain] Sale of Stock [Domain] Loss Contingencies [Table] Loss Contingencies [Table] Plan Name [Domain] Plan Name [Domain] Percentage of venture owned Equity Method Investment, Ownership Percentage Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Total stockholders' deficit Balance Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 2021 (Remaining Nine Months) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Fair value of debt Change in Fair Value Long-term Debt, Fair Value (Gain) loss on foreign currency exchange rates Foreign Currency Transaction Gain (Loss), before Tax Provision for income taxes Income Tax Expense (Benefit) Total lease liability Operating and Finance Lease Liabilities Operating and Finance Lease Liabilities Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of the period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Proceeds from exercises of warrants - related party Proceeds From Warrant Exercise, Related Party Proceeds From Warrant Exercise, Related Party Total liabilities measured and recorded at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Accrued and other current liabilities Total accrued and other current liabilities Accrued Liabilities, Current Loss per share attributable to common stockholders, diluted (in dollars per share) Earnings Per Share, Diluted Financing lease liabilities Current lease liability Finance Lease, Liability, Current Automatic annual increase reserved for issuance (in shares) Automatic Annual Increase in the Number of Shares Reserved for Issuance Automatic Annual Increase in the Number of Shares Reserved for Issuance Local Phone Number Local Phone Number Issuance of common stock and warrants upon conversion of debt principal and accrued interest amrs_StockIssuedUponConversionOfDebt The fair value of stock issued upon conversion of debt in noncash financing activities. Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Debt Schedule of Debt [Table Text Block] Lease liabilities Increase Decrease in Lease Liabilities Increase Decrease in Lease Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Principal Long-term Debt, Gross Schedule of Long-term Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Accrued interest added to debt principal Accrued interest added to debt principal The element that represents capitalized interest, shown on the cash flow statement under "supplemental disclosures of non-cash investing and financing activities." Entity Emerging Growth Company Entity Emerging Growth Company Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Less: principal converted into common stock Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Principal Repaid in Common Stock Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Principal Repaid in Common Stock Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair value of debt Long Term Debt, Current, Fair Value Long Term Debt, Current, Fair Value Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Weighted-average Grant-date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Accounts receivable - related party Accounts receivable, unbilled - related party [Member] Accounts receivable, unbilled - related party Maximum Maximum [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Noncontrolling Interest Noncontrolling Interest [Member] Gain (loss) from investment in affiliate Gain (Loss) on Investments Probability of Change in Control Measurement Input, Probability of Change in Control [Member] Measurement input using probability of change in control. Accumulated Deficit Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Gates Foundation Purchase Agreement Gates Foundation Purchase Agreement [Member] A security purchase agreement with the Gates Foundation. Purchases of property, plant and equipment amrs_PaymentsToAcquirePropertyPlantAndEquipmentNetOfDisposals The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets, net of disposals. Present value of minimum debt payments Debt Future Minimum Payments, Present Value of Net Minimum Payments Represents the present value of future minimum debt payments, net of interest. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Weighted-average Remaining Contractual Life, in Years Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] May 2017 cash warrants May 2017 Cash Warrants [Member] May 2017 Cash Warrants Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Outstanding (years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Domain] Award Type [Domain] Ginkgo partnership payments obligation, net of current portion Ginkgo partnership payments obligation, net of current portion The amount of partnership payments obligation classified as noncurrent. Deferred cost of products sold, noncurrent - related party Deferred Cost of Products Sold - Related Party, Noncurrent Deferred Cost of Products Sold - Related Party, Noncurrent Total lease payments Lease Liability Payment Due Lease Liability Payment Due Trading Symbol Trading Symbol DSM notes DSM Note [Member] Represents the information pertaining to DSM note. Revenues, related party Revenue from Related Parties Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Outstanding, beginning balance (years) Outstanding, ending balance (years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Debt-related Derivative Liability Derivative Liability, Debt-related [Member] Represents information relating to debt-related derivative liabilities. Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Net Loss Per Share Attributable to Common Shareholders Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Fair Value Measurement Financial Instruments Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Accounts receivable, allowance, related parties Accounts Receivable, Allowance For Credit Loss, Related Parties, Current Accounts Receivable, Allowance For Credit Loss, Related Parties, Current Entity Shell Company Entity Shell Company Debt Instrument Redemption [Table] Debt Instrument Redemption [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Vested or expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price 2023 Finance Lease, Liability, to be Paid, Year Two Accounting Standards or Updates Recently Adopted and Accounting Standards or Updates Not Yet Effective New Accounting Pronouncements, Policy [Policy Text Block] Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Earnings Per Share, Basic [Abstract] Earnings Per Share, Basic [Abstract] EX-101.PRE 15 amrs-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 image_01.jpg begin 644 image_01.jpg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end GRAPHIC 17 image_02.jpg begin 644 image_02.jpg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end GRAPHIC 18 image_03.jpg begin 644 image_03.jpg MB5!.1PT*&@H -24A$4@ !9< #@" ( #PC<\5 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end GRAPHIC 19 image_21.jpg begin 644 image_21.jpg MB5!.1PT*&@H -24A$4@ !L !B" 8 "A^:A< "7!(67, $SE M !,Y0%USO"5 U4E$051XG.W400J$, R%X6[T&"KJ$<0#>"D55]HKZT(W M&2JX&@DS0U0&_L!;-)1^D$"=W%@.# P,# SL06Q=5QG'48JBD#B.)<_S_1SZ MIEAXL&D:<Q7KNLX.6Y9%ZKH^A:JJDGF>[; #'(9A'UG889(DTK;M5]#'F%6!@8'= MC&E_H!:PYS#U(A@8&!@8&!@8&!@8&!C8?V':@[\&[%KLZ@(# P,# P,#>P)[ 5 =A=]2K4" XML 20 amrs-20210331_htm.xml IDEA: XBRL DOCUMENT 0001365916 2021-01-01 2021-03-31 0001365916 2021-05-04 0001365916 2021-03-31 0001365916 2020-12-31 0001365916 us-gaap:ProductMember 2021-01-01 2021-03-31 0001365916 us-gaap:ProductMember 2020-01-01 2020-03-31 0001365916 amrs:LicensesAndRoyaltiesMember 2021-01-01 2021-03-31 0001365916 amrs:LicensesAndRoyaltiesMember 2020-01-01 2020-03-31 0001365916 amrs:GrantsAndCollaborationsMember 2021-01-01 2021-03-31 0001365916 amrs:GrantsAndCollaborationsMember 2020-01-01 2020-03-31 0001365916 2020-01-01 2020-03-31 0001365916 us-gaap:PreferredStockMember 2020-12-31 0001365916 us-gaap:CommonStockMember 2020-12-31 0001365916 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001365916 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001365916 us-gaap:RetainedEarningsMember 2020-12-31 0001365916 us-gaap:NoncontrollingInterestMember 2020-12-31 0001365916 amrs:TotalEquityExcludingMezzanineEquityMember 2020-12-31 0001365916 amrs:MezzanineEquityCommonStockMember 2020-12-31 0001365916 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001365916 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001365916 amrs:TotalEquityExcludingMezzanineEquityMember 2021-01-01 2021-03-31 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-03-31 0001365916 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001365916 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001365916 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001365916 us-gaap:PreferredStockMember 2021-03-31 0001365916 us-gaap:CommonStockMember 2021-03-31 0001365916 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001365916 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001365916 us-gaap:RetainedEarningsMember 2021-03-31 0001365916 us-gaap:NoncontrollingInterestMember 2021-03-31 0001365916 amrs:TotalEquityExcludingMezzanineEquityMember 2021-03-31 0001365916 amrs:MezzanineEquityCommonStockMember 2021-03-31 0001365916 us-gaap:PreferredStockMember 2019-12-31 0001365916 us-gaap:CommonStockMember 2019-12-31 0001365916 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001365916 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001365916 us-gaap:RetainedEarningsMember 2019-12-31 0001365916 us-gaap:NoncontrollingInterestMember 2019-12-31 0001365916 amrs:TotalEquityExcludingMezzanineEquityMember 2019-12-31 0001365916 amrs:MezzanineEquityCommonStockMember 2019-12-31 0001365916 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001365916 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001365916 amrs:TotalEquityExcludingMezzanineEquityMember 2020-01-01 2020-03-31 0001365916 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001365916 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001365916 us-gaap:PreferredStockMember 2020-03-31 0001365916 us-gaap:CommonStockMember 2020-03-31 0001365916 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001365916 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001365916 us-gaap:RetainedEarningsMember 2020-03-31 0001365916 us-gaap:NoncontrollingInterestMember 2020-03-31 0001365916 amrs:TotalEquityExcludingMezzanineEquityMember 2020-03-31 0001365916 amrs:MezzanineEquityCommonStockMember 2020-03-31 0001365916 2019-12-31 0001365916 2020-03-31 0001365916 amrs:KoninklijkeDSMNVDSMMember 2021-01-01 2021-03-31 0001365916 amrs:KoninklijkeDSMNVDSMMember 2020-01-01 2020-03-31 0001365916 2010-09-27 2021-03-31 0001365916 us-gaap:MachineryAndEquipmentMember 2021-03-31 0001365916 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001365916 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001365916 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001365916 amrs:ComputerEquipmentAndSoftwareMember 2021-03-31 0001365916 amrs:ComputerEquipmentAndSoftwareMember 2020-12-31 0001365916 amrs:FurnitureAndOfficeEquipmentVehiclesAndLandMember 2021-03-31 0001365916 amrs:FurnitureAndOfficeEquipmentVehiclesAndLandMember 2020-12-31 0001365916 us-gaap:ConstructionInProgressMember 2021-03-31 0001365916 us-gaap:ConstructionInProgressMember 2020-12-31 0001365916 srt:MinimumMember 2021-03-31 0001365916 srt:MaximumMember 2021-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 amrs:SeniorConvertibleNotesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 amrs:SeniorConvertibleNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 amrs:SeniorConvertibleNotesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 amrs:SeniorConvertibleNotesMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 amrs:SeniorConvertibleNotesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 amrs:SeniorConvertibleNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 amrs:SeniorConvertibleNotesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 amrs:SeniorConvertibleNotesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001365916 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001365916 amrs:ForisConvertibleNoteMember amrs:RelatedPartyConvertibleNotesMember 2021-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:ConvertibleDebtMember amrs:MeasurementInputStockPriceMember 2020-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputDiscountRateMember 2020-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:ConvertibleDebtMember amrs:MeasurementInputProbabilityOfChangeInControlMember 2020-03-31 0001365916 amrs:ForisConvertibleNoteMember 2021-01-01 2021-03-31 0001365916 amrs:ForisConvertibleNoteMember us-gaap:ConvertibleDebtMember 2021-03-31 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2021-03-31 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember amrs:MeasurementInputStockPriceMember 2021-03-31 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputDiscountRateMember 2021-03-31 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-31 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember amrs:MeasurementInputProbabilityOfChangeInControlMember 2021-03-31 0001365916 us-gaap:LongTermDebtMember 2020-12-31 0001365916 us-gaap:LongTermDebtMember 2021-01-01 2021-03-31 0001365916 us-gaap:LongTermDebtMember 2021-03-31 0001365916 us-gaap:FairValueInputsLevel3Member amrs:DerivativeLiabilityDebtRelatedMember 2020-12-31 0001365916 us-gaap:FairValueInputsLevel3Member amrs:DerivativeLiabilityDebtRelatedMember 2021-01-01 2021-03-31 0001365916 us-gaap:FairValueInputsLevel3Member amrs:DerivativeLiabilityDebtRelatedMember 2021-03-31 0001365916 amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember 2020-02-28 0001365916 amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember 2020-02-28 2020-02-28 0001365916 amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember 2021-03-31 0001365916 amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember 2021-01-01 2021-03-31 0001365916 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember 2021-03-31 0001365916 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2021-03-31 0001365916 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0001365916 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0001365916 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2021-03-31 0001365916 srt:MaximumMember us-gaap:MeasurementInputExercisePriceMember 2021-03-31 0001365916 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2020-12-31 0001365916 srt:MaximumMember us-gaap:MeasurementInputExercisePriceMember 2020-12-31 0001365916 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001365916 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001365916 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001365916 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001365916 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-31 0001365916 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-31 0001365916 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001365916 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001365916 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2021-03-31 0001365916 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2021-03-31 0001365916 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001365916 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001365916 us-gaap:MeasurementInputExpectedDividendRateMember 2021-03-31 0001365916 us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2020-12-31 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2020-01-01 2020-12-31 0001365916 us-gaap:ConvertibleDebtMember 2021-03-31 0001365916 us-gaap:ConvertibleDebtMember 2021-01-01 2021-03-31 0001365916 us-gaap:ConvertibleDebtMember 2020-12-31 0001365916 us-gaap:ConvertibleDebtMember 2020-01-01 2020-12-31 0001365916 amrs:ForisConvertibleNoteMember amrs:RelatedPartyConvertibleNotesMember 2021-01-01 2021-03-31 0001365916 amrs:ForisConvertibleNoteMember amrs:RelatedPartyConvertibleNotesMember 2020-12-31 0001365916 amrs:ForisConvertibleNoteMember amrs:RelatedPartyConvertibleNotesMember 2020-01-01 2020-12-31 0001365916 amrs:RelatedPartyConvertibleNotesMember 2021-03-31 0001365916 amrs:RelatedPartyConvertibleNotesMember 2021-01-01 2021-03-31 0001365916 amrs:RelatedPartyConvertibleNotesMember 2020-12-31 0001365916 amrs:RelatedPartyConvertibleNotesMember 2020-01-01 2020-12-31 0001365916 amrs:SchottenfeldNotesMember us-gaap:LoansPayableMember 2021-03-31 0001365916 amrs:SchottenfeldNotesMember us-gaap:LoansPayableMember 2021-01-01 2021-03-31 0001365916 amrs:SchottenfeldNotesMember us-gaap:LoansPayableMember 2020-12-31 0001365916 amrs:SchottenfeldNotesMember us-gaap:LoansPayableMember 2020-01-01 2020-12-31 0001365916 amrs:NikkoNotesMember us-gaap:LoansPayableMember 2021-03-31 0001365916 amrs:NikkoNotesMember us-gaap:LoansPayableMember 2021-01-01 2021-03-31 0001365916 amrs:NikkoNotesMember us-gaap:LoansPayableMember 2020-12-31 0001365916 amrs:NikkoNotesMember us-gaap:LoansPayableMember 2020-01-01 2020-12-31 0001365916 amrs:GinkgoCollaborationNoteMember us-gaap:LoansPayableMember 2021-03-31 0001365916 amrs:GinkgoCollaborationNoteMember us-gaap:LoansPayableMember 2021-01-01 2021-03-31 0001365916 amrs:GinkgoCollaborationNoteMember us-gaap:LoansPayableMember 2020-12-31 0001365916 amrs:GinkgoCollaborationNoteMember us-gaap:LoansPayableMember 2020-01-01 2020-12-31 0001365916 amrs:OtherLoansPayableMember us-gaap:LoansPayableMember 2021-03-31 0001365916 amrs:OtherLoansPayableMember us-gaap:LoansPayableMember 2021-01-01 2021-03-31 0001365916 amrs:OtherLoansPayableMember us-gaap:LoansPayableMember 2020-12-31 0001365916 amrs:OtherLoansPayableMember us-gaap:LoansPayableMember 2020-01-01 2020-12-31 0001365916 us-gaap:LoansPayableMember 2021-03-31 0001365916 us-gaap:LoansPayableMember 2021-01-01 2021-03-31 0001365916 us-gaap:LoansPayableMember 2020-12-31 0001365916 us-gaap:LoansPayableMember 2020-01-01 2020-12-31 0001365916 amrs:ForisDebtMember amrs:RelatedPartyLoanPayableMember 2021-03-31 0001365916 amrs:ForisDebtMember amrs:RelatedPartyLoanPayableMember 2021-01-01 2021-03-31 0001365916 amrs:ForisDebtMember amrs:RelatedPartyLoanPayableMember 2020-12-31 0001365916 amrs:ForisDebtMember amrs:RelatedPartyLoanPayableMember 2020-01-01 2020-12-31 0001365916 amrs:DSMNoteMember amrs:RelatedPartyLoanPayableMember 2021-03-31 0001365916 amrs:DSMNoteMember amrs:RelatedPartyLoanPayableMember 2021-01-01 2021-03-31 0001365916 amrs:DSMNoteMember amrs:RelatedPartyLoanPayableMember 2020-12-31 0001365916 amrs:DSMNoteMember amrs:RelatedPartyLoanPayableMember 2020-01-01 2020-12-31 0001365916 amrs:TheNaxyrisLoanAgreementMember amrs:RelatedPartyLoanPayableMember 2021-03-31 0001365916 amrs:TheNaxyrisLoanAgreementMember amrs:RelatedPartyLoanPayableMember 2021-01-01 2021-03-31 0001365916 amrs:TheNaxyrisLoanAgreementMember amrs:RelatedPartyLoanPayableMember 2020-12-31 0001365916 amrs:TheNaxyrisLoanAgreementMember amrs:RelatedPartyLoanPayableMember 2020-01-01 2020-12-31 0001365916 amrs:RelatedPartyLoanPayableMember 2021-03-31 0001365916 amrs:RelatedPartyLoanPayableMember 2021-01-01 2021-03-31 0001365916 amrs:RelatedPartyLoanPayableMember 2020-12-31 0001365916 amrs:RelatedPartyLoanPayableMember 2020-01-01 2020-12-31 0001365916 2020-01-01 2020-12-31 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2021-02-04 0001365916 amrs:NewSeniorConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2021-02-04 2021-02-04 0001365916 amrs:SchottenfeldSeptember2019CreditAgreementsMember 2021-03-01 0001365916 2021-03-01 2021-03-01 0001365916 amrs:DSMCreditAgreementMember 2017-12-28 0001365916 amrs:DSMCreditAgreementMember us-gaap:UnsecuredDebtMember 2017-12-28 0001365916 amrs:DSMCreditAgreementMember 2017-12-28 2017-12-28 0001365916 amrs:The2019DSMCreditAgreementMember amrs:DSMInternationalBVMember 2019-09-17 0001365916 2019-09-17 0001365916 amrs:DSMCreditAgreementMember 2019-09-17 0001365916 amrs:DSMCreditAgreementMember us-gaap:UnsecuredDebtMember 2019-09-17 0001365916 amrs:DSMCreditAgreementMarch2021AmendmentRelatedTo25MillionDollarNoteMember us-gaap:UnsecuredDebtMember 2021-01-01 2021-03-31 0001365916 amrs:DSMCreditAgreementMarch2021AmendmentMember us-gaap:UnsecuredDebtMember 2021-03-31 0001365916 amrs:DSMCreditAgreementMarch2021AmendmentMember us-gaap:UnsecuredDebtMember 2021-01-01 2021-03-31 0001365916 amrs:DSMCreditAgreementMember us-gaap:UnsecuredDebtMember 2021-01-01 2021-03-31 0001365916 amrs:DSMCreditAgreementMember us-gaap:UnsecuredDebtMember 2021-03-31 0001365916 amrs:LoansPayableAndCreditFacilitiesMember 2021-03-31 0001365916 amrs:RelatedPartyLoansPayableAndCreditFacilitiesMember 2021-03-31 0001365916 amrs:GatesFoundationPurchaseAgreementMember 2021-03-31 0001365916 amrs:GatesFoundationPurchaseAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:HighTrailSilverbackWarrantsMember 2021-03-31 0001365916 amrs:January2020WarrantExerciseRightSharesMember 2021-03-31 0001365916 amrs:April2019PIPEWarrantsMember 2021-03-31 0001365916 srt:MinimumMember amrs:April2019PIPEWarrantsMember 2021-03-31 0001365916 srt:MaximumMember amrs:April2019PIPEWarrantsMember 2021-03-31 0001365916 amrs:NaxyrisLSAWarrantsMember 2021-03-31 0001365916 amrs:October2019NaxyrisWarrantMember 2021-03-31 0001365916 amrs:May20196.50NoteExchangeWarrantsMember 2021-03-31 0001365916 amrs:May2017CashWarrantsMember 2021-03-31 0001365916 amrs:May2017DilutionWarrantsMember 2021-03-31 0001365916 amrs:August2017DilutionWarrantsMember 2021-03-31 0001365916 amrs:July2015RelatedPartyDebtExchange3Member 2021-03-31 0001365916 amrs:OtherMember 2021-03-31 0001365916 amrs:PeriodEndCommonStockWarrantsMember 2021-01-01 2021-03-31 0001365916 amrs:PeriodEndCommonStockWarrantsMember 2020-01-01 2020-03-31 0001365916 amrs:ConvertiblePromissoryNotesMember 2021-01-01 2021-03-31 0001365916 amrs:ConvertiblePromissoryNotesMember 2020-01-01 2020-03-31 0001365916 amrs:StockOptionsToPurchaseCommonStockMember 2021-01-01 2021-03-31 0001365916 amrs:StockOptionsToPurchaseCommonStockMember 2020-01-01 2020-03-31 0001365916 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001365916 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001365916 amrs:PeriodEndPreferredSharesMember 2021-01-01 2021-03-31 0001365916 amrs:PeriodEndPreferredSharesMember 2020-01-01 2020-03-31 0001365916 amrs:AprinnovaJVMember 2021-03-31 0001365916 us-gaap:ProductMember country:US 2021-01-01 2021-03-31 0001365916 amrs:LicensesAndRoyaltiesMember country:US 2021-01-01 2021-03-31 0001365916 amrs:GrantsAndCollaborationsMember country:US 2021-01-01 2021-03-31 0001365916 country:US 2021-01-01 2021-03-31 0001365916 us-gaap:ProductMember country:US 2020-01-01 2020-03-31 0001365916 amrs:LicensesAndRoyaltiesMember country:US 2020-01-01 2020-03-31 0001365916 amrs:GrantsAndCollaborationsMember country:US 2020-01-01 2020-03-31 0001365916 country:US 2020-01-01 2020-03-31 0001365916 us-gaap:ProductMember srt:EuropeMember 2021-01-01 2021-03-31 0001365916 amrs:LicensesAndRoyaltiesMember srt:EuropeMember 2021-01-01 2021-03-31 0001365916 amrs:GrantsAndCollaborationsMember srt:EuropeMember 2021-01-01 2021-03-31 0001365916 srt:EuropeMember 2021-01-01 2021-03-31 0001365916 us-gaap:ProductMember srt:EuropeMember 2020-01-01 2020-03-31 0001365916 amrs:LicensesAndRoyaltiesMember srt:EuropeMember 2020-01-01 2020-03-31 0001365916 amrs:GrantsAndCollaborationsMember srt:EuropeMember 2020-01-01 2020-03-31 0001365916 srt:EuropeMember 2020-01-01 2020-03-31 0001365916 us-gaap:ProductMember srt:AsiaMember 2021-01-01 2021-03-31 0001365916 amrs:LicensesAndRoyaltiesMember srt:AsiaMember 2021-01-01 2021-03-31 0001365916 amrs:GrantsAndCollaborationsMember srt:AsiaMember 2021-01-01 2021-03-31 0001365916 srt:AsiaMember 2021-01-01 2021-03-31 0001365916 us-gaap:ProductMember srt:AsiaMember 2020-01-01 2020-03-31 0001365916 amrs:LicensesAndRoyaltiesMember srt:AsiaMember 2020-01-01 2020-03-31 0001365916 amrs:GrantsAndCollaborationsMember srt:AsiaMember 2020-01-01 2020-03-31 0001365916 srt:AsiaMember 2020-01-01 2020-03-31 0001365916 us-gaap:ProductMember country:BR 2021-01-01 2021-03-31 0001365916 amrs:LicensesAndRoyaltiesMember country:BR 2021-01-01 2021-03-31 0001365916 amrs:GrantsAndCollaborationsMember country:BR 2021-01-01 2021-03-31 0001365916 country:BR 2021-01-01 2021-03-31 0001365916 us-gaap:ProductMember country:BR 2020-01-01 2020-03-31 0001365916 amrs:LicensesAndRoyaltiesMember country:BR 2020-01-01 2020-03-31 0001365916 amrs:GrantsAndCollaborationsMember country:BR 2020-01-01 2020-03-31 0001365916 country:BR 2020-01-01 2020-03-31 0001365916 us-gaap:ProductMember amrs:OtherAreaMember 2021-01-01 2021-03-31 0001365916 amrs:LicensesAndRoyaltiesMember amrs:OtherAreaMember 2021-01-01 2021-03-31 0001365916 amrs:GrantsAndCollaborationsMember amrs:OtherAreaMember 2021-01-01 2021-03-31 0001365916 amrs:OtherAreaMember 2021-01-01 2021-03-31 0001365916 us-gaap:ProductMember amrs:OtherAreaMember 2020-01-01 2020-03-31 0001365916 amrs:LicensesAndRoyaltiesMember amrs:OtherAreaMember 2020-01-01 2020-03-31 0001365916 amrs:GrantsAndCollaborationsMember amrs:OtherAreaMember 2020-01-01 2020-03-31 0001365916 amrs:OtherAreaMember 2020-01-01 2020-03-31 0001365916 amrs:ConsumerMember us-gaap:ProductMember 2021-01-01 2021-03-31 0001365916 amrs:ConsumerMember amrs:LicensesAndRoyaltiesMember 2021-01-01 2021-03-31 0001365916 amrs:ConsumerMember amrs:GrantsAndCollaborationsMember 2021-01-01 2021-03-31 0001365916 amrs:ConsumerMember 2021-01-01 2021-03-31 0001365916 amrs:ConsumerMember us-gaap:ProductMember 2020-01-01 2020-03-31 0001365916 amrs:ConsumerMember amrs:LicensesAndRoyaltiesMember 2020-01-01 2020-03-31 0001365916 amrs:ConsumerMember amrs:GrantsAndCollaborationsMember 2020-01-01 2020-03-31 0001365916 amrs:ConsumerMember 2020-01-01 2020-03-31 0001365916 amrs:IngredientCustomerMember us-gaap:ProductMember 2021-01-01 2021-03-31 0001365916 amrs:IngredientCustomerMember amrs:LicensesAndRoyaltiesMember 2021-01-01 2021-03-31 0001365916 amrs:IngredientCustomerMember amrs:GrantsAndCollaborationsMember 2021-01-01 2021-03-31 0001365916 amrs:IngredientCustomerMember 2021-01-01 2021-03-31 0001365916 amrs:IngredientCustomerMember us-gaap:ProductMember 2020-01-01 2020-03-31 0001365916 amrs:IngredientCustomerMember amrs:LicensesAndRoyaltiesMember 2020-01-01 2020-03-31 0001365916 amrs:IngredientCustomerMember amrs:GrantsAndCollaborationsMember 2020-01-01 2020-03-31 0001365916 amrs:IngredientCustomerMember 2020-01-01 2020-03-31 0001365916 amrs:ResearchAndDevelopmentCustomerMember us-gaap:ProductMember 2021-01-01 2021-03-31 0001365916 amrs:ResearchAndDevelopmentCustomerMember amrs:LicensesAndRoyaltiesMember 2021-01-01 2021-03-31 0001365916 amrs:ResearchAndDevelopmentCustomerMember amrs:GrantsAndCollaborationsMember 2021-01-01 2021-03-31 0001365916 amrs:ResearchAndDevelopmentCustomerMember 2021-01-01 2021-03-31 0001365916 amrs:ResearchAndDevelopmentCustomerMember us-gaap:ProductMember 2020-01-01 2020-03-31 0001365916 amrs:ResearchAndDevelopmentCustomerMember amrs:LicensesAndRoyaltiesMember 2020-01-01 2020-03-31 0001365916 amrs:ResearchAndDevelopmentCustomerMember amrs:GrantsAndCollaborationsMember 2020-01-01 2020-03-31 0001365916 amrs:ResearchAndDevelopmentCustomerMember 2020-01-01 2020-03-31 0001365916 amrs:DSMInternationalBVMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:DSMInternationalBVMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:DSMInternationalBVMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:DSMInternationalBVMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:DSMInternationalBVMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:DSMInternationalBVMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:DSMInternationalBVMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:DSMInternationalBVMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:SephoraMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:SephoraMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:SephoraMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:SephoraMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:SephoraMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:SephoraMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:SephoraMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:SephoraMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:YifanMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:YifanMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:YifanMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:YifanMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:YifanMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:YifanMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:YifanMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:YifanMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:FirmenichMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:FirmenichMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:FirmenichMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:FirmenichMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:FirmenichMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:FirmenichMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:FirmenichMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:FirmenichMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:GivaudanInternationalSaMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:GivaudanInternationalSaMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:GivaudanInternationalSaMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:GivaudanInternationalSaMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:GivaudanInternationalSaMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:GivaudanInternationalSaMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:GivaudanInternationalSaMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:GivaudanInternationalSaMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:AllOtherCustomersMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:AllOtherCustomersMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:AllOtherCustomersMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:AllOtherCustomersMember amrs:SignificantRevenueAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:AllOtherCustomersMember amrs:RenewableProductsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:AllOtherCustomersMember amrs:LicensesAndRoyaltiesMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:AllOtherCustomersMember amrs:GrantsAndCollaborationsMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:AllOtherCustomersMember amrs:SignificantRevenueAgreementMember 2020-01-01 2020-03-31 0001365916 amrs:RenewableProductsMember 2021-01-01 2021-03-31 0001365916 amrs:RenewableProductsMember 2020-01-01 2020-03-31 0001365916 amrs:DSMInternationalBVMember amrs:DSMLicenseAgreementMember 2021-03-31 0001365916 amrs:DSMInternationalBVMember srt:MaximumMember 2021-01-01 2021-03-31 0001365916 amrs:DSMInternationalBVMember amrs:DSMLicenseAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:FinishedGoodsInventoryMember amrs:DSMInternationalBVMember amrs:DSMLicenseAgreementMember 2021-03-31 0001365916 amrs:ReceivablesMember amrs:DSMInternationalBVMember amrs:DSMLicenseAgreementMember 2021-03-31 0001365916 amrs:IntellectualPropertyLicenseMember amrs:DSMInternationalBVMember amrs:DSMLicenseAgreementMember 2021-03-31 0001365916 amrs:DSMInternationalBVMember us-gaap:LicenseMember amrs:DSMLicenseAgreementMember 2021-01-01 2021-03-31 0001365916 amrs:DSMInternationalBVMember amrs:ResearchAndDevelopmentCustomerMember amrs:DSMPerformanceCollabrationMember 2017-12-01 2017-12-31 0001365916 amrs:DSMInternationalBVMember amrs:ResearchAndDevelopmentCustomerMember amrs:DSMPerformanceCollabrationMember 2017-12-31 0001365916 amrs:DSMInternationalBVMember amrs:ResearchAndDevelopmentCustomerMember amrs:DSMPerformanceCollabrationMember 2021-01-01 2021-03-31 0001365916 amrs:DSMInternationalBVMember amrs:DSMIngredientsCollaborationMember 2021-01-01 2021-03-31 0001365916 amrs:DSMInternationalBVMember amrs:ResearchAndDevelopmentCustomerMember amrs:DSMIngredientsCollaborationMember 2021-01-01 2021-03-31 0001365916 amrs:DSMInternationalBVMember amrs:ResearchAndDevelopmentCustomerMember amrs:DSMIngredientsCollaborationMember 2020-01-01 2020-03-31 0001365916 amrs:YifanMember amrs:GrantsAndCollaborationsMember 2021-01-01 2021-03-31 0001365916 amrs:YifanMember amrs:GrantsAndCollaborationsMember 2021-03-31 0001365916 2021-04-01 2021-03-31 0001365916 2022-01-01 2021-03-31 0001365916 2023-01-01 2021-03-31 0001365916 2024-01-01 2021-03-31 0001365916 amrs:ForisNotesMember amrs:RelatedPartyDebtMember amrs:ForisVenturesLLCMember 2021-03-31 0001365916 amrs:ForisNotesMember amrs:RelatedPartyDebtMember amrs:ForisVenturesLLCMember 2020-12-31 0001365916 amrs:DSMNoteMember amrs:RelatedPartyDebtMember amrs:DSMInternationalBVMember 2021-03-31 0001365916 amrs:DSMNoteMember amrs:RelatedPartyDebtMember amrs:DSMInternationalBVMember 2020-12-31 0001365916 amrs:NaxyrisNoteMember amrs:RelatedPartyDebtMember amrs:NaxyrisSAMember 2021-03-31 0001365916 amrs:NaxyrisNoteMember amrs:RelatedPartyDebtMember amrs:NaxyrisSAMember 2020-12-31 0001365916 amrs:RelatedPartyDebtMember 2021-03-31 0001365916 amrs:RelatedPartyDebtMember 2020-12-31 0001365916 amrs:AccountsReceivableUnbilledRelatedPartyMember amrs:DSMInternationalBVMember 2021-03-31 0001365916 amrs:AccountsReceivableUnbilledRelatedPartyMember amrs:DSMInternationalBVMember 2020-12-31 0001365916 amrs:ContractAssetsRelatedPartyMember amrs:DSMInternationalBVMember 2021-03-31 0001365916 amrs:ContractAssetsRelatedPartyMember amrs:DSMInternationalBVMember 2020-12-31 0001365916 amrs:AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesMember amrs:DSMInternationalBVMember 2021-03-31 0001365916 amrs:AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesMember amrs:DSMInternationalBVMember 2020-12-31 0001365916 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001365916 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001365916 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001365916 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001365916 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001365916 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001365916 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001365916 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001365916 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001365916 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001365916 us-gaap:EmployeeStockOptionMember 2021-03-31 0001365916 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001365916 amrs:A2020EquityIncentivePlanMember 2021-03-31 0001365916 amrs:EquityIncentivePlan2010Member 2021-03-31 0001365916 us-gaap:SubsequentEventMember amrs:PublicStockOfferingSharesFromSellingStockholdersMember 2021-04-08 2021-04-08 0001365916 us-gaap:SubsequentEventMember amrs:PublicStockOfferingSharesFromSellingStockholdersMember 2021-04-08 0001365916 us-gaap:SubsequentEventMember amrs:PublicStockOfferingSharesFromAmyrisMember 2021-04-08 2021-04-08 0001365916 us-gaap:SubsequentEventMember 2021-04-08 0001365916 us-gaap:SubsequentEventMember 2021-04-08 2021-04-08 0001365916 us-gaap:SubsequentEventMember amrs:PublicStockOfferingSellingStockholdersUnderUnderwritingAgreementMember 2021-04-08 2021-04-08 0001365916 us-gaap:SubsequentEventMember amrs:PublicStockOfferingAmyrisUnderUnderwritingAgreementMember 2021-04-08 2021-04-08 shares iso4217:USD iso4217:USD shares pure amrs:installment 0001365916 --12-31 2021 Q1 false P5Y P9M P1Y P1Y 10-Q true 2021-03-31 false 001-34885 AMYRIS, INC. DE 55-0856151 5885 Hollis Street Suite 100 Emeryville CA 94608 510 450-0761 Common Stock, $0.0001 par value per share AMRS NASDAQ Yes Yes Accelerated Filer false false false 291471055 143821000 30152000 283000 309000 154000 137000 27036000 32846000 0 0 391000 12110000 6589000 4178000 2000000 1203000 47639000 42862000 5220000 9801000 19246000 13103000 252225000 146564000 31933000 32875000 9391000 9939000 961000 961000 8680000 8641000 9296000 9994000 9333000 10136000 4770000 3704000 326589000 222814000 44154000 41045000 32121000 30707000 3258000 4170000 5510000 5226000 6163000 4468000 54757000 53387000 55904000 54748000 0 22689000 147110000 163053000 0 0 13873000 26170000 0 0 413687000 159452000 8209000 9732000 31384000 8698000 22467000 22754000 636730000 389859000 5000000 5000000 0.0001 0.0001 5000000 5000000 8280 8280 8280 8280 0 0 0.0001 0.0001 350000000 350000000 273266917 273266917 244951446 244951446 27000 24000 2106214000 1957224000 -49413000 -47375000 -2377943000 -2086692000 -321115000 -176819000 5974000 4774000 -315141000 -172045000 326589000 222814000 1662000 49000 28179000 17854000 143612000 3750000 143800000 5161000 2000000 3018000 4880000 6115000 147274000 6817000 176859000 29130000 22659000 11790000 23332000 17126000 37922000 32014000 83913000 60930000 92946000 -31800000 5813000 15002000 -22745000 3282000 -326785000 -16503000 -27313000 -27319000 -678000 4000 -383334000 -55538000 -290388000 -87338000 55000 91000 392000 -415000 -290051000 -87844000 1200000 0 -291251000 -87844000 -2099000 -1087000 -289152000 -289152000 -86757000 -86757000 -1.08 -1.08 -0.56 -0.56 267733555 155065635 -290051000 -87844000 -2038000 -2549000 -292089000 -90393000 1200000 0 -293289000 -90393000 8280 0 244951446 24000 1957224000 -47375000 -2086692000 4774000 -172045000 5000000 496341 -2000 -2000 2600000 5827164 1000 110574000 110575000 377542 1920000 1920000 15557480 2000 32217000 32219000 6056944 0 0 0 4281000 4281000 -2038000 -2038000 -291251000 1200000 -290051000 8280 0 273266917 27000 2106214000 -49413000 -2377943000 5974000 -315141000 5000000 8280 0 117742677 12000 1543668000 -43804000 -1755653000 609000 -255168000 5000000 6337594 1000 21259000 21260000 3484321 10000000 10000000 10505652 1000 27188000 27189000 1160929 3332000 3332000 24165166 2000 68763000 68765000 15000000 15000000 8904000 8904000 1286000 1286000 5200000 5200000 495581 -8000 -8000 3504000 3504000 -2549000 -2549000 -87844000 -87844000 8280 0 163891920 16000 1708096000 -46353000 -1843497000 609000 -181129000 5000000 -290051000 -87844000 -326785000 -16503000 27313000 27319000 -22745000 3282000 4281000 3504000 2114000 1719000 750000 668000 713000 1292000 -408000 109000 0 42000 392000 -415000 -17275000 5209000 3208000 870000 5686000 4392000 -5129000 -142000 8207000 1430000 4154000 318000 4011000 4009000 -1185000 -1043000 1702000 1873000 108651000 -46375000 2493000 1040000 -2493000 -1040000 2500000 0 2000 8000 23196000 6981000 912000 866000 0 15000000 1920000 0 32219000 3332000 0 13998000 0 10000000 0 15000000 0 188000 7529000 49663000 -44000 19000 113643000 2267000 31422000 1699000 145065000 3966000 143821000 2607000 283000 399000 961000 960000 145065000 3966000 3275000 3152000 0 1527000 59000 0 0 5200000 0 69918000 0 2962000 0 188000 0 747000 110575000 18333000 1121000 1307000 Basis of Presentation and Summary of Significant Accounting Policies<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a leading synthetic biotechnology company active in the Clean Health and Beauty markets through our consumer brands and a top supplier of sustainable and natural ingredients, Amyris, Inc. and our subsidiaries (collectively, Amyris or the Company) apply the Company's proprietary Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products. The Company does so with the use of computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. The Company's biotechnology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that the Company manufactures at industrial scale. Through the combination of our biotechnology platform and our industrial fermentation process, the Company has successfully developed, produced and commercialized many distinct molecules.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 (the 2020 Form 10-K), from which the condensed consolidated balance sheet as of December 31, 2020 is derived. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 1, "Basis of Presentation and Summary of Significant Accounting Policies", to the audited consolidated financial statements in the 2020 Form 10-K includes a discussion of the significant accounting policies and estimates used in the preparation of the Company’s condensed consolidated financial statements. There have been no material changes to the Company's significant accounting policies and estimates during the three months ended March 31, 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Judgements</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards or Updates Recently Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2021, the Company adopted these accounting standards or updates:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In December 2019, the FASB issued ASU 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Simplifying the Accounting for Income Taxes (Topic 740)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Equity Securities, Equity-method Investments and Certain Derivative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the FASB issued ASU 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards or Updates Not Yet Adopted</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Credit Losses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. ASU 2016-13 will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Convertible Debt, and Derivatives and Hedging</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures.</span></div> The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Judgements</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant </span></div>accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed. <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards or Updates Recently Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2021, the Company adopted these accounting standards or updates:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In December 2019, the FASB issued ASU 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Simplifying the Accounting for Income Taxes (Topic 740)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Equity Securities, Equity-method Investments and Certain Derivative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the FASB issued ASU 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards or Updates Not Yet Adopted</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Credit Losses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. ASU 2016-13 will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Convertible Debt, and Derivatives and Hedging</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures.</span></div> Balance Sheet Details<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Doubtful Accounts</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.970%"><tr><td style="width:1.0%"/><td style="width:52.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provisions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Write-offs, Net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three months ended March 31, 2021</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three months ended March 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,800 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,702 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,760 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,752 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,302 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,639 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,862 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred cost of products sold - related party</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred cost of products sold - related party</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,220 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,801 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred cost of products sold, noncurrent - related party</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,939 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,611 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,740 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts reported as "Deferred cost of products sold - related party" are in connection with an agreement with Koninklijke DSM N.V. (DSM) under which DSM will provide capacity for sweetener production at DSM's Brotas, Brazil manufacturing facility through December 2022. Deferred cost of products sold asset is being expensed to cost of products sold on a units of production basis as the Company's sweetener product is sold over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZDgyNzA3NmU5MjQxNGNiZTE2ZGIzZjA0MmIyZDQyL3NlYzo3MmQ4MjcwNzZlOTI0MTRjYmUxNmRiM2YwNDJiMmQ0Ml80My9mcmFnOjExNmQyMjYwZDJkZDRkMjZiOGM0NzE0MGFmNmI4NWYwL3RleHRyZWdpb246MTE2ZDIyNjBkMmRkNGQyNmI4YzQ3MTQwYWY2Yjg1ZjBfMjc0ODc3OTA5MTU3OA_f3aa08df-a1de-46ba-8fbf-cec9ab8531c9">five</span>-year term of the supply agreement. During the three months ended March 31, 2021 and 2020, the Company expensed $1.6 million and $0.1 million, respectively, of the deferred cost of products sold asset to cost of products sold. Inception-to-date amortization through March 31, 2021 totaled $4.9 million.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments, advances and deposits</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,453 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,637 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-inventory production supplies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoverable taxes from Brazilian government entities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,246 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,103 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,880 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,415 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,197 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,362 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,741 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment, vehicles and land</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,450 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,238 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,250 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,730 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,110 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,797)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,235)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,933 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,875 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 to 5 years, and often include one or more options to renew. These renewal terms can extend the lease term from 1 to 5 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. The operating leases are classified as ROU assets under operating leases on the Company's condensed consolidated balance sheets and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make operating lease payments is included in "Lease liabilities" and "Lease liabilities, net of current portion" on the Company's condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company had $9.3 million and $10.1 million of right-of-use assets as of March 31, 2021 and December 31, 2020, respectively. Operating lease liabilities were $13.7 million and $15.0 million as of March 31, 2021 and December 31, 2020, respectively. During the three </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ended March 31, 2021 and 2020, respectively, the Company recorded $1.8 million and $1.5 million of operating lease amortization that was charged to expense, of which $0.2 million and $0.3 million was recorded to cost of products sold. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company has certain contracts for real estate and marketing which may contain lease and non-lease components which it has elected to treat as a single lease component.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the Company's right-of-use assets and related lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"/><td style="width:67.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities, in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,185</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,893</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease obligations, in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$—</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.0%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.0%</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Leases</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has financing leases primarily for laboratory and computer equipment. Assets purchased under financing leases are included in "Right-of-use assets under financing leases, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Accumulated amortization of assets under financing leases totaled $5.3 million and $4.6 million as of March 31, 2021 and December 31, 2020, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturities of Financing and Operating Leases</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of March 31, 2021 were as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:69.736%"><tr><td style="width:1.0%"/><td style="width:51.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ending December 31:<br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing<br/>Leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Leases</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (Remaining Nine Months)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,135 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,320 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,320 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,769 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,260 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,283)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,719 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,977 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liability</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,510 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,768 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,209 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,209 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,719 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,977 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-method investment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,431 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,770 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,704 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,540 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,230 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,721 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,327 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,311 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,344 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ginkgo partnership payments obligation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-related liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,425 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,237 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other current liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,121 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,707 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    The asset retirement obligation represents liabilities incurred but not yet discharged in connection with our 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other noncurrent liabilities</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for unrecognized tax benefit</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,551 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,496 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ginkgo partnership payments obligation, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,461 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,277 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability in connection with acquisition of equity-method investment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,216 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,771 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,467 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,754 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Doubtful Accounts</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.970%"><tr><td style="width:1.0%"/><td style="width:52.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provisions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Write-offs, Net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three months ended March 31, 2021</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three months ended March 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 137000 17000 0 154000 45000 0 0 45000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,800 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,702 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,760 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,752 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,302 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,639 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,862 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12185000 11800000 8702000 10760000 26752000 20302000 47639000 42862000 Deferred cost of products sold - related party<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred cost of products sold - related party</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,220 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,801 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred cost of products sold, noncurrent - related party</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,939 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,611 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,740 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5220000 9801000 9391000 9939000 14611000 19740000 1600000 100000 4900000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments, advances and deposits</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,453 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,637 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-inventory production supplies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoverable taxes from Brazilian government entities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,246 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,103 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 13453000 6637000 3364000 3989000 1020000 1063000 1409000 1414000 19246000 13103000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,880 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,415 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,197 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,362 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,741 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment, vehicles and land</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,450 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,238 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,250 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,730 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,110 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,797)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,235)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,933 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,875 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 49880000 50415000 44800000 45197000 7362000 6741000 3450000 3507000 7238000 7250000 112730000 113110000 80797000 80235000 31933000 32875000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2114000 1719000 P1Y P5Y P1Y P5Y 9300000 10100000 13700000 15000000.0 1800000 1500000 200000 300000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the Company's right-of-use assets and related lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"/><td style="width:67.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities, in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,185</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,893</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease obligations, in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$—</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.0%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.0%</span></td></tr></table></div> 1185000 1893000 0 0 P2Y8M12D P3Y2M12D 0.180 0.180 5300000 4600000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of March 31, 2021 were as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:69.736%"><tr><td style="width:1.0%"/><td style="width:51.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ending December 31:<br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing<br/>Leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Leases</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (Remaining Nine Months)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,135 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,320 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,320 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,769 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,260 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,283)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,719 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,977 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liability</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,510 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,768 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,209 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,209 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,719 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,977 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3491000 5644000 9135000 0 7655000 7655000 0 3320000 3320000 0 150000 150000 0 0 0 3491000 16769000 20260000 233000 3050000 3283000 3258000 13719000 16977000 3258000 5510000 8768000 0 8209000 8209000 3258000 13719000 16977000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-method investment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,431 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,770 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,704 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3431000 2380000 126000 128000 1213000 1196000 4770000 3704000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,540 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,230 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,721 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,327 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,311 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,344 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ginkgo partnership payments obligation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-related liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,425 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,237 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other current liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,121 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,707 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    The asset retirement obligation represents liabilities incurred but not yet discharged in connection with our 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.</span></div> 10540000 8230000 7721000 9327000 5311000 5344000 3003000 3041000 1604000 994000 878000 878000 639000 656000 2425000 2237000 32121000 30707000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other noncurrent liabilities</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.865%"><tr><td style="width:1.0%"/><td style="width:63.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for unrecognized tax benefit</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,551 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,496 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ginkgo partnership payments obligation, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,461 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,277 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability in connection with acquisition of equity-method investment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,216 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,771 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,467 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,754 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7551000 7496000 7461000 7277000 7216000 6771000 111000 111000 128000 1099000 22467000 22754000 Fair Value Measurement<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liabilities Measured and Recorded at Fair Value on a Recurring Basis</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:36.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foris Convertible Note (LSA Amendment)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123,164 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123,164 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Senior Convertible Notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54,757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54,757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Embedded derivatives bifurcated from debt instruments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Freestanding derivative instruments issued in connection with other debt and equity instruments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,451 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,451 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">465,580 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">465,580 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185,249 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185,249 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not hold any financial assets to be measured and recorded at fair value on a recurring basis as of March 31, 2021 and December 31, 2020. Also, there were no transfers between the levels during the three months ended March 31, 2021 or the year ended December 31, 2020.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the asset or liability. The method of determining the fair value of embedded derivative liabilities is described subsequently in this note. Market risk associated with embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value of derivative liabilities are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of derivative instruments".</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of debt".</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Debt — Foris Convertible Note</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021, the contractual outstanding principal of the Foris Convertible Note was $50.0 million, and fair value was $379.4 million. The Company remeasured the fair value of the Foris Convertible Note under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $19.10 stock price, (ii) 10% discount yield, (iii) 0.09% risk free interest rate (iv) 45% equity volatility and (v) 5% probability of change in control. The Company assumed that if a change of control event were to occur, it would occur at the end of the calendar year. The Company recorded a loss of $256.3 million related to change in fair value of the Foris Convertible Note for the three months ended March 31, 2021. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.00 conversion price.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Debt — Senior Convertible Notes</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021, the contractual outstanding principal of the Senior Convertible Notes was $10.0 million, and fair value was $54.8 million. The Company measured the fair value at March 31, 2021 under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $19.10 stock price, (ii) 210% discount yield, (iii) 0.02% risk free interest rate (iv) 45% equity volatility, and (v) 0% probability of change in control. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.50 conversion price.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, the Company recorded a $70.5 million loss from change in fair value of debt in connection with fair value remeasurement of the Senior Convertible Notes, as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.345%"><tr><td style="width:1.0%"/><td style="width:86.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">In thousands</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at December 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from change in fair value</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,510 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: principal converted into common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: fair value adjustment extinguished upon conversion of debt principal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,140)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at March 31, 2021</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,757 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Binomial Lattice Model</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A binomial lattice model was used to determine whether the Foris Convertible Note and the Senior Convertible Notes (Debt Instruments) would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the convertible note will be converted early if the conversion value is greater than the holding value and (ii) the convertible note will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the convertible note is called, the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the convertible note. Using this lattice method, the Company valued the Debt Instruments using the "with-and-without method", where the fair value of the Debt Instruments including the embedded and freestanding features is defined as the "with," and the fair value of the Debt Instruments excluding the embedded and freestanding features is defined as the "without." This method estimates the fair value of the Debt Instruments by looking at the difference in the values of the Debt Instruments with the embedded and freestanding derivatives and the fair value of the Debt Instruments without the embedded and freestanding features. The lattice model uses the stock price, conversion price, maturity date, risk-free interest rate, estimated stock volatility, estimated credit spread and other instrument-specific assumptions. The Company remeasures the fair value of the Debt Instruments and records the change as a gain or loss from change in fair value of debt in the statement of operations for each reporting period.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities Recognized in Connection with the Issuance of Debt Instruments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:59.649%"><tr><td style="width:1.0%"/><td style="width:81.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.812%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,698 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative instruments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,745 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derecognition on settlement or extinguishment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,384 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Freestanding Derivative Instruments</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 28, 2020, the Company entered into forbearance agreements with certain affiliates of the Schottenfeld Group LLC (the Lenders) related to certain defaults under the Schottenfeld Notes. In connection with entering into the forbearance agreements, the Company committed to issuing warrants (Warrants) to the Lenders under certain contingent events for 1.9 million shares of common stock at a $2.87 purchase price and a two-year term. The contingent obligation to issue the Warrants did not meet the derivative scope exception or equity classification criteria and was accounted for as a derivative liability and remeasured each reporting period until settled or extinguished with subsequent changes in fair value recorded through the statement of operations. The fair value of the Warrants derivative liability was determined using a Black-Scholes-Merton option pricing model based on the input assumptions for liability classified warrants table in the valuation methodology section below. At March 31, 2021, the fair value of the contingently issuable Warrants derivative liability was $31.2 million, and for the three months ended March 31, 2021, the Company recorded a $22.7 million loss on change in fair value of derivative instruments.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation Methodology and Approach to Measuring the Derivative Liabilities</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all the outstanding liabilities associated with the Company’s derivatives at March 31, 2021 and December 31, 2020 represent the fair value of freestanding equity instruments. See Note 4, "Debt", and Note 6, "Stockholders' Deficit" for further information regarding these host instruments. There is no current observable market for these types of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">derivatives and, as such, the Company determined the fair value of the freestanding instruments using the Black-Scholes-Merton option pricing model, which is discussed in more detail below.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes-Merton option pricing model to determine the fair value of its liability classified warrants as of March 31, 2021 and December 31, 2020. Input assumptions for these freestanding instruments are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.345%"><tr><td style="width:1.0%"/><td style="width:53.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.646%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range for the Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Input assumptions for liability classified warrants:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Fair value of common stock on issue date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$19.10 – $19.10</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$2.56 – $6.18</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Exercise price of warrants</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.87 – $2.87</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.87 – $3.25</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114% – 114%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94% – 117%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16% – 0.16%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13% – 1.58%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Expected term in years</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 – 2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 – 2</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 %</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in valuation assumptions can have a significant impact on the valuation of the freestanding derivative liabilities and debt that the Company elects to account for at fair value. For example, all other things being equal, generally, an increase in the Company’s stock price, change of control probability, risk-adjusted yields term to maturity/conversion or stock price volatility increases the value of the derivative liability. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Recorded at Carrying Value</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and other current accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable and credit facilities are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of these instruments using observable market-based inputs (Level 2). The carrying amount (the total amount of net debt presented on the balance sheet) of the Company's debt at March 31, 2021 and at December 31, 2020, excluding the debt instruments recorded at fair value, was $49.3 million and $86.5 million, respectively. The fair value of such debt at March 31, 2021 and at December 31, 2020 was $51.1 million and $83.3 million, respectively, and was determined by (i) discounting expected cash flows using current market discount rates estimated for certain of the debt instruments and (ii) using third-party fair value estimates for the remaining debt instruments.</span></div> <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:36.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foris Convertible Note (LSA Amendment)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123,164 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123,164 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Senior Convertible Notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54,757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54,757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Embedded derivatives bifurcated from debt instruments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Freestanding derivative instruments issued in connection with other debt and equity instruments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,451 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,451 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">465,580 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">465,580 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185,249 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185,249 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 379439000 379439000 0 0 123164000 123164000 0 0 54757000 54757000 0 0 53387000 53387000 0 0 188000 188000 0 0 247000 247000 0 0 31196000 31196000 0 0 8451000 8451000 0 0 465580000 465580000 0 0 185249000 185249000 50000000.0 379400000 19.10 0.10 0.0009 0.45 0.05 256300000 3.00 10000000.0 54800000 19.10 2.10 0.0002 0.45 0 3.50 For the three months ended March 31, 2021, the Company recorded a $70.5 million loss from change in fair value of debt in connection with fair value remeasurement of the Senior Convertible Notes, as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.345%"><tr><td style="width:1.0%"/><td style="width:86.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">In thousands</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at December 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from change in fair value</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,510 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: principal converted into common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: fair value adjustment extinguished upon conversion of debt principal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,140)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at March 31, 2021</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,757 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 53387000 -70510000 20000000 49140000 54757000 <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:59.649%"><tr><td style="width:1.0%"/><td style="width:81.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.812%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,698 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative instruments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,745 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derecognition on settlement or extinguishment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,384 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8698000 22745000 59000 31384000 1900000 2.87 P2Y 31200000 22700000 Input assumptions for these freestanding instruments are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.345%"><tr><td style="width:1.0%"/><td style="width:53.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.646%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range for the Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Input assumptions for liability classified warrants:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Fair value of common stock on issue date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$19.10 – $19.10</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$2.56 – $6.18</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Exercise price of warrants</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.87 – $2.87</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.87 – $3.25</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114% – 114%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94% – 117%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16% – 0.16%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13% – 1.58%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Expected term in years</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 – 2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 – 2</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 %</span></td></tr></table> 19.10 19.10 2.56 6.18 2.87 2.87 2.87 3.25 1.14 1.14 0.94 1.17 0.000016 0.000016 0.0013 0.0158 2 2 1 2 0.000 0.000 49300000 86500000 51100000 83300000 Debt<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amounts of debt are as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.590%"><tr><td style="width:1.0%"/><td style="width:29.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unaccreted Debt Discount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unaccreted Debt Discount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Convertible notes payable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior convertible notes</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,020 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,737 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,020 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,367 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Related party convertible notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foris convertible note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,041 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329,398 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">379,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,041 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,123 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123,164 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Loans payable and credit facilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Schottenfeld notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(240)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,260 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nikko notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,737 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,012 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,802 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(759)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,043 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ginkgo note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other loans payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,746 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(725)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,021 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,529 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(999)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,530 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Related party loans payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foris note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DSM notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,254)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,746 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,557 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Naxyris note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(412)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,502 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,914 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,666)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,248 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,914 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,936)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,978 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,721 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,391)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374,135 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483,465 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,504 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,935)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,490 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263,059 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55,904)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,437)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427,561 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,622 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Senior Convertible Notes Conversion</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2021, the Company received a notice of conversion from HT Investments MA, LLC (HT) with respect to $20.0 million of its outstanding Senior Convertible Notes, pursuant to which the Company was required to issue 5.7 million shares of common stock per the conversion price stated in the agreement and cancelled the outstanding Note. Also, under the terms of the Senior Convertible Note, HT was required to return 2.6 million shares of common stock outstanding under the Pre-Delivery Shares provision once the Company had fully repaid the principal balance. HT fulfilled its obligation to return these shares in accordance with the contractual requirement, and as a result the Company net settled the $20 million principal conversion by issuing 3.1 million of incremental shares to HT.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion of the HT Senior Convertible Note, the Company recorded a $31.9 million loss upon extinguishment of debt, which was primarily comprised of a fair value adjustment upon repayment of the note's principal. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the Senior Convertible Notes.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schottenfeld Note Exchange</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, the Company entered into an Exchange and Settlement Agreement (Exchange Agreement) with Schottenfeld Opportunities Fund II, L.P. and certain other holders of notes under the Credit and Security Agreement dated November 14, 2019 (Schottenfeld Notes). Pursuant to the terms of the Exchange Agreement, the Company paid all accrued and unpaid interest on the $12.5 million principal balance outstanding under the Schottenfeld Notes, and issued 4.1 million net shares of common stock in a cashless exchange and cancellation of all amounts due and outstanding under the Notes and related loan documents and all warrants held by each of the holders of Schottenfeld Notes.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion of the Schottenfeld note balance, the Company recorded a $28.9 million loss upon extinguishment of debt, which primarily represented the fair value of common shares issued in excess of debt principal extinguished. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the Schottenfeld Notes.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DSM Notes Amendments and Repayment</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 28, 2017, the Company and DSM Finance, a wholly owned subsidiary of Koninklijke DSM N.V. (DSM), entered into a credit agreement (the DSM Credit Agreement) to make available to the Company an unsecured credit facility of $25.0 million. On December 28, 2017, the Company borrowed $25.0 million under the DSM Credit Agreement and issued a promissory note to DSM Finance. The $25 million Note matures on December 31, 2021 and accrues interest at 10% per annum, payable quarterly.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2019, the Company and DSM entered into a credit agreement (the 2019 DSM Credit Agreement) to make available to the Company a secured credit facility in an aggregate principal amount of $8.0 million. In September 2019, the Company borrowed the $8.0 million in three installments. The promissory notes issued under the 2019 DSM Credit Agreement (i) mature on August 7, 2022, (ii) accrue interest at a rate of 12.5% per annum, payable quarterly and (iii) are secured by a first-priority lien on certain Company intellectual property licensed to DSM.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into amendments (the March 2021 Amendments) to the $25 million Note and the $8 million Note that provided for (i) the prepayment of the $8 million Note, (ii) a $15 million partial prepayment of the $25 million Note and (iii) extension of the maturity date from December 31, 2021 to April 15, 2022 for the remaining $10 million principal balance under the $25 million Note, in exchange for a $2.5 million prepayment fee The Company repaid $23 million on March 31, 2021 to extinguish the $8 million Note and to partially repay the $25 million Note.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the March 2021 Amendments, and concluded the before and after cash flows resulting from the amendments were not significantly different and accounted for the amendments to the Notes as a debt modification. Consequently, the $2.5 million Prepayment Fee was recorded as an incremental debt discount to the remaining $10 million principal balance under the $25 million Note. The Company will accrete the adjusted discount over the Note’s amended remaining term using the effective interest method.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the DSM notes.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Minimum Payments</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum payments under the Company's debt agreements as of March 31, 2021 are as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.912%"><tr><td style="width:1.0%"/><td style="width:41.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loans<br/>Payable and Credit Facilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Party Convertible Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Party Loans Payable and Credit Facilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (Remaining Nine Months)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,189 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,260 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,782 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,231 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,268 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,578 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,379 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,225 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,189 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,195 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,578 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,161 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,123 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,449)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,537)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,247)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,402)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of minimum debt payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,020 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,746 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,041 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,914 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,721 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion of debt principal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,020)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,280)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent portion of debt principal</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,466 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,041 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,914 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,421 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amounts of debt are as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.590%"><tr><td style="width:1.0%"/><td style="width:29.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unaccreted Debt Discount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unaccreted Debt Discount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Convertible notes payable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior convertible notes</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,020 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,737 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,020 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,367 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Related party convertible notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foris convertible note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,041 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329,398 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">379,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,041 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,123 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123,164 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Loans payable and credit facilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Schottenfeld notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(240)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,260 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nikko notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,737 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,012 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,802 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(759)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,043 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ginkgo note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other loans payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,746 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(725)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,021 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,529 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(999)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,530 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Related party loans payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foris note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DSM notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,254)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,746 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,557 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Naxyris note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(412)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,502 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,914 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,666)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,248 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,914 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,936)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,978 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,721 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,391)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374,135 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483,465 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,504 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,935)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,490 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263,059 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55,904)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,437)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427,561 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,622 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10020000 0 44737000 54757000 30020000 0 23367000 53387000 50041000 0 329398000 379439000 50041000 0 73123000 123164000 0 0 0 0 12500000 -240000 0 12260000 2737000 -725000 0 2012000 2802000 -759000 0 2043000 12000000 0 0 12000000 12000000 0 0 12000000 1009000 0 0 1009000 1227000 0 0 1227000 15746000 -725000 0 15021000 28529000 -999000 0 27530000 5000000 0 0 5000000 5000000 0 0 5000000 10000000 -4254000 0 5746000 33000000 -2443000 0 30557000 23914000 -412000 0 23502000 23914000 -493000 0 23421000 38914000 -4666000 0 34248000 61914000 -2936000 0 58978000 114721000 -5391000 374135000 483465000 170504000 -3935000 96490000 263059000 55904000 77437000 427561000 185622000 20000000.0 5700000 2600000 20000000 3100000 -31900000 12500000 4100000 28900000 25000000.0 25000000.0 25000000 0.10 8000000.0 8000000.0 3 0.125 25000000 8000000 8000000 15000000 25000000 10000000 25000000 2500000 23000000 8000000 25000000 2500000 10000000 25000000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum payments under the Company's debt agreements as of March 31, 2021 are as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.912%"><tr><td style="width:1.0%"/><td style="width:41.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loans<br/>Payable and Credit Facilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Party Convertible Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Party Loans Payable and Credit Facilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (Remaining Nine Months)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,189 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,260 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,782 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,231 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,268 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,578 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,379 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,225 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,189 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,195 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,578 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,161 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,123 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,449)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,537)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,247)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,402)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of minimum debt payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,020 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,746 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,041 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,914 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,721 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion of debt principal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,020)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,280)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent portion of debt principal</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,466 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,041 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,914 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,421 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11189000 2260000 0 2782000 16231000 0 13268000 59578000 42379000 115225000 0 399000 0 0 399000 0 398000 0 0 398000 0 397000 0 0 397000 0 1473000 0 0 1473000 11189000 18195000 59578000 45161000 134123000 1169000 2449000 9537000 6247000 19402000 10020000 15746000 50041000 38914000 114721000 10020000 1280000 0 0 11300000 0 14466000 50041000 38914000 103421000 Mezzanine EquityMezzanine equity at March 31, 2021 and December 31, 2020 is comprised of proceeds from shares of common stock sold on May 10, 2016 to the Bill &amp; Melinda Gates Foundation (the Gates Foundation). In connection with the stock sale, the Company and the Gates Foundation entered into an agreement under which the Company agreed to expend an aggregate amount not less than the proceeds from the stock sale to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. If the Company defaults in its obligation to use the proceeds from the stock sale as set forth above or defaults under certain other commitments in the agreement, the Gates Foundation will have the right to request that the Company redeem, or facilitate the purchase by a <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third party, the shares then held by the Gates Foundation at a price per share equal to the greater of (i) the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable, or (ii) an amount equal to $17.10 plus a compounded annual return of 10%.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company's remaining research and development obligation under this arrangement was $0.3 million.</span></div> 17.10 0.10 300000 Stockholders' Deficit<div style="text-align:justify;text-indent:22.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Warrants and Rights Activity Summary</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various debt and equity transactions (see Note 4, “Debt” above and Note 4, "Debt" and Note 6, “Stockholders’ Deficit” in Part II, Item 8 of the 2020 Form 10-K), the Company has issued warrants exercisable for shares of common stock. The following table summarizes warrants outstanding at March 31, 2021:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:53.508%"><tr><td style="width:1.0%"/><td style="width:55.457%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:21.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Transaction</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number Outstanding as of March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise Price per Share as of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Blackwell and Silverback warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.25 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 2020 warrant exercise right shares</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,209,608 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2019 PIPE warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,381,940 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$4.76/$5.02</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Naxyris LSA warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 2019 Naxyris warrant</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 2019 6.50% Note Exchange warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">960,225 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 2017 cash warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,863,056 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 2017 dilution warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,085,893 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">August 2017 dilution warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,028,983 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 2015 related party debt exchange</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58,690 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.15 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,406 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160.05 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,589,801 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Warrant Exercises</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March 31, 2021, warrant-holders exercised warrants to purchase approximately 24.8 million shares of the Company’s common stock at a weighted-average exercise price of $3.06 per share, for net proceeds to the Company of $32.2 million. Some of the exercises were cashless or in connection with the Schottenfeld Note Exchange, which resulted in fewer shares being issued than the number of warrant-shares exercised. As a result, 21.6 million shares were issued.</span></div> The following table summarizes warrants outstanding at March 31, 2021:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:53.508%"><tr><td style="width:1.0%"/><td style="width:55.457%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:21.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Transaction</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number Outstanding as of March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise Price per Share as of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Blackwell and Silverback warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.25 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 2020 warrant exercise right shares</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,209,608 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2019 PIPE warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,381,940 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$4.76/$5.02</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Naxyris LSA warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 2019 Naxyris warrant</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 2019 6.50% Note Exchange warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">960,225 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 2017 cash warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,863,056 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 2017 dilution warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,085,893 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">August 2017 dilution warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,028,983 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 2015 related party debt exchange</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58,690 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.15 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,406 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160.05 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,589,801 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr></table> 1000000 3.25 4209608 2.87 1381940 4.76 5.02 2000000 2.87 2000000 3.87 960225 2.87 1863056 2.87 3085893 0.00 3028983 0.00 58690 0.15 1406 160.05 19589801 24800000 3.06 32200000 21600000 Net Loss per Share Attributable to Common Stockholders<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, basic loss per share was the same as diluted loss per share, because the inclusion of all potentially dilutive securities outstanding was antidilutive.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the two-class method when computing net loss per common share when shares are issued that meet the definition of participating securities. The two-class method requires income available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The two-class method also requires losses for the period to be allocated between common stock and participating securities based on their respective rights if the participating security contractually participates in losses. The Company’s convertible preferred stock are participating securities as they contractually entitle the holders of such shares to participate in dividends and contractually require the holders of such shares to participate in the Company’s losses.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted loss per share:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"/><td style="width:74.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except shares and per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss attributable to Amyris, Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(291,251)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(87,844)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Less: losses allocated to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,099 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,087 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss attributable to Amyris, Inc. common stockholders, basic and diluted</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(289,152)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(86,757)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267,733,555 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155,065,635 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Loss per share, basic and diluted</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.08)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"/><td style="width:74.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period-end common stock warrants</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,416,235 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,518,519 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convertible promissory notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,540,447 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,217,185 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period-end stock options to purchase common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,205,576 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,578,264 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period-end restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,653,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,298,639 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period-end preferred stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,943,661 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,943,661 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total potentially dilutive securities excluded from computation of diluted loss per share</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,759,559 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,556,268 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:8pt;padding-right:468pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%">______________</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.</span></div> <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted loss per share:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"/><td style="width:74.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except shares and per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss attributable to Amyris, Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(291,251)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(87,844)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Less: losses allocated to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,099 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,087 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss attributable to Amyris, Inc. common stockholders, basic and diluted</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(289,152)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(86,757)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267,733,555 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155,065,635 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Loss per share, basic and diluted</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.08)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> -291251000 -87844000 -2099000 -1087000 -289152000 -86757000 267733555 267733555 155065635 155065635 -1.08 -1.08 -0.56 -0.56 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"/><td style="width:74.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period-end common stock warrants</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,416,235 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,518,519 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convertible promissory notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,540,447 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,217,185 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period-end stock options to purchase common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,205,576 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,578,264 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period-end restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,653,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,298,639 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period-end preferred stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,943,661 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,943,661 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total potentially dilutive securities excluded from computation of diluted loss per share</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,759,559 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,556,268 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:8pt;padding-right:468pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%">______________</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.</span></div> 13416235000 50518519000 19540447000 9217185000 6205576000 5578264000 6653640000 5298639000 1943661000 1943661000 47759559000 72556268000 Commitments and Contingencies<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantor Arrangements</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements whereby it indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the executive officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of March 31, 2021 and December 31, 2020.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foris Convertible Note (see Note 4, "Debt") is collateralized by first-priority liens on substantially all of the Company's assets, including Company intellectual property, other than certain Company intellectual property licensed to DSM and the Company's shares of Aprinnova. Certain of the Company’s subsidiaries have guaranteed the Company’s obligations under the Foris Convertible Note.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of the Company under the Naxyris Note (see Note 4, "Debt") are (i) guaranteed by the Subsidiary Guarantors and (ii) secured by a perfected security interest in substantially all of the assets of the Company and the Subsidiary Guarantors (the Collateral), junior in payment priority to Foris subject to certain limitations and exceptions, as well as the terms of the Intercreditor Agreement.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nikko $3.9 million note is collateralized by a first-priority lien on 10.0% of the Aprinnova JV interests owned by the Company.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but will only be recorded when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgement. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2019, a securities class action complaint was filed against Amyris and our CEO, John G. Melo, and former CFO, Kathleen Valiasek, in the U.S. District Court for the Northern District of California. The complaint seeks unspecified damages on behalf of a purported class that would comprise all persons and entities that purchased or otherwise acquired our securities between March 15, 2018 and March 19, 2019. The complaint, which was amended by the lead plaintiff on September 13, 2019, alleges securities law violations based on statements and omissions made by the Company during such period. On October 25, 2019, the defendants filed a motion to dismiss the securities class action complaint, which was denied by the court on October 5, 2020. The Company filed its answer to the securities class action complaint on October 26, 2020. Subsequent to the filing of the securities class action complaint described above, on June 21, 2019 and October 1, 2019, respectively, two separate purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California (Bonner v. Doerr, et al., and Carlson v. Doerr, et al.) based on similar allegations to those made in the securities class action complaint and naming the Company, and certain of the Company’s current and former officers and directors, as defendants. The derivative lawsuits sought to recover, on the Company’s behalf, unspecified damages purportedly sustained by the Company in connection with allegedly misleading statements and omissions made in connection with the Company’s securities filings. The derivative lawsuits were dismissed on October 18, 2019 (Bonner) and December 10, 2019 (Carlson), without prejudice. On November 3, 2020, Bonner re-filed its derivative complaint against the Company in San Mateo County Superior Court. The Company filed its demurrer to the complaint on January 13, 2021 and attended a preliminary hearing on April 22, 2021. An additional shareholder derivative complaint (Kimbrough v. Melo, et al.), substantially identical to the Bonner complaint, was filed on December 18, 2020 in the United States District Court for the Northern District of California. On February 19, 2021, the Company filed its motion to dismiss the Kimbrough complaint. In response, the Kimbrough complaint was dismissed in federal court on March 4, 2021 and refiled in state court on March 12, 2021. By agreement, the Kimbrough and Bonner complaints were consolidated for all purposes on April 9, 2021. By May 10, 2021, the derivative shareholder plaintiffs will either file a new complaint or designate one of the existing complaints as operative. A briefing schedule on a demurrer to that complaint will be negotiated no later than May 24, 2021. The Company believes the securities class action and derivative complaints lack merit, and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result from these matters.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2020, LAVVAN, Inc. (Lavvan) filed a suit against the Company in the United States District Court for the Southern District of New York alleging breach of contract, patent infringement, and trade secret misappropriation in connection with that certain Research, Collaboration and License Agreement between Lavvan and Amyris, dated March 18, 2019, as amended (Cannabinoid Agreement). Amyris filed motions to compel arbitration or to dismiss on October 2, 2020. On October 30, Lavvan filed its opposition to the motions and the Company filed its reply to such opposition on November 13, 2020. The matter is fully briefed and the parties are awaiting an order from the Court. The Company believes the suit lacks merit and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result therefrom.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may arise in the ordinary course of business are subject to many uncertainties and outcomes, and are not predictable with reasonable assurance; therefore, an estimate of all the reasonably possible losses cannot be determined at this time. If one or more of these legal disputes or claims resulted in settlements or legal proceedings that were resolved against the Company for amounts in excess of management’s </span></div>expectations, the Company’s condensed consolidated financial statements for the relevant reporting period could be materially adversely affected. 3900000 0.100 Revenue Recognition and Contract Assets and Liabilities<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Disaggregation of Revenue</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:25.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.142%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,090 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,340 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,944 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,944 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,972 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,346 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149,118 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,242 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,356 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,759 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,405 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,689 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,018 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,759 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,777 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,179 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,880 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,859 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,854 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,115 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,130 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by major product and service, as well as by customer type:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:25.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.749%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.749%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consumer</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,653 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,653 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,065 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,065 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ingredients</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,526 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156,326 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,789 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,950 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,880 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,880 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7.75pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,179 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,880 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,859 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,854 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,115 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,130 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Significant Revenue Agreements</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2020 Form 10-K), the Company recognized the following revenue for the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021 and 2020</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"/><td style="width:25.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.034%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DSM - related party</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,662 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,612 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,274 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,750 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,018 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,817 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sephora</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,441 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,441 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,446 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,446 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yifan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,709 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,709 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Firmenich</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">379 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,229 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,411 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,801 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Givaudan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal revenue from significant revenue agreements</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,692 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,489 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,981 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,833 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,882 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from all other customers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,487 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,021 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,248 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from all customers</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,179 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,880 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,859 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,854 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,115 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,130 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">DSM License Agreement and Contract Assignment</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company and DSM entered into a license agreement and asset purchase agreement pursuant to which DSM acquired exclusive rights to the Company’s Flavor and Fragrance (F&amp;F) product portfolio. The Company granted DSM exclusive licenses covering specific intellectual property (F&amp;F Intellectual Property License) of the Company and assigned the Company’s rights and obligations under certain F&amp;F ingredients supply agreements to DSM, in exchange for non-refundable upfront consideration totaling $150 million, and up to $235 million of contingent consideration if and when certain </span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial milestones are achieved in each of the calendar years 2022 through 2024. DSM also acquired the Company’s F&amp;F finished goods inventory on-hand, unbilled accounts receivables and billed accounts receivable that were uncollected at closing. The Company and DSM also entered into a 15-year manufacturing agreement whereby the Company will manufacture certain F&amp;F ingredients for DSM to supply to third parties.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the licenses to be functional intellectual property licenses allowing DSM the immediate use of and benefit from the technology, and concluded the licenses and related assigned F&amp;F ingredients supply agreements, the asset purchase agreement and the manufacturing agreement were revenue contracts within the scope of ASC 606. The Company identified three distinct performance obligations: (i) F&amp;F license, (ii) finished goods inventory and (iii) receivables, that once delivered are satisfied at a point in time. The Company also concluded the additional contingent consideration and manufacturing supply agreement represent variable consideration that will be fully constrained until the commercial targets are probable of achievement and the products are manufactured and sold. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the $150 million transaction price to the three revenue performance obligations using the residual approach. The transaction price was first allocated to the transferred inventory and receivables at the stand-alone selling price for these performance obligations, and the residual consideration was allocated to the F&amp;F intellectual property licenses:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:6.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.75pt">Finished goods inventory - $1.5 million</span></div><div style="padding-left:36pt;text-align:justify;text-indent:6.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.75pt">Receivables - $4.9 million</span></div><div style="padding-left:36pt;text-align:justify;text-indent:6.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.75pt">F&amp;F intellectual property licenses - $143.6 million</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also concluded the F&amp;F intellectual property licenses and the assigned F&amp;F supply agreements had been fully delivered with no further performance obligation upon closing the transaction, and recognized license revenue of $143.6 million in the period ended March 31, 2021.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the related party nature of the transaction with DSM, who is a significant shareholder with two members on the Company’s board of directors, the Company performed a fair value assessment of the F&amp;F intellectual property licenses under an income approach using a discounted cash flow model, in part with the assistance of a third-party valuation firm, and concluded the $143.6 million residual consideration received in exchange for the F&amp;F intellectual property licenses approximated the fair value and stand-alone selling price of the F&amp;F intellectual property licenses.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">DSM Performance Agreement</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company and DSM entered into a research and development services agreement (Performance Agreement), pursuant to which the Company would provide services to DSM relating to the further development of the technology underlying farnesene-related products in exchange for certain bonus payments in the event that specific performance metrics were achieved. If the Company did not meet the established metrics under the Performance Agreement, the Company would be required to pay $1.9 million to DSM. The Company accounted for the Performance Agreement under ASC 606 as a combined transaction with the Farnesene license granted to DSM in connection with the sale of the Brotas facility in December 2017. The Performance Agreement was allocated $1.2 million of the transaction price under a relative fair value allocation approach, and was recorded as a contract asset reflecting the Company’s right to receive additional consideration and deferred revenue reflecting the probability of returning to DSM a portion of the cash received under the combined transaction. In the first quarter of 2021, the Company and DSM determined the performance metrics would not be reasonably achieved without the Company providing further research and development services and concluded the Performance Agreement and related activities should be terminated. As a result, the Company paid DSM $1.9 million and reduced the deferred revenue liability, and expensed the contract asset balance and recorded $1.9 million of additional research and development expense during the three months ended March 31, 2021.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">DSM Ingredients Collaboration</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the September 2017 research and development collaboration agreement, as amended, the Company provides DSM with research and development services for specific field of use ingredients. The Company concluded the amended agreement contained a single performance obligation to provide research and development services delivered over time and that revenue recognition is based on an input measure of progress as labor hours are expended each quarter. DSM funds the development work with payments of $2.0 million quarterly from October 1, 2020 to September 30, 2021 for services singularly focused on achieving a certain fermentation yield and cost target over the twelve-month period. During the three months ended March 31, 2021 and 2020, the Company recognized $2.0 million and $3.0 million of collaboration revenue in connection with the amended agreement.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Yifan Collaborations</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration agreement with Yifan Pharmaceutical Co., Ltd. (Yifan), a leading Chinese pharmaceutical company. During the three months ended March 31, 2021 and 2020, the Company recognized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.7 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of collaboration revenue, and $16.6 million of cumulative-to-date collaboration revenue in connection with the agreement. At March 31, 2021, the Company also recorded a $5.9 million contract asset in connection with the Collaboration Agreement.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about the DSM ingredients collaboration and Yifan collaboration, see the Company's 2020 Form 10-K, Part II, Item 8, Note 10, "Revenue Recognition".</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a contract results i</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not passed to the customer.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade receivables are recorded for the sale of goods or the performance of services at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.327%"><tr><td style="width:1.0%"/><td style="width:64.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,036 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,846 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable - related party, net</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,110 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,589 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract assets - related party</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,163 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,468 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities, noncurrent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.93pt">As of March 31, 2021 and December 31, 2020, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.128%"><tr><td style="width:1.0%"/><td style="width:55.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2021</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total from all customers</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,105 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the disclosure provisions of ASC 606, the table above excludes estimated future revenues for performance obligations that are part of a contract that has an original expected duration of one year or less or a performance obligation with variable consideration that is recognized using the sales-based royalty exception for licenses of intellectual </span></div>property. Additionally, approximately $297.8 million of estimated future revenue is excluded from the table above, as that amount represents constrained variable consideration. <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:25.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.142%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,090 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,340 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,944 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,944 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,972 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,346 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149,118 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,242 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,356 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,759 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,405 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,689 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,018 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,759 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,777 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,179 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,880 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,859 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,854 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,115 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,130 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by major product and service, as well as by customer type:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:25.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.749%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.749%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consumer</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,653 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,653 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,065 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,065 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ingredients</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,526 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156,326 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,789 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,950 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,880 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,880 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7.75pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,179 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,880 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,859 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,854 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,115 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,130 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 20090000 0 250000 20340000 11944000 0 0 11944000 2972000 143800000 2346000 149118000 3242000 5161000 3356000 11759000 4405000 2284000 6689000 2018000 0 2759000 4777000 313000 313000 577000 0 0 577000 399000 399000 73000 0 0 73000 28179000 143800000 4880000 176859000 17854000 5161000 6115000 29130000 15653000 0 0 15653000 9065000 0 0 9065000 12526000 143800000 0 156326000 8789000 5161000 0 13950000 0 0 4880000 4880000 0 0 6115000 6115000 28179000 143800000 4880000 176859000 17854000 5161000 6115000 29130000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2020 Form 10-K), the Company recognized the following revenue for the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021 and 2020</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"/><td style="width:25.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.034%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewable Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Licenses and Royalties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grants and Collaborations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DSM - related party</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,662 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,612 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,274 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,750 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,018 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,817 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sephora</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,441 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,441 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,446 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,446 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yifan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,709 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,709 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Firmenich</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">379 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,229 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,411 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,801 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Givaudan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal revenue from significant revenue agreements</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,692 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,489 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,981 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,833 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,882 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from all other customers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,487 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,021 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,248 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from all customers</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,179 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,800 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,880 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,859 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,854 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,161 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,115 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,130 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1662000 143612000 2000000 147274000 49000 3750000 3018000 6817000 4441000 0 0 4441000 4446000 0 0 4446000 0 0 2284000 2284000 0 0 2709000 2709000 379000 188000 205000 772000 1229000 1411000 161000 2801000 210000 0 0 210000 2109000 0 0 2109000 6692000 143800000 4489000 154981000 7833000 5161000 5888000 18882000 21487000 0 391000 21878000 10021000 0 227000 10248000 28179000 143800000 4880000 176859000 17854000 5161000 6115000 29130000 150000000 235000000 P15Y 150000000 1500000 4900000 143600000 143600000 143600000 1900000 1200000 1900000 1900000 2000000.0 2000000.0 3000000.0 2300000 2700000 16600000 5900000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.327%"><tr><td style="width:1.0%"/><td style="width:64.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,036 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,846 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable - related party, net</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,110 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,589 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract assets - related party</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,163 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,468 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities, noncurrent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.93pt">As of March 31, 2021 and December 31, 2020, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets.</span></div> 27036000 32846000 391000 12110000 6589000 4178000 2000000 1203000 6163000 4468000 111000 111000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.128%"><tr><td style="width:1.0%"/><td style="width:55.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2021</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total from all customers</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,105 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 143000 3103000 1430000 429000 5105000 297800000 Related Party Transactions<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Debt</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, "Debt," for details of the DSM Notes Amendments and Repayments that occurred during the three months ended March 31, 2021.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party debt was as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"/><td style="width:28.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">In thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unaccreted Debt Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unaccreted Debt Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foris notes</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,041 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329,398 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384,439 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,041 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,123 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,164 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DSM notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,254)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,746 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,557 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Naxyris note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(412)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,502 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,955 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,666)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329,398 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413,687 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,955 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,936)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,123 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182,142 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Revenue</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9, "Revenue Recognition", for information about the March 31, 2021 DSM License Agreement and Contract Assignment.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Accounts Receivable, Unbilled Receivables and Accounts Payable</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party accounts receivable, contract assets and accounts payable were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:69.444%"><tr><td style="width:1.0%"/><td style="width:55.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - related party</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,110 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets - related party</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,302 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,011 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party debt was as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"/><td style="width:28.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">In thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unaccreted Debt Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unaccreted Debt Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foris notes</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,041 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329,398 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384,439 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,041 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,123 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,164 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DSM notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,254)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,746 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,557 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Naxyris note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(412)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,502 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,955 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,666)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329,398 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413,687 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,955 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,936)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,123 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182,142 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 55041000 0 329398000 384439000 55041000 0 73123000 128164000 10000000 4254000 0 5746000 33000000 2443000 0 30557000 23914000 412000 0 23502000 23914000 493000 0 23421000 88955000 4666000 329398000 413687000 111955000 2936000 73123000 182142000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party accounts receivable, contract assets and accounts payable were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:69.444%"><tr><td style="width:1.0%"/><td style="width:55.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - related party</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,110 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets - related party</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,302 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,011 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 391000 12110000 2000000 1203000 10302000 5011000 Stock-based Compensation<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s stock option activity and related information for the three months ended March 31, 2021 was as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"><tr><td style="width:1.0%"/><td style="width:45.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quantity of Stock Options</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>Remaining<br/>Contractual<br/>Life, in Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value, in Thousands</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,502,096 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.64 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,408 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,390)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,538)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - March 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,205,576 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,615 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest after March 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697,447 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,493 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259,029 </span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,884 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s restricted stock units (RSUs) activity and related information for the three months ended March 31, 2021 was as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.871%"><tr><td style="width:1.0%"/><td style="width:52.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.438%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quantity of Restricted Stock Units</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average Grant-date Fair Value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average Remaining Contractual Life, in Years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,043,909 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,903 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.53 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496,492)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239,680)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - March 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,653,640 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest after March 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,082,165 </span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three months ended March 31, 2021 and 2020 is reflected in the condensed consolidated statements of operations as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.228%"><tr><td style="width:1.0%"/><td style="width:57.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.431%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,156 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was unrecognized compensation expense of $30.0 million related to stock options and RSUs. The Company expects to recognize this expense over a weighted-average period of 2.4 years.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evergreen Shares for 2020 Equity Incentive Plan and 2010 Employee Stock Purchase Plan</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Board approved increases to the number of shares available for issuance under the Company's 2020 Equity Incentive Plan (the 2020 Equity Plan) and 2010 Employee Stock Purchase Plan (the 2010 ESPP).</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in shares in connection with the 2020 Equity Plan represented an automatic annual increase in the number of shares available for grant and issuance under the 2020 Equity Plan of 12,247,572 shares (Evergreen Shares). This increase is equal to approximately 5.0% of the 244,951,446 total outstanding shares of the Company’s common stock as of December 31, 2020. This automatic increase was effective as of January 1, 2021.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in shares in connection with the 2010 ESPP represented an automatic annual increase in the number of shares reserved for issuance of 42,077 shares, which represents the remaining allowable under the existing 1,666,666 maximum limit for share issuance under the 2010 ESPP. This automatic increase was effective as of January 1, 2021.</span></div> <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s stock option activity and related information for the three months ended March 31, 2021 was as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"><tr><td style="width:1.0%"/><td style="width:45.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quantity of Stock Options</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>Remaining<br/>Contractual<br/>Life, in Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value, in Thousands</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,502,096 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.64 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,408 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,390)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,538)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - March 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,205,576 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,615 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest after March 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697,447 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,493 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259,029 </span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,884 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6502096 7.64 P7Y7M6D 8875000 131408 14.52 375390 5.12 52538 38.21 6205576 7.68 P7Y4M24D 82615000 5697447 7.91 P7Y3M18D 75493000 1259029 18.19 P5Y9M18D 12884000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s restricted stock units (RSUs) activity and related information for the three months ended March 31, 2021 was as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.871%"><tr><td style="width:1.0%"/><td style="width:52.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.438%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quantity of Restricted Stock Units</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average Grant-date Fair Value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average Remaining Contractual Life, in Years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,043,909 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,903 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.53 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496,492)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239,680)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - March 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,653,640 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest after March 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,082,165 </span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td></tr></table></div> 7043909 4.18 P1Y6M 345903 13.53 496492 4.34 239680 4.22 6653640 4.65 P1Y4M24D 6082165 4.65 P1Y3M18D <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three months ended March 31, 2021 and 2020 is reflected in the condensed consolidated statements of operations as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.228%"><tr><td style="width:1.0%"/><td style="width:57.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.431%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,156 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 63000 0 1062000 1065000 3156000 2439000 4281000 3504000 30000000.0 P2Y4M24D 12247572 0.050 244951446 42077 1666666 Subsequent Events<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Primary and Secondary Offering</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2021, the Company entered into an underwriting agreement (the Underwriting Agreement) with J.P. Morgan Securities LLC and Cowen and Company, LLC (the Underwriters) and with certain stockholders of the Company (the Selling Stockholders), pursuant to which the Selling Stockholders agreed to sell 11,390,797 shares of common stock of the Company, par value $0.0001 per share and Amyris agreed to issue and sell 7,656,822, at a public offering price of $15.75 per share. DSM International B.V. and affiliates of Vivo Capital LLC were the Secondary Offering Selling Stockholders. Under the terms of the Underwriting Agreement, the Selling Stockholders and Amyris granted the Underwriters a 30-day option to purchase up to an additional 1,708,619 shares of Common Stock from the Selling Stockholders and 1,148,523 shares of Common Stock from Amyris. The Underwriters exercised this option in full.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net proceeds to the Company from the 8,805,345 new shares issued by the Company were approximately $130.7 million (inclusive of the underwriters’ option to purchase additional shares), after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not receive any proceeds from the sale of common stock in the secondary offering by the Selling Stockholders.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ingredion Agreement</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2021, the Company and Ingredion Incorporated entered into a Membership Interest Purchase Agreement (MIPA) under which (i) the Company will assign and transfer certain contracts for the sale and distribution of RebM to Ingredion’s subsidiary, PureCircle, which will become the exclusive global business-to-business commercialization partner for the Company’s sugar reduction technology that includes fermented RebM; (ii) the Company and Ingredion will enter into certain intellectual property license agreements to make, have made, commercialize and advance the development of sustainably sourced, zero-calorie, nature-based sweeteners and potentially other types of fermentation-based ingredients; (iii) Ingredion will purchase 31% of all of the membership interests in Amyris RealSweet LLC, a wholly owned subsidiary of the Company incorporated on April 15, 2021 (RealSweet), which entity will own the new manufacturing facility under construction in Brazil, and; (iv) The parties will enter into an R&amp;D collaboration agreement to create and advance the development of sustainably sourced, zero-calorie, nature-based sweeteners, and potentially other types of fermentation-based food ingredients. The Company will continue to own and market its Purecane™ consumer brand offering of tabletop and culinary sweetener products to consumers. Under the terms of the license agreement, the Company will receive an upfront $10 million license fee at closing and additional milestone payments in the aggregate of $35 million upon achievement of certain manufacturing cost targets and RebM sales revenue. The Company will also receive $30 million of cash and non-cash consideration from Ingredion in exchange for their 31% interest in RealSweet. Additionally, the Company will earn a profit share from future Reb M sales by PureCircle. The closing of the MIPA is subject to customary closing conditions.</span></div> 11390797 0.0001 7656822 15.75 P30D 1708619 1148523 8805345 130700000 XML 21 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page - shares
3 Months Ended
Mar. 31, 2021
May 04, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 001-34885  
Entity Registrant Name AMYRIS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 55-0856151  
Entity Address, Address Line One 5885 Hollis Street  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Emeryville  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94608  
City Area Code 510  
Local Phone Number 450-0761  
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol AMRS  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   291,471,055
Entity Central Index Key 0001365916  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Amendment Flag false  

XML 22 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 143,821 $ 30,152
Restricted cash 283 309
Accounts receivable, net of allowance of $154 and $137, respectively 27,036 32,846
Accounts receivable - related party, net of allowance of $0 and $0, respectively 391 12,110
Contract assets 6,589 4,178
Contract assets - related party 2,000 1,203
Inventories 47,639 42,862
Deferred cost of products sold - related party 5,220 9,801
Prepaid expenses and other current assets 19,246 13,103
Total current assets 252,225 146,564
Property, plant and equipment, net 31,933 32,875
Deferred cost of products sold, noncurrent - related party 9,391 9,939
Restricted cash, noncurrent 961 961
Recoverable taxes from Brazilian government entities 8,680 8,641
Right-of-use assets under financing leases, net 9,296 9,994
Right-of-use assets under operating leases, net 9,333 10,136
Other assets 4,770 3,704
Total assets 326,589 222,814
Current liabilities:    
Accounts payable 44,154 41,045
Accrued and other current liabilities 32,121 30,707
Financing lease liabilities 3,258 4,170
Operating lease liabilities 5,510 5,226
Contract liabilities 6,163 4,468
Debt, current portion (includes instrument measured at fair value of $54,757 and $53,387, respectively) 55,904 54,748
Related party debt, current portion 0 22,689
Total current liabilities 147,110 163,053
Long-term debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively) 13,873 26,170
Related party debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively) 413,687 159,452
Operating lease liabilities, net of current portion 8,209 9,732
Derivative liabilities 31,384 8,698
Other noncurrent liabilities 22,467 22,754
Total liabilities 636,730 389,859
Commitments and contingencies
Mezzanine equity: Contingently redeemable common stock 5,000 5,000
Stockholders’ deficit:    
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 8,280 shares issued and outstanding as of March 31, 2021 and December 31, 2020 0 0
Common stock - $0.0001 par value, 350,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 273,266,917 and 244,951,446 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively 27 24
Additional paid-in capital 2,106,214 1,957,224
Accumulated other comprehensive loss (49,413) (47,375)
Accumulated deficit (2,377,943) (2,086,692)
Total Amyris, Inc. stockholders’ deficit (321,115) (176,819)
Noncontrolling interest 5,974 4,774
Total stockholders' deficit (315,141) (172,045)
Total liabilities, mezzanine equity and stockholders' deficit $ 326,589 $ 222,814
XML 23 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Accounts receivable, allowance $ 154 $ 137
Accounts receivable, allowance, related parties 0 0
Fair value of debt 54,757 53,387
Fair value of long-term debt 0 0
Related party debt, net, fair value $ 0 $ 0
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 8,280 8,280
Preferred stock, shares outstanding (in shares) 8,280 8,280
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 350,000,000 350,000,000
Common stock, shares issued (in shares) 273,266,917 273,266,917
Common stock, shares outstanding (in shares) 244,951,446 244,951,446
XML 24 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue:    
Revenue $ 176,859 $ 29,130
Cost and operating expenses:    
Cost of products sold 22,659 11,790
Research and development 23,332 17,126
Sales, general and administrative 37,922 32,014
Total cost and operating expenses 83,913 60,930
Income (loss) from operations 92,946 (31,800)
Other income (expense):    
Interest expense (5,813) (15,002)
(Loss) gain from change in fair value of derivative instruments (22,745) 3,282
Loss from change in fair value of debt (326,785) (16,503)
Loss upon extinguishment of debt (27,313) (27,319)
Other (expense) income, net (678) 4
Total other expense, net (383,334) (55,538)
Loss before income taxes and loss from investment in affiliate (290,388) (87,338)
Provision for income taxes (55) (91)
Gain (loss) from investment in affiliate 392 (415)
Net loss (290,051) (87,844)
Less: income attributable to noncontrolling interest in Aprinnova (1,200) 0
Net loss attributable to Amyris, Inc. (291,251) (87,844)
Less: losses allocated to participating securities 2,099 1,087
Net loss attributable to Amyris, Inc. common stockholders, diluted (289,152) (86,757)
Net loss attributable to Amyris, Inc. common stockholders, basic $ (289,152) $ (86,757)
Earnings Per Share, Basic [Abstract]    
Loss per share attributable to common stockholders, basic (in dollars per share) $ (1.08) $ (0.56)
Loss per share attributable to common stockholders, diluted (in dollars per share) $ (1.08) $ (0.56)
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted (in shares) 267,733,555 155,065,635
Product    
Revenue:    
Revenue $ 28,179 $ 17,854
Licenses and Royalties    
Revenue:    
Revenue 143,800 5,161
Grants and Collaborations    
Revenue:    
Revenue $ 4,880 $ 6,115
XML 25 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Operations (Parentheticals) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenues, related party $ 147,274 $ 6,817
Product    
Revenues, related party 1,662 49
Licenses and Royalties    
Revenues, related party 143,612 3,750
Grants and Collaborations    
Revenues, related party $ 2,000 $ 3,018
XML 26 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Comprehensive loss:    
Net loss $ (290,051) $ (87,844)
Foreign currency translation adjustment (2,038) (2,549)
Total comprehensive loss (292,089) (90,393)
Less: income attributable to noncontrolling interest in Aprinnova (1,200) 0
Comprehensive loss attributable to Amyris, Inc. $ (293,289) $ (90,393)
XML 27 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity - USD ($)
$ in Thousands
Total
Senior convertible notes
Convertible notes payable
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Noncontrolling Interest
Total Stockholders' Deficit
Mezzanine Equity - Common Stock
Balance (in shares) at Dec. 31, 2019     8,280 117,742,677            
Balance at Dec. 31, 2019     $ 0 $ 12 $ 1,543,668 $ (43,804) $ (1,755,653) $ 609 $ (255,168) $ 5,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)       495,581            
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock         (8)       (8)  
Issuance of common stock and warrants upon conversion of debt principal (in shares)       6,337,594            
Issuance of common stock and warrants upon conversion of debt principal       $ 1 21,259       21,260  
Issuance of common stock upon exercise of warrants (in shares)       1,160,929            
Issuance of common stock upon exercise of warrants         3,332       3,332  
Issuance of common stock upon exercise of warrants - related party (in shares)       24,165,166            
Issuance of common stock upon exercise of warrants - related party       $ 2 68,763       68,765  
Issuance of common stock in private placement (in shares)       3,484,321            
Issuance of common stock in private placement         10,000       10,000  
Issuance of common stock in private placement - related party (in shares)       10,505,652            
Issuance of common stock in private placement - related party       $ 1 27,188       27,189  
Exercise of common stock rights warrant - related party         15,000       15,000  
Issuance of common stock right warrant - related party         8,904       8,904  
Modification of previously issued common stock warrants         1,286       1,286  
Derecognition of liability warrants to equity         5,200       5,200  
Stock-based compensation         3,504       3,504  
Foreign currency translation adjustment           (2,549)     (2,549)  
Net loss attributable to Amyris, Inc. $ (87,844)           (87,844)   (87,844)  
Balance (in shares) at Mar. 31, 2020     8,280 163,891,920            
Balance at Mar. 31, 2020     $ 0 $ 16 1,708,096 (46,353) (1,843,497) 609 (181,129) 5,000
Balance (in shares) at Dec. 31, 2020     8,280 244,951,446            
Balance at Dec. 31, 2020 $ (172,045)   $ 0 $ 24 1,957,224 (47,375) (2,086,692) 4,774 (172,045) 5,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)       496,341            
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock         (2)       (2)  
Issuance of common stock and warrants upon conversion of debt principal (in shares)       5,827,164            
Issuance of common stock and warrants upon conversion of debt principal       $ 1 110,574       110,575  
Issuance of common stock upon exercise of stock options (in shares) 375,390     377,542            
Issuance of common stock upon exercise of stock options         1,920       1,920  
Issuance of common stock upon exercise of warrants (in shares) 24,800,000     15,557,480            
Issuance of common stock upon exercise of warrants       $ 2 32,217       32,219  
Issuance of common stock upon exercise of warrants - related party (in shares)       6,056,944            
Issuance of common stock upon exercise of warrants - related party       $ 0 0       0  
Stock-based compensation         4,281       4,281  
Foreign currency translation adjustment           (2,038)     (2,038)  
Net loss attributable to Amyris, Inc. $ (291,251)           (291,251) 1,200 (290,051)  
Balance (in shares) at Mar. 31, 2021     8,280 273,266,917            
Balance at Mar. 31, 2021 $ (315,141)   $ 0 $ 27 $ 2,106,214 $ (49,413) $ (2,377,943) $ 5,974 $ (315,141) $ 5,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shares to be returned per agreement (in shares)   2,600,000                
XML 28 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating activities    
Net loss $ (290,051) $ (87,844)
Adjustments to reconcile net loss to net cash used in operating activities:    
(Gain) loss from change in fair value of debt 326,785 16,503
Loss upon extinguishment of debt 27,313 27,319
(Gain) loss from change in fair value of derivative instruments 22,745 (3,282)
Stock-based compensation 4,281 3,504
Depreciation and amortization 2,114 1,719
Amortization of right-of-use assets under operating leases 750 668
Accretion of debt discount 713 1,292
(Gain) loss on foreign currency exchange rates 408 (109)
Other 0 42
(Gain) loss from investment in affiliate (392) 415
Changes in assets and liabilities:    
Accounts receivable 17,275 (5,209)
Contract assets (3,208) (870)
Inventories (5,686) (4,392)
Deferred cost of products sold - related party 5,129 142
Prepaid expenses and other assets (8,207) (1,430)
Accounts payable 4,154 318
Accrued and other liabilities 4,011 4,009
Lease liabilities (1,185) (1,043)
Contract liabilities 1,702 1,873
Net cash provided by (used in) operating activities 108,651 (46,375)
Investing activities    
Purchases of property, plant and equipment (2,493) (1,040)
Net cash used in investing activities (2,493) (1,040)
Financing activities    
Issuance costs incurred in connection with debt modification (2,500) 0
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units (2) (8)
Principal payments on debt (23,196) (6,981)
Principal payments on financing leases (912) (866)
Proceeds from exercise of common stock rights warrant - related party 0 15,000
Proceeds from exercises of common stock options 1,920 0
Proceeds from exercises of warrants 32,219 3,332
Proceeds from exercises of warrants - related party 0 13,998
Proceeds from issuance of common and preferred stock in private placement, net of issuance costs 0 10,000
Proceeds from issuance of common and preferred stock in private placement, net of issuance costs - related party 0 15,000
Proceeds from issuance of debt, net of issuance costs 0 188
Net cash provided by financing activities 7,529 49,663
Effect of exchange rate changes on cash, cash equivalents and restricted cash (44) 19
Net increase in cash, cash equivalents and restricted cash 113,643 2,267
Cash, cash equivalents and restricted cash at beginning of period 31,422 1,699
Cash, cash equivalents and restricted cash at end of the period 145,065 3,966
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets    
Cash and cash equivalents 143,821 2,607
Restricted cash, current 283 399
Restricted cash, noncurrent 961 960
Total cash, cash equivalents and restricted cash 145,065 3,966
Supplemental disclosures of cash flow information:    
Cash paid for interest 3,275 3,152
Supplemental disclosures of non-cash investing and financing activities:    
Accrued interest added to debt principal 0 1,527
Derecognition of derivative liabilities to equity upon extinguishment of debt 59 0
Derecognition of derivative liabilities upon exercise of warrants 0 5,200
Exercise of common stock warrants in exchange for debt principal and accrued interest reduction 0 69,918
Fair value of embedded features in connection with private placement 0 2,962
Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances 0 188
Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances - related party 0 747
Issuance of common stock and warrants upon conversion of debt principal and accrued interest 110,575 18,333
Unpaid property, plant and equipment balances in accounts payable and accrued liabilities at end of period $ 1,121 $ 1,307
XML 29 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Parentheticals) - shares
3 Months Ended
Feb. 04, 2021
Mar. 31, 2021
Senior convertible notes | Convertible notes payable    
Shares to be returned per agreement (in shares) 2,600,000 2,600,000
XML 30 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Basis of Presentation and Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies
As a leading synthetic biotechnology company active in the Clean Health and Beauty markets through our consumer brands and a top supplier of sustainable and natural ingredients, Amyris, Inc. and our subsidiaries (collectively, Amyris or the Company) apply the Company's proprietary Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products. The Company does so with the use of computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. The Company's biotechnology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that the Company manufactures at industrial scale. Through the combination of our biotechnology platform and our industrial fermentation process, the Company has successfully developed, produced and commercialized many distinct molecules.

The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 (the 2020 Form 10-K), from which the condensed consolidated balance sheet as of December 31, 2020 is derived. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

Significant Accounting Policies

Note 1, "Basis of Presentation and Summary of Significant Accounting Policies", to the audited consolidated financial statements in the 2020 Form 10-K includes a discussion of the significant accounting policies and estimates used in the preparation of the Company’s condensed consolidated financial statements. There have been no material changes to the Company's significant accounting policies and estimates during the three months ended March 31, 2021.

Use of Estimates and Judgements

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant
accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed.

Accounting Standards or Updates Recently Adopted

In the three months ended March 31, 2021, the Company adopted these accounting standards or updates:

Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

Accounting Standards or Updates Not Yet Adopted

Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. ASU 2016-13 will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

Convertible Debt, and Derivatives and Hedging In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures.
XML 31 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Details Balance Sheet Details
Allowance for Doubtful Accounts
(In thousands)Balance at Beginning of YearProvisionsWrite-offs, NetBalance at End of Period
Three months ended March 31, 2021$137 $17 $— $154 
Three months ended March 31, 2020$45 $— $— $45 

Inventories
(In thousands)March 31, 2021December 31, 2020
Raw materials$12,185 $11,800 
Work-in-process8,702 10,760 
Finished goods26,752 20,302 
Inventories$47,639 $42,862 

Deferred cost of products sold - related party
(In thousands)March 31, 2021December 31, 2020
Deferred cost of products sold - related party$5,220 $9,801 
Deferred cost of products sold, noncurrent - related party9,391 9,939 
Total $14,611 $19,740 

Amounts reported as "Deferred cost of products sold - related party" are in connection with an agreement with Koninklijke DSM N.V. (DSM) under which DSM will provide capacity for sweetener production at DSM's Brotas, Brazil manufacturing facility through December 2022. Deferred cost of products sold asset is being expensed to cost of products sold on a units of production basis as the Company's sweetener product is sold over the five-year term of the supply agreement. During the three months ended March 31, 2021 and 2020, the Company expensed $1.6 million and $0.1 million, respectively, of the deferred cost of products sold asset to cost of products sold. Inception-to-date amortization through March 31, 2021 totaled $4.9 million.

Prepaid expenses and other current assets
(In thousands)March 31, 2021December 31, 2020
Prepayments, advances and deposits$13,453 $6,637 
Non-inventory production supplies3,364 3,989 
Recoverable taxes from Brazilian government entities1,020 1,063 
Other1,409 1,414 
Total prepaid expenses and other current assets$19,246 $13,103 

Property, Plant and Equipment, Net
(In thousands)March 31, 2021December 31, 2020
Machinery and equipment$49,880 $50,415 
Leasehold improvements44,800 45,197 
Computers and software7,362 6,741 
Furniture and office equipment, vehicles and land3,450 3,507 
Construction in progress7,238 7,250 
112,730 113,110 
Less: accumulated depreciation and amortization(80,797)(80,235)
Property, plant and equipment, net$31,933 $32,875 

During the three months ended March 31, 2021 and 2020, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows:
Three Months Ended March 31,
(In thousands)20212020
Depreciation and amortization expense$2,114 $1,719 

Leases

Operating Leases

The Company has operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 to 5 years, and often include one or more options to renew. These renewal terms can extend the lease term from 1 to 5 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. The operating leases are classified as ROU assets under operating leases on the Company's condensed consolidated balance sheets and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make operating lease payments is included in "Lease liabilities" and "Lease liabilities, net of current portion" on the Company's condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company had $9.3 million and $10.1 million of right-of-use assets as of March 31, 2021 and December 31, 2020, respectively. Operating lease liabilities were $13.7 million and $15.0 million as of March 31, 2021 and December 31, 2020, respectively. During the three
ended March 31, 2021 and 2020, respectively, the Company recorded $1.8 million and $1.5 million of operating lease amortization that was charged to expense, of which $0.2 million and $0.3 million was recorded to cost of products sold.

Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company has certain contracts for real estate and marketing which may contain lease and non-lease components which it has elected to treat as a single lease component.

Information related to the Company's right-of-use assets and related lease liabilities were as follows:
Three Months Ended March 31,
20212020
Cash paid for operating lease liabilities, in thousands$1,185$1,893
Right-of-use assets obtained in exchange for new operating lease obligations, in thousands$—$—
Weighted-average remaining lease term2.73.2
Weighted-average discount rate18.0%18.0%

Financing Leases

The Company has financing leases primarily for laboratory and computer equipment. Assets purchased under financing leases are included in "Right-of-use assets under financing leases, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Accumulated amortization of assets under financing leases totaled $5.3 million and $4.6 million as of March 31, 2021 and December 31, 2020, respectively.

Maturities of Financing and Operating Leases

Maturities of lease liabilities as of March 31, 2021 were as follows:
Years ending December 31:
(In thousands)
Financing
Leases
Operating
Leases
Total Leases
2021 (Remaining Nine Months)$3,491 $5,644 $9,135 
2022— 7,655 7,655 
2023— 3,320 3,320 
2024— 150 150 
2025— — — 
Total lease payments3,491 16,769 20,260 
Less: amount representing interest(233)(3,050)(3,283)
Total lease liability$3,258 $13,719 $16,977 
Current lease liability$3,258 $5,510 $8,768 
Noncurrent lease liability— 8,209 8,209 
Total lease liability$3,258 $13,719 $16,977 

Other Assets
(In thousands)March 31, 2021December 31, 2020
Equity-method investment$3,431 $2,380 
Deposits126 128 
Other1,213 1,196 
Total other assets$4,770 $3,704 
Accrued and Other Current Liabilities
(In thousands)March 31, 2021December 31, 2020
Payroll and related expenses$10,540 $8,230 
Accrued interest7,721 9,327 
Contract termination fees5,311 5,344 
Asset retirement obligation(1)
3,003 3,041 
Professional services1,604 994 
Ginkgo partnership payments obligation878 878 
Tax-related liabilities639 656 
Other2,425 2,237 
Total accrued and other current liabilities$32,121 $30,707 
______________
(1)    The asset retirement obligation represents liabilities incurred but not yet discharged in connection with our 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.


Other noncurrent liabilities
(In thousands)March 31, 2021December 31, 2020
Liability for unrecognized tax benefit$7,551 $7,496 
Ginkgo partnership payments obligation, net of current portion7,461 7,277 
Liability in connection with acquisition of equity-method investment7,216 6,771 
Contract liabilities, net of current portion111 111 
Other128 1,099 
Total other noncurrent liabilities$22,467 $22,754 
XML 32 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurement
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurement Fair Value Measurement
Liabilities Measured and Recorded at Fair Value on a Recurring Basis

The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy:

(In thousands)March 31, 2021December 31, 2020
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Liabilities
Foris Convertible Note (LSA Amendment)$— $— $379,439 $379,439 $— $— $123,164 $123,164 
Senior Convertible Notes— — 54,757 54,757 — — 53,387 53,387 
Embedded derivatives bifurcated from debt instruments— — 188 188 — — 247 247 
Freestanding derivative instruments issued in connection with other debt and equity instruments— — 31,196 31,196 — — 8,451 8,451 
Total liabilities measured and recorded at fair value$— $— $465,580 $465,580 $— $— $185,249 $185,249 

The Company did not hold any financial assets to be measured and recorded at fair value on a recurring basis as of March 31, 2021 and December 31, 2020. Also, there were no transfers between the levels during the three months ended March 31, 2021 or the year ended December 31, 2020.

The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the asset or liability. The method of determining the fair value of embedded derivative liabilities is described subsequently in this note. Market risk associated with embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates.

Changes in fair value of derivative liabilities are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of derivative instruments".

Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of debt".

Fair Value of Debt — Foris Convertible Note

At March 31, 2021, the contractual outstanding principal of the Foris Convertible Note was $50.0 million, and fair value was $379.4 million. The Company remeasured the fair value of the Foris Convertible Note under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $19.10 stock price, (ii) 10% discount yield, (iii) 0.09% risk free interest rate (iv) 45% equity volatility and (v) 5% probability of change in control. The Company assumed that if a change of control event were to occur, it would occur at the end of the calendar year. The Company recorded a loss of $256.3 million related to change in fair value of the Foris Convertible Note for the three months ended March 31, 2021. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.00 conversion price.

Fair Value of Debt — Senior Convertible Notes

At March 31, 2021, the contractual outstanding principal of the Senior Convertible Notes was $10.0 million, and fair value was $54.8 million. The Company measured the fair value at March 31, 2021 under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $19.10 stock price, (ii) 210% discount yield, (iii) 0.02% risk free interest rate (iv) 45% equity volatility, and (v) 0% probability of change in control. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.50 conversion price.

For the three months ended March 31, 2021, the Company recorded a $70.5 million loss from change in fair value of debt in connection with fair value remeasurement of the Senior Convertible Notes, as follows:
In thousands
Fair value at December 31, 2020$53,387 
Loss from change in fair value70,510 
Less: principal converted into common stock(20,000)
Less: fair value adjustment extinguished upon conversion of debt principal(49,140)
Fair value at March 31, 2021$54,757 

Binomial Lattice Model

A binomial lattice model was used to determine whether the Foris Convertible Note and the Senior Convertible Notes (Debt Instruments) would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the convertible note will be converted early if the conversion value is greater than the holding value and (ii) the convertible note will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the convertible note is called, the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the convertible note. Using this lattice method, the Company valued the Debt Instruments using the "with-and-without method", where the fair value of the Debt Instruments including the embedded and freestanding features is defined as the "with," and the fair value of the Debt Instruments excluding the embedded and freestanding features is defined as the "without." This method estimates the fair value of the Debt Instruments by looking at the difference in the values of the Debt Instruments with the embedded and freestanding derivatives and the fair value of the Debt Instruments without the embedded and freestanding features. The lattice model uses the stock price, conversion price, maturity date, risk-free interest rate, estimated stock volatility, estimated credit spread and other instrument-specific assumptions. The Company remeasures the fair value of the Debt Instruments and records the change as a gain or loss from change in fair value of debt in the statement of operations for each reporting period.

Derivative Liabilities Recognized in Connection with the Issuance of Debt Instruments

The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3):
(In thousands)Derivative Liability
Balance at December 31, 2020$8,698 
Change in fair value of derivative instruments22,745 
Derecognition on settlement or extinguishment(59)
Balance at March 31, 2021$31,384 

Freestanding Derivative Instruments

On February 28, 2020, the Company entered into forbearance agreements with certain affiliates of the Schottenfeld Group LLC (the Lenders) related to certain defaults under the Schottenfeld Notes. In connection with entering into the forbearance agreements, the Company committed to issuing warrants (Warrants) to the Lenders under certain contingent events for 1.9 million shares of common stock at a $2.87 purchase price and a two-year term. The contingent obligation to issue the Warrants did not meet the derivative scope exception or equity classification criteria and was accounted for as a derivative liability and remeasured each reporting period until settled or extinguished with subsequent changes in fair value recorded through the statement of operations. The fair value of the Warrants derivative liability was determined using a Black-Scholes-Merton option pricing model based on the input assumptions for liability classified warrants table in the valuation methodology section below. At March 31, 2021, the fair value of the contingently issuable Warrants derivative liability was $31.2 million, and for the three months ended March 31, 2021, the Company recorded a $22.7 million loss on change in fair value of derivative instruments.

Valuation Methodology and Approach to Measuring the Derivative Liabilities

Substantially all the outstanding liabilities associated with the Company’s derivatives at March 31, 2021 and December 31, 2020 represent the fair value of freestanding equity instruments. See Note 4, "Debt", and Note 6, "Stockholders' Deficit" for further information regarding these host instruments. There is no current observable market for these types of
derivatives and, as such, the Company determined the fair value of the freestanding instruments using the Black-Scholes-Merton option pricing model, which is discussed in more detail below.

The Company used the Black-Scholes-Merton option pricing model to determine the fair value of its liability classified warrants as of March 31, 2021 and December 31, 2020. Input assumptions for these freestanding instruments are as follows:
Range for the Period
Input assumptions for liability classified warrants:March 31, 2021December 31, 2020
Fair value of common stock on issue date
$19.10 – $19.10
$2.56 – $6.18
Exercise price of warrants
$2.87 – $2.87
$2.87 – $3.25
Expected volatility
114% – 114%
94% – 117%
Risk-free interest rate
0.16% – 0.16%
0.13% – 1.58%
Expected term in years
2 – 2
1 – 2
Dividend yield0.0 %0.0 %

Changes in valuation assumptions can have a significant impact on the valuation of the freestanding derivative liabilities and debt that the Company elects to account for at fair value. For example, all other things being equal, generally, an increase in the Company’s stock price, change of control probability, risk-adjusted yields term to maturity/conversion or stock price volatility increases the value of the derivative liability.

Assets and Liabilities Recorded at Carrying Value

Financial Assets and Liabilities

The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and other current accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable and credit facilities are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of these instruments using observable market-based inputs (Level 2). The carrying amount (the total amount of net debt presented on the balance sheet) of the Company's debt at March 31, 2021 and at December 31, 2020, excluding the debt instruments recorded at fair value, was $49.3 million and $86.5 million, respectively. The fair value of such debt at March 31, 2021 and at December 31, 2020 was $51.1 million and $83.3 million, respectively, and was determined by (i) discounting expected cash flows using current market discount rates estimated for certain of the debt instruments and (ii) using third-party fair value estimates for the remaining debt instruments.
XML 33 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Debt
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Debt Debt
Net carrying amounts of debt are as follows:
March 31, 2021December 31, 2020
(In thousands)PrincipalUnaccreted Debt DiscountChange in Fair ValueNetPrincipalUnaccreted Debt DiscountChange in Fair ValueNet
Convertible notes payable
Senior convertible notes$10,020 $— $44,737 $54,757 $30,020 $— $23,367 $53,387 
Related party convertible notes payable
Foris convertible note50,041 — 329,398 379,439 50,041 — 73,123 123,164 
Loans payable and credit facilities
Schottenfeld notes— — — — 12,500 (240)— 12,260 
Nikko notes2,737 (725)— 2,012 2,802 (759)— 2,043 
Ginkgo note12,000 — — 12,000 12,000 — — 12,000 
Other loans payable1,009 — — 1,009 1,227 — — 1,227 
15,746 (725)— 15,021 28,529 (999)— 27,530 
Related party loans payable
Foris note5,000 — — 5,000 5,000 — — 5,000 
DSM notes10,000 (4,254)— 5,746 33,000 (2,443)— 30,557 
Naxyris note23,914 (412)— 23,502 23,914 (493)— 23,421 
38,914 (4,666)— 34,248 61,914 (2,936)— 58,978 
Total debt$114,721 $(5,391)$374,135 483,465 $170,504 $(3,935)$96,490 263,059 
Less: current portion(55,904)(77,437)
Long-term debt, net of current portion$427,561 $185,622 

Senior Convertible Notes Conversion

On February 4, 2021, the Company received a notice of conversion from HT Investments MA, LLC (HT) with respect to $20.0 million of its outstanding Senior Convertible Notes, pursuant to which the Company was required to issue 5.7 million shares of common stock per the conversion price stated in the agreement and cancelled the outstanding Note. Also, under the terms of the Senior Convertible Note, HT was required to return 2.6 million shares of common stock outstanding under the Pre-Delivery Shares provision once the Company had fully repaid the principal balance. HT fulfilled its obligation to return these shares in accordance with the contractual requirement, and as a result the Company net settled the $20 million principal conversion by issuing 3.1 million of incremental shares to HT.

Upon conversion of the HT Senior Convertible Note, the Company recorded a $31.9 million loss upon extinguishment of debt, which was primarily comprised of a fair value adjustment upon repayment of the note's principal.

See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the Senior Convertible Notes.

Schottenfeld Note Exchange

On March 1, 2021, the Company entered into an Exchange and Settlement Agreement (Exchange Agreement) with Schottenfeld Opportunities Fund II, L.P. and certain other holders of notes under the Credit and Security Agreement dated November 14, 2019 (Schottenfeld Notes). Pursuant to the terms of the Exchange Agreement, the Company paid all accrued and unpaid interest on the $12.5 million principal balance outstanding under the Schottenfeld Notes, and issued 4.1 million net shares of common stock in a cashless exchange and cancellation of all amounts due and outstanding under the Notes and related loan documents and all warrants held by each of the holders of Schottenfeld Notes.

Upon conversion of the Schottenfeld note balance, the Company recorded a $28.9 million loss upon extinguishment of debt, which primarily represented the fair value of common shares issued in excess of debt principal extinguished.

See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the Schottenfeld Notes.
DSM Notes Amendments and Repayment

On December 28, 2017, the Company and DSM Finance, a wholly owned subsidiary of Koninklijke DSM N.V. (DSM), entered into a credit agreement (the DSM Credit Agreement) to make available to the Company an unsecured credit facility of $25.0 million. On December 28, 2017, the Company borrowed $25.0 million under the DSM Credit Agreement and issued a promissory note to DSM Finance. The $25 million Note matures on December 31, 2021 and accrues interest at 10% per annum, payable quarterly.

On September 17, 2019, the Company and DSM entered into a credit agreement (the 2019 DSM Credit Agreement) to make available to the Company a secured credit facility in an aggregate principal amount of $8.0 million. In September 2019, the Company borrowed the $8.0 million in three installments. The promissory notes issued under the 2019 DSM Credit Agreement (i) mature on August 7, 2022, (ii) accrue interest at a rate of 12.5% per annum, payable quarterly and (iii) are secured by a first-priority lien on certain Company intellectual property licensed to DSM.

In March 2021, the Company entered into amendments (the March 2021 Amendments) to the $25 million Note and the $8 million Note that provided for (i) the prepayment of the $8 million Note, (ii) a $15 million partial prepayment of the $25 million Note and (iii) extension of the maturity date from December 31, 2021 to April 15, 2022 for the remaining $10 million principal balance under the $25 million Note, in exchange for a $2.5 million prepayment fee The Company repaid $23 million on March 31, 2021 to extinguish the $8 million Note and to partially repay the $25 million Note.

The Company evaluated the March 2021 Amendments, and concluded the before and after cash flows resulting from the amendments were not significantly different and accounted for the amendments to the Notes as a debt modification. Consequently, the $2.5 million Prepayment Fee was recorded as an incremental debt discount to the remaining $10 million principal balance under the $25 million Note. The Company will accrete the adjusted discount over the Note’s amended remaining term using the effective interest method.

See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the DSM notes.

Future Minimum Payments

Future minimum payments under the Company's debt agreements as of March 31, 2021 are as follows:
(In thousands)Convertible NotesLoans
Payable and Credit Facilities
Related Party Convertible NotesRelated Party Loans Payable and Credit FacilitiesTotal
2021 (Remaining Nine Months)$11,189 $2,260 $— $2,782 $16,231 
2022— 13,268 59,578 42,379 115,225 
2023— 399 — — 399 
2024— 398 — — 398 
2025— 397 — — 397 
Thereafter— 1,473 — — 1,473 
Total future minimum payments11,189 18,195 59,578 45,161 134,123 
Less: amount representing interest(1,169)(2,449)(9,537)(6,247)(19,402)
Present value of minimum debt payments10,020 15,746 50,041 38,914 114,721 
Less: current portion of debt principal(10,020)(1,280)— — (11,300)
Noncurrent portion of debt principal$— $14,466 $50,041 $38,914 $103,421 
XML 34 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Mezzanine Equity
3 Months Ended
Mar. 31, 2021
Temporary Equity Disclosure [Abstract]  
Mezzanine Equity Mezzanine EquityMezzanine equity at March 31, 2021 and December 31, 2020 is comprised of proceeds from shares of common stock sold on May 10, 2016 to the Bill & Melinda Gates Foundation (the Gates Foundation). In connection with the stock sale, the Company and the Gates Foundation entered into an agreement under which the Company agreed to expend an aggregate amount not less than the proceeds from the stock sale to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. If the Company defaults in its obligation to use the proceeds from the stock sale as set forth above or defaults under certain other commitments in the agreement, the Gates Foundation will have the right to request that the Company redeem, or facilitate the purchase by a
third party, the shares then held by the Gates Foundation at a price per share equal to the greater of (i) the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable, or (ii) an amount equal to $17.10 plus a compounded annual return of 10%.

As of March 31, 2021, the Company's remaining research and development obligation under this arrangement was $0.3 million.
XML 35 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Deficit
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Stockholders' Deficit Stockholders' Deficit
Warrants and Rights Activity Summary

In connection with various debt and equity transactions (see Note 4, “Debt” above and Note 4, "Debt" and Note 6, “Stockholders’ Deficit” in Part II, Item 8 of the 2020 Form 10-K), the Company has issued warrants exercisable for shares of common stock. The following table summarizes warrants outstanding at March 31, 2021:
TransactionNumber Outstanding as of March 31, 2021Exercise Price per Share as of March 31, 2021
Blackwell and Silverback warrants1,000,000 $3.25 
January 2020 warrant exercise right shares4,209,608 $2.87 
April 2019 PIPE warrants1,381,940 
$4.76/$5.02
Naxyris LSA warrants2,000,000 $2.87 
October 2019 Naxyris warrant2,000,000 $3.87 
May 2019 6.50% Note Exchange warrants960,225 $2.87 
May 2017 cash warrants1,863,056 $2.87 
May 2017 dilution warrants3,085,893 $0.00 
August 2017 dilution warrants3,028,983 $0.00 
July 2015 related party debt exchange58,690 $0.15 
Other1,406 $160.05 
19,589,801 

Warrant Exercises

During the three months ended March 31, 2021, warrant-holders exercised warrants to purchase approximately 24.8 million shares of the Company’s common stock at a weighted-average exercise price of $3.06 per share, for net proceeds to the Company of $32.2 million. Some of the exercises were cashless or in connection with the Schottenfeld Note Exchange, which resulted in fewer shares being issued than the number of warrant-shares exercised. As a result, 21.6 million shares were issued.
XML 36 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share Attributable to Common Shareholders
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Common Shareholders Net Loss per Share Attributable to Common Stockholders
For the three months ended March 31, 2021 and 2020, basic loss per share was the same as diluted loss per share, because the inclusion of all potentially dilutive securities outstanding was antidilutive.

The Company follows the two-class method when computing net loss per common share when shares are issued that meet the definition of participating securities. The two-class method requires income available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The two-class method also requires losses for the period to be allocated between common stock and participating securities based on their respective rights if the participating security contractually participates in losses. The Company’s convertible preferred stock are participating securities as they contractually entitle the holders of such shares to participate in dividends and contractually require the holders of such shares to participate in the Company’s losses.
The following table presents the calculation of basic and diluted loss per share:
Three Months Ended March 31,
(In thousands, except shares and per share amounts)20212020
Numerator:
Net loss attributable to Amyris, Inc.$(291,251)$(87,844)
Less: losses allocated to participating securities2,099 1,087 
Net loss attributable to Amyris, Inc. common stockholders, basic and diluted$(289,152)$(86,757)
Denominator:
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted267,733,555 155,065,635 
Loss per share, basic and diluted$(1.08)$(0.56)

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive:
Three Months Ended March 31,
20212020
Period-end common stock warrants13,416,235 50,518,519 
Convertible promissory notes(1)
19,540,447 9,217,185 
Period-end stock options to purchase common stock6,205,576 5,578,264 
Period-end restricted stock units6,653,640 5,298,639 
Period-end preferred stock1,943,661 1,943,661 
Total potentially dilutive securities excluded from computation of diluted loss per share47,759,559 72,556,268 
______________
(1)    The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.
XML 37 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Guarantor Arrangements

The Company has agreements whereby it indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the executive officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of March 31, 2021 and December 31, 2020.

The Foris Convertible Note (see Note 4, "Debt") is collateralized by first-priority liens on substantially all of the Company's assets, including Company intellectual property, other than certain Company intellectual property licensed to DSM and the Company's shares of Aprinnova. Certain of the Company’s subsidiaries have guaranteed the Company’s obligations under the Foris Convertible Note.

The obligations of the Company under the Naxyris Note (see Note 4, "Debt") are (i) guaranteed by the Subsidiary Guarantors and (ii) secured by a perfected security interest in substantially all of the assets of the Company and the Subsidiary Guarantors (the Collateral), junior in payment priority to Foris subject to certain limitations and exceptions, as well as the terms of the Intercreditor Agreement.

The Nikko $3.9 million note is collateralized by a first-priority lien on 10.0% of the Aprinnova JV interests owned by the Company.
Other Matters

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but will only be recorded when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgement. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

On April 3, 2019, a securities class action complaint was filed against Amyris and our CEO, John G. Melo, and former CFO, Kathleen Valiasek, in the U.S. District Court for the Northern District of California. The complaint seeks unspecified damages on behalf of a purported class that would comprise all persons and entities that purchased or otherwise acquired our securities between March 15, 2018 and March 19, 2019. The complaint, which was amended by the lead plaintiff on September 13, 2019, alleges securities law violations based on statements and omissions made by the Company during such period. On October 25, 2019, the defendants filed a motion to dismiss the securities class action complaint, which was denied by the court on October 5, 2020. The Company filed its answer to the securities class action complaint on October 26, 2020. Subsequent to the filing of the securities class action complaint described above, on June 21, 2019 and October 1, 2019, respectively, two separate purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California (Bonner v. Doerr, et al., and Carlson v. Doerr, et al.) based on similar allegations to those made in the securities class action complaint and naming the Company, and certain of the Company’s current and former officers and directors, as defendants. The derivative lawsuits sought to recover, on the Company’s behalf, unspecified damages purportedly sustained by the Company in connection with allegedly misleading statements and omissions made in connection with the Company’s securities filings. The derivative lawsuits were dismissed on October 18, 2019 (Bonner) and December 10, 2019 (Carlson), without prejudice. On November 3, 2020, Bonner re-filed its derivative complaint against the Company in San Mateo County Superior Court. The Company filed its demurrer to the complaint on January 13, 2021 and attended a preliminary hearing on April 22, 2021. An additional shareholder derivative complaint (Kimbrough v. Melo, et al.), substantially identical to the Bonner complaint, was filed on December 18, 2020 in the United States District Court for the Northern District of California. On February 19, 2021, the Company filed its motion to dismiss the Kimbrough complaint. In response, the Kimbrough complaint was dismissed in federal court on March 4, 2021 and refiled in state court on March 12, 2021. By agreement, the Kimbrough and Bonner complaints were consolidated for all purposes on April 9, 2021. By May 10, 2021, the derivative shareholder plaintiffs will either file a new complaint or designate one of the existing complaints as operative. A briefing schedule on a demurrer to that complaint will be negotiated no later than May 24, 2021. The Company believes the securities class action and derivative complaints lack merit, and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result from these matters.

On September 10, 2020, LAVVAN, Inc. (Lavvan) filed a suit against the Company in the United States District Court for the Southern District of New York alleging breach of contract, patent infringement, and trade secret misappropriation in connection with that certain Research, Collaboration and License Agreement between Lavvan and Amyris, dated March 18, 2019, as amended (Cannabinoid Agreement). Amyris filed motions to compel arbitration or to dismiss on October 2, 2020. On October 30, Lavvan filed its opposition to the motions and the Company filed its reply to such opposition on November 13, 2020. The matter is fully briefed and the parties are awaiting an order from the Court. The Company believes the suit lacks merit and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result therefrom.

The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may arise in the ordinary course of business are subject to many uncertainties and outcomes, and are not predictable with reasonable assurance; therefore, an estimate of all the reasonably possible losses cannot be determined at this time. If one or more of these legal disputes or claims resulted in settlements or legal proceedings that were resolved against the Company for amounts in excess of management’s
expectations, the Company’s condensed consolidated financial statements for the relevant reporting period could be materially adversely affected.
XML 38 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition and Contract Assets and Liabilities
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Recognition and Contract Assets and Liabilities Revenue Recognition and Contract Assets and Liabilities
Disaggregation of Revenue

The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer:
Three Months Ended March 31,
(In thousands)20212020
Renewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotalRenewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotal
United States$20,090 $— $250 $20,340 $11,944 $— $— $11,944 
Europe2,972 143,800 2,346 149,118 3,242 5,161 3,356 11,759 
Asia4,405 2,284 6,689 2,018 — 2,759 4,777 
Brazil313 313 577 — — 577 
Other399 399 73 — — 73 
$28,179 $143,800 $4,880 $176,859 $17,854 $5,161 $6,115 $29,130 

The following table presents revenue by major product and service, as well as by customer type:
Three Months Ended March 31,
(In thousands)20212020
Renewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotalRenewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotal
Consumer$15,653 $— $— $15,653 $9,065 $— $— $9,065 
Ingredients12,526 143,800 — 156,326 8,789 5,161 — 13,950 
Research and development— — 4,880 4,880 — — 6,115 6,115 
$28,179 $143,800 $4,880 $176,859 $17,854 $5,161 $6,115 $29,130 

Revenue from Significant Revenue Agreements

In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2020 Form 10-K), the Company recognized the following revenue for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
(In thousands)20212020
Renewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotalRenewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotal
DSM - related party$1,662 $143,612 $2,000 $147,274 $49 $3,750 $3,018 $6,817 
Sephora4,441 — — 4,441 4,446 — — 4,446 
Yifan— — 2,284 2,284 — — 2,709 2,709 
Firmenich379 188 205 772 1,229 1,411 161 2,801 
Givaudan210 — — 210 2,109 — — 2,109 
Subtotal revenue from significant revenue agreements6,692 143,800 4,489 154,981 7,833 5,161 5,888 18,882 
Revenue from all other customers21,487 — 391 21,878 10,021 — 227 10,248 
Total revenue from all customers$28,179 $143,800 $4,880 $176,859 $17,854 $5,161 $6,115 $29,130 

DSM License Agreement and Contract Assignment

On March 31, 2021, the Company and DSM entered into a license agreement and asset purchase agreement pursuant to which DSM acquired exclusive rights to the Company’s Flavor and Fragrance (F&F) product portfolio. The Company granted DSM exclusive licenses covering specific intellectual property (F&F Intellectual Property License) of the Company and assigned the Company’s rights and obligations under certain F&F ingredients supply agreements to DSM, in exchange for non-refundable upfront consideration totaling $150 million, and up to $235 million of contingent consideration if and when certain
commercial milestones are achieved in each of the calendar years 2022 through 2024. DSM also acquired the Company’s F&F finished goods inventory on-hand, unbilled accounts receivables and billed accounts receivable that were uncollected at closing. The Company and DSM also entered into a 15-year manufacturing agreement whereby the Company will manufacture certain F&F ingredients for DSM to supply to third parties.

The Company determined the licenses to be functional intellectual property licenses allowing DSM the immediate use of and benefit from the technology, and concluded the licenses and related assigned F&F ingredients supply agreements, the asset purchase agreement and the manufacturing agreement were revenue contracts within the scope of ASC 606. The Company identified three distinct performance obligations: (i) F&F license, (ii) finished goods inventory and (iii) receivables, that once delivered are satisfied at a point in time. The Company also concluded the additional contingent consideration and manufacturing supply agreement represent variable consideration that will be fully constrained until the commercial targets are probable of achievement and the products are manufactured and sold.

The Company allocated the $150 million transaction price to the three revenue performance obligations using the residual approach. The transaction price was first allocated to the transferred inventory and receivables at the stand-alone selling price for these performance obligations, and the residual consideration was allocated to the F&F intellectual property licenses:
Finished goods inventory - $1.5 million
Receivables - $4.9 million
F&F intellectual property licenses - $143.6 million

The Company also concluded the F&F intellectual property licenses and the assigned F&F supply agreements had been fully delivered with no further performance obligation upon closing the transaction, and recognized license revenue of $143.6 million in the period ended March 31, 2021.

Due to the related party nature of the transaction with DSM, who is a significant shareholder with two members on the Company’s board of directors, the Company performed a fair value assessment of the F&F intellectual property licenses under an income approach using a discounted cash flow model, in part with the assistance of a third-party valuation firm, and concluded the $143.6 million residual consideration received in exchange for the F&F intellectual property licenses approximated the fair value and stand-alone selling price of the F&F intellectual property licenses.

DSM Performance Agreement

In December 2017, the Company and DSM entered into a research and development services agreement (Performance Agreement), pursuant to which the Company would provide services to DSM relating to the further development of the technology underlying farnesene-related products in exchange for certain bonus payments in the event that specific performance metrics were achieved. If the Company did not meet the established metrics under the Performance Agreement, the Company would be required to pay $1.9 million to DSM. The Company accounted for the Performance Agreement under ASC 606 as a combined transaction with the Farnesene license granted to DSM in connection with the sale of the Brotas facility in December 2017. The Performance Agreement was allocated $1.2 million of the transaction price under a relative fair value allocation approach, and was recorded as a contract asset reflecting the Company’s right to receive additional consideration and deferred revenue reflecting the probability of returning to DSM a portion of the cash received under the combined transaction. In the first quarter of 2021, the Company and DSM determined the performance metrics would not be reasonably achieved without the Company providing further research and development services and concluded the Performance Agreement and related activities should be terminated. As a result, the Company paid DSM $1.9 million and reduced the deferred revenue liability, and expensed the contract asset balance and recorded $1.9 million of additional research and development expense during the three months ended March 31, 2021.

DSM Ingredients Collaboration

Pursuant to the September 2017 research and development collaboration agreement, as amended, the Company provides DSM with research and development services for specific field of use ingredients. The Company concluded the amended agreement contained a single performance obligation to provide research and development services delivered over time and that revenue recognition is based on an input measure of progress as labor hours are expended each quarter. DSM funds the development work with payments of $2.0 million quarterly from October 1, 2020 to September 30, 2021 for services singularly focused on achieving a certain fermentation yield and cost target over the twelve-month period. During the three months ended March 31, 2021 and 2020, the Company recognized $2.0 million and $3.0 million of collaboration revenue in connection with the amended agreement.
Yifan Collaborations

The Company has a collaboration agreement with Yifan Pharmaceutical Co., Ltd. (Yifan), a leading Chinese pharmaceutical company. During the three months ended March 31, 2021 and 2020, the Company recognized $2.3 million and $2.7 million of collaboration revenue, and $16.6 million of cumulative-to-date collaboration revenue in connection with the agreement. At March 31, 2021, the Company also recorded a $5.9 million contract asset in connection with the Collaboration Agreement.

For more information about the DSM ingredients collaboration and Yifan collaboration, see the Company's 2020 Form 10-K, Part II, Item 8, Note 10, "Revenue Recognition".

Contract Assets and Liabilities

When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional.

Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not passed to the customer.

Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade receivables are recorded for the sale of goods or the performance of services at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company.

Contract Balances

The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers:
(In thousands)March 31, 2021December 31, 2020
Accounts receivable, net$27,036 $32,846 
Accounts receivable - related party, net$391 $12,110 
Contract assets$6,589 $4,178 
Contract assets - related party$2,000 $1,203 
Contract liabilities$6,163 $4,468 
Contract liabilities, noncurrent(1)
$111 $111 

(1)As of March 31, 2021 and December 31, 2020, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets.

Remaining Performance Obligations

The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2021.
(In thousands)As of March 31, 2021
Remaining 2021$143 
20223,103 
20231,430 
2024 and thereafter429 
Total from all customers$5,105 

In accordance with the disclosure provisions of ASC 606, the table above excludes estimated future revenues for performance obligations that are part of a contract that has an original expected duration of one year or less or a performance obligation with variable consideration that is recognized using the sales-based royalty exception for licenses of intellectual
property. Additionally, approximately $297.8 million of estimated future revenue is excluded from the table above, as that amount represents constrained variable consideration.
XML 39 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions
3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
Related Party Debt

See Note 4, "Debt," for details of the DSM Notes Amendments and Repayments that occurred during the three months ended March 31, 2021.

Related party debt was as follows:
March 31, 2021December 31, 2020
In thousandsPrincipalUnaccreted Debt DiscountChange in Fair ValueNetPrincipalUnaccreted Debt DiscountChange in Fair ValueNet
Foris notes$55,041 $— $329,398 $384,439 $55,041 $— $73,123 $128,164 
DSM notes10,000 (4,254)— 5,746 33,000 (2,443)— 30,557 
Naxyris note23,914 (412)— 23,502 23,914 (493)— 23,421 
$88,955 $(4,666)$329,398 $413,687 $111,955 $(2,936)$73,123 $182,142 

Related Party Revenue

See Note 9, "Revenue Recognition", for information about the March 31, 2021 DSM License Agreement and Contract Assignment.

Related Party Accounts Receivable, Unbilled Receivables and Accounts Payable

Related party accounts receivable, contract assets and accounts payable were as follows:

(In thousands)March 31, 2021December 31, 2020
Accounts receivable - related party$391 $12,110 
Contract assets - related party$2,000 $1,203 
Accounts payable$10,302 $5,011 
XML 40 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation Stock-based Compensation
The Company’s stock option activity and related information for the three months ended March 31, 2021 was as follows:
Quantity of Stock OptionsWeighted-
average
Exercise
Price
Weighted-average
Remaining
Contractual
Life, in Years
Aggregate
Intrinsic
Value, in Thousands
Outstanding - December 31, 20206,502,096 $7.64 7.6$8,875 
Granted131,408 $14.52 
Exercised(375,390)$5.12 
Forfeited or expired(52,538)$38.21 
Outstanding - March 31, 20216,205,576 $7.68 7.4$82,615 
Vested or expected to vest after March 31, 20215,697,447 $7.91 7.3$75,493 
Exercisable at March 31, 20211,259,029 $18.19 5.8$12,884 
The Company’s restricted stock units (RSUs) activity and related information for the three months ended March 31, 2021 was as follows:
Quantity of Restricted Stock UnitsWeighted-average Grant-date Fair ValueWeighted-average Remaining Contractual Life, in Years
Outstanding - December 31, 20207,043,909 $4.18 1.5
Awarded345,903 $13.53 
Released(496,492)$4.34 
Forfeited(239,680)$4.22 
Outstanding - March 31, 20216,653,640 $4.65 1.4
Vested or expected to vest after March 31, 20216,082,165 $4.65 1.3

Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three months ended March 31, 2021 and 2020 is reflected in the condensed consolidated statements of operations as follows:
Three Months Ended March 31,
(In thousands)20212020
Cost of products sold$63 $— 
Research and development1,062 1,065 
Sales, general and administrative3,156 2,439 
Total stock-based compensation expense$4,281 $3,504 

As of March 31, 2021, there was unrecognized compensation expense of $30.0 million related to stock options and RSUs. The Company expects to recognize this expense over a weighted-average period of 2.4 years.

Evergreen Shares for 2020 Equity Incentive Plan and 2010 Employee Stock Purchase Plan

In March 2021, the Board approved increases to the number of shares available for issuance under the Company's 2020 Equity Incentive Plan (the 2020 Equity Plan) and 2010 Employee Stock Purchase Plan (the 2010 ESPP).

The increase in shares in connection with the 2020 Equity Plan represented an automatic annual increase in the number of shares available for grant and issuance under the 2020 Equity Plan of 12,247,572 shares (Evergreen Shares). This increase is equal to approximately 5.0% of the 244,951,446 total outstanding shares of the Company’s common stock as of December 31, 2020. This automatic increase was effective as of January 1, 2021.

The increase in shares in connection with the 2010 ESPP represented an automatic annual increase in the number of shares reserved for issuance of 42,077 shares, which represents the remaining allowable under the existing 1,666,666 maximum limit for share issuance under the 2010 ESPP. This automatic increase was effective as of January 1, 2021.
XML 41 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events
3 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Primary and Secondary Offering

On April 8, 2021, the Company entered into an underwriting agreement (the Underwriting Agreement) with J.P. Morgan Securities LLC and Cowen and Company, LLC (the Underwriters) and with certain stockholders of the Company (the Selling Stockholders), pursuant to which the Selling Stockholders agreed to sell 11,390,797 shares of common stock of the Company, par value $0.0001 per share and Amyris agreed to issue and sell 7,656,822, at a public offering price of $15.75 per share. DSM International B.V. and affiliates of Vivo Capital LLC were the Secondary Offering Selling Stockholders. Under the terms of the Underwriting Agreement, the Selling Stockholders and Amyris granted the Underwriters a 30-day option to purchase up to an additional 1,708,619 shares of Common Stock from the Selling Stockholders and 1,148,523 shares of Common Stock from Amyris. The Underwriters exercised this option in full.

Net proceeds to the Company from the 8,805,345 new shares issued by the Company were approximately $130.7 million (inclusive of the underwriters’ option to purchase additional shares), after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
The Company did not receive any proceeds from the sale of common stock in the secondary offering by the Selling Stockholders.

Ingredion Agreement

On May 3, 2021, the Company and Ingredion Incorporated entered into a Membership Interest Purchase Agreement (MIPA) under which (i) the Company will assign and transfer certain contracts for the sale and distribution of RebM to Ingredion’s subsidiary, PureCircle, which will become the exclusive global business-to-business commercialization partner for the Company’s sugar reduction technology that includes fermented RebM; (ii) the Company and Ingredion will enter into certain intellectual property license agreements to make, have made, commercialize and advance the development of sustainably sourced, zero-calorie, nature-based sweeteners and potentially other types of fermentation-based ingredients; (iii) Ingredion will purchase 31% of all of the membership interests in Amyris RealSweet LLC, a wholly owned subsidiary of the Company incorporated on April 15, 2021 (RealSweet), which entity will own the new manufacturing facility under construction in Brazil, and; (iv) The parties will enter into an R&D collaboration agreement to create and advance the development of sustainably sourced, zero-calorie, nature-based sweeteners, and potentially other types of fermentation-based food ingredients. The Company will continue to own and market its Purecane™ consumer brand offering of tabletop and culinary sweetener products to consumers. Under the terms of the license agreement, the Company will receive an upfront $10 million license fee at closing and additional milestone payments in the aggregate of $35 million upon achievement of certain manufacturing cost targets and RebM sales revenue. The Company will also receive $30 million of cash and non-cash consideration from Ingredion in exchange for their 31% interest in RealSweet. Additionally, the Company will earn a profit share from future Reb M sales by PureCircle. The closing of the MIPA is subject to customary closing conditions.
XML 42 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of accounting The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.
Use of Estimates and Judgements
Use of Estimates and Judgements

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant
accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed.
Accounting Standards or Updates Recently Adopted and Accounting Standards or Updates Not Yet Effective
Accounting Standards or Updates Recently Adopted

In the three months ended March 31, 2021, the Company adopted these accounting standards or updates:

Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

Accounting Standards or Updates Not Yet Adopted

Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. ASU 2016-13 will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

Convertible Debt, and Derivatives and Hedging In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures.
XML 43 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details (Tables)
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Allowance for Doubtful Accounts
Allowance for Doubtful Accounts
(In thousands)Balance at Beginning of YearProvisionsWrite-offs, NetBalance at End of Period
Three months ended March 31, 2021$137 $17 $— $154 
Three months ended March 31, 2020$45 $— $— $45 
Inventories
Inventories
(In thousands)March 31, 2021December 31, 2020
Raw materials$12,185 $11,800 
Work-in-process8,702 10,760 
Finished goods26,752 20,302 
Inventories$47,639 $42,862 
Deferred Cost of Products Sold Deferred cost of products sold - related party
(In thousands)March 31, 2021December 31, 2020
Deferred cost of products sold - related party$5,220 $9,801 
Deferred cost of products sold, noncurrent - related party9,391 9,939 
Total $14,611 $19,740 
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets
(In thousands)March 31, 2021December 31, 2020
Prepayments, advances and deposits$13,453 $6,637 
Non-inventory production supplies3,364 3,989 
Recoverable taxes from Brazilian government entities1,020 1,063 
Other1,409 1,414 
Total prepaid expenses and other current assets$19,246 $13,103 
Property, Plant and Equipment, Net
Property, Plant and Equipment, Net
(In thousands)March 31, 2021December 31, 2020
Machinery and equipment$49,880 $50,415 
Leasehold improvements44,800 45,197 
Computers and software7,362 6,741 
Furniture and office equipment, vehicles and land3,450 3,507 
Construction in progress7,238 7,250 
112,730 113,110 
Less: accumulated depreciation and amortization(80,797)(80,235)
Property, plant and equipment, net$31,933 $32,875 
Schedule Of Depreciation and Amortization
During the three months ended March 31, 2021 and 2020, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows:
Three Months Ended March 31,
(In thousands)20212020
Depreciation and amortization expense$2,114 $1,719 
Lease, Cost
Information related to the Company's right-of-use assets and related lease liabilities were as follows:
Three Months Ended March 31,
20212020
Cash paid for operating lease liabilities, in thousands$1,185$1,893
Right-of-use assets obtained in exchange for new operating lease obligations, in thousands$—$—
Weighted-average remaining lease term2.73.2
Weighted-average discount rate18.0%18.0%
Lessee, Lease Liability, Maturity
Maturities of lease liabilities as of March 31, 2021 were as follows:
Years ending December 31:
(In thousands)
Financing
Leases
Operating
Leases
Total Leases
2021 (Remaining Nine Months)$3,491 $5,644 $9,135 
2022— 7,655 7,655 
2023— 3,320 3,320 
2024— 150 150 
2025— — — 
Total lease payments3,491 16,769 20,260 
Less: amount representing interest(233)(3,050)(3,283)
Total lease liability$3,258 $13,719 $16,977 
Current lease liability$3,258 $5,510 $8,768 
Noncurrent lease liability— 8,209 8,209 
Total lease liability$3,258 $13,719 $16,977 
Other Assets
Other Assets
(In thousands)March 31, 2021December 31, 2020
Equity-method investment$3,431 $2,380 
Deposits126 128 
Other1,213 1,196 
Total other assets$4,770 $3,704 
Accrued and Other Current Liabilities
Accrued and Other Current Liabilities
(In thousands)March 31, 2021December 31, 2020
Payroll and related expenses$10,540 $8,230 
Accrued interest7,721 9,327 
Contract termination fees5,311 5,344 
Asset retirement obligation(1)
3,003 3,041 
Professional services1,604 994 
Ginkgo partnership payments obligation878 878 
Tax-related liabilities639 656 
Other2,425 2,237 
Total accrued and other current liabilities$32,121 $30,707 
______________
(1)    The asset retirement obligation represents liabilities incurred but not yet discharged in connection with our 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.
Other Liabilities
Other noncurrent liabilities
(In thousands)March 31, 2021December 31, 2020
Liability for unrecognized tax benefit$7,551 $7,496 
Ginkgo partnership payments obligation, net of current portion7,461 7,277 
Liability in connection with acquisition of equity-method investment7,216 6,771 
Contract liabilities, net of current portion111 111 
Other128 1,099 
Total other noncurrent liabilities$22,467 $22,754 
XML 44 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurement (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy:

(In thousands)March 31, 2021December 31, 2020
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Liabilities
Foris Convertible Note (LSA Amendment)$— $— $379,439 $379,439 $— $— $123,164 $123,164 
Senior Convertible Notes— — 54,757 54,757 — — 53,387 53,387 
Embedded derivatives bifurcated from debt instruments— — 188 188 — — 247 247 
Freestanding derivative instruments issued in connection with other debt and equity instruments— — 31,196 31,196 — — 8,451 8,451 
Total liabilities measured and recorded at fair value$— $— $465,580 $465,580 $— $— $185,249 $185,249 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation For the three months ended March 31, 2021, the Company recorded a $70.5 million loss from change in fair value of debt in connection with fair value remeasurement of the Senior Convertible Notes, as follows:
In thousands
Fair value at December 31, 2020$53,387 
Loss from change in fair value70,510 
Less: principal converted into common stock(20,000)
Less: fair value adjustment extinguished upon conversion of debt principal(49,140)
Fair value at March 31, 2021$54,757 
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation
The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3):
(In thousands)Derivative Liability
Balance at December 31, 2020$8,698 
Change in fair value of derivative instruments22,745 
Derecognition on settlement or extinguishment(59)
Balance at March 31, 2021$31,384 
Fair Value Measurement Inputs and Valuation Techniques Input assumptions for these freestanding instruments are as follows:
Range for the Period
Input assumptions for liability classified warrants:March 31, 2021December 31, 2020
Fair value of common stock on issue date
$19.10 – $19.10
$2.56 – $6.18
Exercise price of warrants
$2.87 – $2.87
$2.87 – $3.25
Expected volatility
114% – 114%
94% – 117%
Risk-free interest rate
0.16% – 0.16%
0.13% – 1.58%
Expected term in years
2 – 2
1 – 2
Dividend yield0.0 %0.0 %
XML 45 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Debt (Tables)
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Schedule of Debt
Net carrying amounts of debt are as follows:
March 31, 2021December 31, 2020
(In thousands)PrincipalUnaccreted Debt DiscountChange in Fair ValueNetPrincipalUnaccreted Debt DiscountChange in Fair ValueNet
Convertible notes payable
Senior convertible notes$10,020 $— $44,737 $54,757 $30,020 $— $23,367 $53,387 
Related party convertible notes payable
Foris convertible note50,041 — 329,398 379,439 50,041 — 73,123 123,164 
Loans payable and credit facilities
Schottenfeld notes— — — — 12,500 (240)— 12,260 
Nikko notes2,737 (725)— 2,012 2,802 (759)— 2,043 
Ginkgo note12,000 — — 12,000 12,000 — — 12,000 
Other loans payable1,009 — — 1,009 1,227 — — 1,227 
15,746 (725)— 15,021 28,529 (999)— 27,530 
Related party loans payable
Foris note5,000 — — 5,000 5,000 — — 5,000 
DSM notes10,000 (4,254)— 5,746 33,000 (2,443)— 30,557 
Naxyris note23,914 (412)— 23,502 23,914 (493)— 23,421 
38,914 (4,666)— 34,248 61,914 (2,936)— 58,978 
Total debt$114,721 $(5,391)$374,135 483,465 $170,504 $(3,935)$96,490 263,059 
Less: current portion(55,904)(77,437)
Long-term debt, net of current portion$427,561 $185,622 
Schedule of Long-term Debt Instruments
Future minimum payments under the Company's debt agreements as of March 31, 2021 are as follows:
(In thousands)Convertible NotesLoans
Payable and Credit Facilities
Related Party Convertible NotesRelated Party Loans Payable and Credit FacilitiesTotal
2021 (Remaining Nine Months)$11,189 $2,260 $— $2,782 $16,231 
2022— 13,268 59,578 42,379 115,225 
2023— 399 — — 399 
2024— 398 — — 398 
2025— 397 — — 397 
Thereafter— 1,473 — — 1,473 
Total future minimum payments11,189 18,195 59,578 45,161 134,123 
Less: amount representing interest(1,169)(2,449)(9,537)(6,247)(19,402)
Present value of minimum debt payments10,020 15,746 50,041 38,914 114,721 
Less: current portion of debt principal(10,020)(1,280)— — (11,300)
Noncurrent portion of debt principal$— $14,466 $50,041 $38,914 $103,421 
XML 46 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Deficit (Tables)
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Schedule of Stockholders' Equity Note, Warrants or Rights The following table summarizes warrants outstanding at March 31, 2021:
TransactionNumber Outstanding as of March 31, 2021Exercise Price per Share as of March 31, 2021
Blackwell and Silverback warrants1,000,000 $3.25 
January 2020 warrant exercise right shares4,209,608 $2.87 
April 2019 PIPE warrants1,381,940 
$4.76/$5.02
Naxyris LSA warrants2,000,000 $2.87 
October 2019 Naxyris warrant2,000,000 $3.87 
May 2019 6.50% Note Exchange warrants960,225 $2.87 
May 2017 cash warrants1,863,056 $2.87 
May 2017 dilution warrants3,085,893 $0.00 
August 2017 dilution warrants3,028,983 $0.00 
July 2015 related party debt exchange58,690 $0.15 
Other1,406 $160.05 
19,589,801 
XML 47 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table presents the calculation of basic and diluted loss per share:
Three Months Ended March 31,
(In thousands, except shares and per share amounts)20212020
Numerator:
Net loss attributable to Amyris, Inc.$(291,251)$(87,844)
Less: losses allocated to participating securities2,099 1,087 
Net loss attributable to Amyris, Inc. common stockholders, basic and diluted$(289,152)$(86,757)
Denominator:
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted267,733,555 155,065,635 
Loss per share, basic and diluted$(1.08)$(0.56)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive:
Three Months Ended March 31,
20212020
Period-end common stock warrants13,416,235 50,518,519 
Convertible promissory notes(1)
19,540,447 9,217,185 
Period-end stock options to purchase common stock6,205,576 5,578,264 
Period-end restricted stock units6,653,640 5,298,639 
Period-end preferred stock1,943,661 1,943,661 
Total potentially dilutive securities excluded from computation of diluted loss per share47,759,559 72,556,268 
______________
(1)    The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.
XML 48 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition and Contract Assets and Liabilities (Tables)
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer:
Three Months Ended March 31,
(In thousands)20212020
Renewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotalRenewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotal
United States$20,090 $— $250 $20,340 $11,944 $— $— $11,944 
Europe2,972 143,800 2,346 149,118 3,242 5,161 3,356 11,759 
Asia4,405 2,284 6,689 2,018 — 2,759 4,777 
Brazil313 313 577 — — 577 
Other399 399 73 — — 73 
$28,179 $143,800 $4,880 $176,859 $17,854 $5,161 $6,115 $29,130 

The following table presents revenue by major product and service, as well as by customer type:
Three Months Ended March 31,
(In thousands)20212020
Renewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotalRenewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotal
Consumer$15,653 $— $— $15,653 $9,065 $— $— $9,065 
Ingredients12,526 143,800 — 156,326 8,789 5,161 — 13,950 
Research and development— — 4,880 4,880 — — 6,115 6,115 
$28,179 $143,800 $4,880 $176,859 $17,854 $5,161 $6,115 $29,130 
Revenue in Connection with Significant Revenue Agreement
In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2020 Form 10-K), the Company recognized the following revenue for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
(In thousands)20212020
Renewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotalRenewable ProductsLicenses and RoyaltiesGrants and CollaborationsTotal
DSM - related party$1,662 $143,612 $2,000 $147,274 $49 $3,750 $3,018 $6,817 
Sephora4,441 — — 4,441 4,446 — — 4,446 
Yifan— — 2,284 2,284 — — 2,709 2,709 
Firmenich379 188 205 772 1,229 1,411 161 2,801 
Givaudan210 — — 210 2,109 — — 2,109 
Subtotal revenue from significant revenue agreements6,692 143,800 4,489 154,981 7,833 5,161 5,888 18,882 
Revenue from all other customers21,487 — 391 21,878 10,021 — 227 10,248 
Total revenue from all customers$28,179 $143,800 $4,880 $176,859 $17,854 $5,161 $6,115 $29,130 
Contract with Customer, Asset and Liability
The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers:
(In thousands)March 31, 2021December 31, 2020
Accounts receivable, net$27,036 $32,846 
Accounts receivable - related party, net$391 $12,110 
Contract assets$6,589 $4,178 
Contract assets - related party$2,000 $1,203 
Contract liabilities$6,163 $4,468 
Contract liabilities, noncurrent(1)
$111 $111 

(1)As of March 31, 2021 and December 31, 2020, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2021.
(In thousands)As of March 31, 2021
Remaining 2021$143 
20223,103 
20231,430 
2024 and thereafter429 
Total from all customers$5,105 
XML 49 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Schedule of Related Party Debt
Related party debt was as follows:
March 31, 2021December 31, 2020
In thousandsPrincipalUnaccreted Debt DiscountChange in Fair ValueNetPrincipalUnaccreted Debt DiscountChange in Fair ValueNet
Foris notes$55,041 $— $329,398 $384,439 $55,041 $— $73,123 $128,164 
DSM notes10,000 (4,254)— 5,746 33,000 (2,443)— 30,557 
Naxyris note23,914 (412)— 23,502 23,914 (493)— 23,421 
$88,955 $(4,666)$329,398 $413,687 $111,955 $(2,936)$73,123 $182,142 
Schedule of Related Party Accounts Receivables
Related party accounts receivable, contract assets and accounts payable were as follows:

(In thousands)March 31, 2021December 31, 2020
Accounts receivable - related party$391 $12,110 
Contract assets - related party$2,000 $1,203 
Accounts payable$10,302 $5,011 
XML 50 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation (Tables)
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity
The Company’s stock option activity and related information for the three months ended March 31, 2021 was as follows:
Quantity of Stock OptionsWeighted-
average
Exercise
Price
Weighted-average
Remaining
Contractual
Life, in Years
Aggregate
Intrinsic
Value, in Thousands
Outstanding - December 31, 20206,502,096 $7.64 7.6$8,875 
Granted131,408 $14.52 
Exercised(375,390)$5.12 
Forfeited or expired(52,538)$38.21 
Outstanding - March 31, 20216,205,576 $7.68 7.4$82,615 
Vested or expected to vest after March 31, 20215,697,447 $7.91 7.3$75,493 
Exercisable at March 31, 20211,259,029 $18.19 5.8$12,884 
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
The Company’s restricted stock units (RSUs) activity and related information for the three months ended March 31, 2021 was as follows:
Quantity of Restricted Stock UnitsWeighted-average Grant-date Fair ValueWeighted-average Remaining Contractual Life, in Years
Outstanding - December 31, 20207,043,909 $4.18 1.5
Awarded345,903 $13.53 
Released(496,492)$4.34 
Forfeited(239,680)$4.22 
Outstanding - March 31, 20216,653,640 $4.65 1.4
Vested or expected to vest after March 31, 20216,082,165 $4.65 1.3
Share-based Payment Arrangement, Expensed and Capitalized, Amount
Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three months ended March 31, 2021 and 2020 is reflected in the condensed consolidated statements of operations as follows:
Three Months Ended March 31,
(In thousands)20212020
Cost of products sold$63 $— 
Research and development1,062 1,065 
Sales, general and administrative3,156 2,439 
Total stock-based compensation expense$4,281 $3,504 
XML 51 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated deficit $ (2,377,943) $ (2,086,692)
XML 52 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Balance at Beginning of Year $ 137 $ 45
Provisions 17 0
Write-offs, Net 0 0
Balance at End of Period $ 154 $ 45
XML 53 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Raw materials $ 12,185 $ 11,800
Work-in-process 8,702 10,760
Finished goods 26,752 20,302
Inventories $ 47,639 $ 42,862
XML 54 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Deferred Cost of Products Sold - Related Party (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Deferred cost of products sold - related party $ 5,220 $ 9,801
Deferred cost of products sold, noncurrent - related party 9,391 9,939
Total $ 14,611 $ 19,740
XML 55 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 126 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]        
Deferred cost of products sold, amortization     $ 4,900  
Right-of-use assets under operating leases, net $ 9,333   9,333 $ 10,136
Operating lease liability 13,719   13,719 15,000
Operating lease expense 1,800 $ 1,500    
Lease, cost 200 300    
Finance lease, right-of-use asset amortization $ 5,300   $ 5,300 $ 4,600
Koninklijke DSM N.V (DSM)        
Property, Plant and Equipment [Line Items]        
Supply agreement term (years) 5 years      
Deferred cost of products sold, amortization $ 1,600 $ 100    
Minimum        
Property, Plant and Equipment [Line Items]        
Operating lease remaining lease term (years) 1 year   1 year  
Operating lease renewal term (years) 1 year   1 year  
Maximum        
Property, Plant and Equipment [Line Items]        
Operating lease remaining lease term (years) 5 years   5 years  
Operating lease renewal term (years) 5 years   5 years  
XML 56 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Prepayments, advances and deposits $ 13,453 $ 6,637
Non-inventory production supplies 3,364 3,989
Recoverable taxes from Brazilian government entities 1,020 1,063
Other 1,409 1,414
Total prepaid expenses and other current assets $ 19,246 $ 13,103
XML 57 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 112,730 $ 113,110
Less: accumulated depreciation and amortization (80,797) (80,235)
Property, plant and equipment, net 31,933 32,875
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 49,880 50,415
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 44,800 45,197
Computers and software    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 7,362 6,741
Furniture and office equipment, vehicles and land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 3,450 3,507
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 7,238 $ 7,250
XML 58 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Depreciation and Amortization (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Depreciation and amortization expense $ 2,114 $ 1,719
XML 59 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash paid for operating lease liabilities, in thousands $ 1,185 $ 1,893
Right-of-use assets obtained in exchange for new operating lease obligations, in thousands $ 0 $ 0
Weighted-average remaining lease term 2 years 8 months 12 days 3 years 2 months 12 days
Weighted-average discount rate 18.00% 18.00%
XML 60 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Maturities of Financing and Operating Leases (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Financing Leases    
2021 (Remaining Nine Months) $ 3,491  
2022 0  
2023 0  
2024 0  
2025 0  
Total lease payments 3,491  
Less: amount representing interest (233)  
Total lease liability 3,258  
Current lease liability 3,258 $ 4,170
Noncurrent lease liability 0  
Operating Leases    
2021 (Remaining Nine Months) 5,644  
2022 7,655  
2023 3,320  
2024 150  
2025 0  
Total lease payments 16,769  
Less: amount representing interest (3,050)  
Total lease liability 13,719 15,000
Current lease liability 5,510 5,226
Noncurrent lease liability 8,209 $ 9,732
2021 (Remaining Nine Months) 9,135  
2022 7,655  
2023 3,320  
2024 150  
2025 0  
Total lease payments 20,260  
Less: amount representing interest (3,283)  
Total lease liability 16,977  
Current lease liability 8,768  
Noncurrent lease liability $ 8,209  
XML 61 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Other Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Equity-method investment $ 3,431 $ 2,380
Deposits 126 128
Other 1,213 1,196
Total other assets $ 4,770 $ 3,704
XML 62 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accrued interest $ 7,721 $ 9,327
Payroll and related expenses 10,540 8,230
Contract termination fees 5,311 5,344
Asset retirement obligation 3,003 3,041
Professional services 1,604 994
Ginkgo partnership payments obligation 878 878
Tax-related liabilities 639 656
Other 2,425 2,237
Total accrued and other current liabilities $ 32,121 $ 30,707
XML 63 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Details - Other Noncurrent Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Liability for unrecognized tax benefit $ 7,551 $ 7,496
Ginkgo partnership payments obligation, net of current portion 7,461 7,277
Liability in connection with acquisition of equity-method investment 7,216 6,771
Contract liabilities, net of current portion 111 111
Other 128 1,099
Total other noncurrent liabilities $ 22,467 $ 22,754
XML 64 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Embedded derivatives bifurcated from debt instruments $ 188 $ 247
Freestanding derivative instruments issued in connection with other debt and equity instruments 31,196 8,451
Total liabilities measured and recorded at fair value 465,580 185,249
Foris Convertible Note (LSA Amendment)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of debt 379,439 123,164
Senior Convertible Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of debt 54,757 53,387
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Embedded derivatives bifurcated from debt instruments 0 0
Freestanding derivative instruments issued in connection with other debt and equity instruments 0 0
Total liabilities measured and recorded at fair value 0 0
Level 1 | Foris Convertible Note (LSA Amendment)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of debt 0 0
Level 1 | Senior Convertible Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of debt 0 0
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Embedded derivatives bifurcated from debt instruments 0 0
Freestanding derivative instruments issued in connection with other debt and equity instruments 0 0
Total liabilities measured and recorded at fair value 0 0
Level 2 | Foris Convertible Note (LSA Amendment)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of debt 0 0
Level 2 | Senior Convertible Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of debt 0 0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Embedded derivatives bifurcated from debt instruments 188 247
Freestanding derivative instruments issued in connection with other debt and equity instruments 31,196 8,451
Total liabilities measured and recorded at fair value 465,580 185,249
Level 3 | Foris Convertible Note (LSA Amendment)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of debt 379,439 123,164
Level 3 | Senior Convertible Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of debt $ 54,757 $ 53,387
XML 65 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurement - Fair Value of Debt — Foris Convertible Note (LSA Amendment) (Details)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
$ / shares
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Principal $ 114,721   $ 170,504
Long term debt, fair value 483,465   263,059
Loss from change in fair value of debt (326,785) $ (16,503)  
Convertible notes payable      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Principal  
Long term debt, fair value  
Related party convertible notes payable      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Principal  
Long term debt, fair value  
Foris Convertible Note (LSA Amendment)      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Loss from change in fair value of debt $ 256,300    
Foris Convertible Note (LSA Amendment) | Convertible notes payable      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares $ 3.00    
Foris Convertible Note (LSA Amendment) | Convertible notes payable | Measurement Input, Stock Price      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Measurement input   19.10  
Foris Convertible Note (LSA Amendment) | Convertible notes payable | Measurement Input, Discount Rate      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Measurement input   0.10  
Foris Convertible Note (LSA Amendment) | Convertible notes payable | Risk-free Interest Rate      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Measurement input   0.0009  
Foris Convertible Note (LSA Amendment) | Convertible notes payable | Stock Price Volatility      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Measurement input   0.45  
Foris Convertible Note (LSA Amendment) | Convertible notes payable | Probability of Change in Control      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Measurement input   0.05  
Foris Convertible Note (LSA Amendment) | Related party convertible notes payable      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Principal $ 50,041   50,041
Long term debt, fair value $ 379,439   $ 123,164
XML 66 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurement - Fair Value of Debt — Senior Convertible Notes (Details)
$ / shares in Units, $ in Thousands
Mar. 31, 2021
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Principal $ 114,721 $ 170,504
Long term debt, fair value 483,465 263,059
Convertible notes payable    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Principal
Long term debt, fair value
Senior convertible notes | Convertible notes payable    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Principal 10,020 30,020
Long term debt, fair value $ 54,757 $ 53,387
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares $ 3.50  
Senior convertible notes | Convertible notes payable | Measurement Input, Stock Price    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Measurement input 19.10  
Senior convertible notes | Convertible notes payable | Measurement Input, Discount Rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Measurement input 2.10  
Senior convertible notes | Convertible notes payable | Risk-free Interest Rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Measurement input 0.0002  
Senior convertible notes | Convertible notes payable | Stock Price Volatility    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Measurement input 0.45  
Senior convertible notes | Convertible notes payable | Probability of Change in Control    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Measurement input 0  
XML 67 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurement - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Less: fair value adjustment extinguished upon conversion of debt principal $ (49,140)
Long-term Debt  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Fair value, beginning balance 53,387
Loss from change in fair value 70,510
Less: principal converted into common stock (20,000)
Fair value, ending balance $ 54,757
XML 68 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Derecognition on settlement or extinguishment $ (49,140)
Debt-related Derivative Liability | Level 3  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Fair value, beginning balance 8,698
Change in fair value of derivative instruments 22,745
Derecognition on settlement or extinguishment (59)
Fair value, ending balance $ 31,384
XML 69 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurement - Freestanding Derivative Instruments (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended
Feb. 28, 2020
Mar. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Exercise price per share (in dollars per share)   $ 3.25
Warrants Issued In Connection with September 2019 and November 2019 Shottenfeld Notes    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Class of warrant or right, number of securities called by warrants or rights (in shares) 1.9  
Exercise price per share (in dollars per share) $ 2.87  
Class of warrant or right, term 2 years  
Warrants and rights outstanding, derivative liability   $ 31.2
Fair value adjustment of warrants   $ 22.7
XML 70 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details)
Mar. 31, 2021
Dec. 31, 2020
Expected Diviend Yield    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 0.000 0.000
Minimum | Share Price    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 19.10 2.56
Minimum | Measurement Input, Exercise Price    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 2.87 2.87
Minimum | Stock Price Volatility    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 1.14 0.94
Minimum | Risk-free Interest Rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 0.000016 0.0013
Minimum | Measurement Input, Expected Term    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 2 1
Maximum | Share Price    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 19.10 6.18
Maximum | Measurement Input, Exercise Price    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 2.87 3.25
Maximum | Stock Price Volatility    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 1.14 1.17
Maximum | Risk-free Interest Rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 0.000016 0.0158
Maximum | Measurement Input, Expected Term    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Embedded derivative liability, measurement input 2 2
XML 71 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurement - Financial Assets and Liabilities (Details) - USD ($)
$ in Millions
Mar. 31, 2021
Dec. 31, 2020
Fair Value Disclosures [Abstract]    
Combined debt amount $ 49.3 $ 86.5
Debt instrument fair value disclosure $ 51.1 $ 83.3
XML 72 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Debt Components (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Principal $ 114,721 $ 170,504
Unaccreted debt discount (5,391) (3,935)
Debt change in fair value gain loss 374,135 96,490
Net 483,465 263,059
Less: current portion (55,904) (77,437)
Long-term debt, net of current portion 427,561 185,622
Convertible notes payable    
Debt Instrument [Line Items]    
Principal
Unaccreted debt discount
Debt change in fair value gain loss
Net
Convertible notes payable | Senior convertible notes    
Debt Instrument [Line Items]    
Principal 10,020 30,020
Unaccreted debt discount 0 0
Debt change in fair value gain loss 44,737 23,367
Net 54,757 53,387
Related party convertible notes payable    
Debt Instrument [Line Items]    
Principal
Unaccreted debt discount
Debt change in fair value gain loss
Net
Related party convertible notes payable | Foris Convertible Note (LSA Amendment)    
Debt Instrument [Line Items]    
Principal 50,041 50,041
Unaccreted debt discount 0 0
Debt change in fair value gain loss 329,398 73,123
Net 379,439 123,164
Loans payable and credit facilities    
Debt Instrument [Line Items]    
Principal 15,746 28,529
Unaccreted debt discount (725) (999)
Debt change in fair value gain loss 0 0
Net 15,021 27,530
Loans payable and credit facilities | Schottenfeld notes    
Debt Instrument [Line Items]    
Principal 0 12,500
Unaccreted debt discount 0 (240)
Debt change in fair value gain loss 0 0
Net 0 12,260
Loans payable and credit facilities | Nikko notes    
Debt Instrument [Line Items]    
Principal 2,737 2,802
Unaccreted debt discount (725) (759)
Debt change in fair value gain loss 0 0
Net 2,012 2,043
Loans payable and credit facilities | Ginkgo note    
Debt Instrument [Line Items]    
Principal 12,000 12,000
Unaccreted debt discount 0 0
Debt change in fair value gain loss 0 0
Net 12,000 12,000
Loans payable and credit facilities | Other loans payable    
Debt Instrument [Line Items]    
Principal 1,009 1,227
Unaccreted debt discount 0 0
Debt change in fair value gain loss 0 0
Net 1,009 1,227
Related party loans payable    
Debt Instrument [Line Items]    
Principal 38,914 61,914
Unaccreted debt discount (4,666) (2,936)
Debt change in fair value gain loss 0 0
Net 34,248 58,978
Related party loans payable | Foris note    
Debt Instrument [Line Items]    
Principal 5,000 5,000
Unaccreted debt discount 0 0
Debt change in fair value gain loss 0 0
Net 5,000 5,000
Related party loans payable | DSM notes    
Debt Instrument [Line Items]    
Principal 10,000 33,000
Unaccreted debt discount (4,254) (2,443)
Debt change in fair value gain loss 0 0
Net 5,746 30,557
Related party loans payable | Naxyris note    
Debt Instrument [Line Items]    
Principal 23,914 23,914
Unaccreted debt discount (412) (493)
Debt change in fair value gain loss 0 0
Net $ 23,502 $ 23,421
XML 73 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Future Minimum Payments (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Debt Instrument [Line Items]  
2021 (Remaining Nine Months) $ 16,231
2022 115,225
2023 399
2024 398
2025 397
Thereafter 1,473
Total future minimum payments 134,123
Less: amount representing interest (19,402)
Present value of minimum debt payments 114,721
Less: current portion of debt principal (11,300)
Noncurrent portion of debt principal 103,421
Convertible notes payable  
Debt Instrument [Line Items]  
2021 (Remaining Nine Months) 11,189
2022 0
2023 0
2024 0
2025 0
Thereafter 0
Total future minimum payments 11,189
Less: amount representing interest (1,169)
Present value of minimum debt payments 10,020
Less: current portion of debt principal (10,020)
Noncurrent portion of debt principal 0
Loans Payable and Credit Facilities  
Debt Instrument [Line Items]  
2021 (Remaining Nine Months) 2,260
2022 13,268
2023 399
2024 398
2025 397
Thereafter 1,473
Total future minimum payments 18,195
Less: amount representing interest (2,449)
Present value of minimum debt payments 15,746
Less: current portion of debt principal (1,280)
Noncurrent portion of debt principal 14,466
Related party convertible notes payable  
Debt Instrument [Line Items]  
2021 (Remaining Nine Months) 0
2022 59,578
2023 0
2024 0
2025 0
Thereafter 0
Total future minimum payments 59,578
Less: amount representing interest (9,537)
Present value of minimum debt payments 50,041
Less: current portion of debt principal 0
Noncurrent portion of debt principal 50,041
Related Party Loans Payable and Credit Facilities  
Debt Instrument [Line Items]  
2021 (Remaining Nine Months) 2,782
2022 42,379
2023 0
2024 0
2025 0
Thereafter 0
Total future minimum payments 45,161
Less: amount representing interest (6,247)
Present value of minimum debt payments 38,914
Less: current portion of debt principal 0
Noncurrent portion of debt principal $ 38,914
XML 74 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Senior Convertible Notes (Details) - USD ($)
3 Months Ended
Mar. 01, 2021
Feb. 04, 2021
Mar. 31, 2021
Mar. 31, 2020
Debt Instrument [Line Items]        
Gain (loss) on extinguishment of debt $ (28,900,000)   $ 27,313,000 $ 27,319,000
Senior convertible notes | Convertible notes payable        
Debt Instrument [Line Items]        
Debt instrument, face amount   $ 20,000,000.0    
Conversion of convertible securities   $ 5,700,000    
Shares to be returned per agreement (in shares)   2,600,000 2,600,000  
Shares issued for conversion settlement (in shares)   3,100,000    
Gain (loss) on extinguishment of debt   $ 31,900,000    
XML 75 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Schottfield Debt (Details) - USD ($)
$ in Thousands, shares in Millions
3 Months Ended
Mar. 01, 2021
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Debt Instrument [Line Items]        
Principal   $ 114,721   $ 170,504
Conversion of stock, shares issued 4.1      
Loss upon extinguishment of debt $ 28,900 $ (27,313) $ (27,319)  
Schottenfeld Exchange Agreement        
Debt Instrument [Line Items]        
Principal $ 12,500      
XML 76 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - DSM Amendments and Repayment (Details)
3 Months Ended
Dec. 28, 2017
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 17, 2019
USD ($)
installment
Debt Instrument [Line Items]        
Principal   $ 114,721,000 $ 170,504,000  
Number of installments | installment       3
The 2019 DSM Credit Agreement | DSM - related party        
Debt Instrument [Line Items]        
Line of credit facility, maximum borrowing capacity       $ 8,000,000.0
DSM Credit Agreement        
Debt Instrument [Line Items]        
Line of credit facility, maximum borrowing capacity $ 25,000,000.0      
Proceeds from long-term lines of credit $ 25,000,000      
Debt instrument, interest rate, stated percentage 10.00%     12.50%
DSM Credit Agreement | Unsecured Debt        
Debt Instrument [Line Items]        
Line of credit facility, maximum borrowing capacity $ 25,000,000     $ 8,000,000
Principal   10,000,000    
Debt instrument, unamortized discount   2,500,000    
Extinguishment of debt, amount   8,000,000    
DSM Credit Agreement - March 2021 Amendment | Unsecured Debt        
Debt Instrument [Line Items]        
Principal   10,000,000    
Debt instrument, unamortized discount   2,500,000    
Repayments of debt   23,000,000    
DSM Credit Agreement - March 2021 Amendment Related To 25 Million Dollar Note | Unsecured Debt        
Debt Instrument [Line Items]        
Extinguishment of debt, amount   $ 15,000,000    
XML 77 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Mezzanine Equity (Details Textual) - Gates Foundation Purchase Agreement
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 31, 2021
USD ($)
$ / shares
Subsidiary, Sale of Stock [Line Items]  
Stock price (in dollars per share) | $ / shares $ 17.10
Compound annual return (percentage) 10.00%
Research and development obligation, remaining amount | $ $ 0.3
XML 78 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Deficit - Warrant Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 19,589,801  
Exercise price per share (in dollars per share) $ 3.25  
Exercises (in shares) (24,800,000)  
Exercise price per share of warrant exercised (in dollars per share) $ 3.06  
Proceeds from exercises of warrants $ 32,219 $ 3,332
Additional warrants issued (in shares) 21,600,000  
Blackwell and Silverback warrants    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 1,000,000  
January 2020 warrant exercise right shares    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 4,209,608  
Exercise price per share (in dollars per share) $ 2.87  
April 2019 PIPE warrants    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 1,381,940  
April 2019 PIPE warrants | Minimum    
Class of Warrant or Right [Line Items]    
Exercise price per share (in dollars per share) $ 4.76  
April 2019 PIPE warrants | Maximum    
Class of Warrant or Right [Line Items]    
Exercise price per share (in dollars per share) $ 5.02  
Naxyris LSA warrants    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 2,000,000  
Exercise price per share (in dollars per share) $ 2.87  
October 2019 Naxyris warrant    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 2,000,000  
Exercise price per share (in dollars per share) $ 3.87  
May 2019 6.50% Note Exchange warrants    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 960,225  
Exercise price per share (in dollars per share) $ 2.87  
May 2017 cash warrants    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 1,863,056  
Exercise price per share (in dollars per share) $ 2.87  
May 2017 dilution warrants    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 3,085,893  
Exercise price per share (in dollars per share) $ 0.00  
August 2017 dilution warrants    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 3,028,983  
Exercise price per share (in dollars per share) $ 0.00  
July 2015 related party debt exchange    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 58,690  
Exercise price per share (in dollars per share) $ 0.15  
Other    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 1,406  
Exercise price per share (in dollars per share) $ 160.05  
XML 79 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share Attributable to Common Shareholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Numerator:    
Net loss attributable to Amyris, Inc. $ (291,251) $ (87,844)
Less: losses allocated to participating securities 2,099 1,087
Net Income (Loss) Available to Common Stockholders, Basic, Total $ (289,152) $ (86,757)
Denominator:    
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares) 267,733,555 155,065,635
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares) 267,733,555 155,065,635
Loss per share attributable to common stockholders, diluted (in dollars per share) $ (1.08) $ (0.56)
Loss per share attributable to common stockholders, basic (in dollars per share) $ (1.08) $ (0.56)
XML 80 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share Attributable to Common Shareholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) 47,759,559,000 72,556,268,000
Period-end common stock warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) 13,416,235,000 50,518,519,000
Convertible promissory notes    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) 19,540,447,000 9,217,185,000
Period-end stock options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) 6,205,576,000 5,578,264,000
Period-end restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) 6,653,640,000 5,298,639,000
Period-end preferred stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) 1,943,661,000 1,943,661,000
XML 81 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - Guarantor Arrangements (Details)
$ in Millions
Mar. 31, 2021
USD ($)
Aprinnova JV [Member]  
Loss Contingencies [Line Items]  
Percentage of venture owned 10.00%
Nikko notes | Loans payable and credit facilities  
Loss Contingencies [Line Items]  
Debt instrument, face amount $ 3.9
XML 82 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Revenue $ 176,859 $ 29,130
Consumer    
Disaggregation of Revenue [Line Items]    
Revenue 15,653 9,065
Ingredients    
Disaggregation of Revenue [Line Items]    
Revenue 156,326 13,950
Research and development    
Disaggregation of Revenue [Line Items]    
Revenue 4,880 6,115
United States    
Disaggregation of Revenue [Line Items]    
Revenue 20,340 11,944
Europe    
Disaggregation of Revenue [Line Items]    
Revenue 149,118 11,759
Asia    
Disaggregation of Revenue [Line Items]    
Revenue 6,689 4,777
Brazil    
Disaggregation of Revenue [Line Items]    
Revenue 313 577
Other    
Disaggregation of Revenue [Line Items]    
Revenue 399 73
Renewable Products    
Disaggregation of Revenue [Line Items]    
Revenue 28,179 17,854
Renewable Products | Consumer    
Disaggregation of Revenue [Line Items]    
Revenue 15,653 9,065
Renewable Products | Ingredients    
Disaggregation of Revenue [Line Items]    
Revenue 12,526 8,789
Renewable Products | Research and development    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Renewable Products | United States    
Disaggregation of Revenue [Line Items]    
Revenue 20,090 11,944
Renewable Products | Europe    
Disaggregation of Revenue [Line Items]    
Revenue 2,972 3,242
Renewable Products | Asia    
Disaggregation of Revenue [Line Items]    
Revenue 4,405 2,018
Renewable Products | Brazil    
Disaggregation of Revenue [Line Items]    
Revenue 313 577
Renewable Products | Other    
Disaggregation of Revenue [Line Items]    
Revenue 399 73
Licenses and Royalties    
Disaggregation of Revenue [Line Items]    
Revenue 143,800 5,161
Licenses and Royalties | Consumer    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Licenses and Royalties | Ingredients    
Disaggregation of Revenue [Line Items]    
Revenue 143,800 5,161
Licenses and Royalties | Research and development    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Licenses and Royalties | United States    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Licenses and Royalties | Europe    
Disaggregation of Revenue [Line Items]    
Revenue 143,800 5,161
Licenses and Royalties | Asia    
Disaggregation of Revenue [Line Items]    
Revenue 0
Licenses and Royalties | Brazil    
Disaggregation of Revenue [Line Items]    
Revenue 0
Licenses and Royalties | Other    
Disaggregation of Revenue [Line Items]    
Revenue 0
Grants and Collaborations    
Disaggregation of Revenue [Line Items]    
Revenue 4,880 6,115
Grants and Collaborations | Consumer    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Grants and Collaborations | Ingredients    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Grants and Collaborations | Research and development    
Disaggregation of Revenue [Line Items]    
Revenue 4,880 6,115
Grants and Collaborations | United States    
Disaggregation of Revenue [Line Items]    
Revenue 250 0
Grants and Collaborations | Europe    
Disaggregation of Revenue [Line Items]    
Revenue 2,346 3,356
Grants and Collaborations | Asia    
Disaggregation of Revenue [Line Items]    
Revenue 2,284 2,759
Grants and Collaborations | Brazil    
Disaggregation of Revenue [Line Items]    
Revenue 0
Grants and Collaborations | Other    
Disaggregation of Revenue [Line Items]    
Revenue $ 0
XML 83 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Revenue $ 176,859 $ 29,130
Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 154,981 18,882
DSM - related party | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 147,274 6,817
Sephora | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 4,441 4,446
Yifan | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 2,284 2,709
Firmenich | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 772 2,801
Givaudan | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 210 2,109
Revenue from all other customers | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 21,878 10,248
Renewable Products    
Disaggregation of Revenue [Line Items]    
Revenue 28,179 17,854
Renewable Products | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 6,692 7,833
Renewable Products | DSM - related party | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 1,662 49
Renewable Products | Sephora | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 4,441 4,446
Renewable Products | Yifan | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Renewable Products | Firmenich | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 379 1,229
Renewable Products | Givaudan | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 210 2,109
Renewable Products | Revenue from all other customers | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 21,487 10,021
Licenses and Royalties    
Disaggregation of Revenue [Line Items]    
Revenue 143,800 5,161
Licenses and Royalties | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 143,800 5,161
Licenses and Royalties | DSM - related party | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 143,612 3,750
Licenses and Royalties | Sephora | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Licenses and Royalties | Yifan | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Licenses and Royalties | Firmenich | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 188 1,411
Licenses and Royalties | Givaudan | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Licenses and Royalties | Revenue from all other customers | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Grants and Collaborations    
Disaggregation of Revenue [Line Items]    
Revenue 4,880 6,115
Grants and Collaborations | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 4,489 5,888
Grants and Collaborations | DSM - related party | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 2,000 3,018
Grants and Collaborations | Sephora | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Grants and Collaborations | Yifan | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 2,284 2,709
Grants and Collaborations | Firmenich | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 205 161
Grants and Collaborations | Givaudan | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Grants and Collaborations | Revenue from all other customers | Significant Revenue Agreement    
Disaggregation of Revenue [Line Items]    
Revenue $ 391 $ 227
XML 84 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]    
Accounts receivable, net $ 27,036 $ 32,846
Accounts receivable - related party, net 391 12,110
Contract assets 6,589 4,178
Contract assets - related party 2,000 1,203
Contract liabilities 6,163 4,468
Contract liabilities, noncurrent $ 111 $ 111
XML 85 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, Amount $ 5,105
Constrained variable consideration amount $ 297,800
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, expected timing of satisfaction, period 9 months
Revenue, remaining performance obligation, Amount $ 143
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year
Revenue, remaining performance obligation, Amount $ 3,103
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year
Revenue, remaining performance obligation, Amount $ 1,430
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, expected timing of satisfaction, period
Revenue, remaining performance obligation, Amount $ 429
XML 86 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition and Contract Assets and Liabilities - DSM License Agreement and Contract Asset (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Revenue $ 176,859 $ 29,130
DSM - related party | Maximum    
Disaggregation of Revenue [Line Items]    
Contingent considerations, maximum 235,000  
DSM - related party | DSM License Agreement    
Disaggregation of Revenue [Line Items]    
Estimated total unconstrained transaction price $ 150,000  
Supply agreement term (years) 15 years  
DSM - related party | DSM License Agreement | License    
Disaggregation of Revenue [Line Items]    
Revenue $ 143,600  
DSM - related party | DSM License Agreement | Finished Goods Inventory    
Disaggregation of Revenue [Line Items]    
Estimated total unconstrained transaction price 1,500  
DSM - related party | DSM License Agreement | Receivables    
Disaggregation of Revenue [Line Items]    
Estimated total unconstrained transaction price 4,900  
DSM - related party | DSM License Agreement | Intellectual Property License    
Disaggregation of Revenue [Line Items]    
Estimated total unconstrained transaction price $ 143,600  
XML 87 R67.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition and Contract Assets and Liabilities - DSM Performance Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Dec. 31, 2017
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]      
Research and development   $ 23,332 $ 17,126
Research and development | DSM Performance Collabration | DSM - related party      
Disaggregation of Revenue [Line Items]      
Contingent considerations, maximum $ 1,900    
Estimated total unconstrained transaction price $ 1,200    
Contingent consideration received   1,900  
Research and development   $ 1,900  
XML 88 R68.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition and Contract Assets and Liabilities - DSM Ingredients Collaboration (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Revenue $ 176,859 $ 29,130
DSM - related party | DSM Ingredients Collaboration    
Disaggregation of Revenue [Line Items]    
Quarterly payments 2,000  
DSM - related party | DSM Ingredients Collaboration | Research and development    
Disaggregation of Revenue [Line Items]    
Revenue $ 2,000 $ 3,000
XML 89 R69.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition and Contract Assets and Liabilities - Yifan Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Including Assessed Tax $ 176,859 $ 29,130  
Contract assets 6,589   $ 4,178
Significant Revenue Agreement      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Including Assessed Tax 154,981 18,882  
Grants and Collaborations      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Including Assessed Tax 4,880 6,115  
Grants and Collaborations | Significant Revenue Agreement      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Including Assessed Tax 4,489 5,888  
Yifan | Significant Revenue Agreement      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Including Assessed Tax 2,284 2,709  
Yifan | Grants and Collaborations      
Disaggregation of Revenue [Line Items]      
Revenue from contract with customer, cumulative to date 16,600    
Contract assets 5,900    
Yifan | Grants and Collaborations | Significant Revenue Agreement      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Including Assessed Tax $ 2,284 $ 2,709  
XML 90 R70.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions - Related Party Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Related Party Transaction [Line Items]    
Principal $ 114,721 $ 170,504
Net 483,465 263,059
Related Party Debt    
Related Party Transaction [Line Items]    
Principal 88,955 111,955
Unaccreted Debt Discount (4,666) (2,936)
Change in Fair Value 329,398 73,123
Net 413,687 182,142
Foris notes | Related Party Debt | Foris note    
Related Party Transaction [Line Items]    
Principal 55,041 55,041
Unaccreted Debt Discount 0 0
Change in Fair Value 329,398 73,123
Net 384,439 128,164
DSM notes | Related Party Debt | DSM notes    
Related Party Transaction [Line Items]    
Principal 10,000 33,000
Unaccreted Debt Discount (4,254) (2,443)
Change in Fair Value 0 0
Net 5,746 30,557
Naxyris note | Related Party Debt | Naxyris note    
Related Party Transaction [Line Items]    
Principal 23,914 23,914
Unaccreted Debt Discount (412) (493)
Change in Fair Value 0 0
Net $ 23,502 $ 23,421
XML 91 R71.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Related Party Transaction [Line Items]    
Accounts payable $ 0 $ 22,689
DSM notes | Accounts receivable - related party    
Related Party Transaction [Line Items]    
Accounts receivable, unbilled, related party 391 12,110
DSM notes | Contract assets - related party    
Related Party Transaction [Line Items]    
Accounts receivable, unbilled, related party 2,000 1,203
DSM notes | Accounts payable    
Related Party Transaction [Line Items]    
Accounts payable $ 10,302 $ 5,011
XML 92 R72.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Quantity of Stock Options    
Outstanding, beginning balance (in shares) 6,502,096  
Granted (in shares) 131,408  
Exercised (in shares) (375,390)  
Forfeited or expired (in shares) (52,538)  
Outstanding, ending balance (in shares) 6,205,576 6,502,096
Vested or expected to vest (in shares) 5,697,447  
Exercisable (in shares) 1,259,029  
Weighted- average Exercise Price    
Outstanding, beginning balance (in dollars per share) $ 7.64  
Granted (in dollars per share) 14.52  
Exercised (in dollars per share) 5.12  
Forfeited or expired (in dollars per share) 38.21  
Outstanding, ending balance (in dollars per share) 7.68 $ 7.64
Vested or expected to vest (in dollars per share) 7.91  
Exercisable (in dollars per share) $ 18.19  
Weighted-average Remaining Contractual Life, in Years    
Outstanding (years) 7 years 4 months 24 days 7 years 7 months 6 days
Vested or expected to vest (years) 7 years 3 months 18 days  
Exercisable (years) 5 years 9 months 18 days  
Aggregate Intrinsic Value, in Thousands    
Outstanding (years) $ 82,615 $ 8,875
Vested or expected to vest 75,493  
Exercisable $ 12,884  
XML 93 R73.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Quantity of Restricted Stock Units    
Outstanding , beginning balance (in shares) 7,043,909  
Awarded (in shares) 345,903  
Released (in shares) (496,492)  
Forfeited (in shares) (239,680)  
Outstanding, ending balance (in shares) 6,653,640 7,043,909
Vested or expected to vest (in shares) 6,082,165  
Weighted-average Grant-date Fair Value    
Outstanding, beginning balance (in dollars per share) $ 4.18  
Awarded (in dollars per share) 13.53  
Released (in dollars per share) 4.34  
Forfeited (in dollars per share) 4.22  
Outstanding, ending balance (in dollars per share) 4.65 $ 4.18
Vested or expected to vest (in dollars per share) $ 4.65  
Weighted-average Remaining Contractual Life, in Years    
Outstanding, beginning balance (years) 1 year 4 months 24 days 1 year 6 months
Outstanding, ending balance (years) 1 year 4 months 24 days 1 year 6 months
Vested or expected to vest (years) 1 year 3 months 18 days  
XML 94 R74.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 4,281 $ 3,504
Cost of products sold    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 63 0
Research and development    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 1,062 1,065
Sales, general and administrative    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 3,156 $ 2,439
XML 95 R75.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Additional Information (Details)
$ in Millions
3 Months Ended
Mar. 31, 2021
USD ($)
shares
Employee Stock Option  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Compensation expense related to stock options and RSUs | $ $ 30.0
Weighted-average period 2 years 4 months 24 days
2020 Equity Incentive Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Automatic annual increase available for grant and issuance (in shares) 12,247,572
Automatic annual increase in shares available for grant and issuance, percentage of outstanding stock 5.00%
Equity Incentive Plan, 2010  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Automatic annual increase reserved for issuance (in shares) 42,077
Remaining number of shares reserved for issuance, maximum limit 1,666,666
XML 96 R76.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events - Primary and Secondary Offering (Details) - USD ($)
$ / shares in Units, $ in Millions
Apr. 08, 2021
Mar. 31, 2021
Dec. 31, 2020
Subsequent Event [Line Items]      
Common stock, par value (in dollars per share)   $ 0.0001 $ 0.0001
Subsequent Event      
Subsequent Event [Line Items]      
Shares issued (in dollars per share) $ 15.75    
Allotment option agreement, term 30 days    
Issuance of common stock in public offering (in shares) 8,805,345    
Purchase price of sale of stock $ 130.7    
Subsequent Event | Public Stock Offering - Shares from Selling Stockholders      
Subsequent Event [Line Items]      
Number of shares issued in sale of stock (in shares) 11,390,797    
Common stock, par value (in dollars per share) $ 0.0001    
Subsequent Event | Public Stock Offering - Shares from Amyris      
Subsequent Event [Line Items]      
Number of shares issued in sale of stock (in shares) 7,656,822    
Subsequent Event | Public Stock Offering - Selling Stockholders Underwriting Agreement      
Subsequent Event [Line Items]      
Number of shares issued in sale of stock (in shares) 1,708,619    
Subsequent Event | Public Stock Offering - Amyris Underwriting Agreement      
Subsequent Event [Line Items]      
Number of shares issued in sale of stock (in shares) 1,148,523    
EXCEL 97 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 98 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 99 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 100 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 412 469 1 false 122 0 false 5 false false R1.htm 0001001 - Document - Cover Page Sheet http://amyris.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://amyris.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations Sheet http://amyris.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Operations (Parentheticals) Sheet http://amyris.com/role/CondensedConsolidatedStatementsofOperationsParentheticals Condensed Consolidated Statements of Operations (Parentheticals) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity Sheet http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity Statements 7 false false R8.htm 1008008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 1407401 - Statement - Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Parentheticals) Sheet http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Parentheticals) Statements 9 false false R10.htm 2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 10 false false R11.htm 2104102 - Disclosure - Balance Sheet Details Sheet http://amyris.com/role/BalanceSheetDetails Balance Sheet Details Notes 11 false false R12.htm 2118103 - Disclosure - Fair Value Measurement Sheet http://amyris.com/role/FairValueMeasurement Fair Value Measurement Notes 12 false false R13.htm 2128104 - Disclosure - Debt Sheet http://amyris.com/role/Debt Debt Notes 13 false false R14.htm 2135105 - Disclosure - Mezzanine Equity Sheet http://amyris.com/role/MezzanineEquity Mezzanine Equity Notes 14 false false R15.htm 2137106 - Disclosure - Stockholders' Deficit Sheet http://amyris.com/role/StockholdersDeficit Stockholders' Deficit Notes 15 false false R16.htm 2140107 - Disclosure - Net Loss Per Share Attributable to Common Shareholders Sheet http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholders Net Loss Per Share Attributable to Common Shareholders Notes 16 false false R17.htm 2144108 - Disclosure - Commitments and Contingencies Sheet http://amyris.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 17 false false R18.htm 2146109 - Disclosure - Revenue Recognition and Contract Assets and Liabilities Sheet http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilities Revenue Recognition and Contract Assets and Liabilities Notes 18 false false R19.htm 2156110 - Disclosure - Related Party Transactions Sheet http://amyris.com/role/RelatedPartyTransactions Related Party Transactions Notes 19 false false R20.htm 2160111 - Disclosure - Stock-based Compensation Sheet http://amyris.com/role/StockbasedCompensation Stock-based Compensation Notes 20 false false R21.htm 2166112 - Disclosure - Subsequent Events Sheet http://amyris.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 22 false false R23.htm 2305301 - Disclosure - Balance Sheet Details (Tables) Sheet http://amyris.com/role/BalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://amyris.com/role/BalanceSheetDetails 23 false false R24.htm 2319302 - Disclosure - Fair Value Measurement (Tables) Sheet http://amyris.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://amyris.com/role/FairValueMeasurement 24 false false R25.htm 2329303 - Disclosure - Debt (Tables) Sheet http://amyris.com/role/DebtTables Debt (Tables) Tables http://amyris.com/role/Debt 25 false false R26.htm 2338304 - Disclosure - Stockholders' Deficit (Tables) Sheet http://amyris.com/role/StockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://amyris.com/role/StockholdersDeficit 26 false false R27.htm 2341305 - Disclosure - Loss Per Share (Tables) Sheet http://amyris.com/role/LossPerShareTables Loss Per Share (Tables) Tables 27 false false R28.htm 2347306 - Disclosure - Revenue Recognition and Contract Assets and Liabilities (Tables) Sheet http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesTables Revenue Recognition and Contract Assets and Liabilities (Tables) Tables http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilities 28 false false R29.htm 2357307 - Disclosure - Related Party Transactions (Tables) Sheet http://amyris.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://amyris.com/role/RelatedPartyTransactions 29 false false R30.htm 2361308 - Disclosure - Stock-based Compensation (Tables) Sheet http://amyris.com/role/StockbasedCompensationTables Stock-based Compensation (Tables) Tables http://amyris.com/role/StockbasedCompensation 30 false false R31.htm 2403402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) Details http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies 31 false false R32.htm 2406403 - Disclosure - Balance Sheet Details - Allowance for Doubtful Accounts (Details) Sheet http://amyris.com/role/BalanceSheetDetailsAllowanceforDoubtfulAccountsDetails Balance Sheet Details - Allowance for Doubtful Accounts (Details) Details 32 false false R33.htm 2407404 - Disclosure - Balance Sheet Details - Inventories (Details) Sheet http://amyris.com/role/BalanceSheetDetailsInventoriesDetails Balance Sheet Details - Inventories (Details) Details 33 false false R34.htm 2408405 - Disclosure - Balance Sheet Details - Deferred Cost of Products Sold - Related Party (Details) Sheet http://amyris.com/role/BalanceSheetDetailsDeferredCostofProductsSoldRelatedPartyDetails Balance Sheet Details - Deferred Cost of Products Sold - Related Party (Details) Details 34 false false R35.htm 2409406 - Disclosure - Balance Sheet Details - Additional Information (Details) Sheet http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails Balance Sheet Details - Additional Information (Details) Details 35 false false R36.htm 2410407 - Disclosure - Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) Sheet http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) Details 36 false false R37.htm 2411408 - Disclosure - Balance Sheet Details - Property, Plant and Equipment (Details) Sheet http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails Balance Sheet Details - Property, Plant and Equipment (Details) Details 37 false false R38.htm 2412409 - Disclosure - Balance Sheet Details - Depreciation and Amortization (Details) Sheet http://amyris.com/role/BalanceSheetDetailsDepreciationandAmortizationDetails Balance Sheet Details - Depreciation and Amortization (Details) Details 38 false false R39.htm 2413410 - Disclosure - Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details) Sheet http://amyris.com/role/BalanceSheetDetailsRightofuseAssetsandRelatedLeaseLiabilitiesDetails Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details) Details 39 false false R40.htm 2414411 - Disclosure - Balance Sheet Details - Maturities of Financing and Operating Leases (Details) Sheet http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails Balance Sheet Details - Maturities of Financing and Operating Leases (Details) Details 40 false false R41.htm 2415412 - Disclosure - Balance Sheet Details - Other Assets (Details) Sheet http://amyris.com/role/BalanceSheetDetailsOtherAssetsDetails Balance Sheet Details - Other Assets (Details) Details 41 false false R42.htm 2416413 - Disclosure - Balance Sheet Details - Accrued and Other Current Liabilities (Details) Sheet http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails Balance Sheet Details - Accrued and Other Current Liabilities (Details) Details 42 false false R43.htm 2417414 - Disclosure - Balance Sheet Details - Other Noncurrent Liabilities (Details) Sheet http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails Balance Sheet Details - Other Noncurrent Liabilities (Details) Details 43 false false R44.htm 2420415 - Disclosure - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) Sheet http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) Details 44 false false R45.htm 2421416 - Disclosure - Fair Value Measurement - Fair Value of Debt ??? Foris Convertible Note (LSA Amendment) (Details) Sheet http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails Fair Value Measurement - Fair Value of Debt ??? Foris Convertible Note (LSA Amendment) (Details) Details 45 false false R46.htm 2422417 - Disclosure - Fair Value Measurement - Fair Value of Debt ??? Senior Convertible Notes (Details) Notes http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails Fair Value Measurement - Fair Value of Debt ??? Senior Convertible Notes (Details) Details 46 false false R47.htm 2423418 - Disclosure - Fair Value Measurement - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Sheet http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails Fair Value Measurement - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Details 47 false false R48.htm 2424419 - Disclosure - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) Sheet http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) Details 48 false false R49.htm 2425420 - Disclosure - Fair Value Measurement - Freestanding Derivative Instruments (Details) Sheet http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails Fair Value Measurement - Freestanding Derivative Instruments (Details) Details 49 false false R50.htm 2426421 - Disclosure - Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) Sheet http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) Details 50 false false R51.htm 2427422 - Disclosure - Fair Value Measurement - Financial Assets and Liabilities (Details) Sheet http://amyris.com/role/FairValueMeasurementFinancialAssetsandLiabilitiesDetails Fair Value Measurement - Financial Assets and Liabilities (Details) Details 51 false false R52.htm 2430423 - Disclosure - Debt - Debt Components (Details) Sheet http://amyris.com/role/DebtDebtComponentsDetails Debt - Debt Components (Details) Details 52 false false R53.htm 2431424 - Disclosure - Debt - Future Minimum Payments (Details) Sheet http://amyris.com/role/DebtFutureMinimumPaymentsDetails Debt - Future Minimum Payments (Details) Details 53 false false R54.htm 2432425 - Disclosure - Debt - Senior Convertible Notes (Details) Notes http://amyris.com/role/DebtSeniorConvertibleNotesDetails Debt - Senior Convertible Notes (Details) Details 54 false false R55.htm 2433426 - Disclosure - Debt - Schottfield Debt (Details) Sheet http://amyris.com/role/DebtSchottfieldDebtDetails Debt - Schottfield Debt (Details) Details 55 false false R56.htm 2434427 - Disclosure - Debt - DSM Amendments and Repayment (Details) Sheet http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails Debt - DSM Amendments and Repayment (Details) Details 56 false false R57.htm 2436428 - Disclosure - Mezzanine Equity (Details Textual) Sheet http://amyris.com/role/MezzanineEquityDetailsTextual Mezzanine Equity (Details Textual) Details http://amyris.com/role/MezzanineEquity 57 false false R58.htm 2439429 - Disclosure - Stockholders' Deficit - Warrant Activity (Details) Sheet http://amyris.com/role/StockholdersDeficitWarrantActivityDetails Stockholders' Deficit - Warrant Activity (Details) Details 58 false false R59.htm 2442430 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) Sheet http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails Net Loss Per Share Attributable to Common Shareholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) Details 59 false false R60.htm 2443431 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) Sheet http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails Net Loss Per Share Attributable to Common Shareholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) Details 60 false false R61.htm 2445432 - Disclosure - Commitments and Contingencies - Guarantor Arrangements (Details) Sheet http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails Commitments and Contingencies - Guarantor Arrangements (Details) Details 61 false false R62.htm 2448433 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) Sheet http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) Details 62 false false R63.htm 2449434 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) Sheet http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) Details 63 false false R64.htm 2450435 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) Sheet http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesContractBalancesDetails Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) Details 64 false false R65.htm 2451436 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) Sheet http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRemainingPerformanceObligationsDetails Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) Details 65 false false R66.htm 2452437 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - DSM License Agreement and Contract Asset (Details) Sheet http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails Revenue Recognition and Contract Assets and Liabilities - DSM License Agreement and Contract Asset (Details) Details 66 false false R67.htm 2453438 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - DSM Performance Agreement (Details) Sheet http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails Revenue Recognition and Contract Assets and Liabilities - DSM Performance Agreement (Details) Details 67 false false R68.htm 2454439 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - DSM Ingredients Collaboration (Details) Sheet http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails Revenue Recognition and Contract Assets and Liabilities - DSM Ingredients Collaboration (Details) Details 68 false false R69.htm 2455440 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Yifan Agreement (Details) Sheet http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails Revenue Recognition and Contract Assets and Liabilities - Yifan Agreement (Details) Details 69 false false R70.htm 2458441 - Disclosure - Related Party Transactions - Related Party Debt (Details) Sheet http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails Related Party Transactions - Related Party Debt (Details) Details 70 false false R71.htm 2459442 - Disclosure - Related Party Transactions - Related Party Accounts Receivable (Details) Sheet http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails Related Party Transactions - Related Party Accounts Receivable (Details) Details 71 false false R72.htm 2462443 - Disclosure - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) Sheet http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) Details 72 false false R73.htm 2463444 - Disclosure - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) Sheet http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) Details 73 false false R74.htm 2464445 - Disclosure - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) Sheet http://amyris.com/role/StockbasedCompensationEmployeeServiceSharebasedCompensationAllocationofRecognizedPeriodCostsDetails Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) Details 74 false false R75.htm 2465446 - Disclosure - Stock-based Compensation - Additional Information (Details) Sheet http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails Stock-based Compensation - Additional Information (Details) Details 75 false false R76.htm 2467447 - Disclosure - Subsequent Events - Primary and Secondary Offering (Details) Sheet http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails Subsequent Events - Primary and Secondary Offering (Details) Details 76 false false All Reports Book All Reports amrs-20210331.htm amrs-20210331.xsd amrs-20210331_cal.xml amrs-20210331_def.xml amrs-20210331_lab.xml amrs-20210331_pre.xml exhibit10012021q1.htm exhibit10022021q1.htm exhibit31012021q1.htm exhibit31022021q1.htm exhibit32012021q1.htm exhibit32022021q1.htm exhibit4022021q1.htm exhibit4032021q1.htm exhibit5012021q1.htm http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 103 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "amrs-20210331.htm": { "axisCustom": 1, "axisStandard": 28, "contextCount": 412, "dts": { "calculationLink": { "local": [ "amrs-20210331_cal.xml" ] }, "definitionLink": { "local": [ "amrs-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "amrs-20210331.htm" ] }, "labelLink": { "local": [ "amrs-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "amrs-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "amrs-20210331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 669, "entityCount": 1, "hidden": { "http://amyris.com/20210331": 1, "http://fasb.org/us-gaap/2020-01-31": 4, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 10 }, "keyCustom": 111, "keyStandard": 358, "memberCustom": 79, "memberStandard": 39, "nsprefix": "amrs", "nsuri": "http://amyris.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://amyris.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - Balance Sheet Details", "role": "http://amyris.com/role/BalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118103 - Disclosure - Fair Value Measurement", "role": "http://amyris.com/role/FairValueMeasurement", "shortName": "Fair Value Measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128104 - Disclosure - Debt", "role": "http://amyris.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "amrs:MezzanineEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135105 - Disclosure - Mezzanine Equity", "role": "http://amyris.com/role/MezzanineEquity", "shortName": "Mezzanine Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "amrs:MezzanineEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137106 - Disclosure - Stockholders' Deficit", "role": "http://amyris.com/role/StockholdersDeficit", "shortName": "Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140107 - Disclosure - Net Loss Per Share Attributable to Common Shareholders", "role": "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholders", "shortName": "Net Loss Per Share Attributable to Common Shareholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144108 - Disclosure - Commitments and Contingencies", "role": "http://amyris.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146109 - Disclosure - Revenue Recognition and Contract Assets and Liabilities", "role": "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilities", "shortName": "Revenue Recognition and Contract Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156110 - Disclosure - Related Party Transactions", "role": "http://amyris.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://amyris.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ie96ea30c5b354d6aa1b6f0155bec302e_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2160111 - Disclosure - Stock-based Compensation", "role": "http://amyris.com/role/StockbasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2166112 - Disclosure - Subsequent Events", "role": "http://amyris.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Balance Sheet Details (Tables)", "role": "http://amyris.com/role/BalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319302 - Disclosure - Fair Value Measurement (Tables)", "role": "http://amyris.com/role/FairValueMeasurementTables", "shortName": "Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329303 - Disclosure - Debt (Tables)", "role": "http://amyris.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338304 - Disclosure - Stockholders' Deficit (Tables)", "role": "http://amyris.com/role/StockholdersDeficitTables", "shortName": "Stockholders' Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341305 - Disclosure - Loss Per Share (Tables)", "role": "http://amyris.com/role/LossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347306 - Disclosure - Revenue Recognition and Contract Assets and Liabilities (Tables)", "role": "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesTables", "shortName": "Revenue Recognition and Contract Assets and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "amrs:ScheduleOfRelatedPartyDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2357307 - Disclosure - Related Party Transactions (Tables)", "role": "http://amyris.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "amrs:ScheduleOfRelatedPartyDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "role": "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "lang": "en-US", "name": "amrs:AccountsReceivableAllowanceForCreditLossRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2361308 - Disclosure - Stock-based Compensation (Tables)", "role": "http://amyris.com/role/StockbasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ie96ea30c5b354d6aa1b6f0155bec302e_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Balance Sheet Details - Allowance for Doubtful Accounts (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsAllowanceforDoubtfulAccountsDetails", "shortName": "Balance Sheet Details - Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ie9ba19d637874d3eb47d88ed8d18ec2a_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Balance Sheet Details - Inventories (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsInventoriesDetails", "shortName": "Balance Sheet Details - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "amrs:DeferredCostofProductsSoldRelatedPartyCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Balance Sheet Details - Deferred Cost of Products Sold - Related Party (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsDeferredCostofProductsSoldRelatedPartyDetails", "shortName": "Balance Sheet Details - Deferred Cost of Products Sold - Related Party (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "lang": "en-US", "name": "amrs:DeferredCostofProductsSoldRelatedPartyNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i213979b8fa6b4479b7273ab9ae0cb7d0_D20100927-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "amrs:DeferredCostofProductsSoldAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Balance Sheet Details - Additional Information (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "shortName": "Balance Sheet Details - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i213979b8fa6b4479b7273ab9ae0cb7d0_D20100927-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "amrs:DeferredCostofProductsSoldAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410407 - Disclosure - Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411408 - Disclosure - Balance Sheet Details - Property, Plant and Equipment (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails", "shortName": "Balance Sheet Details - Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amrs:ScheduleOfDepreciationAndAmortizationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412409 - Disclosure - Balance Sheet Details - Depreciation and Amortization (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsDepreciationandAmortizationDetails", "shortName": "Balance Sheet Details - Depreciation and Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amrs:ScheduleOfDepreciationAndAmortizationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413410 - Disclosure - Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsRightofuseAssetsandRelatedLeaseLiabilitiesDetails", "shortName": "Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amrs:LesseeLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414411 - Disclosure - Balance Sheet Details - Maturities of Financing and Operating Leases (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails", "shortName": "Balance Sheet Details - Maturities of Financing and Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amrs:LesseeLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415412 - Disclosure - Balance Sheet Details - Other Assets (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsOtherAssetsDetails", "shortName": "Balance Sheet Details - Other Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amrs:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416413 - Disclosure - Balance Sheet Details - Accrued and Other Current Liabilities (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails", "shortName": "Balance Sheet Details - Accrued and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amrs:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417414 - Disclosure - Balance Sheet Details - Other Noncurrent Liabilities (Details)", "role": "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails", "shortName": "Balance Sheet Details - Other Noncurrent Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ia905011819244ff98285746291639de1_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "amrs:EquityConversionFeatureEmbeddedDerivativeLiabilityFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420415 - Disclosure - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details)", "role": "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "shortName": "Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ia905011819244ff98285746291639de1_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "amrs:EquityConversionFeatureEmbeddedDerivativeLiabilityFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421416 - Disclosure - Fair Value Measurement - Fair Value of Debt \u2014 Foris Convertible Note (LSA Amendment) (Details)", "role": "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "shortName": "Fair Value Measurement - Fair Value of Debt \u2014 Foris Convertible Note (LSA Amendment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i7cb493348b474e25bc3e4c54fc4fac96_D20210101-20210331", "decimals": "-5", "lang": "en-US", "name": "amrs:DebtChangesinFairValueGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422417 - Disclosure - Fair Value Measurement - Fair Value of Debt \u2014 Senior Convertible Notes (Details)", "role": "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "shortName": "Fair Value Measurement - Fair Value of Debt \u2014 Senior Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "iac565aa5e6964a3ea8bce22b8a651c5a_I20210331", "decimals": "2", "lang": "en-US", "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423418 - Disclosure - Fair Value Measurement - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)", "role": "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "shortName": "Fair Value Measurement - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i35e121e2f3c54ea1868090c171d26b97_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424419 - Disclosure - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details)", "role": "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails", "shortName": "Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i6346dbf028034868b5fb27dae9602e9b_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425420 - Disclosure - Fair Value Measurement - Freestanding Derivative Instruments (Details)", "role": "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails", "shortName": "Fair Value Measurement - Freestanding Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i39bea47bcc6448df821e3e595b1e8f65_I20200228", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Operations (Parentheticals)", "role": "http://amyris.com/role/CondensedConsolidatedStatementsofOperationsParentheticals", "shortName": "Condensed Consolidated Statements of Operations (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i4035d6e2f4c14627b71e7834be640994_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EmbeddedDerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426421 - Disclosure - Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details)", "role": "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails", "shortName": "Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i4035d6e2f4c14627b71e7834be640994_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EmbeddedDerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427422 - Disclosure - Fair Value Measurement - Financial Assets and Liabilities (Details)", "role": "http://amyris.com/role/FairValueMeasurementFinancialAssetsandLiabilitiesDetails", "shortName": "Fair Value Measurement - Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430423 - Disclosure - Debt - Debt Components (Details)", "role": "http://amyris.com/role/DebtDebtComponentsDetails", "shortName": "Debt - Debt Components (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "amrs:LongTermDebtFutureMinimumPaymentsRemainderOfTheYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431424 - Disclosure - Debt - Future Minimum Payments (Details)", "role": "http://amyris.com/role/DebtFutureMinimumPaymentsDetails", "shortName": "Debt - Future Minimum Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "amrs:LongTermDebtFutureMinimumPaymentsRemainderOfTheYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i8398ceae4b304b90b138ecee14f8ce77_D20210301-20210301", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432425 - Disclosure - Debt - Senior Convertible Notes (Details)", "role": "http://amyris.com/role/DebtSeniorConvertibleNotesDetails", "shortName": "Debt - Senior Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i5fd2487bfb3d4f87b8f88e75ec8c1cf0_I20210204", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433426 - Disclosure - Debt - Schottfield Debt (Details)", "role": "http://amyris.com/role/DebtSchottfieldDebtDetails", "shortName": "Debt - Schottfield Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i8398ceae4b304b90b138ecee14f8ce77_D20210301-20210301", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ConversionOfStockSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434427 - Disclosure - Debt - DSM Amendments and Repayment (Details)", "role": "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails", "shortName": "Debt - DSM Amendments and Repayment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ie0b9cdb3639f46fc889093ea65b4411d_I20190917", "decimals": "INF", "lang": "en-US", "name": "amrs:DebtNumberOfInstallments", "reportCount": 1, "unique": true, "unitRef": "installment", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i9143255b48b345bf99f29f86bb374256_I20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436428 - Disclosure - Mezzanine Equity (Details Textual)", "role": "http://amyris.com/role/MezzanineEquityDetailsTextual", "shortName": "Mezzanine Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i9143255b48b345bf99f29f86bb374256_I20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439429 - Disclosure - Stockholders' Deficit - Warrant Activity (Details)", "role": "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails", "shortName": "Stockholders' Deficit - Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442430 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details)", "role": "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails", "shortName": "Net Loss Per Share Attributable to Common Shareholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "role": "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443431 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)", "role": "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails", "shortName": "Net Loss Per Share Attributable to Common Shareholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ife72fca9cd5f4514a03ca366e215091a_I20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445432 - Disclosure - Commitments and Contingencies - Guarantor Arrangements (Details)", "role": "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails", "shortName": "Commitments and Contingencies - Guarantor Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ife72fca9cd5f4514a03ca366e215091a_I20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448433 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details)", "role": "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails", "shortName": "Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i6c1cbee23d72441a91f0d88f9b67d555_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449434 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details)", "role": "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "shortName": "Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amrs:RevenueInConnectionWithSignificantRevenueAgreementTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ib62f771b4adc49d597bff4c2925377dc_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "amrs:AccountsReceivableNetCurrentExcludingRelatedParties", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450435 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details)", "role": "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesContractBalancesDetails", "shortName": "Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451436 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details)", "role": "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRemainingPerformanceObligationsDetails", "shortName": "Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452437 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - DSM License Agreement and Contract Asset (Details)", "role": "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "shortName": "Revenue Recognition and Contract Assets and Liabilities - DSM License Agreement and Contract Asset (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ib07e27c19a51486a8006e1d8cd388e9c_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "amrs:RevenueFromContractWithCustomerAgreementContingentConsiderations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453438 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - DSM Performance Agreement (Details)", "role": "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "shortName": "Revenue Recognition and Contract Assets and Liabilities - DSM Performance Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i13e7471bcd9f4e07b9f3e4f237d83ef0_D20171201-20171231", "decimals": "-5", "lang": "en-US", "name": "amrs:RevenueFromContractWithCustomerAgreementContingentConsiderations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454439 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - DSM Ingredients Collaboration (Details)", "role": "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "shortName": "Revenue Recognition and Contract Assets and Liabilities - DSM Ingredients Collaboration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i79f79d0143e145e7bda3cd71e55555ea_D20210101-20210331", "decimals": "-5", "lang": "en-US", "name": "amrs:RevenueFromContractWithCustomerQuarterlyPayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455440 - Disclosure - Revenue Recognition and Contract Assets and Liabilities - Yifan Agreement (Details)", "role": "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails", "shortName": "Revenue Recognition and Contract Assets and Liabilities - Yifan Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ib8e051fabcc343fe8ff91077d43c49e0_D20210101-20210331", "decimals": "-5", "lang": "en-US", "name": "amrs:RevenueFromContractWithCustomerCumulativeToDate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i61b9a2cd3a074731be9fe1bde0bfd3d3_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity", "role": "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i61b9a2cd3a074731be9fe1bde0bfd3d3_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458441 - Disclosure - Related Party Transactions - Related Party Debt (Details)", "role": "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails", "shortName": "Related Party Transactions - Related Party Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amrs:ScheduleOfRelatedPartyDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i6bf3859f84864a11a2019c6624acc2ba_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459442 - Disclosure - Related Party Transactions - Related Party Accounts Receivable (Details)", "role": "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails", "shortName": "Related Party Transactions - Related Party Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amrs:ScheduleOfRelatedPartyAccountsReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ib54b03c5e8b24eb58c0c7c6e88f4b964_I20210331", "decimals": "-3", "lang": "en-US", "name": "amrs:AccountsReceivableUnbilledRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "ie96ea30c5b354d6aa1b6f0155bec302e_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462443 - Disclosure - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details)", "role": "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails", "shortName": "Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i788e56d31ec7414bad77e27602a45e7d_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463444 - Disclosure - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details)", "role": "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails", "shortName": "Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "iee48d528f6e94db1a036623e80623605_D20210101-20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464445 - Disclosure - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)", "role": "http://amyris.com/role/StockbasedCompensationEmployeeServiceSharebasedCompensationAllocationofRecognizedPeriodCostsDetails", "shortName": "Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i93461fedff8e4669b0841aa3261c2697_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465446 - Disclosure - Stock-based Compensation - Additional Information (Details)", "role": "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails", "shortName": "Stock-based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i93461fedff8e4669b0841aa3261c2697_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "id6325d3fa512498d8c5baf809a277430_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467447 - Disclosure - Subsequent Events - Primary and Secondary Offering (Details)", "role": "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails", "shortName": "Subsequent Events - Primary and Secondary Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i17c694693c8c47d18f4deaf1bc88f37f_I20210408", "decimals": "2", "lang": "en-US", "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1008008 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "i95ddcb0a00754a669312eec266384da5_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "amrs:DebtInstrumentGainLossOnChangeInFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amrs-20210331.htm", "contextRef": "if03ada5b554148a9909503a78362860c_D20210204-20210204", "decimals": "-5", "first": true, "lang": "en-US", "name": "amrs:CommonStockSharesToBeReturnedUponConversionOfConvertibleDebt", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1407401 - Statement - Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Parentheticals)", "role": "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals", "shortName": "Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null } }, "segmentCount": 122, "tag": { "amrs_A2020EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Equity Incentive Plan", "label": "2020 Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "A2020EquityIncentivePlanMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "amrs_AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Payable, Accrued Liabilities, And Other Current Liabilities", "label": "Accounts Payable, Accrued Liabilities, And Other Current Liabilities [Member]", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "amrs_AccountsReceivableAllowanceForCreditLossRelatedPartiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Allowance For Credit Loss, Related Parties, Current", "label": "Accounts Receivable, Allowance For Credit Loss, Related Parties, Current", "terseLabel": "Accounts receivable, allowance, related parties" } } }, "localname": "AccountsReceivableAllowanceForCreditLossRelatedPartiesCurrent", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "amrs_AccountsReceivableNetCurrentExcludingRelatedParties": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable Net Current Excluding Related Parties", "label": "Accounts Receivable Net Current Excluding Related Parties", "terseLabel": "Accounts receivable, net of allowance of $154 and $137, respectively", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrentExcludingRelatedParties", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_AccountsReceivableUnbilledRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Unbilled, Related Party", "label": "Accounts Receivable, Unbilled, Related Party", "terseLabel": "Accounts receivable, unbilled, related party" } } }, "localname": "AccountsReceivableUnbilledRelatedParty", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "amrs_AccountsReceivableUnbilledRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts receivable, unbilled - related party", "label": "Accounts receivable, unbilled - related party [Member]", "terseLabel": "Accounts receivable - related party" } } }, "localname": "AccountsReceivableUnbilledRelatedPartyMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "amrs_AcquisitionOfPropertyPlantAndEquipmentUnderAccountsPayableAccruedLiabilitiesAndNotesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable", "label": "Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable", "terseLabel": "Unpaid property, plant and equipment balances in accounts payable and accrued liabilities at end of period" } } }, "localname": "AcquisitionOfPropertyPlantAndEquipmentUnderAccountsPayableAccruedLiabilitiesAndNotesPayable", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_AdditionalPaidInCapitalCommonStockAndOther": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions and amount of additional paid-in capital (APIC) classified as other.", "label": "Additional paid-in capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStockAndOther", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "amrs_AdjustmentToAdditionalPaidInCapitalExerciseOfCommonStockRightsWarrantRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment To Additional Paid In Capital, Exercise Of Common Stock Rights Warrant, Related Party", "label": "Adjustment To Additional Paid In Capital, Exercise Of Common Stock Rights Warrant, Related Party", "terseLabel": "Exercise of common stock rights warrant - related party" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalExerciseOfCommonStockRightsWarrantRelatedParty", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "amrs_AdjustmentToAdditionalPaidInCapitalExtinguishmentOfLiabilityWarrantsToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment To Additional Paid In Capital, Extinguishment Of Liability Warrants to Equity", "label": "Adjustment To Additional Paid In Capital, Extinguishment Of Liability Warrants to Equity", "terseLabel": "Derecognition of liability warrants to equity" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalExtinguishmentOfLiabilityWarrantsToEquity", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "amrs_AdjustmentToAdditionalPaidInCapitalIssuanceOfCommonStockRightsWarrantRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment To Additional Paid In Capital, Issuance Of Common Stock Rights Warrant, Related Party", "label": "Adjustment To Additional Paid In Capital, Issuance Of Common Stock Rights Warrant, Related Party", "terseLabel": "Issuance of common stock right warrant - related party" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalIssuanceOfCommonStockRightsWarrantRelatedParty", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "amrs_AdjustmentsToAdditionalPaidInCapitalModificationOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Modification Of Warrants", "label": "Adjustments To Additional Paid In Capital, Modification Of Warrants", "terseLabel": "Modification of previously issued common stock warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalModificationOfWarrants", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "amrs_AdjustmentstoAdditionalPaidinCapitalWarrantExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid-in Capital Warrant Exercised", "label": "Adjustments to Additional Paid-in Capital Warrant Exercised", "terseLabel": "Issuance of common stock upon exercise of warrants" } } }, "localname": "AdjustmentstoAdditionalPaidinCapitalWarrantExercised", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "amrs_AllOtherCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents all other customers that are not in connection with the significant revenue agreements.", "label": "All Other Customers [Member]", "terseLabel": "Revenue from all other customers" } } }, "localname": "AllOtherCustomersMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_AllotmentOptionAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allotment Option Agreement, Term", "label": "Allotment Option Agreement, Term", "terseLabel": "Allotment option agreement, term" } } }, "localname": "AllotmentOptionAgreementTerm", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "durationItemType" }, "amrs_Amrs_ClassOfWarrantOrRightTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents term of warrants.", "label": "amrs_Class Of Warrant Or Right, Term", "terseLabel": "Class of warrant or right, term" } } }, "localname": "Amrs_ClassOfWarrantOrRightTerm", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails" ], "xbrltype": "durationItemType" }, "amrs_AmyrisRealSweetLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amyris RealSweet LLC", "label": "Amyris RealSweet LLC [Member]", "terseLabel": "Amyris RealSweet LLC" } } }, "localname": "AmyrisRealSweetLLCMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_April2019PIPEWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April 2019 PIPE Warrants", "label": "April 2019 PIPE Warrants [Member]", "terseLabel": "April 2019 PIPE warrants" } } }, "localname": "April2019PIPEWarrantsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_AprinnovaJVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aprinnova JV", "label": "Aprinnova JV [Member]", "terseLabel": "Aprinnova JV [Member]" } } }, "localname": "AprinnovaJVMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails" ], "xbrltype": "domainItemType" }, "amrs_August2017DilutionWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "August 2017 Dilution Warrants", "label": "August 2017 Dilution Warrants [Member]", "terseLabel": "August 2017 dilution warrants" } } }, "localname": "August2017DilutionWarrantsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_AutomaticAnnualIncreaseinSharesAvailableforGrantandIssuancePercentageofOutstandingStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Automatic Annual Increase in Shares Available for Grant and Issuance, Percentage of Outstanding Stock", "label": "Automatic Annual Increase in Shares Available for Grant and Issuance, Percentage of Outstanding Stock", "terseLabel": "Automatic annual increase in shares available for grant and issuance, percentage of outstanding stock" } } }, "localname": "AutomaticAnnualIncreaseinSharesAvailableforGrantandIssuancePercentageofOutstandingStock", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "amrs_AutomaticAnnualIncreaseintheNumberofSharesAvailableforGrantandIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Automatic Annual Increase in the Number of Shares Available for Grant and Issuance", "label": "Automatic Annual Increase in the Number of Shares Available for Grant and Issuance", "terseLabel": "Automatic annual increase available for grant and issuance (in shares)" } } }, "localname": "AutomaticAnnualIncreaseintheNumberofSharesAvailableforGrantandIssuance", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "amrs_AutomaticAnnualIncreaseintheNumberofSharesReservedforIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Automatic Annual Increase in the Number of Shares Reserved for Issuance", "label": "Automatic Annual Increase in the Number of Shares Reserved for Issuance", "terseLabel": "Automatic annual increase reserved for issuance (in shares)" } } }, "localname": "AutomaticAnnualIncreaseintheNumberofSharesReservedforIssuance", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "amrs_CapitalizedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The element that represents capitalized interest, shown on the cash flow statement under \"supplemental disclosures of non-cash investing and financing activities.\"", "label": "Accrued interest added to debt principal", "terseLabel": "Accrued interest added to debt principal" } } }, "localname": "CapitalizedInterest", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights, Exercised", "label": "Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights, Exercised", "terseLabel": "Exercise price per share of warrant exercised (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "amrs_ClassOfWarrantsOrRightIssuedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights issued during the reporting period.", "label": "Additional Warrants Issued (in shares)", "terseLabel": "Additional warrants issued (in shares)" } } }, "localname": "ClassOfWarrantsOrRightIssuedInPeriod", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "amrs_CommonStockSharesIssuedForConversionSettlement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Shares Issued For Conversion Settlement", "label": "Common Stock, Shares Issued For Conversion Settlement", "terseLabel": "Shares issued for conversion settlement (in shares)" } } }, "localname": "CommonStockSharesIssuedForConversionSettlement", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtSeniorConvertibleNotesDetails" ], "xbrltype": "sharesItemType" }, "amrs_CommonStockSharesToBeReturnedUponConversionOfConvertibleDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Shares to be Returned Upon Conversion of Convertible Debt", "label": "Common Stock, Shares to be Returned Upon Conversion of Convertible Debt", "terseLabel": "Shares to be returned per agreement (in shares)" } } }, "localname": "CommonStockSharesToBeReturnedUponConversionOfConvertibleDebt", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails" ], "xbrltype": "sharesItemType" }, "amrs_CompoundAnnualReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The rate of annual return added on the redemption base price when the Company redeems its stock.", "label": "Compound Annual Return", "terseLabel": "Compound annual return (percentage)" } } }, "localname": "CompoundAnnualReturn", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/MezzanineEquityDetailsTextual" ], "xbrltype": "percentItemType" }, "amrs_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents computer equipment and software.", "label": "Computer Equipment and Software [Member]", "terseLabel": "Computers and software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "amrs_ConsumerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consumer", "label": "Consumer [Member]", "terseLabel": "Consumer" } } }, "localname": "ConsumerMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "amrs_ContractAssetsRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Assets - Related Party", "label": "Contract Assets - Related Party [Member]", "terseLabel": "Contract assets - related party" } } }, "localname": "ContractAssetsRelatedPartyMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "amrs_ContractTerminationLiabilityCurrent": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of contract termination liabilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Contract termination", "terseLabel": "Contract termination fees" } } }, "localname": "ContractTerminationLiabilityCurrent", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_ContractWithCustomerAssetRelatedPartyAfterAllowanceForCreditLossCurrent": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract with Customer, Asset, Related Party, After Allowance for Credit Loss, Current", "label": "Contract with Customer, Asset, Related Party, After Allowance for Credit Loss, Current", "terseLabel": "Contract assets - related party" } } }, "localname": "ContractWithCustomerAssetRelatedPartyAfterAllowanceForCreditLossCurrent", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_ContractWithCustomerContingentConsiderationPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Contingent Consideration Paid", "label": "Contract With Customer, Contingent Consideration Paid", "terseLabel": "Contingent consideration received" } } }, "localname": "ContractWithCustomerContingentConsiderationPaid", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails" ], "xbrltype": "monetaryItemType" }, "amrs_ConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to convertible promissory notes.", "label": "Convertible Promissory Notes [Member]", "terseLabel": "Convertible promissory notes" } } }, "localname": "ConvertiblePromissoryNotesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "amrs_DSMCreditAgreementMarch2021AmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSM Credit Agreement - March 2021 Amendment", "label": "DSM Credit Agreement - March 2021 Amendment [Member]", "terseLabel": "DSM Credit Agreement - March 2021 Amendment" } } }, "localname": "DSMCreditAgreementMarch2021AmendmentMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "domainItemType" }, "amrs_DSMCreditAgreementMarch2021AmendmentRelatedTo25MillionDollarNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSM Credit Agreement - March 2021 Amendment Related To 25 Million Dollar Note", "label": "DSM Credit Agreement - March 2021 Amendment Related To 25 Million Dollar Note [Member]", "terseLabel": "DSM Credit Agreement - March 2021 Amendment Related To 25 Million Dollar Note" } } }, "localname": "DSMCreditAgreementMarch2021AmendmentRelatedTo25MillionDollarNoteMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "domainItemType" }, "amrs_DSMCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to DSM Credit Agreement.", "label": "DSM Credit Agreement [Member]", "terseLabel": "DSM Credit Agreement" } } }, "localname": "DSMCreditAgreementMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "domainItemType" }, "amrs_DSMIngredientsCollaborationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSM Ingredients Collaboration", "label": "DSM Ingredients Collaboration [Member]", "terseLabel": "DSM Ingredients Collaboration" } } }, "localname": "DSMIngredientsCollaborationMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails" ], "xbrltype": "domainItemType" }, "amrs_DSMInternationalBVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to DSM International B.V.", "label": "DSM International B.V. [Member]", "terseLabel": "DSM - related party", "verboseLabel": "DSM notes" } } }, "localname": "DSMInternationalBVMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_DSMLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSM License Agreement", "label": "DSM License Agreement [Member]", "terseLabel": "DSM License Agreement" } } }, "localname": "DSMLicenseAgreementMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails" ], "xbrltype": "domainItemType" }, "amrs_DSMNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to DSM note.", "label": "DSM Note [Member]", "terseLabel": "DSM notes" } } }, "localname": "DSMNoteMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "domainItemType" }, "amrs_DSMPerformanceCollabrationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DSM Performance Collabration", "label": "DSM Performance Collabration [Member]", "terseLabel": "DSM Performance Collabration" } } }, "localname": "DSMPerformanceCollabrationMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_DebtChangeinFairValueGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Changes in Fair Value Gain Loss", "label": "Debt Change in Fair Value Gain Loss", "terseLabel": "Debt change in fair value gain loss" } } }, "localname": "DebtChangeinFairValueGainLoss", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_DebtChangesinFairValueGainLoss": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Changes in Fair Value, Gain (Loss)", "label": "Debt Changes in Fair Value, Gain (Loss)", "terseLabel": "Loss from change in fair value of debt" } } }, "localname": "DebtChangesinFairValueGainLoss", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "amrs_DebtFutureMinimumPaymentsInterestIncludedInPayments": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtFutureMinimumPaymentsDetails": { "order": 1.0, "parentTag": "amrs_DebtFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the interest that is included in future payments on debt, which amount is subtracted from total future minimum payments in order to calculate the present value of minimum debt payments.", "label": "Debt, Future Minimum Payments, Interest Included in Payments", "negatedLabel": "Less: amount representing interest" } } }, "localname": "DebtFutureMinimumPaymentsInterestIncludedInPayments", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_DebtFutureMinimumPaymentsPresentValueOfNetMinimumPayments": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtFutureMinimumPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the present value of future minimum debt payments, net of interest.", "label": "Debt Future Minimum Payments, Present Value of Net Minimum Payments", "totalLabel": "Present value of minimum debt payments" } } }, "localname": "DebtFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_DebtFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the current portion of the present value of the net minimum payments on debt.", "label": "Debt Future Minimum Payments, Present Value of Net Minimum PaymentsCurrentMaturities", "negatedTerseLabel": "Less: current portion of debt principal" } } }, "localname": "DebtFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsCurrentMaturities", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_DebtFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the noncurrent portion of the present value of the net minimum payments on debt.", "label": "Noncurrent portion of debt principal", "terseLabel": "Noncurrent portion of debt principal" } } }, "localname": "DebtFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsNoncurrent", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_DebtInstrumentGainLossOnChangeInFairValue": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Gain (Loss) On Change In Fair Value", "label": "Debt Instrument, Gain (Loss) On Change In Fair Value", "negatedTerseLabel": "(Gain) loss from change in fair value of debt" } } }, "localname": "DebtInstrumentGainLossOnChangeInFairValue", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_DebtNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt, Number Of Installments", "label": "Debt, Number Of Installments", "terseLabel": "Number of installments" } } }, "localname": "DebtNumberOfInstallments", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "integerItemType" }, "amrs_DeferredCostofProductsSoldAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Cost of Products Sold, Amortization", "label": "Deferred Cost of Products Sold, Amortization", "terseLabel": "Deferred cost of products sold, amortization" } } }, "localname": "DeferredCostofProductsSoldAmortization", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "amrs_DeferredCostofProductsSoldRelatedParty": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsDeferredCostofProductsSoldRelatedPartyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Cost of Products Sold - Related Party", "label": "Deferred Cost of Products Sold - Related Party", "totalLabel": "Total" } } }, "localname": "DeferredCostofProductsSoldRelatedParty", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsDeferredCostofProductsSoldRelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "amrs_DeferredCostofProductsSoldRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsDeferredCostofProductsSoldRelatedPartyDetails": { "order": 1.0, "parentTag": "amrs_DeferredCostofProductsSoldRelatedParty", "weight": 1.0 }, "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Cost of Products Sold, Related Party, Current", "label": "Deferred Cost of Products Sold, Related Party, Current", "terseLabel": "Deferred cost of products sold - related party" } } }, "localname": "DeferredCostofProductsSoldRelatedPartyCurrent", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsDeferredCostofProductsSoldRelatedPartyDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "amrs_DeferredCostofProductsSoldRelatedPartyNoncurrent": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsDeferredCostofProductsSoldRelatedPartyDetails": { "order": 2.0, "parentTag": "amrs_DeferredCostofProductsSoldRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Cost of Products Sold - Related Party, Noncurrent", "label": "Deferred Cost of Products Sold - Related Party, Noncurrent", "terseLabel": "Deferred cost of products sold, noncurrent - related party" } } }, "localname": "DeferredCostofProductsSoldRelatedPartyNoncurrent", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsDeferredCostofProductsSoldRelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "amrs_DeferredCostofProductsSoldTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Cost of Products Sold [Table Text Block]", "label": "Deferred Cost of Products Sold [Table Text Block]", "terseLabel": "Deferred Cost of Products Sold" } } }, "localname": "DeferredCostofProductsSoldTableTextBlock", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "amrs_DerecognitionOfDerivativeLiabilitiesToEquityUponExtinguishmentOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derecognition of Derivative Liabilities to Equity upon Extinguishment of Debt", "label": "Derecognition of Derivative Liabilities to Equity upon Extinguishment of Debt", "terseLabel": "Derecognition of derivative liabilities to equity upon extinguishment of debt" } } }, "localname": "DerecognitionOfDerivativeLiabilitiesToEquityUponExtinguishmentOfDebt", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_DerivativeLiabilityDebtRelatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to debt-related derivative liabilities.", "label": "Derivative Liability, Debt-related [Member]", "terseLabel": "Debt-related Derivative Liability" } } }, "localname": "DerivativeLiabilityDebtRelatedMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "amrs_EquityConversionFeatureEmbeddedDerivativeLiabilityFairValueDisclosures": { "auth_ref": [], "calculation": { "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of equity conversion feature embedded derivative liability.", "label": "Embedded derivatives in connection with the issuance of debt and equity instruments", "terseLabel": "Embedded derivatives bifurcated from debt instruments" } } }, "localname": "EquityConversionFeatureEmbeddedDerivativeLiabilityFairValueDisclosures", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "amrs_EquityConversionFeatureFreestandingDerivativeLiabilityFairValueDisclosures": { "auth_ref": [], "calculation": { "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of equity conversion feature freestanding derivative liability.", "label": "Freestanding derivative instruments in connection with the issuance of equity instruments", "terseLabel": "Freestanding derivative instruments issued in connection with other debt and equity instruments" } } }, "localname": "EquityConversionFeatureFreestandingDerivativeLiabilityFairValueDisclosures", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "amrs_EquityIncentivePlan2010Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the equity incentive plan from 2010.", "label": "Equity Incentive Plan, 2010 [Member]", "terseLabel": "Equity Incentive Plan, 2010" } } }, "localname": "EquityIncentivePlan2010Member", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "amrs_EstimatedTotalUnconstrainedTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated Total Unconstrained Transaction Price", "label": "Estimated Total Unconstrained Transaction Price", "terseLabel": "Estimated total unconstrained transaction price" } } }, "localname": "EstimatedTotalUnconstrainedTransactionPrice", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails" ], "xbrltype": "monetaryItemType" }, "amrs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPrincipalRepaidInCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Principal Repaid in Common Stock", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Principal Repaid in Common Stock", "negatedTerseLabel": "Less: principal converted into common stock" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPrincipalRepaidInCommonStock", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "amrs_FairValueOfEmbeddedFeaturesInConnectionWithDebtIssuancesAndModifications": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value of Embedded Features in Connection with Debt Issuances and Modifications", "label": "Fair Value of Embedded Features in Connection with Debt Issuances and Modifications", "terseLabel": "Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances" } } }, "localname": "FairValueOfEmbeddedFeaturesInConnectionWithDebtIssuancesAndModifications", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_FairValueOfEmbeddedFeaturesInConnectionWithDebtIssuancesAndModificationsOfRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value of Embedded Features in Connection with Debt Issuances and Modifications of Related Party", "label": "Fair Value of Embedded Features in Connection with Debt Issuances and Modifications of Related Party", "terseLabel": "Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances - related party" } } }, "localname": "FairValueOfEmbeddedFeaturesInConnectionWithDebtIssuancesAndModificationsOfRelatedParty", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_FairValueOfEmbeddedFeaturesInConnectionWithPrivatePlacement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value Of Embedded Features In Connection With Private Placement", "label": "Fair Value Of Embedded Features In Connection With Private Placement", "terseLabel": "Fair value of embedded features in connection with private placement" } } }, "localname": "FairValueOfEmbeddedFeaturesInConnectionWithPrivatePlacement", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_FinishedGoodsInventoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finished Goods Inventory", "label": "Finished Goods Inventory [Member]", "terseLabel": "Finished Goods Inventory" } } }, "localname": "FinishedGoodsInventoryMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails" ], "xbrltype": "domainItemType" }, "amrs_FirmenichMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Firmenich S.A., a global flavors and fragrances company.", "label": "Firmenich [Member]", "terseLabel": "Firmenich" } } }, "localname": "FirmenichMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_ForisConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foris Convertible Note", "label": "Foris Convertible Note [Member]", "terseLabel": "Foris Convertible Note (LSA Amendment)" } } }, "localname": "ForisConvertibleNoteMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails" ], "xbrltype": "domainItemType" }, "amrs_ForisDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foris Debt", "label": "Foris Debt [Member]", "terseLabel": "Foris note" } } }, "localname": "ForisDebtMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "domainItemType" }, "amrs_ForisNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foris Notes [Member]", "label": "Foris Notes [Member]", "terseLabel": "Foris note" } } }, "localname": "ForisNotesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "domainItemType" }, "amrs_ForisVenturesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foris Ventures LLC [Member]", "label": "Foris Ventures LLC [Member]", "terseLabel": "Foris notes" } } }, "localname": "ForisVenturesLLCMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "domainItemType" }, "amrs_FurnitureAndOfficeEquipmentVehiclesAndLandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices, vehicles used for road transportation, and real estate held.", "label": "Furniture and Office Equipment, Vehicles and Land [Member]", "terseLabel": "Furniture and office equipment, vehicles and land" } } }, "localname": "FurnitureAndOfficeEquipmentVehiclesAndLandMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "amrs_GainLossFromInvestmentInAffiliate": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) From Investment In Affiliate", "label": "Gain (Loss) From Investment In Affiliate", "negatedTerseLabel": "(Gain) loss from investment in affiliate" } } }, "localname": "GainLossFromInvestmentInAffiliate", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_GatesFoundationPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A security purchase agreement with the Gates Foundation.", "label": "Gates Foundation Purchase Agreement [Member]", "terseLabel": "Gates Foundation Purchase Agreement" } } }, "localname": "GatesFoundationPurchaseAgreementMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/MezzanineEquityDetailsTextual" ], "xbrltype": "domainItemType" }, "amrs_GinkgoCollaborationNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the secured promissory note to Ginkgo.", "label": "Ginkgo Collaboration Note [Member]", "terseLabel": "Ginkgo note" } } }, "localname": "GinkgoCollaborationNoteMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "domainItemType" }, "amrs_GivaudanInternationalSaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Givaudan International, SA.", "label": "Givaudan International, SA [Member]", "terseLabel": "Givaudan" } } }, "localname": "GivaudanInternationalSaMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_GrantsAndCollaborationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to grants and collaborations.", "label": "Grants and Collaborations [Member]", "terseLabel": "Grants and Collaborations" } } }, "localname": "GrantsAndCollaborationsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/CondensedConsolidatedStatementsofOperationsParentheticals", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_HighTrailSilverbackWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "High Trail/Silverback Warrants", "label": "High Trail/Silverback Warrants [Member]", "terseLabel": "Blackwell and Silverback warrants" } } }, "localname": "HighTrailSilverbackWarrantsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_IncreaseDecreaseInDeferredCostsOfRevenue": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in deferred costs of revenue.", "label": "amrs_IncreaseDecreaseInDeferredCostsOfRevenue", "negatedTerseLabel": "Deferred cost of products sold - related party" } } }, "localname": "IncreaseDecreaseInDeferredCostsOfRevenue", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease in Lease Liabilities", "label": "Increase Decrease in Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_IncreaseDecreaseOfRecoverableTaxesOnPurchaseOfFixedAssets": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of increase (decrease) of recoverable taxes on the purchase of fixed assets.", "label": "amrs_IncreaseDecreaseOfRecoverableTaxesOnPurchaseOfFixedAssets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseOfRecoverableTaxesOnPurchaseOfFixedAssets", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_IngredientCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ingredient Customer", "label": "Ingredient Customer [Member]", "terseLabel": "Ingredients" } } }, "localname": "IngredientCustomerMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "amrs_IngredionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ingredion Agreement", "label": "Ingredion Agreement [Member]", "terseLabel": "Ingredion Agreement" } } }, "localname": "IngredionAgreementMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_IngredionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ingredion", "label": "Ingredion [Member]", "terseLabel": "Ingredion" } } }, "localname": "IngredionMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_IntellectualPropertyLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intellectual Property License", "label": "Intellectual Property License [Member]", "terseLabel": "Intellectual Property License" } } }, "localname": "IntellectualPropertyLicenseMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails" ], "xbrltype": "domainItemType" }, "amrs_InventoryWorkInProcessIncludingAdjustments": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, including adjustments, of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work-in-process", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessIncludingAdjustments", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_IssuanceOfCommonStockAndWarrantsUponConversionOfDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Common Stock and Warrants upon Conversion of Debt", "label": "Issuance of Common Stock and Warrants upon Conversion of Debt", "terseLabel": "Issuance of common stock and warrants upon conversion of debt principal (in shares)" } } }, "localname": "IssuanceOfCommonStockAndWarrantsUponConversionOfDebt", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "sharesItemType" }, "amrs_IssuanceOfCommonStockAndWarrantsUponConversionOfDebtAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of Common Stock and Warrants upon Conversion of Debt, Amount", "label": "Issuance of Common Stock and Warrants upon Conversion of Debt, Amount", "terseLabel": "Issuance of common stock and warrants upon conversion of debt principal" } } }, "localname": "IssuanceOfCommonStockAndWarrantsUponConversionOfDebtAmount", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "amrs_January2020WarrantExerciseRightSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January 2020 Warrant Exercise Right Shares", "label": "January 2020 Warrant Exercise Right Shares [Member]", "terseLabel": "January 2020 warrant exercise right shares" } } }, "localname": "January2020WarrantExerciseRightSharesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_July2015RelatedPartyDebtExchange3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July 2015 Related Party Debt Exchange3", "label": "July 2015 Related Party Debt Exchange3 [Member]", "terseLabel": "July 2015 related party debt exchange" } } }, "localname": "July2015RelatedPartyDebtExchange3Member", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_KoninklijkeDSMNVDSMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Koninklijke DSM N.V. (DSM)", "label": "Koninklijke DSM N.V. (DSM) [Member]", "terseLabel": "Koninklijke DSM N.V (DSM)" } } }, "localname": "KoninklijkeDSMNVDSMMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "amrs_LeaseLiabilityPaymentDue": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Payment Due", "label": "Lease Liability Payment Due", "totalLabel": "Total lease payments" } } }, "localname": "LeaseLiabilityPaymentDue", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails_1": { "order": 3.0, "parentTag": "amrs_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Payments Due Year Four", "label": "Lease Liability Payments Due Year Four", "totalLabel": "2025" } } }, "localname": "LeaseLiabilityPaymentsDueYearFour", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails_1": { "order": 4.0, "parentTag": "amrs_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Payments Due Year Three", "label": "Lease Liability Payments Due Year Three", "totalLabel": "2024" } } }, "localname": "LeaseLiabilityPaymentsDueYearThree", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails_1": { "order": 5.0, "parentTag": "amrs_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Payments Due Year Two", "label": "Lease Liability Payments Due Year Two", "totalLabel": "2023" } } }, "localname": "LeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LeaseLiabilityPaymentsRemainderofFiscalYear": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails_1": { "order": 2.0, "parentTag": "amrs_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Payments Remainder of Fiscal Year", "label": "Lease Liability Payments Remainder of Fiscal Year", "totalLabel": "2021 (Remaining Nine Months)" } } }, "localname": "LeaseLiabilityPaymentsRemainderofFiscalYear", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LeaseLiabilityPaymentsYearOne": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails_1": { "order": 1.0, "parentTag": "amrs_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Liability, Payments, Year one", "label": "Lease, Liability, Payments, Year one", "totalLabel": "2022" } } }, "localname": "LeaseLiabilityPaymentsYearOne", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Undiscounted Excess Amount", "label": "Lease Liability Undiscounted Excess Amount", "negatedTotalLabel": "Less: amount representing interest" } } }, "localname": "LeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LesseeLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Lease Liability Maturity [Table Text Block]", "label": "Lessee Lease Liability Maturity [Table Text Block]", "terseLabel": "Lessee, Lease Liability, Maturity" } } }, "localname": "LesseeLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "amrs_LiabilitiesRelatedToEquityMethodInvestmentsNoncurrent": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities Related to Equity Method Investments, Noncurrent", "label": "Liabilities Related to Equity Method Investments, Noncurrent", "terseLabel": "Liability in connection with acquisition of equity-method investment" } } }, "localname": "LiabilitiesRelatedToEquityMethodInvestmentsNoncurrent", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LicensesAndRoyaltiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to licenses and royalties.", "label": "Licenses and Royalties [Member]", "terseLabel": "Licenses and Royalties" } } }, "localname": "LicensesAndRoyaltiesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/CondensedConsolidatedStatementsofOperationsParentheticals", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_LoansPayableAndCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to both loans payable and credit facilities.", "label": "Loans Payable and Credit Facilities [Member]", "terseLabel": "Loans Payable and Credit Facilities" } } }, "localname": "LoansPayableAndCreditFacilitiesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "domainItemType" }, "amrs_LongTermDebtCurrentFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long Term Debt, Current, Fair Value", "label": "Long Term Debt, Current, Fair Value", "verboseLabel": "Fair value of debt" } } }, "localname": "LongTermDebtCurrentFairValue", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "amrs_LongTermDebtFutureMinimumPaymentsDue": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtFutureMinimumPaymentsDetails": { "order": 2.0, "parentTag": "amrs_DebtFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the total future minimum payments that will be due on debt.", "label": "Long-term Debt, Future Minimum Payments, Due", "totalLabel": "Total future minimum payments" } } }, "localname": "LongTermDebtFutureMinimumPaymentsDue", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LongTermDebtFutureMinimumPaymentsDueAfterFourYears": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtFutureMinimumPaymentsDetails": { "order": 1.0, "parentTag": "amrs_LongTermDebtFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of the future minimum payments on debt that is due after four years.", "label": "Long-term Debt, Future Minimum Payments, Due after Four Years", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtFutureMinimumPaymentsDueAfterFourYears", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LongTermDebtFutureMinimumPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtFutureMinimumPaymentsDetails": { "order": 5.0, "parentTag": "amrs_LongTermDebtFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of the future minimum payments on debt that is due in four years.", "label": "Long-term Debt, Future Minimum Payments, Due Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtFutureMinimumPaymentsDueYearFour", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LongTermDebtFutureMinimumPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtFutureMinimumPaymentsDetails": { "order": 3.0, "parentTag": "amrs_LongTermDebtFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of the future minimum payments on debt that is due in three years.", "label": "Long-term Debt, Future Minimum Payments, Due Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtFutureMinimumPaymentsDueYearThree", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LongTermDebtFutureMinimumPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtFutureMinimumPaymentsDetails": { "order": 2.0, "parentTag": "amrs_LongTermDebtFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of the future minimum payments on debt that is due in two years.", "label": "Long-term Debt, Future Minimum Payments, Due Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtFutureMinimumPaymentsDueYearTwo", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LongTermDebtFutureMinimumPaymentsRemainderOfTheYear": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtFutureMinimumPaymentsDetails": { "order": 4.0, "parentTag": "amrs_LongTermDebtFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the future minimum payments on debt that are due in the next fiscal year following the latest fiscal year.", "label": "Long-term Debt, Future Minimum Payments, Remainder of the Year", "terseLabel": "2021 (Remaining Nine Months)" } } }, "localname": "LongTermDebtFutureMinimumPaymentsRemainderOfTheYear", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LongTermDebtFutureMinimumPaymentsYearOne": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtFutureMinimumPaymentsDetails": { "order": 6.0, "parentTag": "amrs_LongTermDebtFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of the future minimum payments on debt that is due in two years.", "label": "Long-term Debt, Future Minimum Payments, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtFutureMinimumPaymentsYearOne", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LongTermDebtNetFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Net, Fair Value", "label": "Long-term Debt, Net, Fair Value", "terseLabel": "Fair value of long-term debt" } } }, "localname": "LongTermDebtNetFairValue", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "amrs_LongtermDebtCurrentMaturitiesIncludingDueToRelatedParties": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtDebtComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current including due to related parties. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "amrs_LongtermDebtCurrentMaturitiesIncludingDueToRelatedParties", "negatedTerseLabel": "Less: current portion" } } }, "localname": "LongtermDebtCurrentMaturitiesIncludingDueToRelatedParties", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LongtermDebtExcludingCurrentMaturitiesIncludingDueToRelatedParties": { "auth_ref": [], "calculation": { "http://amyris.com/role/DebtDebtComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent, including due to related parties and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "amrs_LongtermDebtExcludingCurrentMaturitiesIncludingDueToRelatedParties", "terseLabel": "Long-term debt, net of current portion" } } }, "localname": "LongtermDebtExcludingCurrentMaturitiesIncludingDueToRelatedParties", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_LossUponExtinguishmentOfDebt": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of loss recorded during the period upon the extinguishment of debt.", "label": "Loss upon conversion or extinguishment of debt", "terseLabel": "Loss upon extinguishment of debt" } } }, "localname": "LossUponExtinguishmentOfDebt", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_May2017CashWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May 2017 Cash Warrants", "label": "May 2017 Cash Warrants [Member]", "terseLabel": "May 2017 cash warrants" } } }, "localname": "May2017CashWarrantsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_May2017DilutionWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the may 2017 dilution warrants.", "label": "May 2017 Dilution Warrants [Member]", "terseLabel": "May 2017 dilution warrants" } } }, "localname": "May2017DilutionWarrantsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_May20196.50NoteExchangeWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May 2019 6.50% Note Exchange Warrants", "label": "May 2019 6.50% Note Exchange Warrants [Member]", "terseLabel": "May 2019 6.50% Note Exchange warrants" } } }, "localname": "May20196.50NoteExchangeWarrantsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_MeasurementInputProbabilityOfChangeInControlMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input using probability of change in control.", "label": "Measurement Input, Probability of Change in Control [Member]", "terseLabel": "Probability of Change in Control" } } }, "localname": "MeasurementInputProbabilityOfChangeInControlMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "amrs_MeasurementInputStockPriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Stock Price", "label": "Measurement Input, Stock Price [Member]", "terseLabel": "Measurement Input, Stock Price" } } }, "localname": "MeasurementInputStockPriceMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "amrs_MezzanineEquityCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mezzanine Equity Common Stock [Member]", "label": "Mezzanine Equity Common Stock [Member]", "terseLabel": "Mezzanine Equity - Common Stock" } } }, "localname": "MezzanineEquityCommonStockMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "domainItemType" }, "amrs_MezzanineEquityDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of mezzanine equity.", "label": "Mezzanine Equity Disclosure [Text Block]", "terseLabel": "Mezzanine Equity" } } }, "localname": "MezzanineEquityDisclosureTextBlock", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/MezzanineEquity" ], "xbrltype": "textBlockItemType" }, "amrs_NaxyrisLSAWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Naxyris LSA Warrants", "label": "Naxyris LSA Warrants [Member]", "terseLabel": "Naxyris LSA warrants" } } }, "localname": "NaxyrisLSAWarrantsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_NaxyrisNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Naxyris Note", "label": "Naxyris Note [Member]", "terseLabel": "Naxyris note" } } }, "localname": "NaxyrisNoteMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "domainItemType" }, "amrs_NaxyrisSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Naxyris S.A.", "label": "Naxyris S.A. [Member]", "terseLabel": "Naxyris note" } } }, "localname": "NaxyrisSAMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "domainItemType" }, "amrs_NewSeniorConvertibleNotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Senior convertible notes due 2022", "label": "New Senior convertible notes due 2022 [Member]", "terseLabel": "Senior convertible notes" } } }, "localname": "NewSeniorConvertibleNotesDue2022Member", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals", "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "amrs_NikkoNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nikko Notes [Member]", "label": "Nikko Notes [Member]", "terseLabel": "Nikko notes" } } }, "localname": "NikkoNotesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails", "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "domainItemType" }, "amrs_NonInventoryProductionSupplies": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-inventory Production Supplies", "label": "Non-inventory Production Supplies", "terseLabel": "Non-inventory production supplies" } } }, "localname": "NonInventoryProductionSupplies", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_NoncashOrPartNoncashExerciseOfCommonStockWarrantsForDebtPrincipalAndAccruedInterestReduction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash Or Part Noncash, Exercise Of Common Stock Warrants For Debt Principal And Accrued Interest Reduction", "label": "Noncash Or Part Noncash, Exercise Of Common Stock Warrants For Debt Principal And Accrued Interest Reduction", "terseLabel": "Exercise of common stock warrants in exchange for debt principal and accrued interest reduction" } } }, "localname": "NoncashOrPartNoncashExerciseOfCommonStockWarrantsForDebtPrincipalAndAccruedInterestReduction", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_October2019NaxyrisWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October 2019 Naxyris Warrant", "label": "October 2019 Naxyris Warrant [Member]", "terseLabel": "October 2019 Naxyris warrant" } } }, "localname": "October2019NaxyrisWarrantMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Right of use Asset Amortization", "label": "Operating Lease Right of use Asset Amortization", "terseLabel": "Amortization of right-of-use assets under operating leases" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_OperatingandFinanceLeaseLiabilities": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and Finance Lease Liabilities", "label": "Operating and Finance Lease Liabilities", "totalLabel": "Total lease liability" } } }, "localname": "OperatingandFinanceLeaseLiabilities", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_OperatingandFinanceLeaseLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 1.0, "parentTag": "amrs_OperatingandFinanceLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and Finance Lease Liabilities, Current", "label": "Operating and Finance Lease Liabilities, Current", "totalLabel": "Current lease liability" } } }, "localname": "OperatingandFinanceLeaseLiabilitiesCurrent", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_OperatingandFinanceLeaseLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 2.0, "parentTag": "amrs_OperatingandFinanceLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and Finance Lease Liabilities, Noncurrent", "label": "Operating and Finance Lease Liabilities, Noncurrent", "totalLabel": "Noncurrent lease liability" } } }, "localname": "OperatingandFinanceLeaseLiabilitiesNoncurrent", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_OtherAreaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the other geographic area.", "label": "Other Area [Member]", "terseLabel": "Other" } } }, "localname": "OtherAreaMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "amrs_OtherLoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents other loans payable.", "label": "Other Loans Payable [Member]", "terseLabel": "Other loans payable" } } }, "localname": "OtherLoansPayableMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "domainItemType" }, "amrs_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other [Member]", "label": "Other [Member]", "terseLabel": "Other" } } }, "localname": "OtherMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "amrs_PartnershipPaymentsObligationNoncurrent": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of partnership payments obligation classified as noncurrent.", "label": "Ginkgo partnership payments obligation, net of current portion", "terseLabel": "Ginkgo partnership payments obligation, net of current portion" } } }, "localname": "PartnershipPaymentsObligationNoncurrent", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_PaymentsToAcquireEquityMethodInvestmentConsiderationTransferredForLicenseToSellAndMarket": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to Acquire Equity Method Investment, Consideration Transferred For License To Sell And Market", "label": "Payments to Acquire Equity Method Investment, Consideration Transferred For License To Sell And Market", "terseLabel": "Consideration transferred for license to sell and market" } } }, "localname": "PaymentsToAcquireEquityMethodInvestmentConsiderationTransferredForLicenseToSellAndMarket", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "monetaryItemType" }, "amrs_PaymentsToAcquirePropertyPlantAndEquipmentNetOfDisposals": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets, net of disposals.", "label": "amrs_PaymentsToAcquirePropertyPlantAndEquipmentNetOfDisposals", "negatedTerseLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipmentNetOfDisposals", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_PeriodEndCommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to period-end common stock warrants.", "label": "Period-end Common Stock Warrants [Member]", "terseLabel": "Period-end common stock warrants" } } }, "localname": "PeriodEndCommonStockWarrantsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "amrs_PeriodEndPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to period-end preferred shares.", "label": "Period-end Preferred Shares [Member]", "terseLabel": "Period-end preferred stock" } } }, "localname": "PeriodEndPreferredSharesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "amrs_ProceedsFromCommonStockRightsWarrantExercisesRelatedParty": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from Common Stock Rights Warrant Exercises, Related Party", "label": "Proceeds from Common Stock Rights Warrant Exercises, Related Party", "terseLabel": "Proceeds from exercise of common stock rights warrant - related party" } } }, "localname": "ProceedsFromCommonStockRightsWarrantExercisesRelatedParty", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_ProceedsFromIssuanceOfPrivatePlacementRelatedParty": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance of Private Placement, Related Party", "label": "Proceeds From Issuance of Private Placement, Related Party", "terseLabel": "Proceeds from issuance of common and preferred stock in private placement, net of issuance costs - related party" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacementRelatedParty", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_ProceedsFromWarrantExerciseRelatedParty": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Warrant Exercise, Related Party", "label": "Proceeds From Warrant Exercise, Related Party", "terseLabel": "Proceeds from exercises of warrants - related party" } } }, "localname": "ProceedsFromWarrantExerciseRelatedParty", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_PublicStockOfferingAmyrisUnderUnderwritingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Stock Offering - Amyris Under Underwriting Agreement", "label": "Public Stock Offering - Amyris Under Underwriting Agreement [Member]", "terseLabel": "Public Stock Offering - Amyris Underwriting Agreement" } } }, "localname": "PublicStockOfferingAmyrisUnderUnderwritingAgreementMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "domainItemType" }, "amrs_PublicStockOfferingSellingStockholdersUnderUnderwritingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Stock Offering - Selling Stockholders Under Underwriting Agreement", "label": "Public Stock Offering - Selling Stockholders Under Underwriting Agreement [Member]", "terseLabel": "Public Stock Offering - Selling Stockholders Underwriting Agreement" } } }, "localname": "PublicStockOfferingSellingStockholdersUnderUnderwritingAgreementMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "domainItemType" }, "amrs_PublicStockOfferingSharesFromAmyrisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Stock Offering - Shares from Amyris", "label": "Public Stock Offering - Shares from Amyris [Member]", "terseLabel": "Public Stock Offering - Shares from Amyris" } } }, "localname": "PublicStockOfferingSharesFromAmyrisMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "domainItemType" }, "amrs_PublicStockOfferingSharesFromSellingStockholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Stock Offering - Shares from Selling Stockholders", "label": "Public Stock Offering - Shares from Selling Stockholders [Member]", "terseLabel": "Public Stock Offering - Shares from Selling Stockholders" } } }, "localname": "PublicStockOfferingSharesFromSellingStockholdersMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "domainItemType" }, "amrs_ReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Receivables", "label": "Receivables [Member]", "terseLabel": "Receivables" } } }, "localname": "ReceivablesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails" ], "xbrltype": "domainItemType" }, "amrs_RecoverableTaxesFromBrazilianGovernmentEntities": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Recoverable Taxes, From Brazilian Government Entities", "label": "Recoverable Taxes, From Brazilian Government Entities", "terseLabel": "Recoverable taxes from Brazilian government entities" } } }, "localname": "RecoverableTaxesFromBrazilianGovernmentEntities", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_RecoverableTaxesOnPurchaseOfFixedAssets": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The element that represents recoverable taxes on the purchase of fixed assets.", "label": "Recoverable taxes from Brazilian government entities", "terseLabel": "Recoverable taxes from Brazilian government entities" } } }, "localname": "RecoverableTaxesOnPurchaseOfFixedAssets", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "amrs_RelatedPartyConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about related party convertible notes.", "label": "Related Party Convertible Notes [Member]", "terseLabel": "Related party convertible notes payable" } } }, "localname": "RelatedPartyConvertibleNotesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/DebtFutureMinimumPaymentsDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails" ], "xbrltype": "domainItemType" }, "amrs_RelatedPartyDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to related party debt.", "label": "Related Party Debt [Member]", "terseLabel": "Related Party Debt" } } }, "localname": "RelatedPartyDebtMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "domainItemType" }, "amrs_RelatedPartyDebtNetFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related Party Debt, Net, Fair Value", "label": "Related Party Debt, Net, Fair Value", "terseLabel": "Related party debt, net, fair value" } } }, "localname": "RelatedPartyDebtNetFairValue", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "amrs_RelatedPartyLoanPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to related party loan payable.", "label": "Related Party Loan Payable [Member]", "terseLabel": "Related party loans payable" } } }, "localname": "RelatedPartyLoanPayableMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "domainItemType" }, "amrs_RelatedPartyLoansPayableAndCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to related party loans payable and credit facilities.", "label": "Related Party Loans Payable and Credit Facilities [Member]", "terseLabel": "Related Party Loans Payable and Credit Facilities" } } }, "localname": "RelatedPartyLoansPayableAndCreditFacilitiesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "domainItemType" }, "amrs_RenewableProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Renewable Products.", "label": "Renewable Products [Member]", "terseLabel": "Renewable Products" } } }, "localname": "RenewableProductsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_ResearchAndDevelopmentCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and Development Customer", "label": "Research and Development Customer [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentCustomerMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "amrs_ResearchandDevelopmentObligationRemainingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research and Development Obligation, Remaining Amount", "label": "Research and Development Obligation, Remaining Amount", "terseLabel": "Research and development obligation, remaining amount" } } }, "localname": "ResearchandDevelopmentObligationRemainingAmount", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/MezzanineEquityDetailsTextual" ], "xbrltype": "monetaryItemType" }, "amrs_ResidualApproachPerformanceObligationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Residual Approach Performance Obligation", "label": "Residual Approach Performance Obligation [Axis]", "terseLabel": "Residual Approach Performance Obligation [Axis]" } } }, "localname": "ResidualApproachPerformanceObligationAxis", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails" ], "xbrltype": "stringItemType" }, "amrs_ResidualApproachPerformanceObligationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Residual Approach Performance Obligation [Domain]", "label": "Residual Approach Performance Obligation [Domain]", "terseLabel": "Residual Approach Performance Obligation [Domain]" } } }, "localname": "ResidualApproachPerformanceObligationDomain", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails" ], "xbrltype": "domainItemType" }, "amrs_RevenueFromContractWithCustomerAgreementContingentConsiderations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue from Contract with Customer, Agreement Contingent Considerations", "label": "Revenue from Contract with Customer, Agreement Contingent Considerations", "terseLabel": "Contingent considerations, maximum" } } }, "localname": "RevenueFromContractWithCustomerAgreementContingentConsiderations", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails" ], "xbrltype": "monetaryItemType" }, "amrs_RevenueFromContractWithCustomerCumulativeToDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer, Cumulative To Date", "label": "Revenue From Contract With Customer, Cumulative To Date", "terseLabel": "Revenue from contract with customer, cumulative to date" } } }, "localname": "RevenueFromContractWithCustomerCumulativeToDate", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "amrs_RevenueFromContractWithCustomerQuarterlyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue from Contract with Customer, Quarterly Payments", "label": "Revenue from Contract with Customer, Quarterly Payments", "terseLabel": "Quarterly payments" } } }, "localname": "RevenueFromContractWithCustomerQuarterlyPayments", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "amrs_RevenueInConnectionWithSignificantRevenueAgreementTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue in connection with significant revenue agreement.", "label": "Revenue in Connection with Significant Revenue Agreement [Table Text Block]", "terseLabel": "Revenue in Connection with Significant Revenue Agreement" } } }, "localname": "RevenueInConnectionWithSignificantRevenueAgreementTableTextBlock", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "amrs_RevenueRemainingPerformanceObligationConstrainedVariableConsiderationAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue and represents a constrained variable consideration.", "label": "Revenue, Remaining Performance Obligation Constrained Variable Consideration Amount", "terseLabel": "Constrained variable consideration amount" } } }, "localname": "RevenueRemainingPerformanceObligationConstrainedVariableConsiderationAmount", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_RightofuseAssetObtainedinExchangeforOperatingLeaseLiabilityandAdoptionofNewAccountingPrinciple": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right-of-use Asset Obtained in Exchange for Operating Lease Liability and Adoption of New Accounting Principle", "label": "Right-of-use Asset Obtained in Exchange for Operating Lease Liability and Adoption of New Accounting Principle", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease obligations, in thousands" } } }, "localname": "RightofuseAssetObtainedinExchangeforOperatingLeaseLiabilityandAdoptionofNewAccountingPrinciple", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsRightofuseAssetsandRelatedLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "amrs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accrued and other current liabilities.", "label": "Schedule of Accrued and Other Current Liabilities [Table Text Block]", "terseLabel": "Accrued and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "amrs_ScheduleOfDepreciationAndAmortizationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Depreciation And Amortization [Table Text Block]", "label": "Schedule Of Depreciation And Amortization [Table Text Block]", "terseLabel": "Schedule Of Depreciation and Amortization" } } }, "localname": "ScheduleOfDepreciationAndAmortizationTableTextBlock", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "amrs_ScheduleOfRelatedPartyAccountsReceivablesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party accounts receivables.", "label": "Schedule of Related Party Accounts Receivables [Table Text Block]", "terseLabel": "Schedule of Related Party Accounts Receivables" } } }, "localname": "ScheduleOfRelatedPartyAccountsReceivablesTableTextBlock", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "amrs_ScheduleOfRelatedPartyDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to related party debt.", "label": "Schedule of Related Party Debt [Table Text Block]", "terseLabel": "Schedule of Related Party Debt" } } }, "localname": "ScheduleOfRelatedPartyDebtTableTextBlock", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "amrs_SchottenfeldNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schottenfeld Notes", "label": "Schottenfeld Notes [Member]", "terseLabel": "Schottenfeld notes" } } }, "localname": "SchottenfeldNotesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "domainItemType" }, "amrs_SchottenfeldSeptember2019CreditAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schottenfeld September 2019 Credit Agreements", "label": "Schottenfeld September 2019 Credit Agreements [Member]", "terseLabel": "Schottenfeld Exchange Agreement" } } }, "localname": "SchottenfeldSeptember2019CreditAgreementsMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtSchottfieldDebtDetails" ], "xbrltype": "domainItemType" }, "amrs_SeniorConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Convertible Notes", "label": "Senior Convertible Notes [Member]", "terseLabel": "Senior Convertible Notes" } } }, "localname": "SeniorConvertibleNotesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "amrs_SephoraMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sephora", "label": "Sephora [Member]", "terseLabel": "Sephora" } } }, "localname": "SephoraMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_SettlementOfDerivativeLiabilityIntoEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of the settlement of derivative liability into equity during the period.", "label": "Derecognition of derivative liabilities upon exercise of warrants", "terseLabel": "Derecognition of derivative liabilities upon exercise of warrants" } } }, "localname": "SettlementOfDerivativeLiabilityIntoEquity", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of equity instruments, other than options, that are expected to vest after the balance sheet date.", "label": "Vested or expected to vest (in shares)", "terseLabel": "Vested or expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "amrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the weighted average grant date fair value of equity options, other than options, expected to vest.", "label": "Vested or expected to vest, weighted average grant-date fair value (in dollars per share)", "terseLabel": "Vested or expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "amrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest equity instruments other than options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Vested or expected to vest, weighted average remaining contractual life (Year)", "terseLabel": "Vested or expected to vest (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "durationItemType" }, "amrs_SignificantRevenueAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to the significant revenue agreement.", "label": "Significant Revenue Agreement [Member]", "terseLabel": "Significant Revenue Agreement" } } }, "localname": "SignificantRevenueAgreementMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails" ], "xbrltype": "domainItemType" }, "amrs_StockIssuedDuringPeriodSharesNewIssuesRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares New Issues, Related Party", "label": "Stock Issued During Period, Shares New Issues, Related Party", "terseLabel": "Issuance of common stock in private placement - related party (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesRelatedParty", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "sharesItemType" }, "amrs_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "negatedTerseLabel": "Exercises (in shares)", "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "amrs_StockIssuedDuringPeriodSharesWarrantsExercisedRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Shares Warrants Exercised, Related Party", "label": "Stock Issued During Period Shares Warrants Exercised, Related Party", "terseLabel": "Issuance of common stock upon exercise of warrants - related party" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedRelatedParty", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "amrs_StockIssuedDuringPeriodSharesWarrantsExercisedRelatedPartyShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Shares Warrants Exercised, Related Party, Shares", "label": "Stock Issued During Period Shares Warrants Exercised, Related Party, Shares", "terseLabel": "Issuance of common stock upon exercise of warrants - related party (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedRelatedPartyShares", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "sharesItemType" }, "amrs_StockIssuedDuringPeriodValueNewIssuesRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value New Issues, Related Parties", "label": "Stock Issued During Period, Value New Issues, Related Parties", "terseLabel": "Issuance of common stock in private placement - related party" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesRelatedParties", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "amrs_StockIssuedUponConversionOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued upon conversion of debt in noncash financing activities.", "label": "amrs_StockIssuedUponConversionOfDebt", "terseLabel": "Issuance of common stock and warrants upon conversion of debt principal and accrued interest" } } }, "localname": "StockIssuedUponConversionOfDebt", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amrs_StockOptionsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to stock options to purchase common stock.", "label": "Stock Options to Purchase Common Stock [Member]", "terseLabel": "Period-end stock options to purchase common stock" } } }, "localname": "StockOptionsToPurchaseCommonStockMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "amrs_SupplyAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supply Agreement, Term", "label": "Supply Agreement, Term", "terseLabel": "Supply agreement term (years)" } } }, "localname": "SupplyAgreementTerm", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails" ], "xbrltype": "durationItemType" }, "amrs_The2019DSMCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the \"2019 DSM Credit Agreement\" entered into on September 17, 2019.", "label": "The 2019 DSM Credit Agreement [Member]", "terseLabel": "The 2019 DSM Credit Agreement" } } }, "localname": "The2019DSMCreditAgreementMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "domainItemType" }, "amrs_TheNaxyrisLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Naxyris Loan Agreement [Member]", "label": "The Naxyris Loan Agreement [Member]", "terseLabel": "Naxyris note" } } }, "localname": "TheNaxyrisLoanAgreementMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "domainItemType" }, "amrs_TotalEquityExcludingMezzanineEquityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Equity Excluding Mezzanine Equity", "label": "Total Equity Excluding Mezzanine Equity [Member]", "terseLabel": "Total Stockholders' Deficit" } } }, "localname": "TotalEquityExcludingMezzanineEquityMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "domainItemType" }, "amrs_WarrantsAndRightsOutstandingDerivativeLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants And Rights Outstanding, Derivative Liability", "label": "Warrants And Rights Outstanding, Derivative Liability", "terseLabel": "Warrants and rights outstanding, derivative liability" } } }, "localname": "WarrantsAndRightsOutstandingDerivativeLiability", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "amrs_WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Issued In Connection with September 2019 and November 2019 Shottenfeld Notes", "label": "Warrants Issued In Connection with September 2019 and November 2019 Shottenfeld Notes [Member]", "terseLabel": "Warrants Issued In Connection with September 2019 and November 2019 Shottenfeld Notes" } } }, "localname": "WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "amrs_YifanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yifan [Member]", "label": "Yifan [Member]", "terseLabel": "Yifan" } } }, "localname": "YifanMember", "nsuri": "http://amyris.com/20210331", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails" ], "xbrltype": "domainItemType" }, "country_BR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BRAZIL", "terseLabel": "Brazil" } } }, "localname": "BR", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://amyris.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia [Member]", "terseLabel": "Asia" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r60", "r111" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails", "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r175", "r242", "r246", "r464" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r261", "r263", "r393", "r394", "r395", "r396", "r397", "r398", "r417", "r461", "r465" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r261", "r263", "r393", "r394", "r395", "r396", "r397", "r398", "r417", "r461", "r465" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails", "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r175", "r242", "r246", "r464" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r172", "r242", "r244", "r418", "r460", "r462" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/CondensedConsolidatedStatementsofOperationsParentheticals", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r172", "r242", "r244", "r418", "r460", "r462" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/CondensedConsolidatedStatementsofOperationsParentheticals", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r251", "r261", "r263", "r393", "r394", "r395", "r396", "r397", "r398", "r417", "r461", "r465" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r251", "r261", "r263", "r393", "r394", "r395", "r396", "r397", "r398", "r417", "r461", "r465" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails", "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r173", "r174", "r242", "r245", "r463", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r173", "r174", "r242", "r245", "r463", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r207", "r262", "r385" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Allowance for Doubtful Accounts" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r54", "r114", "r378", "r380" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable, Related Parties, Current", "terseLabel": "Accounts receivable - related party, net of allowance of $0 and $0, respectively", "verboseLabel": "Accounts receivable - related party, net" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued and other current liabilities", "totalLabel": "Total accrued and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r9", "r10", "r46" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r40", "r202" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r64", "r65", "r66", "r449", "r470", "r471" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r63", "r66", "r67", "r116", "r117", "r118", "r318", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r116", "r117", "r118", "r288", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r264", "r266", "r293", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r266", "r284", "r292" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationEmployeeServiceSharebasedCompensationAllocationofRecognizedPeriodCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r28", "r176", "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Year", "terseLabel": "Accounts receivable, allowance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAllowanceforDoubtfulAccountsDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedLabel": "Write-offs, Net" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r85", "r99", "r355" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Accretion of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails", "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetRetirementObligationCurrent": { "auth_ref": [ "r205" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.", "label": "Asset Retirement Obligation, Current", "terseLabel": "Asset retirement obligation" } } }, "localname": "AssetRetirementObligationCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r108", "r160", "r164", "r170", "r183", "r312", "r319", "r341", "r431", "r446" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r58", "r108", "r183", "r312", "r319", "r341" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r267", "r286" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails", "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r324", "r326" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of accounting" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r36", "r101" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets", "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r95", "r101", "r106" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r95", "r346" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r233", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails", "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails", "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price per share (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails", "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Class of warrant or right, number of securities called by warrants or rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Class of warrant or right, outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r233", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r304", "r305", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Revenue Recognition and Contract Assets and Liabilities" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r52", "r206", "r437", "r454" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals", "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - $0.0001 par value, 350,000,000 shares authorized as of March\u00a031, 2021 and December\u00a031, 2020; 273,266,917 and 244,951,446 shares issued and outstanding as of March\u00a031, 2021 and December\u00a031, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r69", "r71", "r72", "r76", "r440", "r457" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to Amyris, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r69", "r71", "r75", "r310", "r323", "r439", "r456" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Contract with Customer, Asset and Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r235", "r237", "r243" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesContractBalancesDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r235", "r236", "r243" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities", "verboseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r235", "r236", "r243" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Contract liabilities, net of current portion", "verboseLabel": "Contract liabilities, noncurrent" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r103", "r104", "r105" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Conversion of stock, shares issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtSchottfieldDebtDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible notes payable" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals", "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/DebtFutureMinimumPaymentsDetails", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r81", "r418" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationEmployeeServiceSharebasedCompensationAllocationofRecognizedPeriodCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r79" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total cost and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Cost and operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r432", "r434", "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals", "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails", "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/DebtSchottfieldDebtDetails", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r19", "r219", "r434", "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Principal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails", "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/DebtSchottfieldDebtDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt instrument, convertible, conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r356", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt instrument fair value disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails", "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/DebtFutureMinimumPaymentsDetails", "http://amyris.com/role/DebtSchottfieldDebtDetails", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals", "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails", "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/DebtSchottfieldDebtDetails", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.", "label": "Debt Instrument Redemption [Table]", "terseLabel": "Debt Instrument Redemption [Table]" } } }, "localname": "DebtInstrumentRedemptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/DebtFutureMinimumPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r49", "r112", "r228", "r229", "r230", "r231", "r355", "r356", "r359", "r444" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails", "http://amyris.com/role/DebtSchottfieldDebtDetails", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r355", "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Debt instrument, unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r220", "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Unaccreted debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r355", "r356", "r357", "r358", "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedLabel": "Unaccreted Debt Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-term and Short-term, Combined Amount", "terseLabel": "Combined debt amount" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r297", "r298" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Liability for unrecognized tax benefit" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsOtherAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r99", "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsDepreciationandAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r99", "r158" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r59" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "verboseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueFromRelatedPartiesNoncurrent": { "auth_ref": [ "r37", "r114", "r378" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).", "label": "Due from Related Parties, Noncurrent", "terseLabel": "Deferred cost of products sold, noncurrent - related party" } } }, "localname": "DueFromRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r42", "r114", "r378" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Related party debt, current portion", "verboseLabel": "Accounts payable" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r50", "r114", "r378" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due to Related Parties, Noncurrent", "terseLabel": "Related party debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively)" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r77", "r121", "r122", "r123", "r124", "r125", "r129", "r132", "r136", "r139", "r140", "r144", "r145", "r441", "r458" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Loss per share attributable to common stockholders, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Earnings Per Share, Basic [Abstract]" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r77", "r121", "r122", "r123", "r124", "r125", "r132", "r136", "r139", "r140", "r144", "r145", "r441", "r458" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Loss per share attributable to common stockholders, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r141", "r142", "r143", "r146" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Shareholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r346" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeLiabilityMeasurementInput": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure embedded derivative liability.", "label": "Embedded Derivative Liability, Measurement Input", "terseLabel": "Embedded derivative liability, measurement input" } } }, "localname": "EmbeddedDerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationEmployeeServiceSharebasedCompensationAllocationofRecognizedPeriodCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Compensation expense related to stock options and RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r116", "r117", "r118", "r120", "r126", "r128", "r147", "r184", "r227", "r232", "r288", "r289", "r290", "r300", "r301", "r347", "r348", "r349", "r350", "r351", "r352", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r0", "r108", "r183", "r341" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r0", "r108", "r183", "r341" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Percentage of venture owned" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails", "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r38", "r161", "r181" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsOtherAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity-method investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Extinguishment of debt, amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r99", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Fair value adjustment of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r327", "r328", "r329", "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails", "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails", "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r333", "r338" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r328", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r336", "r338" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r327", "r328", "r331", "r332", "r339" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r252", "r253", "r258", "r260", "r328", "r390" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r252", "r253", "r258", "r260", "r328", "r391" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r328", "r392" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r333", "r338" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r334" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Loss from change in fair value", "verboseLabel": "Change in fair value of derivative instruments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r335" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Derecognition on settlement or extinguishment", "negatedTerseLabel": "Less: fair value adjustment extinguished upon conversion of debt principal" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value, ending balance", "periodStartLabel": "Fair value, beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails", "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://amyris.com/role/FairValueMeasurementReconciliationforCompoundEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r336", "r339" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "auth_ref": [ "r333", "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Financing Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r361", "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "totalLabel": "Total lease liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r361" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 2.0, "parentTag": "amrs_OperatingandFinanceLeaseLiabilitiesCurrent", "weight": 1.0 }, "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Financing lease liabilities", "verboseLabel": "Current lease liability" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r361" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "verboseLabel": "Noncurrent lease liability" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 1.0, "parentTag": "amrs_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2021 (Remaining Nine Months)" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 2.0, "parentTag": "amrs_LeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amount representing interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r364", "r369" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Principal payments on financing leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r360" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Right-of-use assets under financing leases, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [ "r362", "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "terseLabel": "Finance lease, right-of-use asset amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r179", "r180", "r186", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r342", "r343", "r344", "r345" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "(Gain) loss on foreign currency exchange rates" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r325" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "(Loss) gain from change in fair value of derivative instruments" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r83", "r99", "r178" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "terseLabel": "Gain (loss) from investment in affiliate" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r99", "r223", "r224" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Gain (loss) on extinguishment of debt", "terseLabel": "Loss upon extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/DebtSchottfieldDebtDetails", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r113", "r160", "r163", "r166", "r169", "r171" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes and loss from investment in affiliate" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationEmployeeServiceSharebasedCompensationAllocationofRecognizedPeriodCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationEmployeeServiceSharebasedCompensationAllocationofRecognizedPeriodCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r127", "r128", "r159", "r299", "r302", "r303", "r459" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r98" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r98" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r98" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r98" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedTerseLabel": "Contract assets" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r98" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r98" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r73", "r157", "r354", "r357", "r442" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r93", "r96", "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r10", "r11", "r46" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r29", "r197" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r56" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsInventoriesDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r30", "r197" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r372", "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 2.0, "parentTag": "amrs_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2021 (Remaining Nine Months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r373" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 1.0, "parentTag": "amrs_LeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Operating lease remaining lease term (years)" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease renewal term (years)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45", "r108", "r165", "r183", "r313", "r319", "r320", "r341" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r108", "r183", "r341", "r436", "r452" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, mezzanine equity and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Mezzanine Equity and Stockholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r47", "r108", "r183", "r313", "r319", "r320", "r341" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r327" ], "calculation": { "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured and recorded at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r43", "r112" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Loans payable and credit facilities" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails", "http://amyris.com/role/DebtDebtComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r221", "r434", "r448" ], "calculation": { "http://amyris.com/role/DebtDebtComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Net", "totalLabel": "Net", "verboseLabel": "Long term debt, fair value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Debt, current portion (includes instrument measured at fair value of $54,757 and $53,387, respectively)" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "calculation": { "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Change in Fair Value", "verboseLabel": "Fair value of debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMeasurementInput": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure long-term debt.", "label": "Long-term Debt, Measurement Input", "terseLabel": "Measurement input" } } }, "localname": "LongTermDebtMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt [Member]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively)" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals", "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails", "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/DebtFutureMinimumPaymentsDetails", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r49", "r217" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals", "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails", "http://amyris.com/role/DebtDebtComponentsDetails", "http://amyris.com/role/DebtFutureMinimumPaymentsDetails", "http://amyris.com/role/DebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementFreestandingDerivativeInstrumentsDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingenciesGuarantorArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDisclosures": { "auth_ref": [ "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.", "label": "Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LossContingencyDisclosures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]", "terseLabel": "Measurement Input, Exercise Price" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Expected Diviend Yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Measurement Input, Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Stock Price Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free Interest Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]", "terseLabel": "Share Price" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueofDebtForisConvertibleNoteLSAAmendmentDetails", "http://amyris.com/role/FairValueMeasurementFairValueofDebtSeniorConvertibleNotesDetails", "http://amyris.com/role/FairValueMeasurementMarketbasedAssumptionandEstimatesforCompoundEmbeddedDerivativeLiabilitiesValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r55", "r108", "r183", "r341", "r435", "r451" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestInOperatingPartnerships": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the equity interests owned by noncontrolling partners in an operating partnership included in the entity's consolidated financial statements.", "label": "Noncontrolling Interest in Operating Partnerships", "terseLabel": "Ginkgo partnership payments obligation" } } }, "localname": "MinorityInterestInOperatingPartnerships", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r95" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r95" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r95", "r97", "r100" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r68", "r70", "r74", "r100", "r108", "r119", "r121", "r122", "r123", "r124", "r127", "r128", "r133", "r160", "r163", "r166", "r169", "r171", "r183", "r341", "r438", "r455" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss attributable to Amyris, Inc.", "verboseLabel": "Net loss attributable to Amyris, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r68", "r70", "r127", "r128", "r315", "r322" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 }, "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Less: income attributable to noncontrolling interest in Aprinnova" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r121", "r122", "r123", "r124", "r129", "r130", "r135", "r140", "r160", "r163", "r166", "r169", "r171" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "netLabel": "Net loss attributable to Amyris, Inc. common stockholders, basic", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r131", "r135", "r140" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net loss attributable to Amyris, Inc. common stockholders, diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Standards or Updates Recently Adopted and Accounting Standards or Updates Not Yet Effective" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r116", "r117", "r118", "r232", "r308" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r160", "r163", "r166", "r169", "r171" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r361" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "totalLabel": "Total lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r361" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "verboseLabel": "Current lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r361" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion", "verboseLabel": "Noncurrent lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsMaturitiesofFinancingandOperatingLeasesDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r365", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating lease liabilities, in thousands" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsRightofuseAssetsandRelatedLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r360" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets under operating leases, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r371", "r374" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsRightofuseAssetsandRelatedLeaseLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r370", "r374" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsRightofuseAssetsandRelatedLeaseLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r57" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "auth_ref": [], "calculation": { "http://amyris.com/role/BalanceSheetDetailsOtherAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Other Assets, Miscellaneous, Noncurrent", "verboseLabel": "Other" } } }, "localname": "OtherAssetsMiscellaneousNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsOtherAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Total other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsOtherAssetsDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r310", "r311", "r317" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r46" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities", "totalLabel": "Total other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other liabilities.", "label": "Other Liabilities [Table Text Block]", "terseLabel": "Other Liabilities" } } }, "localname": "OtherLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "auth_ref": [ "r20", "r433", "r447" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.", "label": "Other Sundry Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsOtherNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r92" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Issuance costs incurred in connection with debt modification" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r90" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payment of minimum employee taxes withheld upon net share settlement of restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "terseLabel": "Consideration transferred" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r267", "r286" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of March\u00a031, 2021 and December\u00a031, 2020; 8,280 shares issued and outstanding as of March\u00a031, 2021 and December\u00a031, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r34", "r35" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r5", "r198", "r199" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepayments, advances and deposits" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r89" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from issuance of debt, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r88" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from issuance of common and preferred stock in private placement, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Proceeds from long-term lines of credit" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r88", "r287" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercises of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r88" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercises of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows", "http://amyris.com/role/StockholdersDeficitWarrantActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product", "verboseLabel": "Renewable Products" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/CondensedConsolidatedStatementsofOperationsParentheticals", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r68", "r70", "r94", "r108", "r119", "r127", "r128", "r160", "r163", "r166", "r169", "r171", "r183", "r310", "r314", "r316", "r322", "r323", "r341", "r443" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows", "http://amyris.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r40", "r203" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r39", "r201" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r203", "r453" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r201" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r78", "r187" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provisions" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r259", "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r259", "r377", "r380", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r375", "r376", "r378", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r91" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Principal payments on debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r296", "r484" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationEmployeeServiceSharebasedCompensationAllocationofRecognizedPeriodCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r13", "r101", "r106" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "periodEndLabel": "Restricted cash, current" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r7", "r16", "r101", "r106", "r474" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "periodEndLabel": "Restricted cash, noncurrent" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r1", "r13", "r106" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r7", "r16", "r106", "r474" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash, noncurrent" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Period-end restricted stock units", "verboseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails", "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r232", "r291", "r450", "r469", "r471" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r116", "r117", "r118", "r120", "r126", "r128", "r184", "r288", "r289", "r290", "r300", "r301", "r466", "r468" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r155", "r156", "r162", "r167", "r168", "r172", "r173", "r175", "r241", "r242", "r418" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDisaggregationofRevenueDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r80", "r472" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenues, related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperationsParentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r239" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, remaining performance obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRemainingPerformanceObligationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Purchase price of sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/MezzanineEquityDetailsTextual", "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued in sale of stock (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r49", "r112", "r228", "r229", "r230", "r231", "r355", "r356", "r359", "r444" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r266", "r283", "r292" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationEmployeeServiceSharebasedCompensationAllocationofRecognizedPeriodCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r266", "r283", "r292" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of noncurrent assets.", "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "terseLabel": "Other Assets" } } }, "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r40", "r203" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAdditionalInformationDetails", "http://amyris.com/role/BalanceSheetDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r110", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyAccountsReceivableDetails", "http://amyris.com/role/RelatedPartyTransactionsRelatedPartyDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r267", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails", "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r233", "r265" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Sales, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Sales, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationEmployeeServiceSharebasedCompensationAllocationofRecognizedPeriodCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r98" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-average Remaining Contractual Life, in Years" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Awarded (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Awarded (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding , beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Quantity of Restricted Stock Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "periodStartLabel": "Outstanding, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-average Grant-date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Outstanding, beginning balance (years)", "verboseLabel": "Outstanding, ending balance (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Released (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails", "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Remaining number of shares reserved for issuance, maximum limit" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-average Remaining Contractual Life, in Years" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited or expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r272", "r286" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Quantity of Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "periodStartLabel": "Outstanding, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested or expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "verboseLabel": "Vested or expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested or expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r265", "r269" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails", "http://amyris.com/role/StockbasedCompensationTemporalDisplayofSharebasedCompensationRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited or expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/MezzanineEquityDetailsTextual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value, in Thousands" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested or expected to vest (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issued (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Outstanding balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/StockbasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r53", "r116", "r117", "r118", "r120", "r126", "r128", "r147", "r184", "r227", "r232", "r288", "r289", "r290", "r300", "r301", "r347", "r348", "r349", "r350", "r351", "r352", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/CondensedConsolidatedStatementsofOperationsParentheticals", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r116", "r117", "r118", "r147", "r418" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/CondensedConsolidatedStatementsofOperationsParentheticals", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquityParentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r21", "r22", "r227", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in private placement (in shares)", "verboseLabel": "Issuance of common stock in public offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r227", "r232" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r227", "r232", "r274" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity", "http://amyris.com/role/StockbasedCompensationSharebasedCompensationStockOptionsandStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r53", "r227", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible securities" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtSeniorConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r21", "r22", "r227", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in private placement" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r21", "r22", "r227", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r53", "r227", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r25", "r26", "r108", "r177", "r183", "r341" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Amyris, Inc. stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r108", "r116", "r117", "r118", "r120", "r126", "r183", "r184", "r232", "r288", "r289", "r290", "r300", "r301", "r308", "r309", "r321", "r341", "r347", "r348", "r352", "r467", "r468" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets", "http://amyris.com/role/CondensedConsolidatedStatementsofStockholdersDeficitandMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r107", "r232", "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails", "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r353", "r384" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails", "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r353", "r384" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails", "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r353", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails", "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r353", "r384" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails", "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r383", "r386" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/MezzanineEquityDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/MezzanineEquityDetailsTextual", "http://amyris.com/role/SubsequentEventsPrimaryandSecondaryOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/MezzanineEquityDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Tax-related liabilities" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BalanceSheetDetailsAccruedandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [], "calculation": { "http://amyris.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Mezzanine equity: Contingently redeemable common stock" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity Disclosure [Abstract]", "terseLabel": "Temporary Equity Disclosure [Abstract]" } } }, "localname": "TemporaryEquityDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r179", "r180", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/FairValueMeasurementFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMIngredientsCollaborationDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMLicenseAgreementandContractAssetDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesDSMPerformanceAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesRevenueinConnectionWithSignificantRevenueAgreementDetails", "http://amyris.com/role/RevenueRecognitionandContractAssetsandLiabilitiesYifanAgreementDetails", "http://amyris.com/role/SubsequentEventsIngredionAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "auth_ref": [ "r134", "r137", "r138" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic", "negatedLabel": "Less: losses allocated to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations", "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r99" ], "calculation": { "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedTerseLabel": "(Gain) loss from change in fair value of derivative instruments" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/DebtDSMAmendmentsandRepaymentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r148", "r149", "r150", "r151", "r152", "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates and Judgements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r131", "r140" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r129", "r140" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://amyris.com/role/NetLossPerShareAttributabletoCommonShareholdersCalculationofBasicandDilutedNetLossPerShareofCommonStockDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "65", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2793-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "66", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2814-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/subtopic&trid=2127163" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "450", "URI": "http://asc.fasb.org/subtopic&trid=2127197" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28567-108399" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.11)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r386": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r485": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r486": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r487": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r488": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r489": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" } }, "version": "2.1" } ZIP 104 0001365916-21-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001365916-21-000017-xbrl.zip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�I(I!)3HUK1N=0@M;'L!]ERUQ$J-[&2 M0@@"#5KVJAE)*DFJQ<2QM&<87FD\E(7@O![IV+\C+^5X]N)DPT4JMRB ??,7 M$8CX;(1[+2,*; JGL=3-O!Y$1ZA AIGKX"1DF^\SX$ IE)(8@2M*[!AJ+"%1F4FM M54QJBA[ZL>C++53F5KYD9< MC224G:T)P)A2JKJ6E%HDU2PA[4@T.F4RS.2L3QB2P50!0&*FX,39[*&80K:. MI<[*SKW\F@5L$S#E&$7="6KX&VOQ4FH 7S";L6C-V[W/S=/Z[9'CR4J;Q".I:+C\A=QOM^9J;YXN M-T]=N>GAY.E4GU]54_10F3L]DUM/Y[(\:Q,%M2DF)HG%M#[5A[YOAW/-L6W- M)+%CV6B_3K3] UIHQ]P_X$*##>Q+,0#J-M6?@HIY]:J-:L96QC))O4[,_6," M;$?>SRL[43GP+L5T4+$'$JS!J(E_3%6BIZ==5)&TZWH2VK MC]#V4%X)YJ%K$$#JEQ\:V.99/?X'3=2DTY3$*6:@!*T%P" R&8;"JUU)*E MDJTW&S"1N7/.UV;M( F6P"6* =<,^MP:1R8JE@7&$H_LA.06!#U2J!2!#;@.2V!Y/&DYW*]^C#WF.#$V4U)54&UPJ;BQ](!:HZ7L[R=S/752CS:;K58BW,.<]F XAI? MBK!;*28'X:PU-?3BN=0L0\P1?4O!E@B64K,TEL9 .Q<]3&/*PAIP>"S9)'#> MDAC;O"T PE!(1A**[ 3E5H0_&+ :UY =(93<]RRH>_:8A!S4T90S6P/_O'V" MMK9D]G4L.9)K)"A_F+S$,\;I M.Q4'#C<\OW>08"B+21$H9"L(L0I2<,Y5%98Q!$AE)-S]\ES:B UX3!WN28H M8JRQ$9F& 2$1(B6U%^@]B1]1\X&=8!DVC42R2S6&5GLQ&G18,HNE*+;89' L M.XAW@F5P(N6J7"K1DJP%'#!$5H'EB#G MYC4G_6ZE0-B"K;">_S.2L&6%@G.4<8,-/A@-%()11T8QD%J#7+@O;4DQ,!9CL$8P#E35 MPTJ*Q81(O06 +XULWRN,T3JJ:/]Y;YT'X=KUM=>[7@CI:[3ADZER0\_][7B^ M//)'EJ9-$I>J+>KC(4?,QD2QG"O[G*6,9>'IBS*BW_!A9\&;N_27^_AZC9EJ0O(0@1"]NFQ]3;W0I(RE',9VVHSAZ8/-V1K9]4#V+"9_A\:T7+^8SK$U.-7TYG\_.1.#U0F5,;MM(7K=E6BL6%& !RZDW::.AU)E\K)KZ"\228]7?95<+5C!'*6"#5A8&B4IJ=;B:4?$/TO$_AF.CZ6> MZGLTG%-D3L\OJ+(CYK_-[*%2; ;3K>$R0<*:''-)Q?;"]W$#$B2N)RSX\+S" M)5*87^SOO-F>>=Z*6S3GG6?1N$WIZYF33MR0*^\ MK6! 0VU4-@NDWEU)*-GE5-R.N3OF_K[??Y^,?\+OYP#+?;5 U0!'=?HV6(M9 M0$)5D[KS^SM6KKDD2*6EPL:"%PM!$C'ZRLGVS3$AR!@ZX'PBJ/>F*NUXHK]? MO),$<2K92R:7$,2;X[#J\/AP?:.RTFV(94JP??)+>VG(1BT("I MR 9L=UC?SLBC-'K9>2(/H:4$$+R4R(@,H;1 EAE'.Z>^43RYGN44 SDPMYJB M@^!"(09L7HU' I^X# W]J3HQ_GT?=Y$&^E!.<#*=3)]^<'7C[NL74D^%'TU. M])3[[5!_NVA8^['#RP'V!M%OKN?"?^%9O\X%=+ M6S#J_8]U7$V9@LM'$9%6 %\RNV)1% L6H/_".=2MF'>Q8U[=]1F>S MD522ARB$$5V6$CAQKM6&H5GW\>F+.T*G]_0!S,_>F[OX?C:?+ YFIZO+E/IQ M-GVJ$<1)OV6?-7EG]N!8<><'/;CHAU=URZO7?:01Q.(-TQ;?G5\]\OZW_H<^ MB;.Y+'[\\?9(X@MC*6?'?2FA 66K_C$G>D8-8?':.,EDL7)WD(.MO#3\; MJP-\?:Z>Z_#6B GZNV/OXLM]POA;%T/(C4OPN3:+#JJIF5U!2WVYM?H6TOH; MPAT#AV#@"A4A-9]#:1ER!+3*0V-+C=$!UNIHC1>]5H__NE@%:"VH1-+''@WT M10*QD(.OQDG-E48@C]8%D]6-$PI QM<@6;6"4- PJJ8:)6<-Z$N$]1\GW^%Q MG^L[/!(Y_7%6W]_Q=*O6OH*\^'4+WD]3FAP?"U]%;%M$YNH&<]7!3(6RE)8@ M)""))D3C"^36)(Y@,.^(,XC%:=FV&@(Y08$2+"772+!@:!42#[XZ_*>)4L(2J5 MI":P0,BIUQGKY>K[GBQ>?S;=>H5S_C7H_95DB]/YI.=6')[.ZO.?IA-U8X<_ MC026D)Q4=N1R*!8@''XH+/ZR_FAL;P6E21 MM=6KNX+00H <5!!A[=L+I'=Q;'5,[8'O3>OL1 Y/E:#]G>_*DLN3;L\6ISU= M\..5NT8YRDH"\,XJJKDH@*[4W(I&4;&D"K6-H:/KFL(YR-[ G'*L!=%1<."C MHX:F)'39LS-Y%/WG/@O.#^_^[,F^'Z\J-L1IPOV2K 0(1 F6L*''.$N'$C^%".CR?3IS_(5.9XK##? MXI->2?6T;[1\*1=(;Z3O[3FJU)R"6!PDC#DW,5'-M%%G7/C]V',']7A'=?$0 M;1-N+0O$6,ADL(C>15N=:JW1!C-W3UX"+D V<+/9%25_;*-JOK ,VPYM1,<6W!FHP@^B@XJ)6-5+3?_0V 4:0^__@ M&*?O-V#JYN?NO\[T8ZIM[;=X*?VTD0PNIM)22C[T(N(I&8U+H)%UV86 ,/RN MR#^$R0?@<&H?1@()S8UYA M<[/^N>1?9SU Z>7_?VN1WSOA^JTQ[)G\B=;XZJE_IGBK%S:Y;X>6"%@B1O%6 M7Z9@T+=P.?)W[!HAN]ZU2U<)\V>*A;C@F]=XI_==#JX158_%^Y9"PE;]MMBE M6R<]PWYSR#*\*;*IQM+W/]7<$PMM;L""S5+52-NG-@Y3M(%#7E*M&GB9EI=) M?4VEB7%EGJAWMKDR?JGG/K50;)4/)@.*ADF5RQ>H_L-FT>R,7 M=DQ;.=.^GKR^J9)L=C:OLGCS\DB0EQ^>)R^__4;_NDCIV(C MDV\&'#D&]\\^N?'K>Q:GY\?*K)/)=.]()D^/3F_Z^.+T_[Z:\.G138W$__=7 M[YS7/\T>'D^>3F_V"0>9Z^'%"YQ^^PW-O];KOOGYS>5__/E\3H[GLUO M_G]F^;__V_2[[S4\F1R?W_P_CY0#BQL'\NK&P]D)3O_/?RYPNMA;Z--J;TY< M3'Z1FQ;THR]?OGKS79)>1^V@7'XWZ_H7^NG@WJ.[=VXW<,;MP[NW+C[/[?_Z];!#W=OW+Z_OW_O\/#>_8,!OX+]I*_P M,RZ.U R>/.7V[_Y88S VQVA8FI?W'.)H"WLH7^69$!N M7_$/4:L1UL)(PBR?_JTZ$D9BL1$(M+ABIFV#I*-SJC*??#(K%QY)/<+>6\PY MD=3I>U/[2EV=H-SYUIM*SQ8ES0F^-JX#%7]?FDKOVP>\_ZU)JF?N9.?;X7MU M4C^QEX>5+Y>UJVU2ZWQBU9.]B]K[6NNPL8,/W^]>'9YLPVIG-[YG[_(#J;6; M5SU2[>S1ZHD]KUT=MNN-75AM[)\T.Y\N:IW]5A4WSVN5OUKQ/;#:EAE7%[T[JG_\^J;ZOXEIE^Z)YLO?- MO?^;NG__U3[$[6_FI(>:G_>NFB=?6:VSRZJ='5AO[%W5&]6KYN M-6&U\JY5>RJ[G\MU;O^]P?NYSY4_(F<#U.F^?4;3*\?(1[8U.3W=.#? M7/_C#]<:G+;U971WBKLJ/O3'-]\?MJQNCR\Y[)V.85RI3]SK1%Z^C^EVC\1B_%"PW_&%\4 MI"N\P9N83?RN7VS_Z)=S1R5X2^KH;:D;F>-Y U+1EW 8/QW7+M+*N$J]MM'M M=F]H>A?WX=7>6>0WOM^^W/>GO?YP):'K7=O]JUSSOCS_P=OXMU#QN]R\/&?KM:^>ND%J&M M5MSC'JI_;I+:U9^=^/=Y_7.M$^\9-?^6YQ\:V\/J ;R(?Q]ICD/ 3@-.N (T M;@W00C" !4=$$@ZQ(1M;__U?:0[S'S\&OFOU>1G-6)@>_)14%'JP]VE[O[&S M_Z%9VM_Y6-]OE#Y^VC_XM%UKE!KU4B1-C0+XORROW2\-B7_G.MU*61 M#U**KHEW__U?B,,_7A)RWKB4GA.O>.STY:77?=^]#W,^%C>U,W*75A)QGDZ6 MJE?5(T25DG&M :(2 2H9 H9K E)XBVG&):)Z8ZN:LA)'>T90N906_#:"E&:6 MR!419%#?!YEJ9:JU5E2K*)!MI22IE>=:AY]W(]KM1([E(J>*/*FR=U&O?+UJ MQL_5TWL__]VJ5_9@[>K3+:YUVHY(B9OQWFJXUCD\L3#R-%IOU$XB8M*(DL?Q MVC1>C]1N<2W/B/?880!9D-'#M!Q(+@*P$A+A**5.A#'7HIEK/ M^9%5B@9J/&#&N0@#6 %)6(CDR3(;&-.*NG2*@@"A4K*?1IN671HQ?I0TOKC4 M[?LO12)]=YB2%G\]R;LXPII[X6 BN D>18!B10&SF$MB'$6 ME$N[M;>;SQ:^U\:TWW8NM!T6>U_JA5+_^YZ7]* T./4V'4.Z4JM;:@T')7M< MN)G?(Z:O3.N*.QX[M8OV%:)IW80CGCFSL\ W%59S]Q;PIJ0/?_*I5TTW2QY^ M^75]D,<2K3^60+U>QP<9I/JHTW[O6]+@Z>#+",53&57_=#QCL*BF*J8?]B_? M]MQJ@OK((:F=Q/MZOX-K)W]W:E?5>-W#D]K)<;RW>%^53_']>S %<2.PWP[^ MXGIE%S8;35S[')_V:AO6.E5:^+#=1-,.B? *:4XT ML%9S0+D@D8GP^*.Q2$K.@C"1B51\6Y_KOG^V1P*3FFPLB_.ROCIU6V4:^F)W MG($SJCE<8>[]VLJR>Z,LQ!/FC0(D\.B](TV!(=P#JDEJBF0D#G9CBS$ )>.( MW0EU/N1=_B(&1OY,%XK X&\%HI=Z_5(OM3(KG9SU6P/7*GJR13[W($M:M>=L M35JQXG'[7W2W=57\_'M&UOD(T^[F_N;!9FEIM=N[GTWN6+F^IMY_I^,!C_]2'> %I),_VL7"QX9(*$@C $K$PA M,FDTT H7@0JD#*&>R61KI62E?T=WMS4H'0S[W@]OV]SRR\(SA%)KVT7GN_L;43]^#R6QHSL#A] M+WAJO?^QW_L6N=QJ!AZ>I?)71X;($($Z1'Q&<;.D-T 9@X'V3+FXK H+OK'U M=OMNSLMTY4-#3U+G?!1T! 9Z!!@GD0SBF#<(<4T""1@JS"A M5LB-+45Y*@%9,4#^[06E*('P=M_K7T]NKJH->V0U,819"UA(V5TDRHZFS )! M+(&6>V/Q[WN+WMT#(]4FFE.I #.*A$56DB@N2' M:Q6@)3S2XPBYE$$ !?])!.HU=?JG;NU(I<>X7=)=5QKZMC]-NUWJ%MN=3O-. M^]'6MDYUN^0OO#U+'6;BKZ,?[ =WBQZ>>"R^F$/ @_@X_:)7__C(TO>]*YV> M]0=GZ>QRV"O%=Q3./L*_F=_38J0TV6T[?+/PDT,E-M73L@R)V,1,SOV(#\G- MB%/S/SF$CSZ0_$E@=[SP1;@)G0Y+@UZ[Y4K74C9^-2[P/2_^((PWVN0' WF+ M2%ELM(;MXAS>:WMM^)L;%)U:T\^0:N4+K*;? M-8[;M<:7B^K5[NU#2%K_W+RH757AX>>]\\/W35AK?"7-ACVO5^+/G_ZF$$7&E 64T.MZ!(R"AH0 Z(DC*W^+0C!([HR84S1#*I7\4 MB3VH=*K[I6^Z?>9334UIM%E2H-SB)1'ASW4@KT=9WM\%@/;S_%N9Z^U72?HP^/'^3W^/GTRW,KY8*BD;%'=2W*D>#$L*CJ[@].5@<_3/NW^^ M^/G!>(+BJ,BM:%RFAV>#E<229YT@T"-",802(V"LC]:4BG2B&U&!2&<8]DIJ M%:UITP]NZ_WTKA7= Q[:SEKOSIOI3_+A6]V4 ?,&IS+5[V5H*XP326&BKG1: MPV%4,=^..M/O=9,];U^6?+3MEZ5BZ&@:3OK-ERIZJ$W,^M+I%>?<@(<%__Y?$.#[F W=8 MO(S^N'[;3]_P\/U=OS%QB(T'[G(CE6PE(!N3(FP OJ9#DQSH;@[A\I5+H4W% MV=R/)]BFX"]PZ($W$9K_9=/-DD4682W"+_Z0-&DDOQ/:,OI%H3*/B$#<>MY2 M^IO<24Y>ND>_#?#SSU-?ST!'P4P*V4AVY4NO?WE?35RB@OVWXS>L)&.Y;LK1 M9+4KUSKL-"_J[ZM7J12G]GGW(MXK;5[MX6KGKZ^1P5P_HH]:[XWCGNMVJ>%'$7>1\DREJ_6)AZ,Z.G( M&G_GJ*,?QQPTZ_BK6\&B)Y77W:#; W_7\!6;]N?9(-[38#7C7U>Z&2J5I]ZZ M#D>'X0=1N'*I=7_PL!7N.RPHC@@BU>SVB@C_V6 4P8O+4#3*+0V_=VJ\#L>G M,'WZKO9E^O+S5OSJ^+6E;GRV7@K*?6L-"NK:U5W;TNT4\$M]5=*;TQ KI_MN M4$J-65KNHI95!M=GG8>P(QNYD$)> *YE2BDR$AA/!?"&$>R0X\C3 M!Q'R_D./>[SBYZC%@SCXQ\.7>O42AV*,8ZEW-BSP) '+6/AO&O/]SR"I3,I= M'*3$DH=K&Z9)$G^@-<-+!/X%W*1ZVO2MR'N+ZG'5;(TY1K,5@8YIGI+GHT=H)!A6F M5&B)D(.(:1%]!ZTA'@^*99!N1*9C6YWHL/WOQF[MW;0[USWKN-YP_(9[$J^* MK2IV:F0N)J0W[D%VI>W M)3S"T%'&& %I'C"@G'@@K7) &(X81\)!B3>VL$)E*E 9LN_MBJ_EZL%0T>.= MN1^0F)_PH]D4/TIN]3 M0W_^!8P3&K@#I+VPV"1XKBDH M3PUMK1;'NK^'Z<>(4;,46J[!0MS/JCYN[S=*NX\O)?IQM<_=$.AZ'+#L#GVG MA#9?EG _^&@A+,03^Y=>FGLI'?<3J_^O1\QG)AM;[[X'A8NN5Z.RC=_.NOK, MM8;>_?ZO?^K9#P+FXT$5QU\/"W'>Z=EVFCRPE:^"YEF?7V.74TNV7G*ETG%/ M_%=A>(JTI3]U.ZJY+QT<>Q\5_#I8U+?'I>OQ?46*=L7;8E+]]6]AUO]UD8RL M_VN_R^I!_9\P[E'QZZ=^]#4W%9J-^"V^5!V5?NT4Y\SWP$-&A'62%9H18QKV2@] PWVG#%G'UV7WT4-XO6ZGFCB? M:BZ_1*:W+0:N@*C?HE.!K5%F3 MWK/O!V?MVQ'3#%OK(B18_2*P13)L+;]$(LBC*=U+A7>M89'#6F!0_$7[^N<$ M8>W>X"R5VFR;WMEPW)RUM-\:?,VXM#Y20)X9?UT99*(9F99?)M4HY#/LQZTI M,.ECOV>]2S"406==-IC\)'1[J^H"C9GTY3OQS?;?7Z$X"4P6=M=OJ7 9]\ M>+ 2(IFF2E93?OB!#CZRH(E3S(PZZ[/%OPSLL P[*R"3"&]LU8L.OKO=49.Z M>*F,-VNSM[\,W/ ,-ZL@DFQC:^?BN&5:.;%]C;:4O'**:-;'>6V>W-@ZV'U? MVVY\VM\Y>))&SG>:Q7*T-+T',AXS4^.%/O:*]I2FWNQX+@_VM.:O"&YQ4QUG"&R6WNW6MFMO=[<_E X: MV_&%U"*V]-NGVO:G2GQ?Y?]\[BQ=V@7/(7UJ=VN*-A M,>D(_/MXAI+NI(E4@]^?Y^R^9J;N8Q8G52*.&QP41GAJ),>:/.$]+2,G'G!= MQ#P:M<' #Q\S>F;V[L\S7F=U6TC?7ND'AKJ<]?M1S$NZ6/$W,RC,"Y<1K,+: MI;8K"5IM^H?_SUGKFVZ/VBU,K^(]CP9+*_" _WC,@_QQ.R:V3$_PX'">LX&[ M-9G'<8*9(T$SA*F23EIF=)!0Z*('CR3S%X+^;R3R /&(PS]D ?-'Z]$T2 MF.VN2W_MW$C+]O"M[O?3.,F_TQRE[_-YR(+G\]1:JF,[[[KUD]K7VON_VX='5J]LO%[W[73H-4/9/^XV;EHUT]V6#.]5OD" MJY__[M0K^YUFH\JJN'I9;S0O#SNUK_%:G6\ M7MF[./S(&#/>$HA] 000X0P$RP4$E]^!( (WP5Y:0&3P@%)# M@404 6\EX4RIX-,H9@++B.'7QX'U(4#[?C#LMXH!RHD"/4@>\;T/=R_RK3)P M/)U!3*/#S;(F@!@S](P&,Z!![>T$+; $&>=# %Y[%-$ .: 082 (PZ1!U#F% M-K:P) NA!+^:DCS=NF8EF;N2W)A,8A7F%!I -8U_**Z!\5H!K;F/"F)8T*ES M 51K8R_G?VCU.%W9MK8(OY;ZWOI(_4S;ETM=/TSU26EV_'DQ/";^\(\%F)[M MZQMXU^M7>F=F&,[:US>\__U^L[8]0=NBEEUK6[Q.V_][__+PLSLUF/+J^^KY M86/OO/9Y_[B6)L96CMN'G5UT6/E*X\]7]?7J$ZPW_@ZURJ4=8B7#6+8,T+KK-@+;U@-7:/;(@@0J@& MF$L&J$0<*(4\T!)2'STJ%:R-@I6*@6\)5CG"V>#4VY0]T[[\20+0+T)U7C"B MJ#O]P9N[^E/SP[$*[5S8]EE:VOV4TN3=1]U/M6=9LV;3K!LOPA 2N'$$$&X@ MH (&(!5$ NE&$,:FL*+$&68VCME1V*)'8FL74NB73?NAT(:$8T#T%!00)WW MP%CH 7*>$()Y8#A%['!9T@5HU_I[("50ZH]$N70:9?ER\1[) SHXR2/?]KUK M#=, K6DUS"SR"=K8^@&+Q(>M>N7+>?.D26I7?WVM5;Z0)MYAU:O]XWJE?5+_ MO'-1_UQ-UP^UDYTC19E 2 6@+/. *B& --8"YSAT42I,X%&9X>*=DRQC*RIC M7XZ44W&O@P+,*PPH(Q@HP200W%!C261KGMXG8]E/><'@T1U-RCHS!YV92'!@ M7!.M)9",1Z$W4D>AQQ801%3<'N,9-*F0:C')#;^:VKQ"GD#6J!?1J!N_@RL3 MV0IG@& 9_0[&(5#,*4!#I"TT1/1#4:,0+B-TUY:LJM^QB%3)^(ZT;.,\TYPI M\/*YAN,5_]P:'K\]&\15\?TBK?HFBI%A8Q;8F,PTI,$CA*T S"$2#3%6P'") M (921Z=FA6\'_;)5?MGSN@JN(0RJYUV4,%Y!\NSYV?;?[+8IIKU\T%\XV M_(4]Z^O5OHS,/T/#+- PF4\3H R!60XTDQC0Y$=+:5+JL5;41]ZOH(Z47Y0Y MR3[TBAOCK#G/UYP;H^JXI\$% H3"&E#F3-0A1@#3*NZ70\$;'C4'ER7/U6W/ MT)V*#[Z?9HO8WJ#(A3GM]]R9C7[SH-=VV7E^7>?Y>C?>QLWHA8_CK3B(.S%) MYC-C?T+I;&,[ *A3RD.$@0$'.I*IT#0ZV-/U),*8)6.;FQI^/]4M5_(7I[X[&#<_ZQ7MZ>U4LZ-LL5_<51[OQ>8P A23UN< 8:&%T2H(T@J?<>9,:WJ@R7D36_"^H4J_@0V>5 M>@&5FC#2%$F%B0*.&0RH"BP:Z=0_QDNL& Y"!)@J(,LHAZR?HU2-WE"W9S?( MC^KWN);0\@K6.H/(TT%D=](N2ZZ$-I1&0YS262+X@]1! UA$D362D6B>-[8P MP]&)9K.AR*,58+Y6^]?5N]?(\LYZ]QR]NS'>QD9(M-%D]]H1SX?:KVVH*V?^7;_7F:[KK'W?D8PO,^'+ MITE;3;CE,MEJ*RA.;?(@,%!!()B""$9+#:U/!VZY8'IM3'76ICEKTXVU#@8K MATE4'P<1H%H8H+PCP&*K4>JQC+Q.VJ06D:^Y/L;Z5D_U2>NO?C6=\>ZX&OAW>M"^]& MYV 96V;"%CMIA96UU"*B@*6$ 5 M6JA*3;B]W$H95 ".0PJHER1J$U5 .B$9Y1BZ$ J5HME@/\=@IW^#7@!G W_= MGJ28;ET*K:[NVO@8I;:/@CW()\BO$YA^5ZR[_Y 6O=B=>O@T\ 6@9#R9"4^^ M3.5L:^2A(=$FXS1'0'H#E*,X.LK62@BI@>D 696QRBG;*VZBLR:]@";=6&;A M/"34>D 94U:$'F;+_-J6N7Z] M[AE1GHTH7Z?<9TD@]<8"&Y $%%D)-'<6,"248=1BF>:JJ3+)N5WK8INS+LU5 MEVZL,^2Z'#&@<+, XFN;H00<34NLO6$:+F)>U/N:Y*/_+%L MU\7F9AV:AP[=V%KBJ4(A&E=!59J>1P70'GH0.().(2X-T1M;I!R]XFQJGUNS M?+^IG4N=Y+(]\#^>_93K@HJO5GV=87 F&)QJAP(QMA@+!8S7Z:C.." Y5 ![ M:&"0@EG"4CW)$^9RO$;9=8:0M8:05RLDSQ R*X3<,"G'!8?6"2 "-H!"&\$$ M!P>,$U)3*:Q*O54QQF6)<@7Y\[5*W*M5'UK:M-I%4EZY5/575[H;WU-*=9?# MRZ*>_LU^/>^VXHH/_*55\:-G6PT<# M/NM"J[@_#\R1&5<+MF_VZX7RMM[=?2H+^& M3S"6DX\C,@L<5](&1K'DT4>@M(S8 M F(E6?570_5? TJ4!H92 K!D%GKIA>4BJCXJ M0YK;33R/W/3/O+NG[_($7\Q'E:]!'M(^3#A3&42> B)3/26D0DH+2X#E@0#J MA 8JR%3GJK 71%@#?=&S!N%ZT*<8%,I3S=]?$$F=EFJ\RW=AB[SV4VCO@ MF?* ELP!BYD.'AEB-!G-WLPU,\_)7XCO2,N6C?"K&N'K9?_<&AZ_/1O$ M5?']C![/0H^IUA).:Q_)N@!4T,CDXSX"I24&B* )8+*L;"QQ0J5N#+)22&"-.?"$1)5RE@%IO >$. :U54BERAI:IGP!<:87,LBN]6U! M8PK,L/S]K/BTUR_TZ[=6U[;/7/R65GI8D&>E@*NM4O?=/M M,Y]&&_QC.4Q>T9WM0Z_[I>'[G?1@8UU\%V_V[W2O62EG4LJOP^K;L5*^5?#P M_XZA[?S=U9_56?WDS_B>'5C_'._UY--5K;%WF9XAK4^]XEI-O'M9/:E>5*_V MV_]WM7->;WQ%U?A:7!]:N_IR%*S TB@&L)46T%0V)Z5'@$CJ%:5"&RDBY:9E MP>Z>0Q4Y#K.(W$LW!,PBM_0BMW>DN/,.!08<#BK-F)5 $<\!I]H&I;3'G$>1 M(V4B[XI_?SS0K*]2L"G7CJV!"O,$1 M9XV0//HJ,%7M<0N(0]AR['QP-NH *ZM%U"S_@BKT"LY*5J$YJ-!$_[M(7**V M$,!Y2F4/5 !)M(D.2G#.0G)J)%V;_'2\G!PWG8WRO? M[SD].+YGJ%.C-SW2*2."L(EQ"*Q26J6J\ MS&?M.Y$M\=T&/$^K)GE>6XU5AI77<(YS:OSSX&2JCXT@ E%N)<"(*T#CI@&C M& ?Q)QXWDCJ8#AT0%64T:U+-:_2QR4K<4+X MP)E,S>?SF"=JZ>X/SF,^G1^F[S_9O8K/V8G_M9OQ^PY/7+M6B?=2V3MO7E51 M[:1)_N_JZ_F1(@1*& 3 PB! I<% W2<_^>QN\6=WN>/PT_5GLM6FCE+. M! B!,T"19T![P^,?&&-$,9:!1Y9$RE+D7,-U\3.R%LU%BVY\#8V((%[8R$," M!C2:#R"C;P]8Y"'$&28T]AM;F*]5[=VBO(G[CO%6U*.8".!?9E;X+'VL/LP* M.Y\NJY4=4JV\BXSP762">[AV]6>K>177XO.[DRK^NQ/7B58;NRRR0GBD&-7, M.@(4D=$FZNA0Z$@(@==40"L\4M MCU>196CI9&CGO+IW5' G*"F0(34Q5Q # M*9E*'8A%D%(&;T+V+9;'M[CG1#63HZ&U\C>7J\_&0OY&S!Q?5_R-CRQ.Q9:HGIB=QEYS"@!@;*2O! M!J@ .6#:,FF\X9!'2RW+&"X@^^D7U*?%M0#)^O1T?9KH J*A8A9J8 )R@ H& M@?(>@1!5*ZI8T%+"-(9:D&RIGU5OW&]]T\E?SGU 7M=E_K[P$ZE+&3J>"!U3 M?3&#]012:(##$@'J*0:&:0MJ::P($$I([QX2S.N^:W]DT^^=;?[ .E^/Y7X9@WDQ:+WIMMK_ MNS'LIUS$VQUOOS_<=M>]G7RT[VH+L]H^0FVG^K$Y[K%R'((@5#23A!E@H,! M6YT2$8,SDB1-N:6OKRU&L]B!+$:O)483%0W"2J89!=X9 VC*8U5(8Q 5W5O* MM7! MSW[-H,%0IX)CU#4$1>J-(TDRA_.0"Z'DY4UJ\7 MUZ^I$;K6$ZM&TW,IH1I(3P6P0A*!HMDEE"Q,O];'F!\DVWS<:TW<;L+[?3K'+$9/J_8-AJCXH"N%NOCV[!#.@U(]:;;3;UV:!6G6!,D$0YZ$$7& ,*%88Z.BQ F@]XP0B M:F%T6.%FQ$1TC]MZNY3W5(_KPLNE!X5PD 1@,#] >S0YFQ;-0@X'VV?#XUX_ MPK?+(KD4(OGUB%%!=4BA.(,YH%9*(&&44*4A9XH9*!*MFTV\G@%O6;S62[PL M9=!H%X!@.'H-2CL@K>( *^F1TTA9?NTUW.LYW 6]D<25]/>]+NE!*G.KZKX] M'CD:!)5+2<**\XB*M[YC?'_J)?C'C(BY*)&NGPT'P_@8D71GF5X*F=XY(M)K MKZ(!]SJ*,S4TRK06&C#C$$0&1D%PLT+FHBSR[F!PEN%R:41+*&J-HQX$EM(X M(9; <*F )6 PMX#Z[3RWF!,-5V@ M^JS98=S;B>RC)Y[$S>W@9'0O^=1D?HKUH[Z4\?LZ?W^M7GU"-?PI,LG]>%T; MG_^OD\-*7)O*8;MZM8-K5U_(;689U^:(0TA\< 8PQ$UDEI!&+94&!,D"XM9P M1^"3CN'F=JZ;I6EUI,G3 +&D,CHFED?,]QHHRAD(2CGHI876LG4Y@YN0RWQ" MLGSR>%&M[!YA)I4@AH+H) M 172>=11!@!R4C'BFL9XYFOP:(;\L6\LO6Q9C MR +SP/$TV\]S 91S$D2OT!$/(\?%=F.+,+CTYV\+06(8QN0 M0PH8[R6@3/ T+"_20FDB V011,-2'HYDN5INN9(20>6B:X'B[@-*:0 R8DFJ M2],^>AX8AK"QA04I8\[+"MUMH'+_E(450+A\D+)LXKAW%'?=02-T]'1=)(02 M8R +QUH:3X_>))J3G1=DY 1["V /HW/T88 &;<( M$!MMM^6&UU3OO^V'<'Q4R0WF ]FX__]BKV>A ?,_YK MAFC5Q(84./)VX)S4_K(>&OL@P,Q/,3$WL,HXZ:(P#V*?,\&BO M@>(DY5XXPK5#J5?/QA9598K('8SY/1ONN>K8TRUWUK&ET[$)1]LK0Z+Q!H$( M!RC7T8H+;8!CTBK(%8/II)^*,A'L575L/4WXN"-/MMBO:+'W_5#'FW4[NM^- M*SJ8V(_*:#LR@,P$(%.SO#@,% =D (8>IM8D""C- M!(4TBY-(L*'F9J[M# M-K-U?OPXD>W.9;\U*)DCZZ^! MKVG]LP8^7P-OK#V"3 C./?!,14<<^UV2C]K1:WJ^\%ZNNK+<19^#2355K?7C_"Q.U[R#",SP.C6'$&I/ZYBF1#[Q7_, [J\^\U&[=KV M65K=C[U^NM/I41G3!"JCT9/0:&K<&8+"1+NM@;2I82CU&,0MY\!:01SWEDKN MHE>.6!G1NST'LE>^+%J[6*\\:^UK:.T$AW#,,LDZPV):^QZ9VDTWO73 M/ _>EFT)__'RR[#4Z+Y< 9*)H<_;79?CKL]#Z\;4^#]"J+<((\"(X(!RBD=- MV750P0CE#)4FG7SP,I-/FP0]!V5Y!A/+^)7Q:]$1JHQ?\\:OR5H,*[GU''!J M":#0/PJ..D_"T_ENHP__G%]?Q/7LCXY M+F-=V_J7Z?]S:[KZ_Q$?FYN*(O@S'<7%Q$;O2\-C7](VE73H;AI!6NKVAO$; MAKWBE;.NCHY;RAN-&NM\=^#=]5.][ V+>V^X]#I??O]JQ14HY*M(HPVMKN[: M5A%#C+\H!J1O/KCAX^M0%K_HM#]'U;IS81?YRWW/#X&C8G/C46>WCS M$6WB'9P-'_[(G 5R^>68TK@"9"X/-OEGND1A!P1V$@LHN%>8(FJ-1]&%)@%2 M;+"C^ BIC>L/'?=O7-4O'IB^UU\CBXO?^D:WS_7E8..?4S?7:77!I&3,8U.7 M8(_N5]WM:G-_]Z!H?C0;?,<3?U8423?9%0E71G' MC,:7'ZO19J%&MPC%Z#4!-R53#[X,-]&#K_WHL@AO*OSPR\^Z[,,?O779>P)G MU\L::9=_R7<^,G[WX(!G_IA0WTBD7L?3D3\#BU&P[[@?>50UON]X4-J)+,F- M>D:5""H_8N[UJZSY0AWFQRWC;[O=2#E[9_$2;E N^0OK$Z,?]VSMNM*I[X]^ M+.E.[RSRK3N!ZGL68!8'8;G%+,7P?K4'AB^N/[^BINW[;[Y[YM_,2YH>!/3Y M7V?%-WO^\TMN[_C]P;A]W_7G!04[[??4>:T#)L$SSZ"%QDMY5"G.(.+_P+,/(\;R M^Z[?Z^R/[OUCO/56:AVZ)%&\^L%U%&__./6VK%6^I,\='S;VVX>-*JM]KK5K MC3U2:]@4E>LT/^^@FRC>'BVB?I6_3PX[NU?-QMY%-=UC9Y?6.E7:/(GWV/AZ M?EC9N;@=Q:M5CCO5]SOG\?J=YDGM.'HQE_&]E\V3+[AY==RJ-M*]__FUVG@7 MJI?PO(C@'<2_R7[;_WO_\O"S.S68\OK[6OOPI'H9OR^M#ZV]WR'5JW:G>14_ MV_ET5:]LH\.3O[[6&ONAUOAR!!F5$C,(M$S#/Z5A0'GK@%'0]P3+;U#>IDRD>'>?6\/CMV>#N%*^_SU]:7LP\/'_;IDZ?JP( M-%Q<0\.1#M 12E+W9DJC;D,-#.,...J",R*UR5 M/E/=/[1L.E$>1??ZO4O=3J1[WIXI$LXJ'2@G#E$"D61*8^8A@9X%(7CV3)<- M#VIO'_8D:I_WSNN-+U>UJ^A)O-^YK%5JQ_7W[TZ:5W]%#^-=I]DY[!PVW''M MZL_"DT XB&@A)/#!1#B) @ D00(PA90CGBFC7(032LH1M%NO$ G)&;8PFH-1)( MZAQ @D?'7YFXOW"$R_*>V8ZY3GS^JK8@RY55[654[<:C8D$B[S0!*F &J P6 M1#OE04@C")AE\26;&C(@?K>",SM4J^10O>_K[G#D3A4Y5:;7UVD;Y^Y3F8@. MUB%NJ4#4*JZ44PY'=AV"(QS[[%,M'2(^1KOPY)ZXSBRW$]'1'@J$3, V]1PU5$4?2I# "'>!1Z" M9"@4;2'OL=PS.U20<(^D=H813[E0VG)##=*"*2\-A=FA6E]1^WKD%49&(P>( M022-J0M *D( PHX&(B'R-B2'*GH&V:%:8N3.+.]E%.W&H0I:T> #!8PS"BAE M$AA,('#0*JLH#]P5?8.DS.[4:RC:@NQ65K274;0;=TJHN(V>6"!H*!K50F!< M$>-3THGX&H%H8XO?VZ8VNU.KY$Z-NGAXLY M)Y(ZS;(+M70HT/H!K_W\U]=JI4F:#8N:G6;DMO%[.[NX^OZO3OU],Z[;5U2M MV*O#RF&H-:I'TA EN>(@>!02K\5 &NN!A(I'+3$&"I+"GZ*,[^GS-[,391DT MC%GD8= T!&HB;*4YS\(([@CDV8E:7V&S1X0:!KU/=DIR0!FF0$;O"83HN2.J MA8.>)8LET=UQWT]UHE:FU]KVL&DVN+\-9QQ]DSK \ZCU*!K0/GRVMT]C0E284*5B:PJ1C:,MY9[-AV\XD M=7"2V>CWR AFU"=_" ,34CD.] )1* CA9F-+DK)"9(F/T[,*OOYY15;!YZC@ M)+T@@4,L(ZE(O3!31HO4BH#(+#347!"(W<86AV65,UK6E'OL=FVOXTN_M7N# MP>^ET.]UKOE'KYMYQ[+PCOHU)1QMUX>X61GW9L*]W4GJ@0-C#@H-L$ (I,T# MDF@!D"'**Z*<8'IC2^&RHC.&8C/UF(<6SC)^? [<8_8YY%D?YZ"/-SP$"^V% M)1(8Y@6@+AB@-$5 >Z2TP\1Y9#>V"+JW8=/"9HIG"C*?I-KZ\-CW2ZTQ$1G' M/'[/^;3KM?+GP/U3[%@>Y.,TDJ--!(2 M2"4(H%19H&VP0!H,E4?.8X53(S1Y3RSK(0.63\ 6Q@BS"KV6"MV0P'34Y:EP MP&O' (T;%DE@" AK"R7C@G+-[80*T-X]RCYM70HV_IGZ/"'(L;T1;>ZHT"3 M/=;=+[Z4?M2M?NF;;H]Z740NUOI6'"''UP;#_EDQ CM3@^=3@]D]W?=QM]*^ MU;N5[[NR>[,I-3_\V/?#7%8Z(_)]FB0/@DLID[\+O:: IB(<[8T#SF(*N5"2 MI20:C,N"WNW[D]G#RAYE9=UZ*=VZ814Z2H#13@(KJ084.KRB.6"\],RLWC&M)>H1#^C%&8]ZW*6ED#H3G_PIA*7_6VQ)8-6]UW5G(3!I6(.20 M-6NAFG7#&!S43@7M@4E-]"A%#AA+,9">2^$ABAPB%>_R,H.+B^5EMO!,MG!V M&C4ZWF.\Y[/6X#@1[LP3%AUH&*2M\=$?VIG:F'I(:)$4\H-'Q 9I3!0@2J865YY#"C2TLRB2?3ZP76MUMH),IP_)3AE&*RO?ZW5[T]EV^:SU*8#U9:ILU\>MLI0"SJ4!5,6],40)P*SSPFGK,54;6US< MG7R3R<"R'3=DG7E)G9F("W@O-<$:" %)FL(K@590 V6)PDH9J1W>V,IEN"MK MY$=EN+W"U(\M_6,M_"^I'$8:84P)#2#R$>"XXT QY@"R MB'OAB74T'2G(U/7K+LPM11I^ULA%Q1>R1LY-(R?B"JG/'N0S]1S7N)2$? ,^$NB=3/ 8"9YU35ELBD$MS/F"9R"6%W:SCB^)!6<>76,=OF!6#*+HV MS ,G4V.U^$\@J4) !":2P%!GV,:6%-'565(5S\SJZ2CRL=_[UAHD^(BJ.,6M M\FG.\XG1?8 8@6[L#_[INSZT\G'S;. UU3E-"NV-A6E BX01O*0!*A@%# W1 ML(6X<\$FMS ?WBP_P\C*\B+*=$QRK=G, MV%6=JN(4.$22&H 3C $JB 5*>0PX1P$;*[Q*59SIJ &RQWLHCU.$5SIG6'/E M6\@A0U:^IRO?#7'P(JB@E4CMSCF@+$3.("$&.!C#K#>$(EJ< 4@ZAW2G? "P M1!K^P0\&;ZX#_WHX[+?,V5";MB\->Z7XR$G%^[UBNE%\U[A%9:M;VC[MM[K= MWC>]E@&%9>U3&3G@S8'H]L1N-7JUJ;VZ/D'-J#@3*DYULO0"N:"X 0H: R@R M+/64"(!PQ"'Q@A:-)5 9S]"*.4'&?U>G7UNB$=G!AGN&8 M$9'ZM@251@]8(+$,3"+#!>8;6__]7Q(C_$>N)5E5@G$=MKA#+K8[E_W6H%R* M&K>98QK+%=.8 L(,LL:O8^3&W;P?;_^U(.6S79R)CLY MU0:%:8BT,Q882A2@6!.@D1> 4V\]0="9$.TD+D-UMVU33KM9RH!75L#E5\ ; MHJJBSBE..?!$:D"UD4#K^&-42H^AMCZD&>"H#*7(L;!5)2*/BH7%9^QT>NG6 M>O;K<:\=78WXBDD*5M0[NU8[Z>=S*Z_NA&(04U#OMU$<1.=;]NRF^SPHVK TC M6Q/2]='W#](NS]VAP@_7/Q@W= QYO27_S(8QND89R37EJI=S8<#*-SEE+6S@;>I7+, M^(;3LR*)K3WM[]WZ\"-\NQ_G?O_ ?5^#1)S1BL^7.<,9 I#7(K ]DH#:6I:.08MIP#0TP 5!H*%+8&1$^+."6Y'IVA M<5$6A)39/:TD?YA]\WC->;%JC5]08Y_)$;@- F9D\_ M!IC/8<(*GB0L7]U'7H277(1_%B_,B_>&#Z7G\%.L0+O-'M8(FJ-1]REQ)](K[&C^ BSC:78VOLU M?KO:W-\]*)=V:V\?5J]EN=FW]4B):P<[E5+\UT']PVYENQ%_.&C$OZH[M<9! MJ?XNOE3]N+_S[_B^W;]W2A_J!P=+]%SW(]]OGZ[-P._SAI".[G^)NC.&.C[M MT7Z_T"CS89I*QH=OZ].!?W/]CS^N[7>K6SQ"\:';K#X2T+%R+EV[Y&:/7&-N4\.&7X29Z\+4?71;#34K5BUR6/?S16Y==--7Z>5#X M03>!/R9^/!*IQ41)[H#&:&[S<3_2L&I\W_&@M!-)EBM5==\>EP@J/QCF_94# M\?]T9BR-V=Q(?OI71&]=KN1R_;.XL7=X,Z9RH]]U9^F'RZW;*70 M]J_VP/#%E6:]U>O^6.[;Z"#V_7'T */'4IQ7O9F78,T6/7K6=99SWXN I%CN M_7^HD7U.)EK*9*)E*"IUDUU4J^RRPY-/%SOLL&9C!]4: MGV"M<=AJ7C4OXNMW3DZJG28]_%Q-GV/5RGZ[5HEWUF@?5QN?XF?W4*WSUTGM M9">^_BY4+\>G)@?P_,AZHE'@&H3 ":!>I<:VV@%EH"',:\Q%F+W#?DXD_(5T M/[?X7RG=O_RN^X((J(,SP!*H 456 &F"36WPE!#$*R_8S&WPUN8L= TX];M> M/_[8+=FS?M]W[65IV(\7:Q<.;$F[D[/1>*VU[&NV].RE/CSV_2FO9U1E.MZT MM^,]:Z0M&SW"=MI<#PU]\;'7+UZ8:E'^4@8,-1Y0RCPPVA- %-7,6Z^I-44/M!D&H>?V9RO$-+*>+K&>WI 9 MS!PW"N.DHAQ0D:85,6F!IS P1Y@F@B0]9?1NK\+,99:?RS1Z0]TN,MJGHX1Y M2,!RT9I[D/(:]^)/[;.TWO<"X'+/4ED-0#R8("Y4!V$E-"D/UH+(6S10GJ8V M+! 1)+AWUJ7(3J0N\O&0F(<,K#G=R?J[4/V](3248DVE10 98D#$:P\TLP0X M$W496NM\JD%1L$P464+U77:NLPIG8KLS#6#,89P\43%XN:9Z-1) M3B)]<4H"3>(>1B*CC?1>6:_RQ,55:4"_UA,75T6Y;E@&(IY%/X$!3@T&-'@# M%(L_,AY08)%^($OSO,65CY[/5;T M+&V96_?P#%H9M)8QJ)9!:S;0FJ"NJ>45C*Q5<<,C:!D-3-S7^(=VBDM(K)-/ M#9 M"K,6379S(?I$(7HI%V0OX7X6!=EL[@79,]0SR^_US"M5Q9TKJY];67W0 MJ+_]?_^N?ZCL[!_\3ZFR\V[W[6ZCM%VKE*H[AX?;M=W:3FEG[]-NH[E$S_L+ M55Q'1=J$\$DEUYAM0C[_VFBVB22?^U7)IL#T25?]\6L2D[G?*]]D$"_1"OQX MMQ02<[^JV(1R=:Z*R?QEX&6N*C<18H^ZZMH5_K-'U2I_[/O@^_W(78LA18\H MIUW7E1B-:IK?,JS16U?AC.,QF_SH!@WEDK^P/KKHW:(K9^J%/&H7^JS.#!Q^E T(GTX=7;MGG>[TSO[09W3<\=@K?+29%&8'?F6\*GBO2;4T^W21]UR MH-4MO=6GK:%NK]V36GO6.6L7(;FB-*/JW=K;V;X91V1(4F^O,O2T/^R_K;Z[/9 M/=B,_QU^WKVL5RQNI@;])WLT_@[5WG^B\?OB[]^=''9VKKZ?S7;^ZE3?UX[K MC<.3>&\7S<;^UUIEAQV^W^\TKRRK-[9Q]>2O=O7]X=?;9[/-3O.\B7=8K5/% MA^GL]WV\GT;[Z^'[>*VKKZQ::5Y6.Y_.#SO[H7J3LWM1._E$CK0P01.A ./> M "H)!QI9"Z1F2*9I=M#JC2U9QO)NWNYCF_&_1N;(&/$[99AXZOQ39'\\$ MDKO)'T]#D<>F+4^:]9%56^F*J14!G42:9IR@X3CGG"C*/J#$,AF <(9D;+(&:PBDU ME4);C9$%P3():-PE8#Q'(#(&9%E44L3EQA:FM*P8*E-Z=YAA9@B9(;P 0W@: MEB2&D+G XD$&38$,$Y1*J3$(CE) %8= (FV!4L9$EP1*JW4"F27#EE_5MM]5 M1FPL1ZD!5V3J5#)H("?6-6Q:T74.F( M0U24B;@[/G1A'52365F9HH.OR#WY M@,QH'2-FOY$"=S@C7IQ].$M*W?4YO'[XW2N" M[4SS>;V9G,8\W6O*QC)?]Q#XM7Y3NUIX%_=*AF2L2RIP;8S&/N#HA,7)&#!8 M_R;-X(IQ7EG^,^C$L#VNL[*%$0[")/SK]3E.-,VV/MLZ_%;/UR LP6#74+-G MEX+!)%5*19>0X,#Y.54&N> MDO :#1$+D5/N<",[C"_7("V UF) 6^?Y6L5; MP90DG$H:E68<>^JP4MIP 3\,4ZNE0KT6(/W']L;Q[_&HT/YKX=%B/ JQFE*2 M+#)<4\1],,@0P1!S&).@@?]+L[%Y_?.7(E0%A,I\E?EJXWRMI.1$K@8@G-?) M<>VEA3^EL E^\3S*HN3:K>0N^]N]UCPPQ5%,1"$N@T).'&'DUSX/-F<%!2A+3D>-(+%8"?@T$*VN3)K?B>; G]?#Y)/=! W 35\/1X%= MOM&X[L?P!H;WXGQT!VGR^ZCK>G$;AEF<#RO@X/X+_'F>[,.S>O%?K\_>_1E. M'>42GO!Q[V3_X]L/X61O^_AD_[>W7V$/MOC;DUV\OWVPIQ^_+R_]1>S&4>M1(9YP%3G M)"># =M!?1VL!#+J30D1A?>68 M6S:B$'M=6."S:5ZRJI[N@XLJ+9:KC?-UOT<<106V2P5>/O8P MSK"8G$,^J*P$!4/&R%SQVD7GHG6:AID27+YF\$!"5TY 6G4"TKK#C_@EUKX[ M;-Z=O#PXS?OUVZG0UQG0BP)L_WP5'W&K0YF;-P\F&+$S!8]0G,2K4(O#2TYB M*BD-4>1\UT$#L2 &&1P5TD(9A8VGBMB-3:941_#EJ(H"9BT&LW6>KY8Y *\3 M\O5]<"IVS[7 :='UYP@EC<'#LJW# \?(62,1]HXJQIP2+C4Y]NB*%QF+J!5H M*O-5YJN-\]4RQU]1??>D^I8BG8.P-EJ%3*02<:DILB$!,S>)13#%E.6F99KS)?:^$$+KKOGG3?4GII6-W$&$.6L1R>(3QR.;63(K!"6K%@2)AJ M/],6[5>\P,4+O*H7N$)5'7LV)[,]M?7HK'B%BQ(L7N'B%?Z^5_CU!#)>9<0X MG':\^(FOSS>\$)\QN;LH.%[!A>+ENN MB9MX7O2^QGH0[/#XEJ2N\/O5Y&W1A1R<2MYHCZSC%'&G)3*:8Z2B@?^/W'KA MS]5@D;;UYFO M,E]EOMKF2B[:[T&UWV5?<@R.2BT],B)BQ+%32+N4D/:,4ZHUMZ1]^J\XDY^Z M,[D!#.0LH$%V)I_&_M#F'5EOCA-B^CG[POM\\I;DK5UCL"BSV MX'(R2*:PCL(0)!SA^5(<1AHS@0@ET1/#6/1R8Y-WJ"[95PN2E?DJ\_4(YJME MP8!%4[934R[Y>V30))J0$Z?#!Z#C6F=[6\1@8;O=3W.W[P4G\?3 <3M79 MBZDV.\K*;#*,K7XXNE!M%UQZ/XX.TI']4MCO*NSW$+,%/Y'1WE%/)#*4YH ? M;) .BB$EO&<2=DD,*9&1=+UY4 M3.Y4 "K/BJ^C*,1B8#ZNJ2WS5;;BPT[M=>>H;2KS?Z\Q+2M,1\MM&V>4\L1$ MH2-06B=)U#@F'+(N4,0CMDA+8Y!C4:3@24S"9G6* M._C^U6GQ\3UI'Y^Z#4>VGV>SI(]: M"9[?S* 98'J/[7W^*VJ?$N$Y=U3,YR_2(*.80%99')/BQ":]L:D[=-4: ]>3 M@Q^WA'Y WM;%1KKF$-<32I8YW\UPY.]2&2Q413L>]&!&ASO_'7='9\#U>N,\ MC:\&=7/(.W>R!)-P0Z6/3UX&@T)=HB3@Q'W*6 M, <><:]M $K8$29"S&E.H87$"H@=.=.'DH3 MBS(98BEGQIB$C29<"@*@)$4L9MC:0L^B_X9B%;_N M?]W[BRL#YK5/B HO (:(0CG6%"5'J+>>>4;(QB8CHD/X]6,5[QF#KHA<_*7 MTUK TRJ1T1:'D')X#,^1T%(;H16C%IO$#-:R4*/U!:6=!5!*-C&9>$(^,(FX M309903TB0@8:O"#GX[^GCB8CT-H,\5[Q]A9HS5PN D<<92P'*+ M%5>,N&A2)"Y$[%)@@67%30RA)0SNP93P[(CX$'_^2^H4,9<8Z2C!)(A>(VL2 M1SX&RB0V1AIWHP#YF2W>*9;)V_T0MX\F#$A$D0YYV 4QXB,Y J%)#SS MCD>'0\Z3(SCK2+FL@%1,>9-P%8JSBVQD41O$A#G*I^35*VC1 M!9W#QF-\QH+[W3"DFF:"G=8=[RXJ"VT]1Y KO!/W ]W^$Z\;L&2-M,*I0)F0B5L"4!*-)9B8T+" MC#J&95#%P[FV"')X@2#6&& 6#IE$!>*>"^1\4@B6FNNH-">"W2CL]JDFV[U: M[':'PW&.%ZP&"49RJ M3NMNWW=/;:]I#N2P'L=0=:?;_U%&&Y;B1^V?KQ)FL:S7/[X9HD@[4D]?#[#E(/THD&41IEN]<.?4SAY VCRXAQ, M#M(V0$F)QUE%59[-Q>,81VA@A")EI 2J+3"RB2ID/'=@3CO,.8Z@BS MXOW=@F0WRZ'\8[)VX0&[L3QMG0S&_4) 5Y2JBY 6#\LFN(B(&^81UQ8C;1U# M*J2DI6"6I1S24J3I/M)0&.*DR<<1V'+GO5/**Z8IUI:38/$UI.GN%%<1M)L( MVEPLB\4A@O&.@G0NQ[(0Y'(\O5WA[&O?PHI*U8+66^RGRU M9[Y6\G9BK2/#-.:D2U$[ $SFJ77&&L^T*=IO[;3?_$F)U0E,A:!1(H(CSD 3 M.B8ITLS(%'BNL^Q/ZH*H[@ MHO**(_A).8(7#E(S6L2P/:[S\2F,,!PX!1K4W2FB:+-O89!VN>8?1XJ]:*_A:Y_EJF7_O;_#H/[8W MCLMP5.R9:\'1A3=/,DV8319I$B58,Y8B8YQ$(JAH@['4^:K9=Z\HNON4-?-^^ZXUHY3KQ!6VB!NK$8N^804Q#T_WNL)5+S*2%%\ M>JL0B\,YGQX/41DG!-(Z7WU(GB$M&$/282NP589*V] *@?/=ZY)6:?U".J]% MS>>DJ5N(^JKR-)>>3&I8%AN0(X+EQ"<>&>\"DDFHH(25+IH2R_EX?+U%PNY' MPN:".)/PQN?R&")HQ)VPR#+M4. D!6J%CCH'<:H.T0^3C>Q1B%DQ4\I\E?EJ MSWRUS.U;U-[]J+V%Z$T;I$A!(*)REJQ\0=WR2)#D6BC#DYS<7LB*KS6W%XH' MN'B O^$!;N[YQR^Q]MUA\^XL T!Q^Q9]5]R^Q>V[X/:=70S9F0)&*"[?59C$ M?%$-YYUVB3 DJ0$#VAN%C(0_-5/8DES^-C39-D'R.H:VADJLGZ 5S%]_U]Y6 M^# >CO+I-+"6+9C1W#/;>V6[,+DO[&EW9'M3;%J&IF+D7 N:+GQ[&$P8H:1' M$@N<'7P>:0=KZ*.7AK"DDP@YPIRQ0)3%H#;:6=K%EBJ^X]HIK;U777HGP+/JO%?-57'UK MY.J;C_0\G':\./^N3S7F,W@&(87A+*%@=40\88V,U@RY&+BS-) 4P,*FO$-D MSI<92$HH@3')".3B*/I=$V6)>4W]B4NJ/D M+82P1+')#D@3.- M&2$N3/6?:(O^*Y[BI^XIWIGS!2]XBIM9&,[\P\4]7'1?*^;KB;B'RU8L\]42 MVOH 7U'EP(;=F>!#3-MM9"<_G6CJ::\MK#9&[+9@_D$CA9[+E1T*,"Z(^Z, M0S89BX)AP9OHN/!I8Y,\4-W-QR*$!;3*?)7Y:L]\M=&74Y3B RO%>1=/,#$) M:2*R41C$02\B'2)&-&H6'/78.]PVM5A*XL/UC([*V0V?E<;1H'+20%%NLU1;#J##D%?%9@X@5Q1#@B-S9U MQ^!2*[Y@5IFO,E^/8+[6U,%3=.)=ZL1Y!X\CVEH9/;(<%"(W'B.M!$%6"^9L M2 I+T3*M6/P[3]V_LS<(W01]:2!MD*K3.G[J#L;#WEG5;8( %[T^)9E;T8C% MP?,XI[;,U].9KW8[>(;?9+/SZNH@S<+1"VM=@;7N'6V-($"3V6^RGP]@OEJMR^GJ+\[5G_-?X=9 M!8+^,YH8R2DBA%G$)\-D_=:[,=Z^@'[_O=F=NF MU[6NV^N.SBYRSGRUVU?SG#G48_%?JZ$GW=F??>.&:#=I(AI65"/!B)+($_.5%!&TXY MR<6C1(>V)Z9\_02P %:9KS)?[9FO=GMOBD*\=X4X[\\1B6":)$:,&-"(-%AD M30*-:+%QR=%DI6Z91BS^G*?NS_GF+2O;SS>JSC)@Y/=.NOWNR?BDBB>GO<%9 MC-7(?H%.?.Z.CH]C+TPRM/E?3Q$[ZT]_7Z2O]?G.-$TV_ILZ_!;/1B6].RK\9+=T?Y%<+"G MPF&E,QDAN1),P#DNV"+B<0C1X)A(VMCD1G2$)FTA)NLG9KC>9K%15W"^["HN(>4,7-.P*M24"LHT6&<@\ZSB9D$XT( M&R\BO!08=>W0<<7_]]3]?XW<(V>'D_MVI[$_;&(\BXNN*+#BHGM<4UOFZ^G, M5\M"MV9D]#I7#1I?<*.17LPII-4FEPP7[9K_;, M5\LBNHJ>;*F>G/?O>$Z3YDXC[$0 10DZTAGOD%/"._C-:!5;IBB+H^>I.WI> M#FKXLU_Y<5W'OC^K1C4\K#=)OV3/X:;X?8I2+'Z?QS6U9;[*?)7Y^O$S6LFH MHEA30;&"IUEK",712Y9BL$RH5-W/\7=OA^S'T4$ZLE\*_U^)__\QRE63IWZRI+2E MS 84@J.(:TZ048PBPJPVW@IIM=C8I!W!30N.>-=/) N$E?EJ"^3?9EA.@?SU M@OQYEX_66HJH$PK<)<2Y\,@XGJ_Z12)2HA0+TQ[,+]Z>I^[M :&O>@ 7E1V- MZJX;CZSKQ9R8:>ODK.X..Q4@RK/BZRG:L/AZ'M?4EODJ\U7FJ\S7?1M*(8JH M@K1>&'X&>A=M2GMB$C4'8 M*X]X( 9IB@.B*AEA%8-EE2W"GN);>3J^%77EC/UJ>SEC4O:M5'NV]L<5(YTJ M0\LU'"K3[3/I_W,&DQD&X^R;R=W^9?KN:'!Z:6^MX<9:+0F-\#$&GV*@,G*K MA#618^HI5C@8%LQ?N[>0>Z;YXH/Q:#BR_3R;):W,2KC]=HK9D[0RRC#L64+! M,HRX8!3I)!G"A#/A>,0XT%QSDNH5L]W=AH3\ .3?M9RVS5/\OW>X#"M,?YL MZHHK4C="I\L1WU]C/0AV>'SE#?WC00]F=#C)PPG4LC?.T_AJ4#>G>7->_*/! M_J"?>UC"H][O0SYQ@KY#05<%L[NH3((&\%EP[,"4B MY>=4::W@[,=\[H6M7,U64E(6($%K 3NM-",!&=)")+3A$,L;*4- CZ?!(^% M0#T/*&B<@*V$@'1T%"GMO)78J<3)QB:1K*,-Z1A:.$OA+&L%4\NZFP[F!34*V@6AM1;:6+0XD)*@DSQE+N/34$>ZLP%DD[ M,#W8MV%M]8/)@F\/@V\7]X,X2]H:&1!Q4@&^&8%@L35R0-:X $*>F-W8Y++# M!+OV@6;!M8)KK<,UIJ1+Q& B*.&)*$V=2 (K++S3/O*":VN/:W-!8LY$&2WU M"+@Y1]PQA1P6'%'+I,1:2Z5,YFV:LPZPN@)M!=K:!6TK.<^,#\Q';X/G0B>C M.)/!.<8C29P'AV@$K.)"2F2MHHA$37Q(1@JF-C8E M7KZW5^S,]HCNTP6M5?@89Y1)S2E7\+^HE6,T11.",#009XJ=N?[(-A\YRR0E M3!F-J!%@:.(HD"%)H8B%#2P1*X4#0J9)A]#K7TM>(V2[(@BW@-YC +T5,,\[ MRB,CU'+AN.#4I12B=,:FI(C5W\&\ G5MA[J=)]K*^-5:RL_)-HU(?'_:#8-_!NZGS;_"3]F/9M[EH]Y#TU%&?Y3TX7'%Q^Q#GHP'GW[([>\,.U?3\YA!N2M#&S^ M9WY$ X2*!DT55C(:R@GW+A*PM5G"@.8TV*_CM\.#WW>VM(_CC\ C^V=O9/SJL#EY6+[8._U6]_/W@S\,6 MC>=JP/OIS0S/?BX8]3 8I6X=HUH)-R>V?@_?,]T6C9 MTV%\/OOEE] =GO;LV?-NOYG.YD.760O0G^E C'QFJ,ECF=[DFSY^.LQGS3 O M,:S)>XH]$_+;;^-G9/Z]*Z+69QT%9A=+RSMK>>T%)006U%QW05=ZK/KV1^\T;I=^\YM#RE7C$+>5UKOU.@.Q^O!+Z6A=_CXYK,&KVH-WQL-H!DR5W#U;<8 P/#\,E7V)+-EII.:?\ M_]Z+T6[QHYB2:^RSQS-:_"A!96/SX#1F/.F_K[*'[A.8-'%8 *3%+?]>I*Y! MLE9\R#IN]^_G8BU;O"TMK]A##WP@>+V=]*T#P38<[%UO!*M$,Q@1@G?88JP$ MMU(:1FB,GDK)- ]6-'F]R"RO%[F=L(97]2!U1VU*ZO5U?W9>=[++WGYX@_>_ M^J_[7__=???A]?'>]A_BW4GS/63_Y.7)'MTE!]O')^?G=1^@+=VA\!]^2W<^ MOX.^'?RVR]_]!I\Y^O7CWH=W)P?;?WQ]=]3K73ZOV_^ZQ]X>O87_H&]'OY[L M;^_PMQ^./[X]>M?;^^V/L_V3MWQ_>[]W\.=_TMX9_K(W"Q7]\/[S_N>_L&"* M11U1TLPB[H)%EC"&O$O42(MMR+<6J<$=+,A])_8J"+ .". %=D)X$G&R/"7N M.'5.)J^2>9_0H"W!P!#A<0( %*,TDPBI$+Q&')D&8LHB XTT$X3-W# M9/9[/-QRKDYL/E:O(\B/[_9BU9\5 (!7\^_>#H^K<3YB[_:KP14&V/-"3UO< M<@4[ZQ:LJ4:HU#,EVKWY?_K-=OL_3[9YJ@V_5^*,:^B-@@K)_)=WP 4)UFD;'*6*.43 M%AN;C,J.TJ(MQ< ?M;3=J\U0I.V.I6UG0=I2H!Y'[!"3.8M;5!$Y+B+2W@%QWN:%5K6VY1,!^EN@ M5=?#]RP";T "=A8$X"!EW"^0O@*DYY1VEYS$ -M<)Z!.)E"'N&2YKB8S*"82 MHG'&T0![G*H.(P^ Z$]0JFZ!/A6ING^I6G2\!F<#(1Z(48P@5?G\Q3+M4 " M5)H&">]-I6K%:^^%)_VX+ZKN?FKB_>&]F=%08@/:U_*) /Z#G+*_Z=<19NEK M#!?F\O:Y8)2#M]4,Y:TEMQ0F6N(8.3(L2<05,"HC1$*>6BH-)I(Y"@J =A0O M7JEU.M<,)YS$_3&)@< 7PY,+.QH/9U.1:)N5Z(6 M/4X&* ]FWB!MK$4<)PH2I3520>%$L#+"DDR)!%Z.]"L.IYN(UW8\K6&'-[NW MLOU0V9.L^J5*1K[N0KT7B!!(% M*V<,(D$*Q*UWR&J#$1,A&:$"F""X*8943NINZ\K$W.[-!W+-/*!!0N-AK.QP M&$?#JLES,7=-HA?!8"B'=.UK^410_Q98U5SHQ7G^A=_SMGZ=NW20W@SC5M[\ M!=QO?%*PNQP>'K0@D20DE =T%SCF0">%6"0FQ! YY\">E%@Q:6WA3@_%G8H4 MW8L4+9ZW49^2)0)LD*@LXKETI.$A(:4<#U%R89G8V)12%X9T.PS)^SK.Z%$. M\JY #?O!N%^BO=O7\HE@]ZTQH)EQ.X_0DZC3[>DF?U7'D^[XI,#V2K"]LT1^ M+ N.>:*1"QI@.PB)M H6.4U]\$IB:R20GQ+8O2[DY]J.HR);MR];BY0H4".C M%12):.FD'H:E6B)*:#[1^+3-US]':1 MI?N3I46NQ!RLA#,@1IAKQ&UBR!HP2W24T0180*((<*4K*L ^8+!VNW5I:?GC M+.(MRP9XXBW+!GCB+>_,43(:G#X,J3X8'<>Z.#]:UW*=#;6'BS[^&NM! ML,/CR]9;L\O/S_^WSG/HOH"V+WN#SX>S122\T IIHL$W:D$+1(@Y95(TD64<[,C M+I1$CBN!!.::<<:"RA%IG#Q 3JQ'&3,SR8 ^; C/Y&)5OJ@.>]G!ABY%9]K> M\@&*SA#ZC+9\4V_Y)I)QF(LMQ>XGZWJ%Q+>OY1.A(@^2O7.W[^M\YVD[3OX% MBC*5B=?G(E&XRBIV*S1L M37G3"VB19V]J"A3.U+J63P7([S-'U3*0S^3@S^[H^,5X"#,6Z^;.>,'SE?!\ M.=N"5E:*X#ABBF+$.2/(<"R0)HZS(&S45C9YF:\(FR\NTM:1I2)(]R=(EQ(N MF!1"= PQ6,(<,:^0H_E'HEH'[%EP(A?N7DY;4FC1JD*5/?W]T:#NEDN#+6SY M5.#Z82G1G P4[%X)N_>62! AP3H2 A)>6B!!CB#-#49 ?T #>\E@\;)1*[4L M)*C])*A(U0-)U:62+R0FG-.W)99=1=XE9)L?5J<0 TO4J%PQX+ZC+QXG)]J. M*=9U4_!EV%0:/JT'8>Q'PVHXZ(4*577LV1&\?VKKT5FA3:UKN)!>1P#]4FI^1\9S_T M9BW'3QS9+W%XT'\UKOUQ\][+[I<8FA.$8C"OAO=OEOB3<232@!T*">?,.\8B M&ZA&0G 6M $%G2L0ZP[%JKBA'H$;JHC;/8O;(KWRB=,0:$")"HHXQ_F2IP_Y M:J?RV%NL!"]3B&.??2W/W.0HQ:U_*) M0/>#$Z,L%+]?2,)6/RPF.II[KX#^2J"_G"5,4B!.T7*4DLWQJB8BPSCP)NI5 MQ((&'D7F39B0PIO6@S<5X6NO\%UR/2FFO3*YQJ4E$T^OHU(@1ES01 KJ1&R$ M[XI;=(5SW4@4FXJ3A6>UNN4Z0_T]G^7]< Q4(P\%TV^*ZM.[XJ /;R +9*FG-M#&N*03]8" M:;(&.:\Q"IR"X<*2CRS7I.E@OEP=LYS7W3CU0*%,;6ZYSHB^-JZIJVY-SY#] MK.#Z2KC^<8DX*2:DYY8BSS'+*64T,LP0Y -5ABA ?>$SKBO\ (&N3U#6'M83 M563M=F7M4ET_6%(F.4541P\<*C'D'' HR7B2,CI"!YPMYG[HAALJ=53^-A_!+SG8_F/E7*WM>QJ'PK-:UO,!^-ZA#K-%H M345F%_/WH"T[/:O*'A2%,(J"N'K MUG*"?,%("B$@"68T@H7ER 0GD*)!\V@P#3ZGS,2Z(\6*!X'7$Y3;)6:/23A; MZ_ J8GH/8GKI*J ,-IJ<;%/)7,8-C:Y[+ K,MM^R_EU MMP*Z&IMK,X.;%)8H%&UM6CY $O[V%Y:872(:3I.# $J/SCH53&E_U$0BQO^. MNZ>Y?$K9VZUKNR#F2$(G**(.-$(IM;-(.-_=[ MBO<4I>W>+KD6:;LW:5NT&U*@1B454?)<(AY9/C-G$0E##2:*6R[4Y,R\W'&] M15?OU+L[+6!:+(>6MRS^HP>IB?0-_]&YN5W\1S?4 U=DN(W4\2 5HL((Q%W6 M \1))".3&F,74@Y.7(UU%?_N6C&U(I^MDL]+Y_+>N4"81=[&B#B0-F0Y%8A) M'RE0->Q<7)6G%??N]5C;RV[?]GTA:6O3LKAWKSJD& ['L(UCE?,_Y_+!?MRD M@P8K!#1)/TY4S.?NZ!CT@AM5)X/03=#W_'+9[:UK^51<4/<95C+S0AVD;9" MF< T26L+@5F!P.QO+^=^QH*X(#U!7@-MX880Y)AU**KDHA-!2=:X=06^7T?3 M8Y&IA_/J?HWU(( 94*3I+J7I4I55E[ WSH$ED!+B7O-<;Y4@$06CG"K,,-_8 M_#__HRFAOZQ%H&[["=1T/^?3\9-NOWLR/JGBR6EO*=37R MOYY4E#D:'-DO^;K&\:"7I_'EH#[,:2 "I4T M8]8@*K#(%94HW$*PVN^-+1+U0!)U*:XV)&;SD8CG($<\ M"8(L"PEAX%PI 0,#X-S8O-_2QX^37=7=ON^>VE[._]SL]0ID+'NB"C-J7;?!_WW1[$^R89S@?"5('PY ;0,/C*<%/)>6\0MM\A%[A"S M3E F$R%$ "EB'6)*]=8U8$9%HNY?HA9)$6&&V@A4"#.N$#><(6.M1]A19U0B M*7*0*-DQ>OE&8"%&MT*,TOF9="^G12CNH_:U?"J0?NONHTF\16SRHYWO_ID% M7,![)?"^HHA8H(EJH$/",(XX80(9J0V*3 K,M,;1NHU-0XJ7: VX4!&)U(Q)_3B1B9RHXLV.#5UDLBAY8*11[.8]SI$;2 -:O)MHC M'K(>4"HB)91R+A+*G7K V(LG*&_W=TVU"-V]"=TB^;(6"ZH)1M)0FD^V$]+4 M:B18(B%0J27+]U1%!U\1/UCBG6Z/A V76-C@-$]R\4"UK^43@?][#1&?TP - M]A],=O\,]4-!^I7,[.7\'T89Q@E7"%LB >DC1CI(CX*3-#KK:,K'=:1CZ , M_1.4KON*%B^"=>N"M4BA8.42QC$AQIS*,>,>&4L%,"HAD[$&PR\E9OS>.-34 M:U5X4_M:/A%D?RC>=-E0+LB^$K(OYV@F2E&->4[5CSGB^5H=&,Q2!%7TG/KH$8LB(NX4V"D^>"1- M"M8E8VW*Q<58QYCE&W6%3OTXG>K.Y"'JG"O5K7\HEHASOF7E>9U[,<-@?IU40\7LVDHZB& ME53#<&*U?8UV-C7T7([EC(%OF7QBX$ M:S%R6%#$$V'(>DF0\IP(9J2S5.=:?B6(:FWX5_&%M;[E$]$7]^T+^[:>*#;[ MC77&NY, M>BY5+%6:@(0XA*U.B N*D<::((:)IZ*EI],Z;Y4[F\L_ M5FIBM;CEXRR,V-([#M\HAWA>/JZ40[QA7/8RA;*$:>VU0\)H@[A5"L$2YYJE M--J '4T<;VRJCJ K7G@H-4O7B705T6R#:%X*\M/28D4=<@DSQ+%P2*> $=:> M$N*C-UAM;'+3 0ANDVRN8[W2JV5P)Z7H&Y]5_.*/;?]]K.I\ECSYO4D?F_E< M9\+JXG_'W4^PX_/%BGP8/5>>*+]?2%WK6JZS4?Y0-><7U<%$0@[2SE0^7H-X M'/2SALC_[5Q(Q.MS86$EO+*=5"S00QD5")'F,.*4>:1<9 MLI)1PU1R01G0&[RDI6T]+2O"UCYA6R1IGKKH!; RJGU. NT4 4S,0#;?B)X MVW'R+_S=&^?5F=="$\U4E,E*RF3YYJPEC"J1 I)8@S+!E",GN$<4E$F*PG%- M\[4^PCJ2M\KD+P+^0.ZX(N M%_!%M@BHGX++J>(\L8BS[&WGRB)'G&.!<16TCD$'HL%@LUGB MB"D2MT82=\EY9SR/!$=$A9"(1VZ129@C(:4(C&$K=7;>=:0I_KL?B'M;C71% M>!GHUN@X%LK5LI8_;M>WS1[XWQ^RIU80Z79K.M!Q%! O64$H-SIH8)DV:6QL MSMG)<,,M'] 5633=2IIN9YE;LD0=!F[)5 1-EV*^*<'@-RJCU!&:TX C]38Y;IPRG!@JF-386R&]FUBT!776"'46^;64AIOH M$_*!.<1U4,@:K8%?&^=),C)(G),^FRM*O3Z\NW/V9;/M34]'&W_'QG'SI;AB MS664UA"WTG*AY=SV8;!<83!VO;BX?YJ%O-VG/!Z#[G4$'/?=7MWCP>7KC+B(%3P%CG6N!^%1=80AE*T/%J[F* M4.9$B$BR7ZS-, M(!.40IIQHC4)\&8 P-8K1J&70*1[YD%%BNY7BBZ5"?!.$>L=8D0$Q$/$R&+O MD72<,$V3-\IN;+(2772KI ?FL?">MK9\(HA]7[QG_WRO%[!>":R7\_,3+X+1 M8)0Z3QGB/ 9D?4B WBYDK@]:-2BLOY56E,P0!A04'QA+@Q$FEM&=)!*"J<4"Z2'PN\ M_B%!NK6P[()G!<]*2/=CQ+-%DD]HI"[B7+;.><0MU<@$:Y#FRDB?0'MI_2,A MW0^"9HUY\(^1A:^#?T/WT^8_X<>L9W//\K"'8CV5PLU_NOH?F^?#N>[';DUX M"?X[Z:59>@]C; )NK?>#$_C^[-ZO^H,1?,,T%'?>V?-[55NY_B+Y^[870\ Y:Y3TT7'E]\ MQ#KHP7CT[8_<\L*T?STYAQG0MS*P^9_']84A_#XB5T?[$=D$#WAN>Y_MV7#C M'PO?<]+MH_E%OHWU:<%T+\6Z-^*SM??V]>YAI]K=?_'M+=^6SKXX #S?/]S9 MKN"WPX/?=[>WCN"/PR/X9V]G_^BP.GA9O=@Z_%?U\O>#/V%4+^"1W?XXAA8- M[6H8^^G-#*5^OFW)/K'U>]C24P22BS3T_$&->KBDK6#P/7LZC,]GO_PR,_Z[ M_68(S8-1)U25%.WE/LF9#??AL_(_]/ M:SP?3[GEM1>4$%A0<]T%7>FQZML?G7_L-9VDY8I;>UO*Z[BT)XC6IOMD1\SZ&0=>Y%2BZ MW3ZP\L$8'AZ&2RG96[+12LLY%O#W5FF[Q2^[F*^QSQ[/:/&C!!4P]<>GI[W& M/ =3';:Q[PV&XSH7JIG6MSR[P5NM5OJUWG(.@K# M=R[EGEH8+6QWV/0 0W%80@);T_*Z44QMVU=/Z@;>?18KV)V*Z"N0V?WX6.*Q M7G]XM[W[]>"W-QSZ]V7_ZQ_TW=&_N_MTA[W[L ??^X:^_3.W>4N7CFI^V_^X M]V&/OSMZS_:V=]C^]KO>7N[#43C9^PIC/'IW_ [:[']XE_;.\)>]%_F89F>T M]P'F8NLO8QR5E#MD9$YN2?*=.^T)$IRXQ),3E/%\4D/5BN?.Y0;NTY'_^ZQE M4.3_!^7_<$'^)8W)4T.0]C0B[EQ .8DTHE00FJP65C3)MXAX@&S2CX=F?L_F M@BE%C=W5[7^"C=T4>>^'*TN^%TNLS2U+PK ?$Y(M[^MQ#.=66 5=AS]' ] 5 M;E2=UEV0AU/;*T+0EI:%G:T!.[MEZ^QKK OC\A3WM@FJ#_H<9 M02O,; 5FMG^X9)G)Y*)ABB$MB !FY@."180?QB4G"7;.I@W@8)H2^DNQS8KT M/YQM5B#@MB!@T3A3CMBH+4=6:XRX#P2YE"B2(GA-L%44LUQY1-#V)41J)5\I M+6^QY>,Q/+8!K?S@?;\[2U0,!ECW4Q.)7/6ZUG5[C?6=+9%\D7)T5HU/H2$, M" 8X[@Z/LV$_^9PK9T>M:7E]@WKMJ#G4;TWX#D[RP(?OZ *UQG):ZS?! E'6$"9X9#\T%43K%AM33(*9H,LQR; MX#8VQ8I)D*XI%[=:=Z: S",!F5LVG:YTG!3H>0CH632SJ%4>LR!0,"8B+K5 MVBB)C$O,LT# TA(W]+3<,?X4&^R)MWQZ-MC4\HJU[PYC;O?9UK4M531:U+)0 MHD=+B>[C+.DPCD:36(FK^-#9;G\TY4.%]ZS >PZ63Y@X6%G$1X>B,!9QQA,R MUGM$E2?"18=3:"GO*2#SF$'FWHZL"M+<&=(L6EA6&F&#"?GD*B&.&48N1(,B M,5)XT!W2J(U-T8'%;!7./!YZO3/'F/W@Y&20.S#P'\_I<]7-M-H?V_[[V-R% M68RY:D(2[>4 K3J&<;-*A7RWI671BX]6+]X'^=X?]',L\D']RM:CZ1\S[#A( M+QKD.,S \><4-UX.ZNR#?#4#BJU^F,9QSJ) 7L] HFC156+ULI#\M_:;MU]2E79E9=&8CU9CW@>5SV#0 M5&@[2#M3)'@Y!8+=_HMS&/@34.#5! 1>S3"@Z,*5=.'.$E/W@DFCG4($2X$X MS@6#DHW(*F$U942I% I3+[CS:)EZ 9_[!)]%(JXH#LY&B9(.#'&C#+(:"R#B M,BJ/@[2"YCK:1JYXI[_P\!OQ\',7>_:A+Y/R'/=2YU?L<.)TS_D!!N/^Z"JZ MWC3H#H=CV_>QQ+RTIF71F8]69[:,JV=_UNX, +;Z86\0N@EF-;\_++IS)=VY MNT3<$\&.Y**$G@)[YTEZ9(R@^0:FB4PZ):0KQ+V T!H2]P(W;8";1:HN-&4R M!8>8]@+QP"S24@5$?,1<^, Y!JI.='&8KS=1KU#5U#:"#Y_:>G16B'M;6A:= M^6AUYCH1]X/T>H(/^62[Q)NNIE?WEFB\4K#&CGFDO*:(>XR1BR(@+!+#D0@@ M2(7&%T@J-+Z SVV SR*I=YX1GZ+.+![ 1P:!K,$1"1VU2=@J;L3&IN(K)FTJ MI/Z:\CC;YTNQ[IG6GW/\YB(I""=T?'A^Y?1O0]X+<6]+RZ(E'ZV6O(]Z$I,+ M8!D6,ES$D)-KO#A'@Y)8XP::\(_E,!C'#2@[6"9#..):4F2Y][D8>*">I*22 MV=@D!'?$JO4E"@TO -/^,)@",+<-,(M46PM+&-4<1>PCXHD1Y'2TB& :@TC: M2^&S_[S#&&L5OCP>MOVFWY1/.ZT'I]"ILTZ.).^/)B[T_XZ[ITUN3&=[$S]X MMY\I=7::#ZM3>]94RY[GV?.I7NRHBO 6$'-XI_;)Z/ MY[H?NS4))_CO1)PV)?EBK$;'L3%'3N#[SW*IO7X6BISG/[\S[MMQZ.:8'1#X M$/O#R6]-<>PFE&=:HL_VH._P0A:_X;-O#GSZ[5Q ]TX'$T%^WD0%=3_%7SYW MP^AXACYSGYJN/+[XB'70@_'HVQ^YY85I_WIR#C-@;F5@\S_S(QHT5#1HJK"2 MT5!.N'>1R.!8P@#U-'#Z%U,;LP\=UQ'.QO M[^P?[FSGWPX/?M_=WCJ"/U[N[F_MO]C=^KTZ/((7]G;VCPY;/ZB?WLQ [>?E MOEYOLW.\\?T!?A@/1]UT=CWX.+'U>Q"!*"-K4$S=]_O3M9\U;EQ3RY#TMGF%"OODV M?O;M][[W6$*?*6VN]=@[9T6OV+,IW0VRP^I,NAYR[&T3K?)\G!EN;@7= ML:WI2W5<9W/@?ZXG/YE\5^19]:L==ILBP*_J.,S5@1MK(SM$#\KP.,91M1U'MMLKDOCP?5EM-0DIDKB6:R>GDLB>5&WIR_77 M+N?P:02O6;YU'8%X!EK[ZU?;AX]6DV(+!4$>O"^KK2$Q!4'6]. IP_\+BCQU?;?H\H?ORVJK28MG:3W73J^]+H<1J+7N_;/J]\%PF$.- MJ\-C6\<"?@_>E]46L(#?>JZ=).L.?GD$>JU[_ZS*Q3.ZHR:$J3E_?#%H3AEC MOQPQMJ(OJZTG+0<;Z[EV?.VQD#>A>&O<^V?5Z_@I]L<1_CVO2%X0\,'[LMHJ M4E80B:%G,WWKEX,3DXCP'CAXJWHRVI+64!\3==.KCV( MR[6&0>@]7>O> XB/W3#^=YR3 .U\RM[E@MX/WI<5=Z#Z'GI?YWKX2A<"5[EV M=J=7)>J.$/_N[DCZ\'VQ_9V_S>T>N3_:]>O-M^#<^ MUW][^Q6>B=\=_2%^9Z][\5^OS][]&4X=Y?+=]O')N^T]?G 4NM /Z-];MO^U M]W'_MS=B'UY_]V$/^O^ZM[_=2WM'[S_O?=WZ*VJN$^Q/1$/DB MLD9/!(\VX M%I9S'RF=).CH]LKPTZU=7)6=^'?W;Y_UK3*SQ^"VNR&KJUS(KR? M\@7GV/2U=S;[0#6H)[V>C.7GRL+WGLV_]'^'358^>,0H;]K?K4.C =IK1G-I M0DY[=I2ST.34%['_'F8UUAT8>'^<8([&]:3[DXFHCF&Z2!T\\O7,?;S>C>K !\Z@R4?SMYN7@R?V7#4Y!LY@35R@!U?8U7'?ORS2UADU 19!36IVYREN24/WFPDUV=/P4S[V#I1M-\ MZ'DC?F/TLWTZ][P4ZY-SM(05]W$(LS_?F6,8]7#L\QMIW(-)"A%V]. TALYT MB^3B2OW09&V/=+5V FKX?52<#D(4Q3/VU4DC<"%1O^*C[3F%S M=#E]S8TRUN257L"@X?%@W N5RUO1AFEQJP_C_EQUJR9QSL57_Q]-!/:K@^U[F[48P^G]SFJRF\5FT=3GT^:%'YX\Y?43IDH!'):!,0)B<@* M(E!B*?@@*,=67"9Y2[*SBL0<6V -#I0.P%8\M?5D(^?'U:'9/(V0O'EV^*QZ M#V@.JK&7R8:/I_F1]H(N3HM-9#WR4]/\MZVM5S\W.[VI.-$]F>M MS])%#=3 M7.>2V+W0B8TRF6WZ/YIF6]E$!@)"<-[*K^/[<6_RC$/T_SUKN&N=R5)F%DOY ML&:=6&5RPB +^TS$*QC[M).+O9\ 0IUS!.?Y_,0&QP MVNU/-2= NWW??!F0HY@57F9@L#2V2OF^\GE?_81]EX!,TMATJHW;,)DW.K/$>]=G%E/)6U3U,^C) MEF NT3D>S@K\Y+;#N5[,(_&T%Y/$Y3#/ %7PUWAX05(F6'_.CN=X2U-(3OTR M7"E18(8P$-T+7=(',\!FV89V_MCVWU^D(KS@1ZMU/XP;W,J/ .LU1B#/8!$/ MI^P)3$%_O,!IR-UQZKOE1V^&N0C:;-Q/C0?!,PZV/3LXVOERL/T&'_SQE^(" M,QD-PB09Q+522%MKD22"PB1+8IF^[ 6B-A$NHI2:0PNJ;3+8$QR4$$QQ1RY3 MJ!:AU(JP_F;B:#C?+XW4_'L<)BK[YK"^X/GZ05Q_4"_:T3+0%2G^G ^[Q-7S7 X/CF=@7M(_3C\X5C^@TR-\;#!O'1^-4FMYG&'WC$]74P;O5XUY MXE#Z5F_J2>CP%(>_Y)B%11B>?*B![(;:908^&CQ_D') M3=7PA2ZM8R]^RE]SZ5SI,B&]Y-XN"77O+Z%N3E-WRQEUVY,<]\ICDQ\]!GD@ ML+YZ,'^KS3>OHH\N]@:?\]'"\#3Z!@H:/^UE\=V?Y!J]%<).XY+ !&@U5[A:3?F1*^6R8*BSKGI:L'??C53^:B^.QF/KN/?P6K M'--!HR@X11RF%&DI-%(T&6<)U][;QT,XY\Q=$(U^L'5H#O#>G(9&Q;Z.&;= MTK;"(/L(5X^.6&,OPFY_!0-U\43)3J9KRD7F &TX/\OCR2P_O_=9O9+#.^L_ MOJ^AHP%-9S@U__?+?6S/JS3(]Z*6YC9N]A[N]OW@)%9']LN%\^N^Q_9=70@] M/#^M@?U"S&2_O-PZ_+7J-G48JZW#-\T[B-!.]5"#6&F!LA_RY+0'VVMF17QG M6:J?C@:GH-<4QS^WOY:<3<0+N3@8Z:@;HS,"-. M!I\:[W^L<]0!F%SYD&5V$)*?,#V F3]J:;[P174^3YV%"5SJG^T-!Q5TJAY\ MBK,3@L:.S($>_MQ ;JRR6=\7SS(&^=PS,Y[)<>+"E^=A^)ZMIZO;F,#YN_,? M\0B=Q=#P((!6?XG ^)\14R+;SH7=C93_ MP*Y430\'WE/:'70!K_\#[S;NP/-/LI\GSK2+#3W9Z/^*X7V&W6E#3<3/ MZ,4%1N=\U_9Y!O.'_20>V$"M3-=DD.N/G7S,=E$ M_0H=61]>J.X\ _#1SQG/L[V= MGSN9Z=,Q,'R;W?%3K0W?-M/EH[/3B>_VXJN>S6_7F^N_YJ2K17KG\1T;W[)] MO \+\3:.;F >W]D$KK]M]R*'C8Z:M'[G WXBOVG)2418VU37A2MT MMPG.:@2_ 0OZR\*\7R@C"GIW''MA=F1W<:;6'-Y-;@PW M\2<7S\T/A$>%V)N&@)X'B0#JCP9U]G0WK>MN;&+:<\Q77H8,[,TYT?3@+1MQ M@XN0_ASN#U_>_ V]!8TTS"=I.[-Q?N["Z/J#STWH]U0'HMY@\'$27G<1$P<3 M C0B*ZA)(#[,9CT_&Q<'F[H(E[F2LT$?'Y*S]G M[;[HM4O-ZN59;.XQP!0G4*J#Q;$WD^MNR #8XFT$T/W3)<_1^SFT?C*BA@M- M5/\B06B^O&$'^VEF_*69 MB8LS,X"9F1B"\Y::_#&@IM<'ZL9S"L,ZMW%GL3H7QMMM(O7UPE6N65:5W699 MU=;-<]^&T/[W_=P7N_O3S9/]GE^W^^_7SYL'TO]V5[]VS_PZ\? M]TY>?]S_[8^SW/;MUS_8WM$?G]_^^9:^_?">O/OP:]K__]E[TZ:VDF5=^*\H M.,/M':%BUSQXGY<(NK%]W7=+M-UT.^"+HT8C$!)'@S'\^C=K22 QV0@D)$1U MAVU K+5J5=;SY%"961<-W/CX15@GL6,8":-QWFN7R,:H4.+)>Q:<"/Y623!S M45FJ"98^?[Y>*^_G^?..8 A4PX6 M'HDFD$B45CP%&Q+1&XO.$QFKHW[>^@=]!V2[W6YWS_(DONOV1IY?=OSV\D>O M>@%__2(MLXEQBS!5H,TUT4A+')"RSL0@!3?\5A7_"PZ&7:Z#2DGN=,&22=K[U3,=FXTV)[__X%=WV84>2+ZCM MUES1HW]F7?RDW$>=<<7B M?K2]=7O7/_(V57_4O76]WNQSKS6(J)M2OPYW'*S;ZTTMTK>=:DOPCZKDX=I[ MO@0N>E"_K5PT;NP1O+O<%A]V6B-_8-@/&]<=A&ADM Q[X9C@05I+G$R8".&B M9YC&+Q]R:(30[!> FN=V';__]M [):7,.437%J"MSV'WT;QD(U13Y<*/R_1 M33CWCW:I@\N?/K87,/KJ'[_&#OZWGCPE\TW_^%&SL'[8.3 M#^+R&GC6\(#^)>'G)_M[^V)_[RO<^RT!UP+>Y;"]N_/A(KL2!^!>-$_^/MD_ M:J?&G_C[O_?>#N#?LR\N! -N&@>7.(*#P;.#82U'7%%E,*9:X7Q4+E.7'NWE M&M@:92<_:=7GCV9<_85!UIY!'A5B^!&57-E1=U!)88[9F./\BCEHDC%*CA&- MWB".'4'628<4US@J(A50"S!'(8Y"'"^'.$99"7"O[X,W%['7#;9_^#C+I')Q M=L'#*0PS&\-<3&R3Z)PGVB.?G *+Q 5D+7Q%=5+!4F 8$.#6>'NTT$RAF>>A MF2 9%8$E*PCE1@<-OHY-&AM+E>(,5Q[. \R2XN$LD$7P%8LHCV-2*J&D:$#< ML82<4 HYY91203MM*-@I@J\2@[RBX!"^9X+7AR#7DP9CKE8W0(9Y[SBPZ#B M2<>@ ]%@=-E,@\240,\2:; U%>A)EFH5J$3><(8X(QR!_"P25 L2'#,"VXTM M+F9CP?E:2P7RJPUY+[ 3PI.(D^4I<<>I;. B7,LE!BF(19 M%+8I:/"-8I0)<6PCTLXK9*76W"B!:7*%& HQ_)08A.8TX$B]38X;IPPGA@HF M-?962.]&6[\E,+)4W$\%1@PAT7F"$M=@$$1#D,6>(QQP$(HE225>CD=PQ_EJ M-_.IGY!"O@,NKWS\3)][,CXH$F M9 PSR"B3#*-86>/7)YGY<@7\J%O^B>U];770N#.KO"NO;4&IS%IM:BD>D\HL MV28U=/Y9O')38;:8VXJ2'/PJDH-_G'3XTM_NJKO?G8'S^:Y>((HEV9N?[-E5 M*^];><\_VWMY)1NK96_UQR&%SO D= ?CSV_::%>6&:RTQN5":\;!;OH4X06_ MQ74));0/]X^:[<9GN-?[C[RYE\=V ,]HM@_>?SJ"<8G]HW>'^WNA==.EV/W\ M#G[OK^\P;GC>5]+<>8O!];C8IW\?'[QOG(,KT6I\?G?8I+]?SR8-).:35B/2 M2EG$4P+C3@>"M,4A!"Q%=&)CB] ZT3.Z%0_&P@)S-@J[O'!V>7QN>F&7I;'+ M9 ?#!B624AH)G .52@NDG2,(,Y^$H"8X(H%=2%UCO&+LLB[6V>=N[QC\;30^ MY?9>$YO>^6IW$N:+9I0%VBOVI->?T$F>^ ^=/T;3_J'JX 6SNCTYEK'0RBRT M8B!$$52M(RT-5*@A,@ I(<6XJQE%)D3P#7E9Q15Z^>.EXJKMZU.JW^ M8>[\U.V&HI"?,X!P.?7O\\P7&__1O'$^I8QIM"EY'9&CE" N'2?": M*:ZS9=BWZ^(8W[7;>V>,8;S7RV"^0G>8-W8O!_>ZXH[SF(>UX=CGM%J 5@N9 MSD"FS=^FS!.1J!"9/7%@N8I"<.04-<@RJ7GEVUBRL<5573+SJ!#D'& QMQV0 M0E6%JI9J#A:JFIFJ)G9?4#*8&#ABP7CPI#!'6HB A,+6@]T7J#= 5;2NY8QV MW_*IZM$)HH\\COP%I!LN*+.U"ICNQ!1[O1A^Z_8'W?1'KQN&?M#_L]L.KSVM M%3>WOPABL:&&(RNM1MP'BW3"&'DNF&3664K4S2;,SF@GI> Q6,*=2WEYOP_ZCY]=Z_V\0*>/G3^ MM-NOSG]Y4]V\]2W>>PS]F KPY!+K8&##P?V7/!V4\[CL&14MY_G03S*7-YO^ M^[ W<9:_1N1ZT1XCF^ &;VS[S)[W-_YY/>>XU4'34IZ'@'[0GORG[<9O((,' MD("R'C.CN>=2R\B$L,ER&&)D;N,1"=1W#NRG$"R)UR7QNB1>E\3K5Y)X/:N) M43*S7Y7?O^A,I_M]C$^C=?='7G9K5?1Y\OM)\PCN^/E3:Y]^.FI>?(+G;8OL M=NSN_=W>/WH+7GZ#-C__?GPS*K!_ I]<'!P>O/_]Z.!]@S7?P[OM')\?O/\H MFI__;C7VFD?[%_MD_^33]0QMSK'CA"4D$G>(TV"05I:CI*,7%"W7Y+JMAZ#2O!%1H:!8:NI;8;0(QDEFD6#2( M:Y604\2AH(FC,@AG LLTQ,R,-%12R5ZR>B_0>BRTII+*/ $EKS52W.9F:8,+3-K&L3S*_'J$:HZ GQU]?E>=V#;M9)95M(U7J0U4XAV M%J*=SH=7R7I&@T4@0B!:3!TR6A+DM=0@1NVMSC6OO"[)XWRIDG!6&&RE&6PU MC,;"8+,QV,14Y$DZ;2V8BE1(Q)FB""2:D,24,6=9BB(SF*DK_KB0\\KDH=W* MJUE ]LHR,M'N0S+)V_O;)U5?SEHOGG9[.8ID^[6-V?82-VJV%VNM3L9])XX( MX:PU.*S!V]BOO1AS+>[H)_^OVVEUCMNMH^-8V_FS46MN_KU9^P6^^D>MVFRO MG1VV_&'UT5FKW<[/_=8*L>;MJ?6MP7EUL'C_+,9![,!OCX>5'V@'^:K_TZ_] MV@-;NU^'?^U%JUV#"1J"#AX,>_FD8?BJU<[W&1SVNL.O\*3+O6$@(;I9^\F+ MVWX_#FJM?LW%?+?X_31V^O#;@^X]%^2!5>38G_HL#]?9/MP&YGIP&&N_=4] M\N_HL!5@*;UY::SVZ-0]&!?>W?&L8K^] MO]CN]I?$K,4Z)&1)B+GR,*?QN81\],8Z+1C)^;*I]2V.<8K.HX4IC;V3+)L\ MM?WAZ6G[?+)F83V,EDW^<'#/.2@CBKO,G8 U'ZH<@_JT9"5'QX94*E2]3A3Y^L>WM8Q@3 M;5Y\)+L[?_'&V1=OF TZ<91 .R+N?406E"1R!@C0A$WJY8 MJS/;DG!4>'@8P]$0SK4VS#@*)I5D5D?LV,]ZMY9F"(V&H*LRUV&6Z+7;W_OI>+=>=#]^;N4 _,2.Q0)0+4)-4$>08AV\) M ]("U6)RZBS?O"_N.UZFFX\V=GD5JEU:B^_I%=/_S9Y6!1H7X"6" 6Q;8;L3 M=@%OO>T,J/Y.J^_;W?ZP]YIK)"Z:VU]PD [@"VPFP.#D04ND16X,0XPF0GL: M5'Q*Z^]KBV+YQ3CCQ7!IMO4K/=W-ZZ)VN>U>,6[I#%X2U$N">DE0?T$)ZDL- M&U>\>EZU9JO7;/B6#XD9D6N(5>G9S!W#UV_SH)S#/+^F&6,]_G:DQM\=@$QY<3SYW23M-J<]GD'($ M?EU$QCN&7++1ZR089GYCB[ Z%VR53F,N/++.//(,'2T*C\R!1R9;BB:&2*4G MR @2$!=8(! :121Q3P(-!J>PL27KDJE5HI$U,L2:W0[XWN,V+=/[4M46R!U- MT%Y=KNNB$Z] E=](KK8H_19]S.ZI(\,!^AQNG7O=DG+[2@O%\S1]WJAP:^-,:%.V\ M>.T\)92]+)-W()(KB;R_$LC;L3P*R\S",M?ZA=MH0"];)"TAN=0T9^UXCUQP MV&"'-7-N8XO4\:SU[$5=KZ:Z+LA:*+*F3]NRVEE!D?8&]#<1#AE'+'C:1!JO M%/.&5(GV<(8A?\/!4_$^4:G1$LJ0AVJLSUTTHA M*QC\116+B=%$>*5<.5E"E&EA]=-+!=.HA/ITYLRL4JE8*A57QH:YOI%X/=FT MD/(C2/G:Z>644\N30R DA[AF&!FM!<*68Z>% AW+JTI%RN^KRUC92L7"8(7! M5L**+ PV=P:;F)6.4,*#9TAHYA&W6B%M@P#?+!!A02>EF*H$*]!"+XW!'GWF MQ[A@8&D5(W_TNJ?P8N=_M&UG O^[?\.6Z3FU(,OKA]>P_A!^V#NO>#1>\F@YE>"5.2S::T%BB(Y)RB,.UD82;)6WRPTV#[>V_Q[@Z,[7WCXN#SN_;NSK$XR'[,WC:\VR?P79K7 MBT%"S*>D!8YBD!%Q%S0"*4H4,!-.X&3!SM[8XJ:N=3F*H##+[!5[;!*VFG@7&&B)3?$'*XG$M9%@KO"ZQB73 M]%G A!6FTN4TI*BX4=3A%&F0#+,H"9?SV:PH8)H?F"8:FJ9(@L&Y(H1EO0RZ MVBAC$%/.!R5MP(D#F$2=F!DK.(L2GF I-X\<#F)OE.32[Z;!F>W%5Z^$M3<6 M\!Z]YXQ'90T/0!V)"NPP3D$4);Q2O'&MVH,X,)B<199Y@;CV%&Q\$9%@SCDE M@_?$;VRI.I.TZ.!G,6BC,9AQK!+8L3A0IY404EOK4S1$DZ*#5PQ+$QT:4HM'R?; M%?7:MWC8\NUQ&BHL\/#JM3.)PH&C!>1!*5>*.$*T((YC'UQ(NFCGE6*4:T4A M.@DKHF!(@N00-RDBYQ-&-%BGJ8D:#/M<\ERE9+[%@ M."0EC95"%.V\8EB::&>"#:91@D[6Q"*>P-PUDF.$O:+:.>PH]QE+ K]X!WFI M:/JMV^D/>N/F1:U.;F7TM1?[)50-2RQIP[A--/((RA<#AQ.P\)W'S.-0]/!* M<? DJ#2,=2!Y+3;R3B1D:BAY>,2Q-]+#&Q$OB&,*5EVR] E2QA%),B2<7(\.\PM(R M;-H'ZF&<'_!C_#TMC^5%@_-9JO8*..<%SND]62R4)XYS!/+#.83%D./*@I'L M&)62 M!H"SKQ<)N86U-5J>TI\4%9]>%15/[2YW MXD\JXDH3D-($9*4"(LU8F'<6YMV=WG^GG@H1DD5&18ZXDP09BR,RA E*(P?^ MS4<7D+IA+Z[[1Z&N0ETK86 6ZIH?=4UMLP0N)!$*"0:$Q8E)R%'!D53:F\B# M)MH!==&Z5H\KV2N-BQ[>N*CJL_ZG/XQAV(Z[:=J/NN$^[55MV%]S&Z.O7V2, M,'G@Y3"K#>()*^2P-XAYI7S 2@HC5[B-T7W46S4MVAGV8/77!H<1_O1BK)W M)8?]6H2QA5K52&4$OLMN*I4'DCFV_N/PXV7_U7JMU?'M8<;8]<^[J59!"W43 M&O;CN"EKK6I24TNMCNWX?$T[UYGVZ[4SVX=? 19OM[MG_3>EE=)+:*5TMQ]^ M.:U ;'&1O_G4S7/Y,OL#[54X;HQP_':"X]POZ &]D)YESE]7\ZQ9#)#57EL/ M[*>U5B^,%PZ:]8+7 YV^G8=8#Z7=UROS[Q_EU#S2T?^!V[,>?OX)W.?HXUGS M_5^L21NB>?&IM7]T+/8O/M#&SEL&CLX9?$\/3AJW_/Q]&'-S9SO' -C^Q3%K MOO^]M;O7/LK/;^R%(W"/X/N#D_V;731X4(FX:)#4C"'NDD!.D82D-U;P:#77 M#&BU3F8]]Z+T_"KT\F1Z\0([(3R).%F>$G><.B>35[FVG&%9T0N^I!= M'[&Z*VJY.L&OZHX/[^%==37KS^5E7NB\W!TFW#V-V0_N?*V]FAFZ;SZ(J&(L ML9:;[]C.>>W0]FO=J_D9Q2MKISU0"3UX<-87-1M.6IU6?Y!_YUL<=PGHUVMM MZW)\H=L[GR1U3)U7E:QOM:M#3C=K^8FWGG)HX6Z]>&+A[CF*&WLG_=K@T YJ M/=OY&D?G1/]H#R%&E13C1DLAN$_>1IIX]%HE38CGU[KK3BD^F#;_)@Q[Y]'V M;JJ]G*8:X]6"J=;+I\LA5M_MP3!?IMY[]$Y"8\_SW>TO6,5@#.4()Z40UY0A M2Y)&TCFJ@N=,VWRHXDUJK@VZ/Y2BB,Q:)RWSV''MB%'4)&(PEL[&D%*1XMRD M*)H@1>-\#((CXTE G*6(3" 2:1RY)!R'(/'&EK@EQ3S/ /I1GY!![(QW1@#7 M'?C3JX&!F#&>;95^%GDO=N)9A?Q^''UCVV.,>YM#)'"/4&W=5'10?;1"D*_& M^RI7R5?1//O"DJ?:2 N6JN>("R)03EQ RM,4$HV!![K*6'^]XCL^:YQ]D<92 M0(1 D3")N$T!&2D\$E;:I#BQ@;![03Z*9P*:QP@/N?' #:">'68&&-1:?<"V M[7<[8)N?USRX$+;Z95#B@RDKXZS5;@/D8\^W\AT.+YGB'LL@/]RW;;_?2BUX M/)@HGW;_NK['>NN:;F?ZB?^GGQ=>R%'8[&5T*H^H*CMQMFT[/M;ZAS'?+;]K M+_NZ_6R]3-WAO_]#4Z+^U1_M\^:%/1P/?;29WWKUVJD]KUH1YXF=GOZ-:EW7VBWKQD;51C7TVS^OTFKS_O3E M>:&GV7//7OOC9FBSMGMCC'=M?%?]H2:#J"38B[[[M0-V*4AP (\X@3?S5:?E M6GX0/"<_>CRJ2PE\L^UAMC%OSD<7W-,?33)8DZ'VGXM/(Q6SG$A\G93RM.VF MO_JQ.DWN*HHB7QM%'<$[?/S" E@<%!,$9.00EU(@PV5",4KB>#38*: HLWD[ M%;0&+E'[(@<'@GJODM421;! P:C0!&D#7D04.H&G[I27 M"HP*O'F[H]^5S.])O,E>;+HWX^?RT*%K'^$Z,%3_-/KLU;;/;_/<-)^=12"T ME::7?X]'>_Z*5]E^=E.U!G\F*(>P]P1QGBARVD0DP;[4/EH52#9=V>;MBKJ7 MPRQ%VG!_T?SXA0<0MHDYGS%+6W*#K.$1,3!R)0G>-LX/V^\631UU3A) M$$\NL0Z,N.'@_DON2B:<+98YC\N>,=S).

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�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end

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